Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
26800.0 | 2015-10-27 00:00:00 UTC | Here's Why Wall Street May Be Dead Wrong About AbbVie | ABBV | https://www.nasdaq.com/articles/heres-why-wall-street-may-be-dead-wrong-about-abbvie-2015-10-27 | nan | nan | AbbVie , a global biopharmaceutical company, is in the midst of its first disappointing year as a publicly traded company. Despite continuing to produce industry-leading growth for its bottom and top lines, the drugmaker's stock has lost nearly a quarter of its value in 2015:
This year, AbbVie's stock has gotten crushed because of lingering doubts about the company's cash flows once anti-inflammatory drug Humira loses exclusivity in the U.S. in 2017, as well as last week's revelation that its hepatitis C drugs Viekira Pak and Technivie were linked to 10 deaths in patients with advanced liver disease.
Source: AbbVie.
Interestingly enough, though, Wall Street has remained a devout fan of AbbVie. Even after the news broke about the company's hep C drugs, for instance, analysts covering this stock barely lowered any of their forward-looking revenue or earnings projections, according to data compiled from S&P Capital IQ .
As a result, the Street's average 12-month price target for this beaten-down biotech stock remains extremely optimistic at $73 a share, meaning that analysts think AbbVie has a potential upside of 43% from current levels. Supporting this price target, the Street expects AbbVie's total revenue to grow by 15.3% and its EPS by 19% next year.
Given this noteworthy disagreement between Wall Street and Mr. Market, let's dig deeper to see if investors should start stuffing their portfolios full of AbbVie stock or avoid it altogether.
AbbVie's problems might be far more serious than some think
To understand why the market has been trashing AbbVie's stock for the better part of the year, I think it's important to first consider the company's balance sheet. AbbVie sports a total debt-to-equity ratio of an eye-popping 568% at last count, largely because of its $21 billion buyout of Pharmacyclics. Putting this number into context, AbbVie's D/E far exceeds that of many of its closest peers:
By comparison, Celgene and Gilead Sciences have both been able to keep their financial leverage from ballooning to such astronomical levels by acquiring relatively smaller companies to build out their clinical pipelines. Celgene, for instance, paid only $7.2 billion for Receptos, and Gilead hasn't made a billion dollar-plus acquisition in almost four years.
This huge amount of financial leverage caused rating agencies such as Moody ' s Corp. to downgrade AbbVie's rating to Baa1, meaning that the company is viewed as a "moderate credit risk." Put it this way: If AbbVie were a person looking to take out a mortgage, that person would probably have trouble doing so -- at least at a reasonable interest rate.
Complicating matters further, Moody's Corp. noted in its review that AbbVie needs to continue generating top-notch growth from key products such as Humira, Viekira Pak, and the newly-acquired Imbruvica -- via the Pharmacyclics acquisition -- to meet its long-term financial obligations. And that's where things start to get really iffy.
Humira's long-term revenues are obviously in question because of its looming U.S. patent expiration. After all, a few analysts have already diverged from their peers on this point, suggesting that biosimilars could devastate Humira's sales by 2018.
And Viekira Pak may never live up to its commercial potential for a variety of reasons, such as these new liver damage warnings that make it even harder to compete against Gilead's rock-star hep C drugs, a rapidly evolving hep C market that should see a handful of newer drugs with shorter treatment times in the near future, and a decline in overall demand for these drugs in most Western nations.
Yet another concern
Blood cancer drug Imbruvica's commercial potential is also a major point of contention. AbbVie's management believes that Imbruvica will eventually generate peak revenue for the company of around $7 billion per year. But there are a lot of moving parts to this estimate.
First off, Imbruvica will need to successfully migrate to earlier lines of treatment for its approved indications and expand into a variety of other B-cell malignancies to achieve this lofty sales target. The catch is that numerous companies -- most notably Celgene -- are targeting some of the same indications with a host of potent experimental-stage drugs.
There is also the distinct possibility that the growing public outcry over drug prices could spill over into the oncology space, which has been largely untouched by this debate so far. Indeed, it's worth noting that pharmacy benefits managers have just started making some potentially game-changing proposals regarding the pricing schemes for new cancer treatments or label expansions for drugs already on the market.
Foolish bottom line
AbbVie's massive Pharmacyclics acquisition may turn out to be a huge anchor around the company's neck. If Humira, Viekira Pak, or Imbruvica miss the mark in terms of annual sales growth moving forward or its profit margins fall because of the raging drug pricing debate, the company may have to look into doing things it has never done, such as suspending share buybacks or cutting its dividend. Put simply, management took on a tremendous amount of risk by paying top dollar for Pharmacyclics, but the potential rewards now look more questionable than ever. That's why you may want to avoid AbbVie for the time being, and instead consider drugmakers with cleaner balance sheets during this period of major uncertainty for the prescription-drug industry.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article Here's Why Wall Street May Be Dead Wrong About AbbVie originally appeared on Fool.com.
George Budwell owns shares of AbbVie, Celgene, and Gilead Sciences. The Motley Fool owns shares of and recommends Celgene and Gilead Sciences. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Putting this number into context, AbbVie's D/E far exceeds that of many of its closest peers: By comparison, Celgene and Gilead Sciences have both been able to keep their financial leverage from ballooning to such astronomical levels by acquiring relatively smaller companies to build out their clinical pipelines. Complicating matters further, Moody's Corp. noted in its review that AbbVie needs to continue generating top-notch growth from key products such as Humira, Viekira Pak, and the newly-acquired Imbruvica -- via the Pharmacyclics acquisition -- to meet its long-term financial obligations. AbbVie , a global biopharmaceutical company, is in the midst of its first disappointing year as a publicly traded company. | Supporting this price target, the Street expects AbbVie's total revenue to grow by 15.3% and its EPS by 19% next year. This huge amount of financial leverage caused rating agencies such as Moody ' s Corp. to downgrade AbbVie's rating to Baa1, meaning that the company is viewed as a "moderate credit risk." Foolish bottom line AbbVie's massive Pharmacyclics acquisition may turn out to be a huge anchor around the company's neck. | Despite continuing to produce industry-leading growth for its bottom and top lines, the drugmaker's stock has lost nearly a quarter of its value in 2015: This year, AbbVie's stock has gotten crushed because of lingering doubts about the company's cash flows once anti-inflammatory drug Humira loses exclusivity in the U.S. in 2017, as well as last week's revelation that its hepatitis C drugs Viekira Pak and Technivie were linked to 10 deaths in patients with advanced liver disease. AbbVie's problems might be far more serious than some think To understand why the market has been trashing AbbVie's stock for the better part of the year, I think it's important to first consider the company's balance sheet. AbbVie , a global biopharmaceutical company, is in the midst of its first disappointing year as a publicly traded company. | Given this noteworthy disagreement between Wall Street and Mr. Market, let's dig deeper to see if investors should start stuffing their portfolios full of AbbVie stock or avoid it altogether. AbbVie's problems might be far more serious than some think To understand why the market has been trashing AbbVie's stock for the better part of the year, I think it's important to first consider the company's balance sheet. AbbVie , a global biopharmaceutical company, is in the midst of its first disappointing year as a publicly traded company. |
26801.0 | 2015-10-23 00:00:00 UTC | AbbVie Slumps, FDA Issues Warning Related to 2 HCV Drugs | ABBV | https://www.nasdaq.com/articles/abbvie-slumps-fda-issues-warning-related-to-2-hcv-drugs-2015-10-23 | nan | nan | AbbVie Inc.' s ABBV shares plunged 10.3% after the FDA came up with a warning related to a couple of hepatitis C virus (HCV) drugs in the company's portfolio - Viekira Pak and Technivie. The FDA stated that both HCV drugs can cause serious liver injury, mostly in patients suffering from underlying advanced liver disease.
The regulatory body has therefore instructed the company to include information about serious liver injury adverse events to the Contraindications, Warnings and Precautions, Postmarketing Experience and Hepatic Impairment sections of the Viekira Pak and Technivie drug labels.
Post-marketing reports of hepatic decompensation and hepatic failure in patients with underlying liver cirrhosis who were on HCV medicines led to the warning. Some of the cases resulted in liver transplantation or death, which were mostly reported in patients taking Viekira Pak who had evidence of advanced cirrhosis even before beginning treatment.
AbbVie has updated the U.S. Product Inserts (USPI) for Viekira Pak and Technivie from "not recommended in Child Pugh B patients" to a contraindication in patients with Child-Pugh B cirrhosis. However, patients classified as Child-Pugh C will remain contraindicated as they have been since approval. The updated USPI for Viekira Pak also includes a recommendation for physicians to assess evidence of hepatic decompensation prior to treatment and during treatment in cirrhotic patients.
AbbVie intends to issue a Dear Health Care Provider letter to inform U.S. healthcare providers about the updates.
While the label update news comes as a disappointment for AbbVie, we note that Gilead Sciences Inc.'s GILD shares were up 5.8% on the news. The company has two HCV drugs, Sovaldi and Harvoni, on the market. Meanwhile, competition in the HCV market is intensifying as several companies including Merck & Co. Inc. MRK are looking to bring their HCV treatments to the market.
AbbVie is a Zacks Rank #2 (Buy) stock. Another favorably ranked stock in the health care sector is AstraZeneca plc AZN , carrying a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBVIE INC (ABBV): Free Stock Analysis Report
ASTRAZENECA PLC (AZN): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
MERCK & CO INC (MRK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc.' s ABBV shares plunged 10.3% after the FDA came up with a warning related to a couple of hepatitis C virus (HCV) drugs in the company's portfolio - Viekira Pak and Technivie. AbbVie has updated the U.S. AbbVie intends to issue a Dear Health Care Provider letter to inform U.S. healthcare providers about the updates. | Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.' s ABBV shares plunged 10.3% after the FDA came up with a warning related to a couple of hepatitis C virus (HCV) drugs in the company's portfolio - Viekira Pak and Technivie. AbbVie has updated the U.S. | AbbVie Inc.' s ABBV shares plunged 10.3% after the FDA came up with a warning related to a couple of hepatitis C virus (HCV) drugs in the company's portfolio - Viekira Pak and Technivie. Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie has updated the U.S. | AbbVie is a Zacks Rank #2 (Buy) stock. AbbVie Inc.' s ABBV shares plunged 10.3% after the FDA came up with a warning related to a couple of hepatitis C virus (HCV) drugs in the company's portfolio - Viekira Pak and Technivie. AbbVie has updated the U.S. |
26802.0 | 2015-10-22 00:00:00 UTC | IVW, V, MA, ABBV: Large Outflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/ivw-v-ma-abbv-large-outflows-detected-etf-2015-10-22 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $40.0 million dollar outflow -- that's a 0.3% decrease week over week (from 111,900,000 to 111,550,000). Among the largest underlying components of IVW, in trading today Visa Inc (Symbol: V) is up about 0.9%, MasterCard Inc (Symbol: MA) is up about 0.9%, and AbbVie Inc. (Symbol: ABBV) is lower by about 1%. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price performance of IVW, versus its 200 day moving average:
Looking at the chart above, IVW's low point in its 52 week range is $85.21 per share, with $119.39 as the 52 week high point - that compares with a last trade of $114.75. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IVW, in trading today Visa Inc (Symbol: V) is up about 0.9%, MasterCard Inc (Symbol: MA) is up about 0.9%, and AbbVie Inc. (Symbol: ABBV) is lower by about 1%. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price performance of IVW, versus its 200 day moving average: Looking at the chart above, IVW's low point in its 52 week range is $85.21 per share, with $119.39 as the 52 week high point - that compares with a last trade of $114.75. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IVW, in trading today Visa Inc (Symbol: V) is up about 0.9%, MasterCard Inc (Symbol: MA) is up about 0.9%, and AbbVie Inc. (Symbol: ABBV) is lower by about 1%. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price performance of IVW, versus its 200 day moving average: Looking at the chart above, IVW's low point in its 52 week range is $85.21 per share, with $119.39 as the 52 week high point - that compares with a last trade of $114.75. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IVW, in trading today Visa Inc (Symbol: V) is up about 0.9%, MasterCard Inc (Symbol: MA) is up about 0.9%, and AbbVie Inc. (Symbol: ABBV) is lower by about 1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $40.0 million dollar outflow -- that's a 0.3% decrease week over week (from 111,900,000 to 111,550,000). For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price performance of IVW, versus its 200 day moving average: Looking at the chart above, IVW's low point in its 52 week range is $85.21 per share, with $119.39 as the 52 week high point - that compares with a last trade of $114.75. | Among the largest underlying components of IVW, in trading today Visa Inc (Symbol: V) is up about 0.9%, MasterCard Inc (Symbol: MA) is up about 0.9%, and AbbVie Inc. (Symbol: ABBV) is lower by about 1%. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price performance of IVW, versus its 200 day moving average: Looking at the chart above, IVW's low point in its 52 week range is $85.21 per share, with $119.39 as the 52 week high point - that compares with a last trade of $114.75. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
26803.0 | 2015-10-22 00:00:00 UTC | Shares of AbbVie Inc Plummeted Today. Here's Why. | ABBV | https://www.nasdaq.com/articles/shares-abbvie-inc-plummeted-today-heres-why-2015-10-22 | nan | nan | What: Shares of pharma giant AbbVie plunged by more than 14% today in late afternoon trading after the company received a warning letter from the FDA related to its two Hepatitis C medications.
So what: The FDA issued a warning related to the company's Hepatitis C treatments Viekira Pak and Technivie, noting that the two drugs can cause serious liver injuries to patients with advanced liver diseases. At least 26 patients around the world have already submitted cases to the FDA related to liver injury that was possibly linked to using Viekira Pak or Technivie, though it should be noted that some of the injuries occurred in patients for whom the medicines were contraindicated.
The FDA noted that any patients taking these drugs should reach out to their providers right away if they develop fatigue, weakness, loss of appetite, nausea and vomiting, yellow eyes or skin, or light-colored stools, as these may be a sign that their liver is being harmed by the medications.
Patients were advised not to stop taking the drugs until they spoke with their healthcare provider first.
AbbVie is now required to add new safety information to the labeling of these two drugs, which certainly took AbbVie's investors by surprise and explains why shares were sold-off so violently.
Now what: Viekira Pak and Technivie are certainly important drugs to AbbVie's financial future, as global sales of Viekira Pak alone topped $385 million in the second quarter, making it AbbVie's second best selling drug. Technivie was only recently approved in July, so investors haven't yet had a chance to see early sales figures yet.
This news also sent shares of Gilead Sciences 6% higher in afternoon trading as its Hepatitis C treatments Harvoni and Sovaldi are the likely choice to fill any void created from doctors not wanting to use Viekira Pak or Technivie.
While it might be tempting to look at AbbVie's stock as a buy after this sell-off, it's probably best to wait until we hear from the company directly about what kind of impact this could have on its financial future before scooping up shares. Investors won't have to wait long, as the company is set to report third quarter results on October 30th, and I'm sure this warning letter and its impact on the firm will be discussed in detail.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article Shares of AbbVie Inc Plummeted Today. Here's Why. originally appeared on Fool.com.
Brian Feroldi owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What: Shares of pharma giant AbbVie plunged by more than 14% today in late afternoon trading after the company received a warning letter from the FDA related to its two Hepatitis C medications. AbbVie is now required to add new safety information to the labeling of these two drugs, which certainly took AbbVie's investors by surprise and explains why shares were sold-off so violently. Now what: Viekira Pak and Technivie are certainly important drugs to AbbVie's financial future, as global sales of Viekira Pak alone topped $385 million in the second quarter, making it AbbVie's second best selling drug. | What: Shares of pharma giant AbbVie plunged by more than 14% today in late afternoon trading after the company received a warning letter from the FDA related to its two Hepatitis C medications. Now what: Viekira Pak and Technivie are certainly important drugs to AbbVie's financial future, as global sales of Viekira Pak alone topped $385 million in the second quarter, making it AbbVie's second best selling drug. AbbVie is now required to add new safety information to the labeling of these two drugs, which certainly took AbbVie's investors by surprise and explains why shares were sold-off so violently. | Now what: Viekira Pak and Technivie are certainly important drugs to AbbVie's financial future, as global sales of Viekira Pak alone topped $385 million in the second quarter, making it AbbVie's second best selling drug. What: Shares of pharma giant AbbVie plunged by more than 14% today in late afternoon trading after the company received a warning letter from the FDA related to its two Hepatitis C medications. AbbVie is now required to add new safety information to the labeling of these two drugs, which certainly took AbbVie's investors by surprise and explains why shares were sold-off so violently. | What: Shares of pharma giant AbbVie plunged by more than 14% today in late afternoon trading after the company received a warning letter from the FDA related to its two Hepatitis C medications. Now what: Viekira Pak and Technivie are certainly important drugs to AbbVie's financial future, as global sales of Viekira Pak alone topped $385 million in the second quarter, making it AbbVie's second best selling drug. AbbVie is now required to add new safety information to the labeling of these two drugs, which certainly took AbbVie's investors by surprise and explains why shares were sold-off so violently. |
26804.0 | 2015-10-22 00:00:00 UTC | Achillion, J&J's HCV Combo Drug Phase IIa Study Started | ABBV | https://www.nasdaq.com/articles/achillion-jjs-hcv-combo-drug-phase-iia-study-started-2015-10-22 | nan | nan | Achillion Pharmaceuticals, Inc.ACHN announced that Alios Biopharma Inc., a part of Johnson & Johnson's JNJ Janssen Pharmaceutical Companies, has started treatment in a phase IIa study evaluating the combination of AL-335, odalasvir (also known as ACH-3102) and Johnson & Johnson's Olysio (simeprevir) in treatment-naïve patients suffering from genotype 1 chronic hepatitis C virus (HCV) infection.
While AL-335 is a nucleotide-based HCV NS5B polymerase inhibitor, odalasvir and Olysio are HCV NS5A inhibitor and HCV NS3/4A protease inhibitor, respectively.
The randomized, open-label, three-arm study (n~60) will be conducted to assess the safety, pharmacokinetics and efficacy of AL-335, odalasvir and Olysio. Patients will be randomized to receive a once-daily, triple direct-acting antiviral regimen across three different treatment durations - four, six or eight weeks.
We remind investors that Achillion had entered into an exclusive global license and collaboration agreement with Janssen for the development and commercialization of one or more of Achillion's key HCV treatments including odalasvir, ACH-3422 and sovaprevir in May 2015.
We are encouraged by the companies' progress with the HCV combination treatment. Per information provided by Achillion, HCV is one of the most common causes of viral hepatitis (inflammation of the liver) and over 150 million people are estimated to be infected with HCV across the world with more than 5 million people in the U.S.
We note that competition in the HCV market is intensifying given the presence of companies like Gilead Sciences Inc. GILD and AbbVie Inc. ABBV .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
ACHILLION PHARM (ACHN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Per information provided by Achillion, HCV is one of the most common causes of viral hepatitis (inflammation of the liver) and over 150 million people are estimated to be infected with HCV across the world with more than 5 million people in the U.S. We note that competition in the HCV market is intensifying given the presence of companies like Gilead Sciences Inc. GILD and AbbVie Inc. ABBV . Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ACHILLION PHARM (ACHN): Free Stock Analysis Report To read this article on Zacks.com click here. The randomized, open-label, three-arm study (n~60) will be conducted to assess the safety, pharmacokinetics and efficacy of AL-335, odalasvir and Olysio. | Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ACHILLION PHARM (ACHN): Free Stock Analysis Report To read this article on Zacks.com click here. Per information provided by Achillion, HCV is one of the most common causes of viral hepatitis (inflammation of the liver) and over 150 million people are estimated to be infected with HCV across the world with more than 5 million people in the U.S. We note that competition in the HCV market is intensifying given the presence of companies like Gilead Sciences Inc. GILD and AbbVie Inc. ABBV . Achillion Pharmaceuticals, Inc.ACHN announced that Alios Biopharma Inc., a part of Johnson & Johnson's JNJ Janssen Pharmaceutical Companies, has started treatment in a phase IIa study evaluating the combination of AL-335, odalasvir (also known as ACH-3102) and Johnson & Johnson's Olysio (simeprevir) in treatment-naïve patients suffering from genotype 1 chronic hepatitis C virus (HCV) infection. | Per information provided by Achillion, HCV is one of the most common causes of viral hepatitis (inflammation of the liver) and over 150 million people are estimated to be infected with HCV across the world with more than 5 million people in the U.S. We note that competition in the HCV market is intensifying given the presence of companies like Gilead Sciences Inc. GILD and AbbVie Inc. ABBV . Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ACHILLION PHARM (ACHN): Free Stock Analysis Report To read this article on Zacks.com click here. Achillion Pharmaceuticals, Inc.ACHN announced that Alios Biopharma Inc., a part of Johnson & Johnson's JNJ Janssen Pharmaceutical Companies, has started treatment in a phase IIa study evaluating the combination of AL-335, odalasvir (also known as ACH-3102) and Johnson & Johnson's Olysio (simeprevir) in treatment-naïve patients suffering from genotype 1 chronic hepatitis C virus (HCV) infection. | Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ACHILLION PHARM (ACHN): Free Stock Analysis Report To read this article on Zacks.com click here. Per information provided by Achillion, HCV is one of the most common causes of viral hepatitis (inflammation of the liver) and over 150 million people are estimated to be infected with HCV across the world with more than 5 million people in the U.S. We note that competition in the HCV market is intensifying given the presence of companies like Gilead Sciences Inc. GILD and AbbVie Inc. ABBV . Click to get this free report >> Want the latest recommendations from Zacks Investment Research? |
26805.0 | 2015-10-20 00:00:00 UTC | 3 Big Questions for Gilead Sciences Inc. in Q3 | ABBV | https://www.nasdaq.com/articles/3-big-questions-gilead-sciences-inc-q3-2015-10-20 | nan | nan | Image source: Gilead Sciences.
Three months ago, there was plenty of anxiety among investors about how well Gilead Sciences performed during second quarter. Gilead's earnings announcement put all of those concerns to rest with stellar performance from its hepatitis C franchise. The biotech is set to release its third-quarter results on October 26.
How will Gilead fare this time around? The answer to that question could depend largely on the answers to the following three questions.
1.How strong were European sales?
The European market played a key role in Gilead's second-quarter success. European revenue jumped 50% year over year to $2 billion. That wasn't nearly as large as U.S. sales, but it was still significant.
Over half of Gilead's revenue in Europe during the second quarter stemmed from hepatitis C drugs Harvoni and Sovaldi. HIV drugs, particularly Eviplera and Stribild, kicked in most of the remaining European revenue.
The third quarter holds the potential for more good news. Sovaldi reimbursement should have expanded in the U.K. over the summer. Many European patients with hep C remain undiagnosed and represent a big opportunity for Gilead.
On the other hand, there's a real risk that the success experienced by Sovaldi and Harvoni could be too much too soon. Many European countries have budget ceilings that hold a cap on how much can be spent on new hep C drugs. It's possible that some of those budget ceilings could be reached in third quarter.
2.Have U.S. payers eased up on restrictions for Harvoni and Sovaldi?
An important question for Gilead in the U.S. relates to payer attitudes about reimbursement for the biotech's expensive hep C drugs, particularly as the pricing of many expensive pharmaceutical drugs is widely being called into question . In the second quarter, there were many more prescriptions written for Harvoni and Sovaldi than there were filled prescriptions. That translates to payer resistance.
A related factor is that Gilead faces competition in the hep C market from AbbVie 's Viekira Pak. AbbVie managed to win some exclusive deals that effectively locked Gilead out for some patients. However, turned out not to be a huge issue -- Gilead estimates that Harvoni is accessible to roughly 83% of all covered lives in the U.S.
A recent report from Advera Health Analytics could give a boost to Gilead in its battle with AbbVie. Advera examined side effects data for Viekira Pak, Harvoni, and Sovaldi. It found that Viekira Pak was most likely to trigger side effects. Harvoni caused the fewest side effects of the three drugs.
Gilead thinks that shortening treatment durations, particularly for Harvoni, could convince U.S. payers to ease up on reimbursement restrictions. The company is also encouraged by third-party reports that appear to bolster its claim that the investment in its high-dollar hep C drugs pays off. Then there's patient advocacy for access to effective hepatitis C treatments. Gilead's third-quarter results should signal whether any significant movement in payer attitudes has been achieved.
3.Were there big shifts in payer mix?
Another important question related to reimbursement pertains to payer mix for Harvoni and Sovaldi. Commercial payers tend to pay more than government programs. If the mix shifts in a meaningful way to higher volumes paid by federal and state governments, it could mean disappointing news for Gilead's third-quarter revenue and earnings.
Gilead knows that there will be a shift to higher Medicaid volumes in the second half of 2015. However, the company thinks that shift will be fairly small. If it's wrong, the third quarter might not be too great.
There's mixed news with respect to the federal Veterans Administration program. As of the second quarter, the VA didn't have funds to buy Gilead's hep C drugs. Gilead doesn't expect that to change until the fourth quarter. The good news is that the VA won't be a factor in reshaping the payer mix for Harvoni and Sovaldi. The bad news is that the VA won't be a factor at all -- at least for the third quarter.
What's expected
Gilead upped its full-year revenue guidance three months ago but left full-year earnings guidance unchanged. That signaled the company's expectations for stronger sales that don't entirely flow down to the bottom line -- something that could occur if the payer mix shifts to higher government pay.
Wall Street expects third-quarter revenue of $7.81 billion and earnings of $2.86 per share. Gilead has done a good job of beating expectations so far in 2015. Strong results from Europe combined with easing payer restrictions and a minimal payer mix shift could mean the big biotech achieves a repeat performance.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article 3 Big Questions for Gilead Sciences Inc. in Q3 originally appeared on Fool.com.
Keith Speights owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A related factor is that Gilead faces competition in the hep C market from AbbVie 's Viekira Pak. AbbVie managed to win some exclusive deals that effectively locked Gilead out for some patients. However, turned out not to be a huge issue -- Gilead estimates that Harvoni is accessible to roughly 83% of all covered lives in the U.S. A recent report from Advera Health Analytics could give a boost to Gilead in its battle with AbbVie. | A related factor is that Gilead faces competition in the hep C market from AbbVie 's Viekira Pak. AbbVie managed to win some exclusive deals that effectively locked Gilead out for some patients. However, turned out not to be a huge issue -- Gilead estimates that Harvoni is accessible to roughly 83% of all covered lives in the U.S. A recent report from Advera Health Analytics could give a boost to Gilead in its battle with AbbVie. | However, turned out not to be a huge issue -- Gilead estimates that Harvoni is accessible to roughly 83% of all covered lives in the U.S. A recent report from Advera Health Analytics could give a boost to Gilead in its battle with AbbVie. A related factor is that Gilead faces competition in the hep C market from AbbVie 's Viekira Pak. AbbVie managed to win some exclusive deals that effectively locked Gilead out for some patients. | A related factor is that Gilead faces competition in the hep C market from AbbVie 's Viekira Pak. AbbVie managed to win some exclusive deals that effectively locked Gilead out for some patients. However, turned out not to be a huge issue -- Gilead estimates that Harvoni is accessible to roughly 83% of all covered lives in the U.S. A recent report from Advera Health Analytics could give a boost to Gilead in its battle with AbbVie. |
26806.0 | 2015-10-20 00:00:00 UTC | 5 Dividend Aristocrats You Can Buy Now | ABBV | https://www.nasdaq.com/articles/5-dividend-aristocrats-you-can-buy-now-2015-10-20 | nan | nan | Photo by Simon Cunningham Follow Flickr Creative Commons.
Whenever a company manages to increase its dividend payment for 25 years in a row, it joins an elite group of companies known as the Dividend Aristocrats. It takes a proven business model to provide that kind of stability, especially considering the financial storm that essentially every company went through in the financial crisis of 2008. When you can find one of these gems trading at a discount, it can be a good idea to tuck a few shares away in your portfolio..
Knowing that, we asked our team of Motley Fool contributors to highlight a dividend aristocrat that they think is a great buy right now. Here's what they had to say:
Brian Feroldi : The dividend aristocrat that I like most right now is pharma giant Abbvie . Since it split off from its parent company Abbott Laboratories in 2013, its stock has been a monster winner, leaving the returns of both the S&P 500 and its former parent in the dust.
AbbVie's megablockbuster drug Humira, which treats a variety of diseases including arthritis, continue to add billions to the company's top line, and is driving much of the revenue growth, which was up an impressive 19.4% in the most-recent quarter when you look at its operations (which ignore currency movements). AbbVie also has several other drugs that are growing quickly, as well as its cancer treatment Imbruvica, Hepatits C treatment Viekira Pak, and digestive health medication Creon. When combined with the the company's cost-cutting efforts, profits grew a strong 31% compared to the year-ago period.
Growth should continue well into the future, as its acquisition of Pharmacyclics should be accretive to earnings by 2017. Biologics may prove to be a long-term threat; but with AbbVie's shares currently yielding 3.6%, and its stock trading for around 11 times 2016 earnings estimates, I think the risk is more than priced in. I consider AbbVie to be a solid choice for investors who want to add some yield to their portfolios.
Selena Maranjian : If you're in the market for a dependable income-generating stock, check out the steel specialist Nucor . It has dropped more than 10% during the past year, and its recent and forward-looking price-to-earnings ratios are 20 and 14, respectively, well below its five-year average of 38. That suggests undervaluation. Meanwhile, its dividend yield recently sat at a solid 3.6%, with the company having paid 170 consecutive quarterly dividends in a row.
It's not all unicorns and rainbows for Nucor right now, though. The U.S. steel industry is facing tough competition from imported steel, while low oil prices have depressed the oil industry, leading to lower demand for steel pipes, among other things. On the plus side, the auto industry is selling a lot of cars, which require a lot of steel, and a recovering housing market will boost demand, as well.
Nucor's problems are not likely to vanish in the near term, but they're not likely to last forever, either. In the meantime, Nucor is one of the most efficient steel companies around. It's raking in close to $20 billion annually, and has generated positive free cash flow in each year except one during the past decade.
It has also been investing in improving its operations, which positions it well for future growth. For example, it bought Skyline Steel in 2012, and has been investing in direct-reduced iron (DRI) manufacturing. With more than $1.6 billion in cash and manageable debt levels, it's ready to capitalize on other opportunities, too.
Steel is a cyclical business, meaning investors should expect lumpiness in demand, prices, and corporate fortunes. Patient believers in Nucor can collect a reliable dividend while waiting for market conditions to improve.
Cheryl Swanson With 53 incredible years of dividend increases under its belt, Johnson and Johnson is a stock I own based on a simple threefold strategy: find management you trust, find a company that rewards shareholders, and hang on.
About half of J&J's sales are overseas, so it's no surprise that the multinational's third-quarter earnings were squeezed by a stronger dollar. Still, as CEO Alex Gorsky pointed out, "new and core products drove solid underlying growth in the quarter." Looking closer, overall earnings topped expectations. Gorsky also lifted the floor on the full-year earnings outlook to $6.15 to $6.20 a share from an earlier range of $6.04 to $6.19.
The market is an irrational beast, which makes it even more appealing to find a safe haven like J&J. Since 2000, J&J has grown its dividend between a high single-digit percentage and low double-digit percentage each year, and the yield is now a strong 3.15%.
In addition, according to FactSet, the company's stock trades for a little more than 15 times forward earnings. That's below its two-year average of 16.2. Bottom line: While foreign-exchange headwinds aren't likely to ease anytime soon, a choice like J&J can lead to a secure stream of income to weather almost any storm.
: One of my favorite Aristocrats is also one of the less famous. It's HCP , incidentally one of only a handful of real estate investment trusts with Aristocratic status. HCP owns and landlords hospitals, medical offices, life science facilities, nursing homes... really, almost any kind of property associated with the healthcare sector.
Given that the massive baby-boomer generation is entering its twilight years, that's been a particularly good business of late. In the first six months of this year, HCP's revenue increased by 14%, while adjusted funds from operations -- a key profitability metric for REITs -- rose 6%. And HCP keeps adding income-generating properties to its portfolio, to the point where total assets under management recently reached more than $24 billion.
Meanwhile, the stock is a bargain these days. It has fallen by 13% so far this year, due in no small part to concerns about an expected interest rate hike from the Fed (which, theoretically, squeezes profitability because it makes a REIT's funding sources more expensive). But if any REIT can outpace pricier funding with organic growth, it's this one. Besides, that weakened price has strengthened the dividend yield; it now stands at a beefy 5.9%.
Sean Williams : If you're looking for a Dividend Aristocrat with a rich payout history and the wherewithal to survive even the bleakest of recessions, then I'd suggest turning your attention to supplemental health and life insurance provider Aflac .
One recent hindrance, which should soon translate into a benefit, is historically low lending rates in the United States. Insurers have pools of money that they use to pay claims and their day-to-day operations, which is called their float. But their float doesn't just sit around in a vault collecting dust. Insurers like Aflac invest their float in short-term fixed-income instruments such as U.S. Treasury bonds. These tools are interest sensitive, and when the Federal Reserve decides to hike lending rates, it should translate into more investment income for insurers of all walks.
Another important point is that Aflac generates about three-quarters of its business from Japan, and the remainder from the United States. The vast majority of its Japanese business is reported in yen, but is translated back into U.S. dollars. In the second quarter, the average yen/dollar exchange rate was 15.7% lower than last year. This does have a negative impact on Aflac's top- and bottom-lines; but investors need to understand that currency fluctuations are beyond the control of the company. Looking at things on an apples-to-apples basis, Aflac's year-over-year EPS declined a more reasonable 1% compared to the 10% top-line figure inclusive of the currency move.
Additionally, Insurers always have superior pricing power in their back pockets. If there's a catastrophe, insurers have all the recourse needed to raise premiums in order to ensure they have adequate capital to pay affected members. However, even in low-claim periods, insurers can still bump insurance rates higher as a way of staying ahead of the curve for when the next catastrophe strikes.
Sporting a market-topping 2.6% yield, a very modest payout ratio of 26% (implying plenty of dividend expansion potential), and riding a 32-year streak of annual dividend increases, I certainly wouldn't call you "quackers" for digging deeper into Aflac.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article 5 Dividend Aristocrats You Can Buy Now originally appeared on Fool.com.
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie's megablockbuster drug Humira, which treats a variety of diseases including arthritis, continue to add billions to the company's top line, and is driving much of the revenue growth, which was up an impressive 19.4% in the most-recent quarter when you look at its operations (which ignore currency movements). Here's what they had to say: Brian Feroldi : The dividend aristocrat that I like most right now is pharma giant Abbvie . AbbVie also has several other drugs that are growing quickly, as well as its cancer treatment Imbruvica, Hepatits C treatment Viekira Pak, and digestive health medication Creon. | Here's what they had to say: Brian Feroldi : The dividend aristocrat that I like most right now is pharma giant Abbvie . AbbVie's megablockbuster drug Humira, which treats a variety of diseases including arthritis, continue to add billions to the company's top line, and is driving much of the revenue growth, which was up an impressive 19.4% in the most-recent quarter when you look at its operations (which ignore currency movements). AbbVie also has several other drugs that are growing quickly, as well as its cancer treatment Imbruvica, Hepatits C treatment Viekira Pak, and digestive health medication Creon. | Here's what they had to say: Brian Feroldi : The dividend aristocrat that I like most right now is pharma giant Abbvie . AbbVie's megablockbuster drug Humira, which treats a variety of diseases including arthritis, continue to add billions to the company's top line, and is driving much of the revenue growth, which was up an impressive 19.4% in the most-recent quarter when you look at its operations (which ignore currency movements). AbbVie also has several other drugs that are growing quickly, as well as its cancer treatment Imbruvica, Hepatits C treatment Viekira Pak, and digestive health medication Creon. | I consider AbbVie to be a solid choice for investors who want to add some yield to their portfolios. Here's what they had to say: Brian Feroldi : The dividend aristocrat that I like most right now is pharma giant Abbvie . AbbVie's megablockbuster drug Humira, which treats a variety of diseases including arthritis, continue to add billions to the company's top line, and is driving much of the revenue growth, which was up an impressive 19.4% in the most-recent quarter when you look at its operations (which ignore currency movements). |
26807.0 | 2015-10-19 00:00:00 UTC | Is Immortality Achievable? AbbVie and Alphabet Seem to Think So | ABBV | https://www.nasdaq.com/articles/immortality-achievable-abbvie-and-alphabet-seem-think-so-2015-10-19 | nan | nan | Ever since the dawn of humanity, we have dreamed of one day overcoming death. And if AbbVie and Calico have their way, this dream may soon be realized.
Source: picserver.org.
On Sept. 18, 2013, Calico, which has since been renamed Alphabet , formed the life science company Calico, initially committing $240 million to this endeavor, but later tacking on an additional $490 million on an as-needed basis. The interesting part is that Calico's stated mission is to understand the biology that controls lifespan. In plain English, Calico's intentions are to cure the underlying causes of aging and aging-related diseases such as cancer and neuro-degeneration.
While that may sound ambitious, to say the least, Calico was able to convince the Illinois-based biopharma AbbVie to join in the effort to unravel the biology of aging, and even commit $750 million to Calico's coffers.
AbbVie and Calico's bold life sciences joint venture is anything but a pipe dream, however. In fact, our understanding of the biology of aging has advanced by leaps and bounds during the last decade, suggesting that game-changing new therapies may indeed be on their way. With this in mind, let's take a deeper dive into the science these two giant companies are hoping to harness in their quest to perhaps make humans immortal -- or, at the very least, significantly extend our lifespans.
Why aging and death might be curable
Cells that can continually divide are essentially immortal -- from lowly protozoans and bacteria to the stem cells of multicellular organisms, such as humans. Death is, therefore, only a prerequisite in so-called terminally differentiated cells, or cells that have transformed into a specific tissue type, such as cardiovascular or neural tissue.
Source: pingnews.com.
The reason is straightforward enough. Every single day, your cells accumulate mutations in their DNA structure due to normal metabolic processes, as well as environmental contaminants. If these cells aren't purged after a certain time period, they may form tumors that could be life-threatening to the organism as a whole.
In fact, this issue is the basis of many forms of cancer. After all, mutated cells that are able to escape immune detection and also fail to undergo what's known as programmed cell death are the main culprits behind tumor formation. Viewed this way, cell death can be seen as nothing more than a critical regulatory function. But that's where the most compelling opportunity for medical intervention lies.
What companies like Calico are attempting to do is to intervene at the cellular level to enhance DNA repair mechanisms. If your cells don't harbor any harmful mutations after all, there's little reason for them to be replaced. Although the details are murky, at best, what Calico's researchers might be doing is first looking into ways to regulate DNA repair in vivo , and then developing ways to shut down the process of programmed cell death in terminally differentiated tissues.
Another potential route would be to use naturally-occurring genetic mutations known to be linked with an increased lifespan in some human families to inform the search on how to artificially manipulate the process of aging. Needless to say, though, we are just starting down this long road -- but the prospects are certainly intriguing, regardless of the exact methodology involved.
Is Alphabet about to produce a disruptive new therapy that can benefit investors?
Curing death, or substantially slowing the aging process, would undoubtedly be a major leap forward in medical science. Any such technology would obviously have eye-popping commercial potential that may even be transformative for large-cap companies such as AbbVie and Alphabet.
Having said that, investors need to understand that such a herculean undertaking is likely to occur over several decades, not a few months or even years. Along the way, AbbVie and Calico probably believe this joint venture will produce at least some approved therapies to justify their largish initial investments, but a quantum leap in our understanding of aging doesn't appear to be imminent. And that's the main reason why investors shouldn't be holding their breaths for a Calico IPO anytime soon.
The most important takeaway from this Sci-Fi-like joint venture between two of the biggest names in biopharma and technology is perhaps that the journey toward greatly expanding the human lifespan has finally begun in earnest.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article Is Immortality Achievable? AbbVie and Alphabet Seem to Think So originally appeared on Fool.com.
George Budwell owns shares of AbbVie. The Motley Fool owns shares of and recommends Alphabet (C shares). Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Along the way, AbbVie and Calico probably believe this joint venture will produce at least some approved therapies to justify their largish initial investments, but a quantum leap in our understanding of aging doesn't appear to be imminent. And if AbbVie and Calico have their way, this dream may soon be realized. While that may sound ambitious, to say the least, Calico was able to convince the Illinois-based biopharma AbbVie to join in the effort to unravel the biology of aging, and even commit $750 million to Calico's coffers. | AbbVie and Calico's bold life sciences joint venture is anything but a pipe dream, however. And if AbbVie and Calico have their way, this dream may soon be realized. While that may sound ambitious, to say the least, Calico was able to convince the Illinois-based biopharma AbbVie to join in the effort to unravel the biology of aging, and even commit $750 million to Calico's coffers. | Along the way, AbbVie and Calico probably believe this joint venture will produce at least some approved therapies to justify their largish initial investments, but a quantum leap in our understanding of aging doesn't appear to be imminent. And if AbbVie and Calico have their way, this dream may soon be realized. While that may sound ambitious, to say the least, Calico was able to convince the Illinois-based biopharma AbbVie to join in the effort to unravel the biology of aging, and even commit $750 million to Calico's coffers. | And if AbbVie and Calico have their way, this dream may soon be realized. AbbVie and Calico's bold life sciences joint venture is anything but a pipe dream, however. While that may sound ambitious, to say the least, Calico was able to convince the Illinois-based biopharma AbbVie to join in the effort to unravel the biology of aging, and even commit $750 million to Calico's coffers. |
26808.0 | 2015-10-16 00:00:00 UTC | The Zacks Analyst Blog Highlights: Alphabet, General Motors, Ford Motor and AbbVie | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-alphabet-general-motors-ford-motor-and-abbvie-2015-10 | nan | nan | For Immediate Release
Chicago, IL - October 16, 2015 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Alphabet ( GOOGL ), General Motors Company ( GM ), Ford Motor ( F ) and AbbVie ( ABBV ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .
Here are highlights from Thursday's Analyst Blog:
5 World-Changing Products Google Is Working on Right Now
For most of us, the Alphabet is still a set of letters (consonants and vowels) that help us pronounce all that we need to. But Google, which reorganized itself under a holding company with that same name, is here to tell us that each letter can do a whole lot more.
So Alphabet's ( GOOGL ) most illustrious letter component is " G " because it stands for Google, or gateway if you like, because of the company's propensity to push accepted frontiers, explore new realms and "boldly go where no man has gone before."
Google brought the web to us and saw to its proliferation. But it's not stopping there. True to its philosophy of exploring the universe and routing it back to us, the company is moving into other areas like automotive, healthcare, high-speed Internet, smart home and improved city life.
Is Automotive the "A" of Alphabet?
Alphabet appears to have two goals in auto. The first with respect to its smart dashboard that allows u to listen to music, get navigation and other pointers to smoothen out your rough days.
The second and more intriguing is its self-driving automobile because heaven only knows what it plans to do with the thing! Will it have a fleet to transport packages or deliver food? Will it run a taxi service? Or will it manufacture and sell them just like General Motors Company ( GM ) and Ford Motor ( F )? Google isn't planning a launch before 2020, so I guess we'll find out soon enough.
Meanwhile the project has accumulated some notable talent: former General Motors, Hyundai and TrueCar executive John Krafcik who is now CEO. A wise choice considering that he has the knowledge, experience (from manufacturing to sales) and contacts that could move the needle for Google. Former Ford and Boeing CEO Alan Mulally is also a member of the board and former GM R&D head Lawrence Burns is now a consultant for Google Auto.
Alphabet has been testing its self driving cars over the past few years and recently started testing on public roads as well. Its USP is safety because it's currently thought that automated driving will greatly reduce accidents arising from driver distractions.
A Toast to Your Heath
Google's Healthcare initiative is actually two.
The first is the majority investment in a company called C alico, which is determined to find cures for age-related diseases, extend life expectancy and, wait for it, "solve cancer." It's headed by former Genentech CEO Arthur Levinson. The company is not about revenue or profits yet and depends instead on investments from folks like Alphabet and AbbVie ( ABBV ) to develop drugs and do research.
Alphabet has acquired an interest in 23andMe, which maintains a fast-growing genomics database. In July this year, it partnered with AncestryDNA of Ancestry.com, which is one of the largest family research organizations with a database of over a million people and family trees going back hundreds of years. This can greatly help Calico research the role of genes in aging and develop suitable drugs. Calico also has drug development and research agreements with the University of Texas Southwestern Medical Centerand the Buck Institute for Research on Aging.
When Google announced its reorganization as Alphabet, the first new company that emerged was L ife Sciences. And it's not without reason because this former Google X project has advanced quite a bit. Its mission is to help us with the detection, prevention and management of serious health conditions.
It has already developed a contact lens to detect diabetes from teardrops that will go into clinical trials next year. It has also partnered with Sanofi for further diabetics research and medical equipment company Dexcom to develop a cheap and convenient glucose monitoring device. A patneship with Novartis was intended to develop and license smart lens technology.
With its purchase of Lift Labs, it now has a smart spoon for patients with hand tremors (as in Parkinson's disease). A nano particles pill for early detection of cancer or heart disease is in the works and research on mental illness (new approach to detection, discovery, study, understanding treatment, etc.) has been initiated.
And if all this isn't enough, it is also collaborating with the Institute for Systems Biology (ISB) to create the Cancer Genomics Cloud. So a perfect blend of technology, biotech and pharma (and it is hiring accordingly).
The Internet Is Never Far from Mind
Alphabet's Project Loon is a fleet of helium-filled balloons flying 20km above the earth where wind direction and speed are stratified. Software algorithms determine optimal position for the balloons and move them there to create a network that can beam Internet services. The life of a balloon is currently between 3 and 6 months, before which it needs to be replaced.
While the project was initially experimental with remote areas in mind, Alphabet has aroused the interest of the Sri Lankan government, which has signed an MoU for large-scale deployment covering the country. African countries are also showing interest. Data speeds have also improved considerably since inception indicating increased commercial viability.
Alphabet has registered two patents with the FAA for drones forming a part of Project Titan with the goal of expanding Project Loon with higher-altitude balloons.
The company will be selling the balloons to telecoms as an infrastructure provider and won't be involved in customer relationships.
And let's not forget Google Fiber, which offers broadband Internet and cable TV to a growing number of locations across the U.S.
Alphabet Building a Nest Too
Depleting natural resources and global warming are growing concerns today so there is an ongoing move to make usage more efficient. There are perhaps few companies that are as aware of this challenge as Google considering the amount it consumes to run and cool its huge data centers.
But through its purchase of a smart thermostat maker called Nest in 2014, Google decided to bring these efficiencies to us as well. Nest is neither the first nor the only supplier in the market, but there are a few reasons why Google can have a more far-reaching effect on the market than perhaps some of the others.
The company came to Google with a Learning Thermostat and a smoke and carbon monoxide detector called Protect. Google said at the time that Nest would mark its entry into the smart home segment, continuing to create more devices that would be increasingly "useful, intuitive and thoughtful." Google hasn't been great at making devices, but Nest does bring some design expertise.
Its devices are simple to set up and use (free apps for both iOS and Android, Heat Link attachment comes with built-in Wifi to directly connect to the Internet) and good to look at, things that can encourage big utility companies to distribute them for free (as Southern Co is doing) or offer huge discounts to encourage usage (as Exelon division ComEd is doing).
ComEd in fact has set a target of selling a million devices in Chicago and Northern Illinois based on its up to $120 subsidy on the $249 Nest or Ecobee smart thermostats that are part of the program. Utility companies are interested in these devices because of the strain on their grids during peak hours or busy days, which increase wear and tear and therefore maintenance costs.
Google has held the company for little over a year and already big things are starting to happen; doesn't matter if Apple doesn't want to sell the things any more. Nest continues to launch new devices such as the security camera through its DropCam acquisition. Nest Weave and the Works With Nest developer program are working on how to get your smart home devices to talk to each other (we're talking lights, locks, fridges, et al).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today . Find out What is happening in the stock market today on zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ALPHABET INC-A (GOOGL): Free Stock Analysis Report
GENERAL MOTORS (GM): Free Stock Analysis Report
FORD MOTOR CO (F): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include the Alphabet ( GOOGL ), General Motors Company ( GM ), Ford Motor ( F ) and AbbVie ( ABBV ). The company is not about revenue or profits yet and depends instead on investments from folks like Alphabet and AbbVie ( ABBV ) to develop drugs and do research. Click to get this free report ALPHABET INC-A (GOOGL): Free Stock Analysis Report GENERAL MOTORS (GM): Free Stock Analysis Report FORD MOTOR CO (F): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include the Alphabet ( GOOGL ), General Motors Company ( GM ), Ford Motor ( F ) and AbbVie ( ABBV ). Click to get this free report ALPHABET INC-A (GOOGL): Free Stock Analysis Report GENERAL MOTORS (GM): Free Stock Analysis Report FORD MOTOR CO (F): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. The company is not about revenue or profits yet and depends instead on investments from folks like Alphabet and AbbVie ( ABBV ) to develop drugs and do research. | Stocks recently featured in the blog include the Alphabet ( GOOGL ), General Motors Company ( GM ), Ford Motor ( F ) and AbbVie ( ABBV ). Click to get this free report ALPHABET INC-A (GOOGL): Free Stock Analysis Report GENERAL MOTORS (GM): Free Stock Analysis Report FORD MOTOR CO (F): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. The company is not about revenue or profits yet and depends instead on investments from folks like Alphabet and AbbVie ( ABBV ) to develop drugs and do research. | Stocks recently featured in the blog include the Alphabet ( GOOGL ), General Motors Company ( GM ), Ford Motor ( F ) and AbbVie ( ABBV ). The company is not about revenue or profits yet and depends instead on investments from folks like Alphabet and AbbVie ( ABBV ) to develop drugs and do research. Click to get this free report ALPHABET INC-A (GOOGL): Free Stock Analysis Report GENERAL MOTORS (GM): Free Stock Analysis Report FORD MOTOR CO (F): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. |
26809.0 | 2015-10-16 00:00:00 UTC | Bristol-Myers' (BMY) Daklinza Gets NICE Recommendation | ABBV | https://www.nasdaq.com/articles/bristol-myers-bmy-daklinza-gets-nice-recommendation-2015-10-16 | nan | nan | Bristol-Myers SquibbBMY announced that the National Institute for Health and Care Excellence (NICE) has recommended Daklinza in England and Wales for the treatment of adults suffering from chronic hepatitis C virus (HCV) infection.
In the EU, Daklinza is approved for use in combination with Gilead Sciences' GILD Solvaldi (sofosbuvir) for treating adults with chronic HCV genotypes 1, 2, 3 and 4 infection. Daklinza is also approved in the U.S. in combination with Solvaldi for the treatment of patients with chronic HCV genotype 3 infection.
Bristol-Myers is looking to expand the Daklinza-Solvaldi label. Earlier this month, Bristol-Myers announced that three of its supplemental New Drug Applications (sNDAs) seeking label expansion for Daklinza will be reviewed on a priority basis by the FDA. The three sNDAs are for the treatment of patients with chronic HCV coinfected with human immunodeficiency virus (HIV-1), patients with advanced cirrhosis (including decompensated cirrhosis), and for patients with post-liver transplant recurrence of HCV.
The combination regimen was granted Breakthrough Therapy designation by the FDA for HCV genotype 1 patients with advanced cirrhosis (Child-Pugh Class B or C) and those who develop genotype 1 HCV recurrence post liver transplant.
For the last couple of years, the highly lucrative HCV market has been the focus area for most big biotech companies. Pricing competition among the approved products is also intense. Gilead Sciences is a key player in the HCV market with drugs like Sovaldi and Harvoni. AbbVie Inc.'s ABBV all-oral, interferon-free therapy with/without ribavirin, Viekira Pak, is also performing well.
Bristol-Myers & Five Prime Therapeutics Collaborate
Meanwhile, Bristol-Myers has entered into an exclusive worldwide license and collaboration agreement with Five Prime Therapeutics FPRX for the development and commercialization of the latter's colony stimulating factor 1 receptor (CSF1R) antibody program, including FPA008 (phase I), for immunology and oncology indications. Five Prime shot up 65.2% on the news.
Bristol-Myers and Five Prime's earlier agreement to evaluate FPA008 in combination with Opdivo will be replaced by the new agreement.
Per the terms of the deal, Bristol-Myers will make an upfront payment of $350 million. Five Prime will also be eligible to receive upward of an estimated $1.3 billion in "development and regulatory milestone payments per anti-CSF1R product for oncology indications (including combinations with Opdivo and any other agent)."
Five Prime will receive up to $1.05 billion in development and regulatory milestone payments per anti-CSF1R product for oncology indications (including combinations with Opdivo and any other agent), and up to $340 million in development and regulatory milestone payments per anti-CSF1R product for non-oncology indications. The company will also receive double-digit royalties and an option to co-promote in the U.S.
Bristol-Myers currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector is AbbVie, carrying a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BRISTOL-MYERS (BMY): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
FIVEPRIME THERA (FPRX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc.'s ABBV all-oral, interferon-free therapy with/without ribavirin, Viekira Pak, is also performing well. A better-ranked stock in the health care sector is AbbVie, carrying a Zacks Rank #2 (Buy). Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report FIVEPRIME THERA (FPRX): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report FIVEPRIME THERA (FPRX): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.'s ABBV all-oral, interferon-free therapy with/without ribavirin, Viekira Pak, is also performing well. A better-ranked stock in the health care sector is AbbVie, carrying a Zacks Rank #2 (Buy). | Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report FIVEPRIME THERA (FPRX): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.'s ABBV all-oral, interferon-free therapy with/without ribavirin, Viekira Pak, is also performing well. A better-ranked stock in the health care sector is AbbVie, carrying a Zacks Rank #2 (Buy). | AbbVie Inc.'s ABBV all-oral, interferon-free therapy with/without ribavirin, Viekira Pak, is also performing well. A better-ranked stock in the health care sector is AbbVie, carrying a Zacks Rank #2 (Buy). Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report FIVEPRIME THERA (FPRX): Free Stock Analysis Report To read this article on Zacks.com click here. |
26810.0 | 2015-10-14 00:00:00 UTC | J&J Posts Mixed Q3 Bag: ETFs in Focus | ABBV | https://www.nasdaq.com/articles/jj-posts-mixed-q3-bag-etfs-focus-2015-10-14 | nan | nan | With the Q3 earnings season kicking off, Johnson & Johnson ( JNJ ) is the first to have reported earnings in the health care space. The world's biggest maker of health care products continued its long streak of earnings beat but revenues came in below our estimates due to currency headwinds. The company lifted its full-year outlook, reflecting confidence in its future growth.
Johnson and Johnson Q3 Results in Focus
Earnings per share came in at $1.49, a nickel above the Zacks Consensus Estimate but 7.4% below the year-ago earnings. Revenues slid 7.4% year over year to $17.1 billion and fell shy of the Zacks Consensus Estimate of $17.4 billion (read: Winning ETF Strategies for Q4 ).
Healthy sales of new drugs including Zytiga, Invokana, Imbruvica, and Xarelto and strength of established drugs such as Stelara, Concerta, Simponi, Invega Sustenna and Prezcobix offset a steep decline in sales of the hepatitis C medicine - Olysio - which has lost its competitive position in the U.S. to its rivals Gilead ( GILD ) and AbbVie ( ABBV ). Notably, Imbruvica is expected to be the blockbuster cancer drug, fetching in about one billion dollars in revenues as early as next year.
In spite of the fact that a strong U.S. dollar would remain a major drag on international revenue growth, the company raised the lower end of the earnings per share guidance range to $6.15-$6.20 from $6.10-$6.20. The new midpoint is above the current Zacks Consensus Estimate of $6.16. The diversified drug maker would also repurchase about $10 billion shares, though the period of time is unknown (see: all the Healthcare ETFs here ).
Market Impact
Based on mixed results, shares of JNJ dropped 0.6% on the day and the following healthcare ETFs with the largest allocation to this behemoth are in focus. Investors should carefully monitor the movement of these funds and grab the opportunity when it arises. This is especially true as these funds have a Zacks ETF Rank of 1 or 'Strong Buy' with a Medium risk outlook, suggesting their outperformance in the months ahead.
iShares U.S. Pharmaceuticals ETF ( IHE )
This ETF targets the pharma corner of the broad health care space and tracks the Dow Jones U.S. Select Pharmaceuticals Index. Holding 43 stocks in its basket, Johnson & Johnson occupies the top position at 10.6%. Pharma takes the largest share at 87.9% while biotech takes the remainder. The product has managed nearly $849 million in its asset base while volume is relatively light at about 62,000 shares a day on average. The fund charges 43 bps in fees per year from investors and has lost 2.3% following the JNJ earnings release.
Health Care Select Sector SPDR Fund ( XLV )
The most popular health care ETF, XLV follows the Health Care Select Sector Index. This fund manages over $13.1 billion in its asset base and trades in heavy volume of more than 11.6 million shares. Expense ratio came in at 0.14% annually. In total, the fund holds 57 securities in its basket with JNJ taking the top spot at 10.3% of the assets. Pharma accounts for 38.4% share from a sector look while biotech, health care providers and services, and equipment and supplies make up for a double-digit exposure each. The fund shed about 1.2% on the day (read: 5 Sector Favorites for Q3 Earnings & Their Hot ETFs ).
iShares U.S. Healthcare ETF ( IYH )
This fund provides exposure to 124 securities by tracking the Dow Jones U.S. Health Care Index. Here again, Johnson & Johnson dominates the fund's return at 9.6% of total assets. In terms of industrial exposure, pharma takes the top spot at 36.2%, followed by biotech (27.2%), and health care equipment (14.8%). The product has amassed nearly $1.8 billion in its asset base while charges 43 bps in annual fees. It trades in solid volume of around 330,000 shares a day and fell 1.4% post JNJ results.
Vanguard Health Care ETF ( VHT )
This ETF tracks the MSCI US Investable Market Health Care 25/50 Index and holds 342 stocks in its basket. Out of these, Johnson & Johnson takes the top spot with at 8.2% allocation. Pharma takes the largest share at 37% while biotech and health care equipment round off the top three spots. VHT is also one of the popular and liquid ETFs with AUM of $5.4 billion and average daily volume of about 348,000 shares. It charges 12 bps in annual fees and expenses. The product lost 1.3% in yesterday's trading session.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
ISHARS-US PHARM (IHE): ETF Research Reports
SPDR-HLTH CR (XLV): ETF Research Reports
ISHARS-US HLTHC (IYH): ETF Research Reports
VIPERS-HLTH CR (VHT): ETF Research Reports
To read this article on Zacks.com click here.
Zacks Investment Research
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Healthy sales of new drugs including Zytiga, Invokana, Imbruvica, and Xarelto and strength of established drugs such as Stelara, Concerta, Simponi, Invega Sustenna and Prezcobix offset a steep decline in sales of the hepatitis C medicine - Olysio - which has lost its competitive position in the U.S. to its rivals Gilead ( GILD ) and AbbVie ( ABBV ). Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ISHARS-US PHARM (IHE): ETF Research Reports SPDR-HLTH CR (XLV): ETF Research Reports ISHARS-US HLTHC (IYH): ETF Research Reports VIPERS-HLTH CR (VHT): ETF Research Reports To read this article on Zacks.com click here. The world's biggest maker of health care products continued its long streak of earnings beat but revenues came in below our estimates due to currency headwinds. | Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ISHARS-US PHARM (IHE): ETF Research Reports SPDR-HLTH CR (XLV): ETF Research Reports ISHARS-US HLTHC (IYH): ETF Research Reports VIPERS-HLTH CR (VHT): ETF Research Reports To read this article on Zacks.com click here. Healthy sales of new drugs including Zytiga, Invokana, Imbruvica, and Xarelto and strength of established drugs such as Stelara, Concerta, Simponi, Invega Sustenna and Prezcobix offset a steep decline in sales of the hepatitis C medicine - Olysio - which has lost its competitive position in the U.S. to its rivals Gilead ( GILD ) and AbbVie ( ABBV ). Health Care Select Sector SPDR Fund ( XLV ) The most popular health care ETF, XLV follows the Health Care Select Sector Index. | Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ISHARS-US PHARM (IHE): ETF Research Reports SPDR-HLTH CR (XLV): ETF Research Reports ISHARS-US HLTHC (IYH): ETF Research Reports VIPERS-HLTH CR (VHT): ETF Research Reports To read this article on Zacks.com click here. Healthy sales of new drugs including Zytiga, Invokana, Imbruvica, and Xarelto and strength of established drugs such as Stelara, Concerta, Simponi, Invega Sustenna and Prezcobix offset a steep decline in sales of the hepatitis C medicine - Olysio - which has lost its competitive position in the U.S. to its rivals Gilead ( GILD ) and AbbVie ( ABBV ). Health Care Select Sector SPDR Fund ( XLV ) The most popular health care ETF, XLV follows the Health Care Select Sector Index. | Healthy sales of new drugs including Zytiga, Invokana, Imbruvica, and Xarelto and strength of established drugs such as Stelara, Concerta, Simponi, Invega Sustenna and Prezcobix offset a steep decline in sales of the hepatitis C medicine - Olysio - which has lost its competitive position in the U.S. to its rivals Gilead ( GILD ) and AbbVie ( ABBV ). Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ISHARS-US PHARM (IHE): ETF Research Reports SPDR-HLTH CR (XLV): ETF Research Reports ISHARS-US HLTHC (IYH): ETF Research Reports VIPERS-HLTH CR (VHT): ETF Research Reports To read this article on Zacks.com click here. Johnson and Johnson Q3 Results in Focus Earnings per share came in at $1.49, a nickel above the Zacks Consensus Estimate but 7.4% below the year-ago earnings. |
26811.0 | 2015-10-14 00:00:00 UTC | Celsion (CLSN) Announces Data on Immunotherapy Candidate | ABBV | https://www.nasdaq.com/articles/celsion-clsn-announces-data-on-immunotherapy-candidate-2015-10-14 | nan | nan | Celsion CorporationCLSN announced data from a preclinical study on its immunotherapy candidate, GEN-1 IL-12, in combination with Avastin and Doxil for the treatment of ovarian cancer.
GEN-1 is Celsion's DNA-based immunotherapy. The company conducted the study to evaluate the efficacy of a combined treatment regimen that consisted of weekly administrations of GEN-1 with therapeutically relevant doses of Doxil and Avastin in a mouse model.
Results from the study showed that the combination of GEN-1 with Avastin and Doxil resulted in a 98% reduction in tumor burden when compared to the untreated control group in a SKOV3 human cell line implanted into immunocompromised (nude) mice.
Celsion is currently enrolling patients in a dose-escalating phase Ib study, OVATION, in newly diagnosed ovarian cancer patients. The trial combines GEN-1 with neo-adjuvant therapies. The aim of the trial is to ascertain a starting dose for the follow-on phase I/II study, which combines GEN-1 with Avastin and Doxil. The company plans to complete enrollment in the OVATION study in 2016. The phase I/II combination trial is expected to begin in mid-2016.
Celsion had also reported positive safety results from a phase I study on GEN-1 as monotherapy in patients with peritoneally metastasized ovarian cancer. Results from a phase Ib study in combination with PEGylated doxorubicin in patients suffering from platinum-resistant ovarian cancer were encouraging.
Meanwhile, GEN-1 also showed preclinical activity in glioblastoma multiforme (brain cancer). Consequently, Celsion plans to initiate a phase I study for this indication soon.
Immuno-oncology has been in focus of late as most leading pharmaceutical companies continue to make significant investments for the development of immuno-oncology therapies.
We note that Bristol-Myers Squibb's BMY immune-oncology drug, Opdivo, is approved for the treatment of metastatic squamous non-small cell lung cancer and unresectable or metastatic melanoma.
Celsion currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are AbbVie Inc. ABBV and Novo Nordisk A/S NVO . Both have a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BRISTOL-MYERS (BMY): Free Stock Analysis Report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
CELSION CORP (CLSN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the health care sector are AbbVie Inc. ABBV and Novo Nordisk A/S NVO . Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report CELSION CORP (CLSN): Free Stock Analysis Report To read this article on Zacks.com click here. Celsion CorporationCLSN announced data from a preclinical study on its immunotherapy candidate, GEN-1 IL-12, in combination with Avastin and Doxil for the treatment of ovarian cancer. | Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report CELSION CORP (CLSN): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are AbbVie Inc. ABBV and Novo Nordisk A/S NVO . Celsion is currently enrolling patients in a dose-escalating phase Ib study, OVATION, in newly diagnosed ovarian cancer patients. | Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report CELSION CORP (CLSN): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are AbbVie Inc. ABBV and Novo Nordisk A/S NVO . Celsion CorporationCLSN announced data from a preclinical study on its immunotherapy candidate, GEN-1 IL-12, in combination with Avastin and Doxil for the treatment of ovarian cancer. | Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report CELSION CORP (CLSN): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are AbbVie Inc. ABBV and Novo Nordisk A/S NVO . Celsion CorporationCLSN announced data from a preclinical study on its immunotherapy candidate, GEN-1 IL-12, in combination with Avastin and Doxil for the treatment of ovarian cancer. |
26812.0 | 2015-10-14 00:00:00 UTC | Abbott Labs Releases Data on Dissolving Heart Stent Absorb | ABBV | https://www.nasdaq.com/articles/abbott-labs-releases-data-on-dissolving-heart-stent-absorb-2015-10-14 | nan | nan | Investors in the pharma/biotech sector eagerly wait for pipeline updates as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give an insight on the commercial potential of the candidate once it is successfully developed and commercialized.
Abbott LaboratoriesABT has announced results from the phase III trial, ABSORB, on drug-eluting coronary bioresorbable vascular scaffold, Absorb, at the end of one year.
The trial compared the safety and effectiveness of Absorb to metallic drug eluting stent, Xience, in about 2,000 patients suffering from coronary artery disease. Absorb is a fully dissolving heart stent.
The trial met its primary endpoint. Results from the trial showed that target lesion failure (TLF) was 7.8% for Absorb versus 6.1% for Xience. However, pre-specified secondary endpoint results were not statistically different and there was no statistically significant difference in the rate of definite and/or probable stent thrombosis.
Results from the trial will be used to support the regulatory approval of Absorb in the U.S.
These data were presented during a late-breaking session at the 27th Transcatheter Cardiovascular Therapeutics (TCT).
Abbott Labs also presented results from another randomized, single-blinded, controlled trial that compared Absorb to Xience at TCT. This trial, ABSORB China, was conducted to support Absorb's approval in China. The trial was conducted in China.
The trial met its primary endpoint of in-segment late loss at one year as Absorb proved its non-inferiority to Xience.
We note that Abbott Labs has completed regulatory submissions for the approval of Absorb in both the U.S. and Japan. These markets along with China represent more than 50% of the world's coronary stent market and hence hold immense scope for growth upon approval.
Meanwhile, Abbott Labs has also received approval for Absorb GT1 in Europe, an improved version of the Absorb stent system that improves the ease of use.
A potential approval of Absorb in the U.S. and China will boost the vascular segment significantly.
However, Abbott Labs expects currency to have a greater-than-expected negative impact on 2015 total sales, which remains a concern.
Abbott Labs currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the healthcare sector include AbbVie Inc. ABBV , Sanofi SNY and Novo Nordisk NVO . All three carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the healthcare sector include AbbVie Inc. ABBV , Sanofi SNY and Novo Nordisk NVO . Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Investors in the pharma/biotech sector eagerly wait for pipeline updates as they play an important role in deciding whether or not to invest in a particular company. | Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the healthcare sector include AbbVie Inc. ABBV , Sanofi SNY and Novo Nordisk NVO . This trial, ABSORB China, was conducted to support Absorb's approval in China. | Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the healthcare sector include AbbVie Inc. ABBV , Sanofi SNY and Novo Nordisk NVO . This trial, ABSORB China, was conducted to support Absorb's approval in China. | Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the healthcare sector include AbbVie Inc. ABBV , Sanofi SNY and Novo Nordisk NVO . Results from the trial will be used to support the regulatory approval of Absorb in the U.S. |
26813.0 | 2015-10-13 00:00:00 UTC | These Big Pharma Companies Are in Need of an Acquisition | ABBV | https://www.nasdaq.com/articles/these-big-pharma-companies-are-need-acquisition-2015-10-13 | nan | nan | Source: Flickr user Nguyen Hung Vu.
Although we're officially over the "patent cliff" -- the multiple year period when dozens of innovator drugs came off patent and were exposed to generic competition -- Big Pharma is far from out of the woods when it comes to long-term growth prospects. Many Big Pharma names are still dealing with languishing established drug sales, or are facing the prospect of ongoing patent losses (but perhaps not of the magnitude that we witnessed within the past couple of years).
Some Big Pharma names have the pipeline to look past potential patent woes and keep growing. One prime example is Johnson & Johnson , which announced earlier this year that it believed it could bring 10 new molecular entities to market by 2020 with the potential to produce $1 billion-plus in sales. Even with the prospect of rheumatoid arthritis blockbuster Remicade losing patent protection within the next couple of years, J&J's long-term growth prospects look strong.
However, other Big Pharma names don't appear to have as strong a long-term growth outlook following the patent cliff. Without making acquisitions, some could, plainly put, struggle to grow.
Here are two Big Pharma names that could be in need of acquisitions to drive growth in the coming decade.
Source: AstraZeneca.
AstraZeneca
Among Big Pharmas with the most uncertain of futures, AstraZeneca has to rank toward the top of the list.
AstraZeneca is pretty much the only Big Pharma company with sales that are expected to contract over the coming five-year period according to Wall Street estimates. The culprit has been generic competition to blockbusters Nexium, a heartburn/acid reflux therapy, and Seroquel, a treatment for schizophrenia, to name a few. Its drop in sales has been somewhat offset with strength in diabetes sales. Needless to say, AstraZeneca is adrift without a sail or paddles at the moment, and it could certainly benefit from an earnings-accretive acquisition or merger.
What might make sense for AstraZeneca? Keeping in mind this is purely hypothetical , an acquisition to consider is Baxalta , the recently spun-off biopharma wing of Baxter International . Baxalta's therapeutic focus on oncology, immunology, and hematology would line up pretty nicely with Astra's therapeutic areas of focus (specifically oncology and immunology). While a buyout wouldn't come cheap, Baxalta would add more than $6 billion in top-line sales for AstraZeneca, should be immediately accretive to EPS, and could result in substantial synergy savings.
The other option is for AstraZeneca and GlaxoSmithKline , which is also struggling, to consider a tie-up. Glaxo's respiratory portfolio and vaccines could possibly complement Astra's high-growth oncology and diabetes focus. However, with Glaxo selling off its oncology segment to Novartis earlier this year, the idea of these two companies combining now just doesn't seem as plausible as it did before Glaxo and Novartis' asset swap was announced.
Source: Pfizer.
Pfizer
An acquisition is almost a certainty for Pfizer. With each quarterly conference call CEO Ian Read and his management team remind investors that M&A activity is critical to the company's future growth prospects. The only true unknown is the size of any future acquisition, although Pfizer is more than likely only going to make needle-moving purchases.
Pfizer has been weighed down by the loss of patents on cholesterol-lowering drug Lipitor, still the best-selling drug of all-time, and Celebrex, an arthritis drug that generated about $3 billion in annual sales. Plus, Pfizer is staring down the eventual loss of exclusivity on nerve-pain drug Lyrica, its second best-selling drug at the moment, within the next couple of years. Helping to offset some of these declines is Ibrance, an oncology drug designed to treat a certain type of breast cancer that could generate $3 billion to $5 billion in peak annual sales.
What company might be on Pfizer's radar (again, hypothetically speaking)? GlaxoSmithKline might make sense given that Pfizer and Glaxo are two global leaders in vaccine development. Additionally, Glaxo's respiratory portfolio could nicely complement Pfizer's cardiovascular and metabolic disease products. Plus, buying U.K.-based Glaxo could allow Pfizer to move its headquarters overseas to a lower corporate tax environment, resulting in substantial cost savings. What could stop this possible deal from materializing is that Glaxo's next-generation COPD and asthma therapies haven't sold as well as expected.
A wildcard idea that could be worth back-of-the-mind consideration is Isis Pharmaceuticals . Isis Pharmaceuticals and its antisense drug development platform would be a long-tail growth play (which could upset antsy Pfizer shareholders), but it has 30 ongoing clinical studies in many overlapping therapeutic fields with Pfizer, such as oncology, inflammation (where the two have partnered for EXC-001 as a treatment for scarring), cardiovascular, and metabolic diseases. The question mark here is whether Isis' multiple other partnerships could turn off a suitor like Pfizer.
Caveat emptor
M&A activity has been shown to drive stock prices and growth prospects higher in the healthcare sector, but it also comes with two words of caution: caveat emptor, or buyer beware. If a company overpays or overreaches for a rival, it could render the benefits of the purchase moot.
Source: Johnson & Johnson.
Although it remains to be seen if it was a good buy or not, AbbVie 's acquisition of Pharmacyclics for $21 billion, or $261.25 per share, could be viewed as a major stretch.
The allure of the deal for AbbVie, other than diversifying its pipeline beyond its reliance on Humira, was to get its hands on blood cancer drug Imbruvica. Imbruvica offered impressive response rates in mantle cell lymphoma and chronic lymphocytic leukemia, and label expansion opportunities could see it producing up to $7 billion per year in sales.
However, Pharmacyclics shares its Imbruvica revenue and profits with Johnson & Johnson, meaning AbbVie doesn't have Imbruvica all to itself. It may also take another seven to 10 years before Imbruvica realizes its full potential. Unless Pharmacyclics' pipeline unearths a few more oncology gems, then AbbVie and its shareholders may regret the purchase of Pharmacyclics.
Long story short, M&A can indeed be a good thing, but you as the investor have to be diligent in analyzing whether a deal really makes sense.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article These Big Pharma Companies Are in Need of an Acquisition originally appeared on Fool.com.
Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen nameTMFUltraLong, track every pick he makes under the screen nameTrackUltraLong, and check him out on Twitter, where he goes by the handle@TMFUltraLong.The Motley Fool recommends Baxter International, Isis Pharmaceuticals, and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Although it remains to be seen if it was a good buy or not, AbbVie 's acquisition of Pharmacyclics for $21 billion, or $261.25 per share, could be viewed as a major stretch. The allure of the deal for AbbVie, other than diversifying its pipeline beyond its reliance on Humira, was to get its hands on blood cancer drug Imbruvica. However, Pharmacyclics shares its Imbruvica revenue and profits with Johnson & Johnson, meaning AbbVie doesn't have Imbruvica all to itself. | Although it remains to be seen if it was a good buy or not, AbbVie 's acquisition of Pharmacyclics for $21 billion, or $261.25 per share, could be viewed as a major stretch. The allure of the deal for AbbVie, other than diversifying its pipeline beyond its reliance on Humira, was to get its hands on blood cancer drug Imbruvica. However, Pharmacyclics shares its Imbruvica revenue and profits with Johnson & Johnson, meaning AbbVie doesn't have Imbruvica all to itself. | Although it remains to be seen if it was a good buy or not, AbbVie 's acquisition of Pharmacyclics for $21 billion, or $261.25 per share, could be viewed as a major stretch. The allure of the deal for AbbVie, other than diversifying its pipeline beyond its reliance on Humira, was to get its hands on blood cancer drug Imbruvica. However, Pharmacyclics shares its Imbruvica revenue and profits with Johnson & Johnson, meaning AbbVie doesn't have Imbruvica all to itself. | Although it remains to be seen if it was a good buy or not, AbbVie 's acquisition of Pharmacyclics for $21 billion, or $261.25 per share, could be viewed as a major stretch. The allure of the deal for AbbVie, other than diversifying its pipeline beyond its reliance on Humira, was to get its hands on blood cancer drug Imbruvica. However, Pharmacyclics shares its Imbruvica revenue and profits with Johnson & Johnson, meaning AbbVie doesn't have Imbruvica all to itself. |
26814.0 | 2015-10-13 00:00:00 UTC | J&J's Results Mixed with Q3 Earnings Beat, Revenue Miss | ABBV | https://www.nasdaq.com/articles/jjs-results-mixed-q3-earnings-beat-revenue-miss-2015-10-13 | nan | nan | Johnson & JohnsonJNJ , the first among the large health care companies to report third quarter 2015 results, beat earnings expectations yet again. The company's third-quarter 2015 earnings were $1.49 per share, beating the Zacks Consensus Estimate of $1.44 per share but down 7.5% from the year-ago period.
Johnson & Johnson - Earnings Surprise | FindTheBest
Third quarter sales of $17.1 billion lagged the Zacks Consensus Estimate of $17.4 billion, and declined 7.4% from the year-ago period.
While operational results increased 0.8%, currency fluctuations had a negative impact of 8.2%.
Including one-time items, Johnson & Johnson reported third quarter earnings of $1.20 per share, down 27.7% from the year-ago period.
Currency Hits Revenues
Third quarter sales decreased 0.6% in the domestic market. Meanwhile, international sales declined 13.7%, consisting of 2.1% operational growth and 15.8% negative currency impact.
Pharmaceutical segment sales declined 7.4% year-over-year to $7.7 billion (operational decline of 0.3%). Sales in the domestic market decreased 4.5% to $4.5 billion, whereas international sales declined 11.1% to $3.2 billion.
New products like Stelara, Xarelto and Invega Sustenna continued to perform well. Other growth drivers include Invokana/Invokamet, Imbruvica and Simponi. Third quarter Zytiga sales were $548 million, down 3.5% year-over-year.
However, hepatitis C virus (HCV) treatment Olysio continued to feel the impact of additional competition with sales declining 90.1% from the year-ago quarter.
The Medical Devices segment posted sales of $6.1 billion, down 7.3% from the year-ago period comprising an operational increase of 0.9% and negative currency movement of 8.2%.
Sales in the domestic market grew 2.0% year-over year to $3 billion; international market sales fell 14.8% year-over-year to $3.1 billion.
Several medical devices markets have been facing challenges in the form of austerity measures, pricing pressure and a slowdown in elective surgeries, which have all contributed to more tempered growth rates.
The Consumer segment recorded revenues of $3.3 billion in the reported quarter, down 7.7% from the third quarter of 2014. Foreign currency movement negatively impacted sales in the segment by 10.8%. Sales in the domestic market increased 8.9% year-over-year to $1.3 billion.
Meanwhile, the international segment recorded a decline of 15.7% with currency having a negative impact of 16.1%. OTC sales increased 22.4% in the U.S. with key products being re-launched. Johnson & Johnson has been working on ensuring reliable and consistent supply of products. OTC products like Zyrtec allergy medications and Tylenol and Motrin analgesics, international feminine protection products, Aveeno, Neutrogena and Listerine oral care products performed well.
2015 Guidance
J&J raised its earnings outlook for 2015 to $6.15 - $6.20 per share (guidance provided with second quarter results: $6.10 - $6.20 per share). The Zacks Consensus Estimate currently stands at $6.16 per share.
The company also announced a share buyback program worth up to $10 billion.
Our Take
Although Johnson & Johnson's third quarter earnings were better-than-expected, all the segments including the usually outperforming Pharmaceutical segment recorded a decline in revenues and total revenues fell short of expectations. Moreover, HCV treatment, Olysio, continued to put in a disappointing performance in the face of increased competition. Zytiga also recorded a decline in sales. Meanwhile, Remicade is facing biosimilar competition in major EU markets. However, the company raised its earnings outlook with third quarter results.
Johnson & Johnson is a Zacks Rank #3 (Hold) stock. Some better-ranked health care stocks include AstraZeneca plc AZN , AbbVie Inc. ABBV and Sanofi SNY . While AstraZeneca is a Zacks Rank #1 (Strong Buy) stock, AbbVie and Sanofi are Zacks Rank #2 (Buy) stocks.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
ASTRAZENECA PLC (AZN): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked health care stocks include AstraZeneca plc AZN , AbbVie Inc. ABBV and Sanofi SNY . While AstraZeneca is a Zacks Rank #1 (Strong Buy) stock, AbbVie and Sanofi are Zacks Rank #2 (Buy) stocks. Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. | Some better-ranked health care stocks include AstraZeneca plc AZN , AbbVie Inc. ABBV and Sanofi SNY . While AstraZeneca is a Zacks Rank #1 (Strong Buy) stock, AbbVie and Sanofi are Zacks Rank #2 (Buy) stocks. Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked health care stocks include AstraZeneca plc AZN , AbbVie Inc. ABBV and Sanofi SNY . While AstraZeneca is a Zacks Rank #1 (Strong Buy) stock, AbbVie and Sanofi are Zacks Rank #2 (Buy) stocks. | Some better-ranked health care stocks include AstraZeneca plc AZN , AbbVie Inc. ABBV and Sanofi SNY . While AstraZeneca is a Zacks Rank #1 (Strong Buy) stock, AbbVie and Sanofi are Zacks Rank #2 (Buy) stocks. Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. |
26815.0 | 2015-10-13 00:00:00 UTC | Want Lower Drug Prices? These 3 Proposals Won't Help You! | ABBV | https://www.nasdaq.com/articles/want-lower-drug-prices-these-3-proposals-wont-help-you-2015-10-13 | nan | nan | Image source: Stockmonkeys.com .
Shares of drug companies have been sinking over the last few weeks as drug pricing has blown up in the media, and politicians have latched on. Lowering drug prices is a hot-bed topic with voters. Don't be surprised if you hear more about it on tonight's Democratic presidential candidate debate.
Unfortunately for consumers -- and fortunately for drugmakers and their investors -- none of these proposals will actually do much to lower drug prices.
Proposal 1: Import drugs from overseas
Most brand-name drugs are cheaper overseas. If we just allow patients to buy drugs in foreign countries and bring them into the U.S., they'll save money. In many cases, the drugs were manufactured in the same plant where the drugs sold in the U.S. were made, and there are plenty of countries with high enough manufacturing standards that we shouldn't be worried.
Why it won't work: Drugmakers don't actually want to charge less in other countries. They're forced to by the governments and figure that some revenue is better than no revenue at all. If widespread importation into the U.S. started, drugmakers would simply limit the supply that could go to foreign countries, and the countries would subsequently limit the export of the drug to ensure there was enough for their citizens.
Proposal 2: Let Medicare negotiate prices
Currently, Medicare gets the lowest price private insurers are able to negotiate, but there are so many people enrolled in Medicare that the agency should be able to get a lower price than private insurers.
Why it won't work: You only have leverage in a negotiation if you're willing to walk away. Private insurers can do that; at some price, it makes more sense to not cover a drug and lose the business from members that might actually want the drug. Foreign governments can do it because their citizens tolerate the inability to be treated with certain drugs.
Would U.S. citizens accept that they -- or their grandmother -- might not be treated by a drug prescribed by their doctor because it wasn't covered by Medicare? The opposition just needs to shout the words "death panel" in a commercial during the evening news, and the idea will get shot down.
Proposal 3: Set maximum out-of-pocket spending for drugs
Whether you're on private insurance, Medicare, or some other public insurance, the government could limit the maximum that anyone has to pay for drugs each month.
Why it won't work: While the consumer will pay less, this won't lower the revenue drugmakers get. The insurance will pay the same amount to drug companies. For public insurance, the lower out-of-pocket payments will have to be made up by raising taxes, increasing Medicare Part D payments, cutting spending elsewhere, or borrowing to increase the deficit.
Assuming private insurers don't want to give up their profits, the lost out-of-pocket expenses will be transferred to consumers in the form of higher premiums. Since insurers can no longer set prices based on preexisting conditions, healthy people will end up picking up a portion of the costs that were previously paid for by those who require large amounts of drugs.
The real threat to drug prices
In one word: competition.
Obviously, generic competition lowers drug prices dramatically, but we've also seen the price of brand-name drugs come down as additional drugs have come on the market. Asthma drugs, insulin, and more recently, hepatitis C drugs have all been forced to offer discounts as insurers pitted drugmakers against each other.
Gilead Sciences , for instance, was able to fetch a premium price for its hepatitis C drug Harvoni when it first launched because it was an all-oral therapy that allowed patients to avoid older injected drugs with horrible side effects. But once AbbVie launched its competing hepatitis C drug Viekira Pak, Gilead Sciences was forced to discount its drug substantially. This year, Gilead Sciences expects to have a gross-to-net discount of 46%, more than double the 22% it ended 2014 with.
Without competition from AbbVie, Gilead Sciences could have told insurers to "take it or leave it" with the current price, and most insurers would have been forced to accept the price. Viekira Pak is arguably inferior to Harvoni, but that doesn't really matter, because at some point, it makes more sense to pay AbbVie for an inferior product and deal with complaints from members.
What investors should look for
The threat of government intervention in drug pricing is pretty minimal, and even if Democrats and Republicans could come to some compromise, the ideas won't have much of an effect on drug pricing.
With the biggest concern being competition, investors should focus on truly innovative companies and avoid drugmakers with me-too drugs that don't offer any advantage over current treatments. Take Vertex Pharmaceuticals , for example. The drugmaker has the only two cystic fibrosis drugs -- Kalydeco and Orkambi -- approved to fix the underlying problem rather than just treat the symptoms, and it has more in clinical development. Vertex Pharmaceuticals won't be competition-free forever, but its head start, combined with the fact that different mutations that cause cystic fibrosis require different drugs, make Vertex Pharmaceuticals a good choice in a market where competition puts pressure on drug prices.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early, in-the-know investors! To be one of them, just click here .
The article Want Lower Drug Prices? These 3 Proposals Won't Help You! originally appeared on Fool.com.
Brian Orelli had a candy resale business at his elementary school with a 100% markup until he started facing competition from another kid. He has no position in any stocks mentioned. The Motley Fool recommends Vertex Pharmaceuticals and Gilead Sciences and owns shares of Gilead Sciences . Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | But once AbbVie launched its competing hepatitis C drug Viekira Pak, Gilead Sciences was forced to discount its drug substantially. Without competition from AbbVie, Gilead Sciences could have told insurers to "take it or leave it" with the current price, and most insurers would have been forced to accept the price. Viekira Pak is arguably inferior to Harvoni, but that doesn't really matter, because at some point, it makes more sense to pay AbbVie for an inferior product and deal with complaints from members. | But once AbbVie launched its competing hepatitis C drug Viekira Pak, Gilead Sciences was forced to discount its drug substantially. Without competition from AbbVie, Gilead Sciences could have told insurers to "take it or leave it" with the current price, and most insurers would have been forced to accept the price. Viekira Pak is arguably inferior to Harvoni, but that doesn't really matter, because at some point, it makes more sense to pay AbbVie for an inferior product and deal with complaints from members. | But once AbbVie launched its competing hepatitis C drug Viekira Pak, Gilead Sciences was forced to discount its drug substantially. Without competition from AbbVie, Gilead Sciences could have told insurers to "take it or leave it" with the current price, and most insurers would have been forced to accept the price. Viekira Pak is arguably inferior to Harvoni, but that doesn't really matter, because at some point, it makes more sense to pay AbbVie for an inferior product and deal with complaints from members. | Without competition from AbbVie, Gilead Sciences could have told insurers to "take it or leave it" with the current price, and most insurers would have been forced to accept the price. But once AbbVie launched its competing hepatitis C drug Viekira Pak, Gilead Sciences was forced to discount its drug substantially. Viekira Pak is arguably inferior to Harvoni, but that doesn't really matter, because at some point, it makes more sense to pay AbbVie for an inferior product and deal with complaints from members. |
26816.0 | 2015-10-13 00:00:00 UTC | Roche (RHHBY) to Buy Adheron Therapeutics for $580M | ABBV | https://www.nasdaq.com/articles/roche-rhhby-to-buy-adheron-therapeutics-for-%24580m-2015-10-13 | nan | nan | Large pharmaceutical companies are often on the lookout for small strategic acquisitions of companies that have a promising pipeline candidate in their portfolio. Sometimes, acquiring a company with a promising early-stage candidate makes sense instead of developing a product from scratch, which involves a lot of time.
Swiss oncology major Roche RHHBY is all set to acquire a privately held biotechnology company, Adheron Therapeutics. Based in Berkeley, CA, Adheron has developed a revolutionary technology that disrupts cell adhesion to treat a variety of inflammatory and autoimmune diseases, such as rheumatoid arthritis (RA) and fibrotic diseases through a cell surface protein called Cadherin-11.
Details of the Acquisition
Per the terms of the agreement, shareholders of Adheron will receive an upfront cash payment of $105 million along with additional contingent milestone payments of up to $475 million.
The acquisition will give Roche access to Adheron's lead candidate, SDP051, a humanized monoclonal antibody targeting Cadherin-11, which is a protein that acts as an adhesive between cells. Cadherin-11 is a key mediator of joint destruction in RA. Adheron has completed a phase I trial on SDP051, which assessed the safety and tolerability of the compound in healthy volunteers.
Our Take
We note that Roche has a strong presence in the oncology market backed by products like Herceptin, Perjeta and Kadcyla. The Adheron acquisition is a step toward Roche's efforts to develop its portfolio beyond oncology to immunology. The company's Actemra/RoActemra is already approved for the treatment of RA, a disease which affects 40 million people around the world.
Roche currently carries a Zacks Rank #3 (Hold). Some better-ranked health care stocks are Sanofi SNY , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . All three stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked health care stocks are Sanofi SNY , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Sometimes, acquiring a company with a promising early-stage candidate makes sense instead of developing a product from scratch, which involves a lot of time. | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked health care stocks are Sanofi SNY , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked health care stocks are Sanofi SNY , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . Based in Berkeley, CA, Adheron has developed a revolutionary technology that disrupts cell adhesion to treat a variety of inflammatory and autoimmune diseases, such as rheumatoid arthritis (RA) and fibrotic diseases through a cell surface protein called Cadherin-11. | Some better-ranked health care stocks are Sanofi SNY , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Based in Berkeley, CA, Adheron has developed a revolutionary technology that disrupts cell adhesion to treat a variety of inflammatory and autoimmune diseases, such as rheumatoid arthritis (RA) and fibrotic diseases through a cell surface protein called Cadherin-11. |
26817.0 | 2015-10-12 00:00:00 UTC | Galapagos (GLPG) Reports Positive Data on GLPG1837 | ABBV | https://www.nasdaq.com/articles/galapagos-glpg-reports-positive-data-on-glpg1837-2015-10-12 | nan | nan | Galapagos NVGLPG announced positive top-line data from a phase I randomized, double-blind, placebo-controlled study on GLPG1837 for the treatment of patients with class III mutation in cystic fibrosis.
Data revealed that the candidate was safe and generally well-tolerated. A phase II study is expected to be initiated by the year end.
According to information provided by the company, approximately 30,000 patients and 80,000 patients are affected by cystic fibrosis in the U.S. and worldwide, respectively.
Galapagos expects to develop GLPG1837 in combination with other candidates in its pipeline, as a potential triple combination therapy for class II cystic fibrosis patients.
We remind investors that Galapagos has a collaboration agreement with AbbVie Inc. ABBV to discover, develop and commercialize potentiator and combination therapies for cystic fibrosis. Under the terms of the agreement, Galapagos received an upfront payment of $45 million from AbbVie. In addition, the company is eligible to receive up to $360 million as developmental, regulatory and sales milestones upon the achievement of minimum annual net sales thresholds, upon approval. The company is also entitled to receive double-digit royalties on net sales.
We note that Galapagos has two candidates under this collaboration - GLPG1837 and GLPG2222. In Dec 2014, the company announced the initiation of the first phase I study on GLPG1837, which triggered a milestone payment worth $10 million from AbbVie. A phase I study on GLPG2222 is expected to be initiated by the year end.
Meanwhile, the company continues to progress on its other candidates. Currently, the company is evaluating filgotinib in a phase II study (data expected in Dec 2015) for the treatment of patients with Crohn's disease. In addition, a phase III study on filgotinib for the treatment patients with rheumatoid arthritis (RA) is expected to be initiated by early 2016.
Another candidate in the company's pipeline, GLPG1205, is being evaluated in a phase II proof-of-concept study (data expected in the fourth quarter of 2015) for the treatment of patients with ulcerative colitis.
Galapagos carries a Zacks Rank #2 (Buy). Other favorably ranked stocks in the health care sector include Nexvet Biopharma Public Limited Company NVET and Anika Therapeutics Inc. ANIK , each sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBVIE INC (ABBV): Free Stock Analysis Report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
GALAPAGOS -ADR (GLPG): Free Stock Analysis Report
NEXVET BIOPHARM (NVET): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We remind investors that Galapagos has a collaboration agreement with AbbVie Inc. ABBV to discover, develop and commercialize potentiator and combination therapies for cystic fibrosis. Under the terms of the agreement, Galapagos received an upfront payment of $45 million from AbbVie. In Dec 2014, the company announced the initiation of the first phase I study on GLPG1837, which triggered a milestone payment worth $10 million from AbbVie. | Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report GALAPAGOS -ADR (GLPG): Free Stock Analysis Report NEXVET BIOPHARM (NVET): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that Galapagos has a collaboration agreement with AbbVie Inc. ABBV to discover, develop and commercialize potentiator and combination therapies for cystic fibrosis. Under the terms of the agreement, Galapagos received an upfront payment of $45 million from AbbVie. | Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report GALAPAGOS -ADR (GLPG): Free Stock Analysis Report NEXVET BIOPHARM (NVET): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that Galapagos has a collaboration agreement with AbbVie Inc. ABBV to discover, develop and commercialize potentiator and combination therapies for cystic fibrosis. Under the terms of the agreement, Galapagos received an upfront payment of $45 million from AbbVie. | Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report GALAPAGOS -ADR (GLPG): Free Stock Analysis Report NEXVET BIOPHARM (NVET): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that Galapagos has a collaboration agreement with AbbVie Inc. ABBV to discover, develop and commercialize potentiator and combination therapies for cystic fibrosis. Under the terms of the agreement, Galapagos received an upfront payment of $45 million from AbbVie. |
26818.0 | 2015-10-09 00:00:00 UTC | 3 Top Ranked Stocks Doling out Sizable Dividends | ABBV | https://www.nasdaq.com/articles/3-top-ranked-stocks-doling-out-sizable-dividends-2015-10-09 | nan | nan | When looking for a nice dividend stock, one should have an elaborate set of criteria to be met. Double digit dividend yields are tempting, but you should do more research to make sure that your investments are dependable. After all, a 30% dividend yield won't be worth much if the stock price ends up going to $0.
Make sure that whatever you're investing in has a nice valuation so that you can worry less about about the negativity which volatility can cause. After all, you don't want to get caught up in bumpy trading when you buy a stock with a high price tag. Fortunately, we have found three top ranked stocks with hefty yields you can depend on. Each of these stocks have earned a "B" for value in our Style Scores. They have all done well in outperforming our EPS consensus estimate as well. The three stocks below deserve your consideration if you're looking for some valuable stocks with considerable yields.
Guess Inc- GES
Guess designs and sells casual apparel across the globe. The fashion brand did well to beat our revenues consensus last quarter. Guess is a Zacks Rank #1 (Strong Buy). It doles out a generous 4% yield to investors.
Guess has a "B" for value in our Style Scores, and for good reason. It trades at a price to book of 1.77, while the industry as a whole trades at a 2.36. The company also has a price to sales of just 0.81. A price to sales under one may suggest that there is value present. Guess has an Enterprise value to EBITDA of just 6.09, and is way ahead of the industry with regards to this valuation.
Guess has beaten our EPS consensus estimate in each of the last four quarters. It has managed to surpass our consensus by an average of 65% per quarter. The corporation reports its earnings on 12/2/15.
AbbVie Inc- ABBV
AbbVie is a research based biopharmaceutical company with a global presence. The company strives to create innovative therapies and drugs to treat serious diseases of the kidney and liver. The company also focuses on advancing treatments for cancer. AbbVie is a Zacks Rank #2 (Buy). The stock has a yield of 3.64%.
AbbVie has some nice growth and value characteristics. For one, the stock has a PEG of just 0.91, and a forward PE of 13.04. ABBV also has an earnings yield of 7.68%. Sales are projected to grow by 15% this year. The company's EPS is expected to be 28.52% higher compared to last year's earnings. The biopharmaceutical corporation has beaten our EPS consensus in each of the last four quarters and it reports earnings on 10/30/15.
Darden Restaurants, Inc- DRI
Darden Restaurants owns several restaurant chains. Some of these franchises include Olive Garden, LongHorn Steakhouse, and Bahama Breeze. The company even owned Red Lobster until mid 2014. Darden is a Zacks Rank #1 (Strong Buy). DRI doles out a 3.3% yield to investors.
Restaurants tend to have pretty high valuations as a whole. For example, the industry trades at a forward PE of 27.39, while Darden's is only 20.52 in comparison. Its price to sales is exceptional at just 1.24. Darden's ROE is 17%, while the industry lags behind at just 12.42%.
Our EPS consensus for this quarter has been rising over the last 90 days. This is encouraging, especially when you consider the fact that Darden has beaten our earnings consensus consistently over the last four quarters. DRI reports its earnings on 12/15/15.
The Zacks Rank is a truly marvelous trading tool. Our ranking system has beaten the S&P 500, yielding an average return of 26% per year for the last 28 years! Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
DARDEN RESTRNT (DRI): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
GUESS INC (GES): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc- ABBV AbbVie is a research based biopharmaceutical company with a global presence. AbbVie is a Zacks Rank #2 (Buy). AbbVie has some nice growth and value characteristics. | Click to get this free report DARDEN RESTRNT (DRI): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report GUESS INC (GES): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc- ABBV AbbVie is a research based biopharmaceutical company with a global presence. AbbVie is a Zacks Rank #2 (Buy). | Click to get this free report DARDEN RESTRNT (DRI): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report GUESS INC (GES): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc- ABBV AbbVie is a research based biopharmaceutical company with a global presence. AbbVie is a Zacks Rank #2 (Buy). | AbbVie Inc- ABBV AbbVie is a research based biopharmaceutical company with a global presence. AbbVie is a Zacks Rank #2 (Buy). AbbVie has some nice growth and value characteristics. |
26819.0 | 2015-10-09 00:00:00 UTC | Biogen, Roche & Novartis Present Data on MS Drugs in Spain | ABBV | https://www.nasdaq.com/articles/biogen-roche-novartis-present-data-on-ms-drugs-in-spain-2015-10-09 | nan | nan | Quite a few pharma/biotech companies presented encouraging data on their multiple sclerosis (MS) candidates at the 31st Congress of the European Committee for Treatment and Research in MS (ECTRIMS) in Barcelona, Spain held this week.
The MS market is getting more crowded with existing players coming out with new drugs and new entrants trying to enter the market.
Market leader Biogen Inc. BIIB , with key drugs like Tecfidera, Avonex and Tysabri, is collaborating with AbbVie ABBV for another MS candidate, Zinbryta. Results from the phase III study, DECIDE, on Zinbryta was published in the New England Journal of Medicine. Data was also presented at the ECTRIMS by the lead investigators of the study.
The study shows that once-monthly Zinbryta improved results on key measures of MS disease activity in patients with relapsing-remitting MS compared to interferon beta-1a 30 mcg intramuscular injection. A post-hoc analysis of data from the study showed Zinbryta was effective in increasing the percentage of patients who showed improved cognitive processing speed and decreased 24-week confirmed disability progression across a broad range of subgroups at two years compared to interferon beta-1a IM. The candidate is currently under review in the U.S and the EU.
Meanwhile, Swiss oncology major, Roche RHHBY announced positive data from phase III studies, OPERA I and OPERA II, on MS candidate, ocrelizumab . The data will be presented at ECTRIMS.
The candidate is being evaluated for the treatment of patients suffering from MS and primary progressive multiple sclerosis (PPMS). Data from the studies showed that ocrelizumab was superior to interferon beta-1a (Rebif) in lowering the three major markers of disease activity over the two-year controlled treatment period in patients suffering from relapsing MS.
Additionally, a separate study, ORATORIO, showed that ocrelizumab significantly reduced the progression of clinical disability sustained for at least 12 weeks (the primary endpoint) and 24 weeks (a secondary endpoint) compared to placebo in patients suffering from PPMS. Consequently, the study met its primary endpoint. In addition, the study met other secondary endpoints of reducing the time required to walk 25 feet, the volume of chronic inflammatory brain lesions and brain volume loss.
The results bode well for Roche, which is trying to expand its portfolio beyond oncology to immunology, neuroscience and ophthalmology. Roche plans to submit data from all three studies to the FDA by early 2016.
Novartis NVS also presented new analysis at ECTRIMS from two phase III trials (FREEDOMS and FREEDOMS II) on MS drug Gilenya, which reinforced its long-term effectiveness. The company conducted a follow-up analysis of pooled data from the FREEDOMS and FREEDOMS II core and extension trials to assess no evidence of disease activity each year for seven years in patients with relapsing MS. Apart from Gilenya, Novartis' Extavia is approved in the EU to treat people with RRMS and secondary progressive MS.
As per National Institutes of Health - National Institute of Neurological Disorders and Stroke and Multiple Sclerosis International Federation, MS is a chronic disease that affects an estimated 2.3 million people around the world with no cure. Hence, the MS market still has a lot of scope for new treatments.
While Biogen and Roche carry a Zacks Rank #3 (Hold), Novartis is a Zacks Rank #4 (Sell) stock. AbbVie carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
BIOGEN INC (BIIB): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Market leader Biogen Inc. BIIB , with key drugs like Tecfidera, Avonex and Tysabri, is collaborating with AbbVie ABBV for another MS candidate, Zinbryta. AbbVie carries a Zacks Rank #2 (Buy). Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Market leader Biogen Inc. BIIB , with key drugs like Tecfidera, Avonex and Tysabri, is collaborating with AbbVie ABBV for another MS candidate, Zinbryta. AbbVie carries a Zacks Rank #2 (Buy). | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Market leader Biogen Inc. BIIB , with key drugs like Tecfidera, Avonex and Tysabri, is collaborating with AbbVie ABBV for another MS candidate, Zinbryta. AbbVie carries a Zacks Rank #2 (Buy). | Market leader Biogen Inc. BIIB , with key drugs like Tecfidera, Avonex and Tysabri, is collaborating with AbbVie ABBV for another MS candidate, Zinbryta. AbbVie carries a Zacks Rank #2 (Buy). Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. |
26820.0 | 2015-10-08 00:00:00 UTC | The Zacks Analyst Blog Highlights: Amgen, Regeneron, Acorda, Amicus and AbbVie | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amgen-regeneron-acorda-amicus-and-abbvie-2015-10-08 | nan | nan | For Immediate Release
Chicago, IL - October 08, 2015 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Amgen ( AMGN ), Regeneron ( REGN ), Acorda ( ACOR ), Amicus ( FOLD ) and AbbVie ( ABBV ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .
Here are highlights from Wednesday's Analyst Blog:
Biotech Stock Roundup
The biotech sector, which has been under pressure due to concerns regarding high pricing, showed signs of recovery last week with the NASDAQ Biotechnology Index gaining 4.07% over the last five trading days (See the last biotech stock roundup here: Pricing Concerns Hit Biotech Stocks, EU Nod for Regeneron's Praluent ).
Amgen ( AMGN ) and Regeneron ( REGN ) got good news with Express Scripts announcing that both their PCSK9 inhibitors will be listed on the National Preferred Formulary. Other major updates this week include pipeline updates and regulatory approvals.
Recap of the Week's Most Important Stories
1. Pharmacy benefit manager (PBM) Express Scripts has said that it will list both Amgen and Regeneron's PCSK9 inhibitors on its National Preferred Formulary putting to rest concerns about which of the treatments will be listed on the formulary that covers about 25 million Americans.
According to the PBM, National Preferred Formulary clients will spend about $750 million on PCSK9 inhibitors, much less than what the industry had forecasted. Moreover, in the backdrop of concerns regarding high pricing, the PBM said that it will provide additional long-term protection for its payers and patients by capping the entire plan cost in 2016 for PCSK9 inhibitors for clients enrolled in the Cholesterol Care Value (CCV) program.
2. Alkermes got some good news with the FDA approving its new schizophrenia treatment, Aristada. The company is prepared to launch Aristada immediately, which should be an important contributor to the company's top-line.
Meanwhile, Acorda's ( ACOR ) shares were up on news that the company has settled its patent infringement lawsuit with Allergan for its flagship product, Ampyra (Read more: Acorda Soars, Settles Ampyra Patent Dispute with Allergan ).
3. Amicus ( FOLD ), focused on developing treatments for rare and orphan diseases, saw its shares plunging on news that it is facing a delay in its regulatory filing plans for its experimental Fabry disease treatment, migalastat, in the U.S. With the FDA asking for additional data, the company will not be able to file an NDA by year end, as planned (Read more: Amicus Therapeutics Plunges on Delay in NDA Submission ).
4. Action in the biosimilars market is heating up. Novartis' Sandoz, which had launched the first biosimilar in the U.S. last month, is now seeking FDA approval for its biosimilar version of another of Amgen's key drugs, Enbrel. Enbrel, a TNF-alpha inhibitor approved for a wide range of autoimmune diseases, delivered sales of about $2.5 billion in the first half of 2015 (Read more: Novartis' Sandoz Files for Enbrel Biosimilar in the U.S. ).
Meanwhile, Baxalta and partner Momenta have moved their biosimilar version of AbbVie's ( ABBV ) blockbuster drug, Humira, into a pivotal study (Read more: Baxalta, Momenta Begin Pivotal Study on Biosimilar of Humira ).
5. XOMA received a much-needed boost with the company entering into an immuno-oncology related agreement with Novartis. The deal will see XOMA receiving $37 million upfront and the scope to get an additional $480 million on the achievement of certain milestones. Novartis has also agreed to push out the maturity date for a $13.5 million loan to 2020.
The deal will provide XOMA with much-needed funds - the company believes that along with its cost-cutting efforts, it has enough to fund operations into 2017 (Read more: XOMA Shoots up on Immuno-Oncology Deal with Novartis ). The Novartis deal comes as a relief for XOMA which has had a challenging year - the company suffered a major setback back in July with its lead pipeline candidate, gevokizumab, failing in a phase III study in patients with Behçet's disease uveitis.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today . Find out What is happening in the stock market today on zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AMGEN INC (AMGN): Free Stock Analysis Report
REGENERON PHARM (REGN): Free Stock Analysis Report
ACORDA THERAPT (ACOR): Free Stock Analysis Report
AMICUS THERAPT (FOLD): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include the Amgen ( AMGN ), Regeneron ( REGN ), Acorda ( ACOR ), Amicus ( FOLD ) and AbbVie ( ABBV ). Meanwhile, Baxalta and partner Momenta have moved their biosimilar version of AbbVie's ( ABBV ) blockbuster drug, Humira, into a pivotal study (Read more: Baxalta, Momenta Begin Pivotal Study on Biosimilar of Humira ). Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report AMICUS THERAPT (FOLD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include the Amgen ( AMGN ), Regeneron ( REGN ), Acorda ( ACOR ), Amicus ( FOLD ) and AbbVie ( ABBV ). Meanwhile, Baxalta and partner Momenta have moved their biosimilar version of AbbVie's ( ABBV ) blockbuster drug, Humira, into a pivotal study (Read more: Baxalta, Momenta Begin Pivotal Study on Biosimilar of Humira ). Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report AMICUS THERAPT (FOLD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report AMICUS THERAPT (FOLD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include the Amgen ( AMGN ), Regeneron ( REGN ), Acorda ( ACOR ), Amicus ( FOLD ) and AbbVie ( ABBV ). Meanwhile, Baxalta and partner Momenta have moved their biosimilar version of AbbVie's ( ABBV ) blockbuster drug, Humira, into a pivotal study (Read more: Baxalta, Momenta Begin Pivotal Study on Biosimilar of Humira ). | Stocks recently featured in the blog include the Amgen ( AMGN ), Regeneron ( REGN ), Acorda ( ACOR ), Amicus ( FOLD ) and AbbVie ( ABBV ). Meanwhile, Baxalta and partner Momenta have moved their biosimilar version of AbbVie's ( ABBV ) blockbuster drug, Humira, into a pivotal study (Read more: Baxalta, Momenta Begin Pivotal Study on Biosimilar of Humira ). Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report AMICUS THERAPT (FOLD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. |
26821.0 | 2015-10-08 00:00:00 UTC | Gilead Is About to Disappoint Investors -- but for All the Right Reasons | ABBV | https://www.nasdaq.com/articles/gilead-about-disappoint-investors-all-right-reasons-2015-10-08 | nan | nan | After a brief summer spike, Gilead Sciences stock has given back most of its gains this year and continues to be seemingly locked into a long-term relationship with $100 a share. The problem is that Wall Street appears to be becoming increasingly convinced that the hepatitis C market has already hit its high-water mark, meaning that the biotech's top line could suffer soon.
GILD data by YCharts .
According to the army of analysts covering this stock, the Street thinks Gilead's earnings and product sales will essentially flatline over the next year. A deeper dive into the numbers, though, reveals a high degree of uncertainty over the drugmaker's top and bottom lines moving forward.
Gilead's estimated 2016 earnings per share, for example, ranges from $9.73 to $14.45. This projected EPS range is several orders of magnitude wider than many of the biotech's closest peers, illustrating just how much debate there is on the Street over Gilead's future growth prospects.
Source: Gilead.
The basic issues underlying this gigantic EPS range are fourfold:
The impact of AbbVie 's competing hep C drug, Viekira Pak, on Gilead's hep C franchise in 2016 and beyond is a big unknown.
The potential introduction of Merck 's experimental hep C therapy could negatively impact the market as a whole via further pricing discounts.
No one has a good feel for how strong Gilead's ex-U.S. sales of its hep C drugs will be moving forward. After all, generic versions of Sovaldi are already available in dozens of low-income countries, and these steeply discounted pills could very well show up illegally in other emerging markets.
Sovaldi from countries with vastly lower prices such as India is apparently starting to show up in Western countries. As many patients are reportedly being denied access to the drug in the U.S., this trend may only grow stronger with time, hurting the biotech's top line.
All these potential headwinds facing Gilead's hep C franchise have contributed to the Street's uncertain outlook, and that's typically bad news for a company's share price. Put simply, the Street desperately wants clarity on Gilead's 2016 revenue before it allows the stock to finally leave $100 a share in the rearview mirror.
Can we get an acquisition, please?
If you've been listening to the Q&A portions of Gilead's conference calls and investor presentations recently, then you're probably well aware that analysts have been constantly peppering management about a potential acquisition -- one so large it could immediately put these lingering revenue questions to rest. So, when Gilead took out a noteworthy $10 billion in new debt a few weeks ago, everyone seemed convinced that this was the lead-up to a major buyout.
While I hate to dash the hopes of Gilead's shareholders, I find it highly doubtful that a major-league acquisition is on the horizon for this biotech. There are a couple of reasons.
First off, Gilead has dramatically increased its share buyback program and instituted a dividend this year. You don't start upping shareholder rewards when you're gearing up for a huge acquisition. That's plain bad business management, as it would tempt the credit agencies to slash your rating.
Next up, I think investors need to understand that a big buyout would be a massive departure from Gilead's playbook. The biotech's usual strategy is to buy smaller drugmakers with early-stage assets. So it's hard to see why Gilead would suddenly forget what got it here and take on a larger company with products already on the market.
Perhaps the final nail in the coffin, though, is that there aren't really any good midsized biotechs or biopharmas that would immediately add to Gilead's earnings. Indeed, peers have faced the exact same problem. Nearly every acquisition this year is expected to be a drag on earnings in the short term. Put simply, a mid- to large-sized acquisition probably wouldn't solve Gilead's short-term earnings conundrum.
What's next?
My gut feeling is that Gilead's real game plan is to continue to develop its own clinical pipeline and perhaps add a few choice pieces via much smaller buyouts than the Street is hoping for right now. In this way, the biotech can use its healthy financial position to buoy its near-term earnings through share buybacks and grow its revenues organically, for the most part.
While that's not as exciting a move as many investors are hoping for, I think it's a prudent one. After all, what investors see right now is a public tug-of-war between the Street's desire for short-term gains, and management's fiscal duty to guide the company to long-term profitability.
Although a multibillion-dollar acquisition might help to juice Gilead's share price in the short term, the right conditions simply don't appear to be in place to make this a wise strategy over the long haul (i.e., there's no good buyout target for a compelling price).
Investors therefore might want to lower their expectations regarding Gilead's M&A aspirations and instead focus on the biotech's robust clinical pipeline, which sports numerous product candidates with blockbuster potential.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article Gilead Is About to Disappoint Investors -- but for All the Right Reasons originally appeared on Fool.com.
George Budwell owns shares of AbbVie and Gilead Sciences. The Motley Fool owns and recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The basic issues underlying this gigantic EPS range are fourfold: The impact of AbbVie 's competing hep C drug, Viekira Pak, on Gilead's hep C franchise in 2016 and beyond is a big unknown. George Budwell owns shares of AbbVie and Gilead Sciences. All these potential headwinds facing Gilead's hep C franchise have contributed to the Street's uncertain outlook, and that's typically bad news for a company's share price. | The basic issues underlying this gigantic EPS range are fourfold: The impact of AbbVie 's competing hep C drug, Viekira Pak, on Gilead's hep C franchise in 2016 and beyond is a big unknown. George Budwell owns shares of AbbVie and Gilead Sciences. According to the army of analysts covering this stock, the Street thinks Gilead's earnings and product sales will essentially flatline over the next year. | The basic issues underlying this gigantic EPS range are fourfold: The impact of AbbVie 's competing hep C drug, Viekira Pak, on Gilead's hep C franchise in 2016 and beyond is a big unknown. George Budwell owns shares of AbbVie and Gilead Sciences. All these potential headwinds facing Gilead's hep C franchise have contributed to the Street's uncertain outlook, and that's typically bad news for a company's share price. | The basic issues underlying this gigantic EPS range are fourfold: The impact of AbbVie 's competing hep C drug, Viekira Pak, on Gilead's hep C franchise in 2016 and beyond is a big unknown. George Budwell owns shares of AbbVie and Gilead Sciences. After a brief summer spike, Gilead Sciences stock has given back most of its gains this year and continues to be seemingly locked into a long-term relationship with $100 a share. |
26822.0 | 2015-10-08 00:00:00 UTC | 3 Pharma Stocks With Big Margins of Safety | ABBV | https://www.nasdaq.com/articles/3-pharma-stocks-big-margins-safety-2015-10-08 | nan | nan | While the company's massive size does limit how fast it can grow, I think investors should expect growth revenue and profit growth in the mid single digits, and when you add in the company's share repurchase program and dividend yield, the stock is certainly capable of producing double-digit returns from here. You won't be doubling your money anytime soon, but for investors looking to put money in the markets today, I think Johnson & Johnson is a great stock to buy and hold for the long term.
Sean Williams: When we're talking about "big margins of safety," I don't know how Gilead Sciences couldn't be the first company out of anyone's mouth.
What makes Gilead's margins so impressive, and what essentially provides the company such a bounty of profits, is its premier position in hepatitis C.
Gilead's bread and butter are its Food and Drug Administration-approved hepatitis C therapies Sovaldi and Harvoni. Both therapies dramatically improved patient quality of life during treatment; in many cases, they shortened the length of treatment from prior-year treatments, and they improved sustained virologic response rates to 90% or greater in most clinical studies. They also come with standard 12-week wholesale costs of $84,000 for Sovaldi and $94,500 for Harvoni.
I've opined that there are only three ways to remove Gilead from its HCV throne. First, a company could attempt to trump it on efficacy, which is going to be tough after it recently reported that the combination of Sovaldi and velpatasvir led to a cure in 98% of the 1,035 patients tested (and seven of the 20 who weren't cured were simply lost to follow-up). This pan-genomic oral cure pretty much seals the deal that Gilead is the top dog in efficacy.
Secondly, a competitor could try and undercut Gilead's pricing. AbbVie tried this with Viekira Pak by forming an exclusive marketing agreement with the nation's largest pharmacy-benefit manager, but Gilead countered with steep discounts and agreements of its own with insurers and other PBMs. Even with these discounts, Gilead still managed nearly $18 billion in free cash flow over the trailing-12-month period and a gross margin of better than 86%.
Lastly, no other company has been able to top Gilead's convenience or treatment timeframe. With Harvoni working in as few as eight weeks for treatment-naive, non-cirrhotic patients, Gilead's HCV therapies remain the top choice of physicians and consumers.
With few challengers to Gilead's HCV product portfolio or pipeline, its moat of margin safety should remain practically unparalleled among pharmaceutical companies.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early, in-the-know investors! To be one of them, just click here .
The article 3 Pharma Stocks With Big Margins of Safety originally appeared on Fool.com.
Brian Feroldi owns shares of Gilead Sciences. George Budwell owns shares of AbbVie, Gilead Sciences, and Johnson & Johnson. Sean Williams has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days .We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie tried this with Viekira Pak by forming an exclusive marketing agreement with the nation's largest pharmacy-benefit manager, but Gilead countered with steep discounts and agreements of its own with insurers and other PBMs. George Budwell owns shares of AbbVie, Gilead Sciences, and Johnson & Johnson. With Harvoni working in as few as eight weeks for treatment-naive, non-cirrhotic patients, Gilead's HCV therapies remain the top choice of physicians and consumers. | George Budwell owns shares of AbbVie, Gilead Sciences, and Johnson & Johnson. AbbVie tried this with Viekira Pak by forming an exclusive marketing agreement with the nation's largest pharmacy-benefit manager, but Gilead countered with steep discounts and agreements of its own with insurers and other PBMs. With Harvoni working in as few as eight weeks for treatment-naive, non-cirrhotic patients, Gilead's HCV therapies remain the top choice of physicians and consumers. | AbbVie tried this with Viekira Pak by forming an exclusive marketing agreement with the nation's largest pharmacy-benefit manager, but Gilead countered with steep discounts and agreements of its own with insurers and other PBMs. George Budwell owns shares of AbbVie, Gilead Sciences, and Johnson & Johnson. Sean Williams: When we're talking about "big margins of safety," I don't know how Gilead Sciences couldn't be the first company out of anyone's mouth. | AbbVie tried this with Viekira Pak by forming an exclusive marketing agreement with the nation's largest pharmacy-benefit manager, but Gilead countered with steep discounts and agreements of its own with insurers and other PBMs. George Budwell owns shares of AbbVie, Gilead Sciences, and Johnson & Johnson. Sean Williams: When we're talking about "big margins of safety," I don't know how Gilead Sciences couldn't be the first company out of anyone's mouth. |
26823.0 | 2015-10-07 00:00:00 UTC | Infinity (INFI) Updates on Duvelisib and IPI-549 on R&D Day | ABBV | https://www.nasdaq.com/articles/infinity-infi-updates-on-duvelisib-and-ipi-549-on-rd-day-2015-10-07 | nan | nan | Infinity Pharmaceuticals, Inc.INFI provided an update on the clinical development program and commercial overview on duvelisib and IPI-549 on its Research and Development (R&D) Day.
Duvelisib is currently being evaluated in a phase II DYNAMO study in patients with refractory indolent non-Hodgkin lymphoma (NHL); and two phase III studies DYNAMO+R and DUO, in patients with previously treated follicular lymphoma and in patients with relapsed/refractory chronic lymphocytic leukemia, respectively. Top-line data from DYNAMO study is expected in the third quarter of 2016, while patient enrolment in DUO study is expected to be completed by year end. Top-line data from DUO study is expected in 2016.
Infinity Pharma expects to submit global regulatory filings for duvelisib for the treatment of patients with refractory indolent NHL by the end of 2016 and plans for a launch in 2017.
Apart from the ongoing studies on duvelisib, Infinity Pharma is looking to initiate 3 additional studies - phase III BRAVURA (for the treatment of patients with relapsed iNHL), phase II FRESCO (for the treatment of patients with relapsed/refractory FL) and a phase Ib/II study on duvelisib by the year end. Moreover, the company plans to get an advice from the FDA on whether its phase III BRAVURA study can serve as a confirmatory study, if DYNAMO supports an accelerated approval.
We note that the company has a collaboration and license agreement with AbbVie Inc. ABBV for global development and commercialization of duvelisib for the treatment of cancer. Infinity Pharma is set to receive $130 million milestone payment from AbbVie for the completion of patient enrollment in the DYNAMO study last month.
Meanwhile, the company expects to begin a phase I study on IPI-549 for the treatment of solid tumors in the first quarter of 2016. An Investigational New Drug application for IPI-549 is expected to be filed by the end of 2015.
Infinity Pharma carries a Zacks Rank #3 (Hold). A couple of well-ranked stocks in the health care sector include Amgen Inc. AMGN and Anika Therapeutics Inc. ANIK , each sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AMGEN INC (AMGN): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
INFINITY PHARMA (INFI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Infinity Pharma is set to receive $130 million milestone payment from AbbVie for the completion of patient enrollment in the DYNAMO study last month. We note that the company has a collaboration and license agreement with AbbVie Inc. ABBV for global development and commercialization of duvelisib for the treatment of cancer. Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report INFINITY PHARMA (INFI): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report INFINITY PHARMA (INFI): Free Stock Analysis Report To read this article on Zacks.com click here. We note that the company has a collaboration and license agreement with AbbVie Inc. ABBV for global development and commercialization of duvelisib for the treatment of cancer. Infinity Pharma is set to receive $130 million milestone payment from AbbVie for the completion of patient enrollment in the DYNAMO study last month. | Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report INFINITY PHARMA (INFI): Free Stock Analysis Report To read this article on Zacks.com click here. We note that the company has a collaboration and license agreement with AbbVie Inc. ABBV for global development and commercialization of duvelisib for the treatment of cancer. Infinity Pharma is set to receive $130 million milestone payment from AbbVie for the completion of patient enrollment in the DYNAMO study last month. | Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report INFINITY PHARMA (INFI): Free Stock Analysis Report To read this article on Zacks.com click here. We note that the company has a collaboration and license agreement with AbbVie Inc. ABBV for global development and commercialization of duvelisib for the treatment of cancer. Infinity Pharma is set to receive $130 million milestone payment from AbbVie for the completion of patient enrollment in the DYNAMO study last month. |
26824.0 | 2015-10-07 00:00:00 UTC | XLV, ABBV, CELG, ESRX: Large Inflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/xlv-abbv-celg-esrx-large-inflows-detected-etf-2015-10-07 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $240.9 million dollar inflow -- that's a 1.9% increase week over week in outstanding units (from 192,665,324 to 196,265,324). Among the largest underlying components of XLV, in trading today AbbVie Inc. (Symbol: ABBV) is trading flat, Celgene Corp. (Symbol: CELG) is up about 3.2%, and Express Scripts Holding Co (Symbol: ESRX) is up by about 1.2%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $56.63 per share, with $77.40 as the 52 week high point - that compares with a last trade of $67.23. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today AbbVie Inc. (Symbol: ABBV) is trading flat, Celgene Corp. (Symbol: CELG) is up about 3.2%, and Express Scripts Holding Co (Symbol: ESRX) is up by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $240.9 million dollar inflow -- that's a 1.9% increase week over week in outstanding units (from 192,665,324 to 196,265,324). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today AbbVie Inc. (Symbol: ABBV) is trading flat, Celgene Corp. (Symbol: CELG) is up about 3.2%, and Express Scripts Holding Co (Symbol: ESRX) is up by about 1.2%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $56.63 per share, with $77.40 as the 52 week high point - that compares with a last trade of $67.23. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today AbbVie Inc. (Symbol: ABBV) is trading flat, Celgene Corp. (Symbol: CELG) is up about 3.2%, and Express Scripts Holding Co (Symbol: ESRX) is up by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $240.9 million dollar inflow -- that's a 1.9% increase week over week in outstanding units (from 192,665,324 to 196,265,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $56.63 per share, with $77.40 as the 52 week high point - that compares with a last trade of $67.23. | Among the largest underlying components of XLV, in trading today AbbVie Inc. (Symbol: ABBV) is trading flat, Celgene Corp. (Symbol: CELG) is up about 3.2%, and Express Scripts Holding Co (Symbol: ESRX) is up by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $240.9 million dollar inflow -- that's a 1.9% increase week over week in outstanding units (from 192,665,324 to 196,265,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $56.63 per share, with $77.40 as the 52 week high point - that compares with a last trade of $67.23. |
26825.0 | 2015-10-07 00:00:00 UTC | Bristol-Myers Gets Priority Review for HCV Drug Daklinza | ABBV | https://www.nasdaq.com/articles/bristol-myers-gets-priority-review-for-hcv-drug-daklinza-2015-10-07 | nan | nan | Bristol-Myers SquibbBMY announced that three of its supplemental New Drug Applications (sNDAs) seeking label expansion for hepatitis C (HCV) drug, Daklinza, will be reviewed on a priority basis by the FDA. A final decision from the FDA is expected within six months.
Bristol-Myers is looking to get Daklinza approved for use in combination with Gilead Sciences' GILD Solvaldi (sofosbuvir) with or without ribavirin. The three sNDAs are for the treatment of patients with chronic HCV coinfected with human immunodeficiency virus (HIV-1), patients with advanced cirrhosis (including decompensated cirrhosis), and for patients with post-liver transplant recurrence of HCV.
Daklinza is already approved in the U.S. in combination with Solvaldi for the treatment of patients with chronic HCV genotype 3 infection. In the EU, the Daklinza-Solvaldi combination is approved for treating adults with chronic HCV genotypes 1, 2, 3 and 4 infection.
The combination regimen was granted Breakthrough Therapy designation by the FDA for HCV genotype 1 patients with advanced cirrhosis (Child-Pugh Class B or C) and those who develop genotype 1 HCV recurrence post liver transplant.
For the last couple of years, the highly lucrative HCV market has been the focus area for most of the big biotech companies. Pricing competition among the approved products is also intense. Gilead Sciences is a key player in the HCV market with drugs like Sovaldi and Harvoni. AbbVie Inc.'s ABBV all-oral, interferon-free therapy with/without ribavirin, Viekira Pak, is also performing well.
Bristol-Myers currently carries a Zacks Rank #3 (Hold). A better ranked stock in the health care sector is AstraZeneca plc AZN , carrying a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ASTRAZENECA PLC (AZN): Free Stock Analysis Report
BRISTOL-MYERS (BMY): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc.'s ABBV all-oral, interferon-free therapy with/without ribavirin, Viekira Pak, is also performing well. Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Daklinza is already approved in the U.S. in combination with Solvaldi for the treatment of patients with chronic HCV genotype 3 infection. | Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.'s ABBV all-oral, interferon-free therapy with/without ribavirin, Viekira Pak, is also performing well. A better ranked stock in the health care sector is AstraZeneca plc AZN , carrying a Zacks Rank #1 (Strong Buy). | Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.'s ABBV all-oral, interferon-free therapy with/without ribavirin, Viekira Pak, is also performing well. The three sNDAs are for the treatment of patients with chronic HCV coinfected with human immunodeficiency virus (HIV-1), patients with advanced cirrhosis (including decompensated cirrhosis), and for patients with post-liver transplant recurrence of HCV. | AbbVie Inc.'s ABBV all-oral, interferon-free therapy with/without ribavirin, Viekira Pak, is also performing well. Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Bristol-Myers is looking to get Daklinza approved for use in combination with Gilead Sciences' GILD Solvaldi (sofosbuvir) with or without ribavirin. |
26826.0 | 2015-10-06 00:00:00 UTC | Who Wins and Loses with the TPP? | ABBV | https://www.nasdaq.com/articles/who-wins-and-loses-tpp-2015-10-06 | nan | nan | On Monday, officials from 12 Pacific rim countries finalized the terms of the Trans-Pacific Partnership (TPP) at a meeting in Atlanta. The trade deal encompasses around 40% of global GDP and has been in the works for a decade.
Lawmakers in the US, Japan, Singapore, Brunei, Vietnam, New Zealand, Australia, Canada, Mexico, Peru, Chile and Malaysia have yet to approve the deal, and it faces stiff domestic opposition in every country that permits opposition. Critics decry the secrecy surrounding TPP negotiations; the text is still not available to the public. Leaked documents provide a glimpse of the agreement, but reflect old drafts.
Special interest groups in every country, from dairy farmers in New Zealand to auto workers in Mexico, Japan, the US and Canada, have cried foul, while at the same time doing their best to influence negotiations. Political rifts have been compounded by upcoming elections in the US and Canada, recent elections in Japan (and Singapore, but that’s a different beast), a defenestration in Australia and growing political discontent in Mexico and Malaysia. Human rights and environmental pressure groups are nervous. Union bosses and small business owners are nervous. Should investors be?
Investing in the TPP
The first question is whether the TPP's many fractious signatories will follow through and adopt the deal. Despite the abundance of controversy, it seems unlikely the pact will founder at this point. The diplomatic equivalent of a supertanker, it has ten years of momentum behind it and the sheer economic mass to propel it through fierce opposition. Its implementation will almost certainly be slow, difficult and uneven. Disagreements will arise. But the largest signatories will probably ratify it, and that means—what?
According to one estimate, the TPP could raise its twelve member countries’ GDP by $285 billion by 2015. According to another, the figure could be just $74 billion by 2035. Dealing with a subject this huge and opaque, reliable forecasts are hard to come by. But a few key issues have received special media attention, and these have relatively clear implications for specific companies. For the pharmaceutical, tobacco and automotive industries, the TPP is big, but it’s not good news for everybody.
Pharmaceuticals
Following July’s TPP summit in Maui, pharmaceutical patent protections remained one of the deal’s biggest sticking points. And so it remained until Sunday, when The Guardian reported that an agreement between the US and Australia had very nearly put the issue to rest (Chile, Peru and other unspecified countries had yet to get on board). The deal may impact US pharmaceutical companies that market “biologics,” a relatively new class of drugs that are being used to treat cancer and other illnesses.
Under the status quo, the US allows manufacturers to retain exclusive access to clinical data for 12 years; the argument is that this privilege encourages R&D investment, spurring innovation. Australia allows for five years, a limit that currently applies to US drug makers in that market; they contend that by allowing biosimilar versions (analogous to generics) to be sold sooner, the shorter window keeps drug prices lower. The US trade delegation had pushed for an extension to eight years, which has met with vigorous public opposition in Australia and elsewhere. In New Zealand, Jane Kelsey, said, “The stark reality is that any such deal would cost New Zealanders' lives.”
The specifics of the new arrangement are unclear. Descriptions indicate there may be two sets of protections, one lasting five years and the other having the potential to last eight. According to Bloomberg, drug makers with significant biologics operations, which stand to benefit from enhanced protections, include AbbVie Inc (ABBV), Celgene Corp (CELG) and Amgen Inc (AMGN). Meanwhile companies such as Pfizer Inc (PFE) might have to wait longer to market biosimilars in these countries. American drug makers may have improved their position in Pacific markets overall, but to what extent, and at whose expense, remains to be seen.
Tobacco
Among the main points of contention surrounding the TPP is the issue of investor-state dispute settlements (ISDSs), which opponents warn will compromise national sovereignty by allowing corporations to sue governments over breaches of commercial treaties. Nobel laureate Joseph Stiglitz has weighed in against the deal, saying “U.S.-based tobacco companies have used foreign investor adjudication mechanisms created by agreements like the TPP to fight regulations intended to curb the public-health scourge of smoking.” He is referring to motions filed by Philip Morris International Inc (PM) against Australia and Uruguay over plain-packaging and graphic warning-label requirements.
ISDSs remain in the finalized TPP deal, but critics have won at least one major concession: tobacco companies will not be allowed to take advantage of the mechanism, a change which could affect Japan Tobacco Inc (ADR: JAPAY) as well as Philip Morris. Other changes to the secretive tribunals will be introduced, including a code of conduct for lawyers, according to TheNew York Times. These compromises could influence future trade deals such as the US-EU Transatlantic Trade and Investment Partnership (TTIP), which in turn could have repercussions for companies not directly affected by the TTP, such as British American Tobacco plc (BTI).
Tobacco companies’ exclusion from the TPP’s ISDS scheme has drawn the ire of Senators Thom Tillis and Richard Burr of North Carolina, both Republicans. “If the carve-out is in there, I’ll work hard to defeat it,” Tillis told the Wall Street Journal on Friday. Such opposition may be an added headache for Obama, who barely won trade-promotion authority (TPA) for the deal and faces a revolt by a number of Democratic factions, including environmentalists, human rights activists, unions and the party’s Sanders-Warren anti-corporate wing.
Automotive
Squabbles over tariffs and local-content requirements for automakers have involved Japan, the US, Canada and Mexico (the second, third, fourth and seventh biggest car exporters by dollar amount in 2014, respectively) all heavily invested in the outcome.
According to CBC News, the deal requires that 45% of imported vehicles and core parts originate in a TPP country, along with 40% of other parts, in order to be sold duty-free. Existing North American Free Trade Agreement (NAFTA) requirements require that 62.5% of a vehicle’s value and 60% of parts be produced within a member country, that is, Canada, the US or Mexico. Japan had been pushing these countries to accept 30% NAFTA-manufactured vehicle imports duty-free.
Ford Motor Company (F) has expressed opposition to the TPP over worries about currency manipulation and has urged Congress to reject the deal. General Motors Company (GM) also stands to lose if initial reports are correct about local-content rule changes. Japanese car makers led by Toyota Motor Corp Ltd (TM), meanwhile, have gained the ability to export vehicles containing more Asian components to North America with reduced tariffs.
Senator Sherrod Brown of Ohio, a Democrat, issued this statement on the issue: “TPP would be devastating to the auto supply chain by reducing the NAFTA standard for rule of origin for autos and auto parts. This would result in a flood of unfair imports, would offshore jobs, and would hurt American workers and manufacturers.” Auto workers in Canada and Mexico are similarly concerned.
Conclusion
If the TPP manages to navigate the domestic challenges it will encounter in nearly every member country, investors can expect to see changes in a number of industries. Tobacco may lose ground to tougher regulations. Biologics makers might enjoy reinforced intellectual property protections, perhaps at the expense of companies marketing biosimilars—not to mention patients. Japanese car companies will have a leg up in NAFTA markets, which may damage North American car makers and the local economies that depend on them.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | According to Bloomberg, drug makers with significant biologics operations, which stand to benefit from enhanced protections, include AbbVie Inc (ABBV), Celgene Corp (CELG) and Amgen Inc (AMGN). Tobacco Among the main points of contention surrounding the TPP is the issue of investor-state dispute settlements (ISDSs), which opponents warn will compromise national sovereignty by allowing corporations to sue governments over breaches of commercial treaties. Nobel laureate Joseph Stiglitz has weighed in against the deal, saying “U.S.-based tobacco companies have used foreign investor adjudication mechanisms created by agreements like the TPP to fight regulations intended to curb the public-health scourge of smoking.” He is referring to motions filed by Philip Morris International Inc (PM) against Australia and Uruguay over plain-packaging and graphic warning-label requirements. | According to Bloomberg, drug makers with significant biologics operations, which stand to benefit from enhanced protections, include AbbVie Inc (ABBV), Celgene Corp (CELG) and Amgen Inc (AMGN). Lawmakers in the US, Japan, Singapore, Brunei, Vietnam, New Zealand, Australia, Canada, Mexico, Peru, Chile and Malaysia have yet to approve the deal, and it faces stiff domestic opposition in every country that permits opposition. According to CBC News, the deal requires that 45% of imported vehicles and core parts originate in a TPP country, along with 40% of other parts, in order to be sold duty-free. | According to Bloomberg, drug makers with significant biologics operations, which stand to benefit from enhanced protections, include AbbVie Inc (ABBV), Celgene Corp (CELG) and Amgen Inc (AMGN). Lawmakers in the US, Japan, Singapore, Brunei, Vietnam, New Zealand, Australia, Canada, Mexico, Peru, Chile and Malaysia have yet to approve the deal, and it faces stiff domestic opposition in every country that permits opposition. Nobel laureate Joseph Stiglitz has weighed in against the deal, saying “U.S.-based tobacco companies have used foreign investor adjudication mechanisms created by agreements like the TPP to fight regulations intended to curb the public-health scourge of smoking.” He is referring to motions filed by Philip Morris International Inc (PM) against Australia and Uruguay over plain-packaging and graphic warning-label requirements. | According to Bloomberg, drug makers with significant biologics operations, which stand to benefit from enhanced protections, include AbbVie Inc (ABBV), Celgene Corp (CELG) and Amgen Inc (AMGN). Lawmakers in the US, Japan, Singapore, Brunei, Vietnam, New Zealand, Australia, Canada, Mexico, Peru, Chile and Malaysia have yet to approve the deal, and it faces stiff domestic opposition in every country that permits opposition. The deal may impact US pharmaceutical companies that market “biologics,” a relatively new class of drugs that are being used to treat cancer and other illnesses. |
26827.0 | 2015-10-06 00:00:00 UTC | Merck's (MRK) All-Oral Ribavirin-Free HCV Data Published | ABBV | https://www.nasdaq.com/articles/mercks-mrk-all-oral-ribavirin-free-hcv-data-published-2015-10-06 | nan | nan | Merck & Co. Inc.MRK announced that results from the first phase III study (C-SURFER) on an investigational, once-daily, all-oral, ribavirin-free chronic hepatitis C virus (HCV) combination regimen of elbasvir and grazoprevir (50mg/100mg) were published in The Lancet.
The study was conducted on treatment-naive as well as treatment-experienced patients suffering from advanced chronic kidney disease (CKD) stages 4 or 5 and chronic HCV genotype 1 (GT1) infection. It included a small phase II pharmacokinetic assessment as well. Data from the study were already presented at The International Liver Congress in Apr 2015.
We note that Merck is developing elbasvir/grazoprevir for multiple HCV genotypes under a broad clinical program including studies on difficult-to-treat conditions like cirrhosis, advanced CKD, HIV/HCV co-infection, inherited blood disorders and those on opiate substitution therapy. Currently, the elbasvir/grazoprevir combination is under priority review with the FDA for the treatment of adults with chronic HCV GT1, 4 or 6 infections, with a response from the agency expected by Jan 28, 2016.
The combination regimen enjoys Breakthrough Therapy status in the U.S. for the treatment of chronic HCV GT1 infection with end-stage renal disease on hemodialysis and chronic HCV GT4 infection. Additionally, the elbasvir/grazoprevir combination is under review in the EU for the treatment of adults suffering from chronic HCV GT1, 3, 4 or 6 infections.
Merck's efforts to build its HCV portfolio are encouraging. However, we remind investors that competition in the HCV market is gradually intensifying. Gilead Sciences' GILD Sovaldi and Harvoni and AbbVie's ABBV Viekira Pak are already approved for the treatment of this disease.
Merck holds a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector is Amgen Inc. AMGN , carrying a Zacks Rank #1 (Strong Buy). AbbVie holds a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MERCK & CO INC (MRK): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
AMGEN INC (AMGN): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Gilead Sciences' GILD Sovaldi and Harvoni and AbbVie's ABBV Viekira Pak are already approved for the treatment of this disease. AbbVie holds a Zacks Rank #2 (Buy). Click to get this free report MERCK & CO INC (MRK): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report MERCK & CO INC (MRK): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Gilead Sciences' GILD Sovaldi and Harvoni and AbbVie's ABBV Viekira Pak are already approved for the treatment of this disease. AbbVie holds a Zacks Rank #2 (Buy). | Click to get this free report MERCK & CO INC (MRK): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Gilead Sciences' GILD Sovaldi and Harvoni and AbbVie's ABBV Viekira Pak are already approved for the treatment of this disease. AbbVie holds a Zacks Rank #2 (Buy). | Gilead Sciences' GILD Sovaldi and Harvoni and AbbVie's ABBV Viekira Pak are already approved for the treatment of this disease. AbbVie holds a Zacks Rank #2 (Buy). Click to get this free report MERCK & CO INC (MRK): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. |
26828.0 | 2015-10-06 00:00:00 UTC | Valeant Shares Down 37% since August; More Pain Ahead? | ABBV | https://www.nasdaq.com/articles/valeant-shares-down-37-since-august-more-pain-ahead-2015-10-06 | nan | nan | Shares of Valeant PharmaceuticalsVRX have plummeted around 37% in the last two months. The downtrend was particularly steep in September after Democratic presidential candidate Hillary Clinton commented on the rising prices of specialty drugs that led to a massive selloff in the biotech sector.
Last week, all 18 Democratic members of the House of Committee on Oversight and Government Reform requested Chairman Jason Chaffetz to issue a subpoena to compel Valeant to provide documents relating to the massive price hike of two of its drugs.
The drugs in question are Isuprel and Nitropres. These drugs were acquired by the company earlier in 2015 and are used by hospitals and other providers to treat serious heart conditions. Since the acquisition, the company has increased their prices by 212% and 525%, respectively. We note that Valeant has been quite aggressive on the acquisition front over the last few years and has now come into the spotlight for hiking prices of the drugs it purchased.
The Democrats believe drug companies should be accountable when they deploy the strategy of buying old, neglected drugs and convert them into high-priced 'specialty' drugs. Valeant was accused of following the same business model as Martin Shkreli, whose company had spiked the price of Daraprim from $13.50 to $750.
The Road Ahead
In response, the chairman of the company has written a letter to its shareholders stating that the company is well-positioned for strong organic growth, even with negligible or no price increases. However, we believe Valeant will not be able to get away with this easily. Hence, investors will continue to bear the brunt of the decline in its stock price.
Pricing dynamics in the health care sector have been in the spotlight since 2014. We remind investors that pharmacy benefit manager Express Scripts Holding Co. ESRX released data in Mar 2015, wherein it was mentioned how new expensive hepatitis C (HCV) therapies, along with the exploitation of loopholes for compounded medications, fueled a phenomenal 13.1% surge in drug spending in the U.S. in 2014.
The Democrats are expected to focus on this issue strongly. It remains to be seen what strategy Valeant will adopt to counter the negative investor sentiment. We expect the company to throw some light on the same on its third-quarterearnings callscheduled for Oct 19.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >> - See more at: http://www.zacks.com/stock/news/192573/apollo-bids-higher-for-xchanging-takeover-shares-up-21#sthash.etqxrSbo.dpuf
Valeant currently holds a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Abbott Laboratories ABT and AbbVie, Inc. ABBV . Both carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >> - See more at: http://www.zacks.com/stock/news/192573/apollo-bids-higher-for-xchanging-takeover-shares-up-21#sthash.etqxrSbo.dpuf
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >> - See more at: http://www.zacks.com/stock/news/192573/apollo-bids-higher-for-xchanging-takeover-shares-up-21#sthash.etqxrSbo.dpuf
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report
VALEANT PHARMA (VRX): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the health care sector are Abbott Laboratories ABT and AbbVie, Inc. ABBV . Click to get this free report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. The downtrend was particularly steep in September after Democratic presidential candidate Hillary Clinton commented on the rising prices of specialty drugs that led to a massive selloff in the biotech sector. | Some better-ranked stocks in the health care sector are Abbott Laboratories ABT and AbbVie, Inc. ABBV . Click to get this free report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Abbott Laboratories ABT and AbbVie, Inc. ABBV . Last week, all 18 Democratic members of the House of Committee on Oversight and Government Reform requested Chairman Jason Chaffetz to issue a subpoena to compel Valeant to provide documents relating to the massive price hike of two of its drugs. | Click to get this free report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Abbott Laboratories ABT and AbbVie, Inc. ABBV . Since the acquisition, the company has increased their prices by 212% and 525%, respectively. |
26829.0 | 2015-10-06 00:00:00 UTC | Baxalta, Momenta Begin Pivotal Study on Biosimilar of Humira | ABBV | https://www.nasdaq.com/articles/baxalta-momenta-begin-pivotal-study-on-biosimilar-of-humira-2015-10-06 | nan | nan | Baxalta IncorporatedBXLT is the latest company to join the race for biosimilars. The company along with Momenta Pharmaceuticals, Inc. MNTA announced the commencement of a pivotal study on their biosimilar candidate, M923, in patients suffering from chronic plaque psoriasis. The companies are developing M923 as a biosimilar version of AbbVie Inc.'s ABBV best-selling drug, Humira (adalimumab). Momenta's shares were up 3.5% on the news.
The randomized, double-blind, active control, multi-center study will be conducted to compare the safety, efficacy and immunogenicity of M923 with Humira. If all goes well, the companies intend to file for approval in 2017 and potentially launch the candidate in 2018.
We note that Humira is approved for the treatment of patients with autoimmune/inflammatory diseases including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis and plaque psoriasis. According to an Evaluate Pharma report (8th Edition - Jun 2015), Humira was the top-selling product in 2014 with the drug generating worldwide sales of approximately $13 billion.
We remind investors that Baxalta is collaborating with Momenta for the development and commercialization of M923. In addition, Baxalta is developing a biosimilar version of Amgen Inc.'s AMGN Enbrel. The candidate is currently in phase III development for rheumatoid arthritis and psoriasis.
We are encouraged by the company's progress with M923. According to sources, the market for biosimilars can grow to $20 billion in 2020. Not surprisingly, pharmaceutical and biotech companies are racing to develop biosimilars.
Both Baxalta and Momenta are Zacks Rank #3 (Hold) stocks. Amgen is a better-ranked stock in the biotech sector carrying a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AMGEN INC (AMGN): Free Stock Analysis Report
MOMENTA PHARMA (MNTA): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
BAXALTA INC (BXLT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The companies are developing M923 as a biosimilar version of AbbVie Inc.'s ABBV best-selling drug, Humira (adalimumab). Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report MOMENTA PHARMA (MNTA): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report BAXALTA INC (BXLT): Free Stock Analysis Report To read this article on Zacks.com click here. The company along with Momenta Pharmaceuticals, Inc. MNTA announced the commencement of a pivotal study on their biosimilar candidate, M923, in patients suffering from chronic plaque psoriasis. | The companies are developing M923 as a biosimilar version of AbbVie Inc.'s ABBV best-selling drug, Humira (adalimumab). Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report MOMENTA PHARMA (MNTA): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report BAXALTA INC (BXLT): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report MOMENTA PHARMA (MNTA): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report BAXALTA INC (BXLT): Free Stock Analysis Report To read this article on Zacks.com click here. The companies are developing M923 as a biosimilar version of AbbVie Inc.'s ABBV best-selling drug, Humira (adalimumab). The company along with Momenta Pharmaceuticals, Inc. MNTA announced the commencement of a pivotal study on their biosimilar candidate, M923, in patients suffering from chronic plaque psoriasis. | The companies are developing M923 as a biosimilar version of AbbVie Inc.'s ABBV best-selling drug, Humira (adalimumab). Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report MOMENTA PHARMA (MNTA): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report BAXALTA INC (BXLT): Free Stock Analysis Report To read this article on Zacks.com click here. The company along with Momenta Pharmaceuticals, Inc. MNTA announced the commencement of a pivotal study on their biosimilar candidate, M923, in patients suffering from chronic plaque psoriasis. |
26830.0 | 2015-10-06 00:00:00 UTC | Why AbbVie Inc.'s Shares Slumped 13% in September | ABBV | https://www.nasdaq.com/articles/why-abbvie-incs-shares-slumped-13-september-2015-10-06 | nan | nan | Amid a widespread industry sell-off, and in the wake of positive trial data from competitor Gilead Sciences , shares in AbbVie, Inc tumbled by 12.8% last month.
AbbVie is under pressure to overcome looming headwinds tied to the fast-approaching patent expiration on its top selling drug, Humira, but its unclear whether its efforts will succeed. In the following slideshow, I highlight the risks to AbbVie and how it hopes to overcome them.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
Why AbbVie Slumped 13% In September from
The article Why AbbVie Inc.'s Shares Slumped 13% in September originally appeared on Fool.com.
Todd Campbell owns shares of Gilead Sciences. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Amid a widespread industry sell-off, and in the wake of positive trial data from competitor Gilead Sciences , shares in AbbVie, Inc tumbled by 12.8% last month. AbbVie is under pressure to overcome looming headwinds tied to the fast-approaching patent expiration on its top selling drug, Humira, but its unclear whether its efforts will succeed. In the following slideshow, I highlight the risks to AbbVie and how it hopes to overcome them. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Amid a widespread industry sell-off, and in the wake of positive trial data from competitor Gilead Sciences , shares in AbbVie, Inc tumbled by 12.8% last month. AbbVie is under pressure to overcome looming headwinds tied to the fast-approaching patent expiration on its top selling drug, Humira, but its unclear whether its efforts will succeed. | Why AbbVie Slumped 13% In September from The article Why AbbVie Inc.'s Shares Slumped 13% in September originally appeared on Fool.com. Amid a widespread industry sell-off, and in the wake of positive trial data from competitor Gilead Sciences , shares in AbbVie, Inc tumbled by 12.8% last month. AbbVie is under pressure to overcome looming headwinds tied to the fast-approaching patent expiration on its top selling drug, Humira, but its unclear whether its efforts will succeed. | Amid a widespread industry sell-off, and in the wake of positive trial data from competitor Gilead Sciences , shares in AbbVie, Inc tumbled by 12.8% last month. AbbVie is under pressure to overcome looming headwinds tied to the fast-approaching patent expiration on its top selling drug, Humira, but its unclear whether its efforts will succeed. In the following slideshow, I highlight the risks to AbbVie and how it hopes to overcome them. |
26831.0 | 2015-10-03 00:00:00 UTC | Healthcare's Trick or Treats: What We're Watching in October | ABBV | https://www.nasdaq.com/articles/healthcares-trick-or-treats-what-were-watching-october-2015-10-03 | nan | nan | The highly anticipated switchover to ICD-10 medical coding kicks October off, and an FDA decision later in the month could move the needle at Shire Plc . All this and more on today's episode of Industry Focus.
A full transcript follows the video.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
Kristine Harjes: What to watch in October. This is Industry Focus.
Welcome to Industry Focus, healthcare edition. Like it or not, October is here. I'd say it's officially time to get in the fall mind-set, start thinking about Halloween costumes and maybe what the month has in store for the healthcare industry. I'm Kristine Harjes and joining me to chat via Skype is healthcare contributor Todd Campbell. Todd, can you believe we're talking about October already?
Todd Campbell: I really can't -- it's a gray sky out here today in New England, and I'm already starting to think about my winter vacation plans. It's just not right.
Harjes: You're way ahead of me. I'm still dwelling on the Thanksgiving plans and Halloween costumes.
Campbell: What will you dress as this year?
Harjes: I have no idea. October sprung up on me, but I guess now that we're here we've got two things on our mind for this month. There's a PDUFA date coming up at the end of the month and a shift in the way medical coding is done.
We'll start with the latter since this change is going into effect tomorrow, October 1. All healthcare providers, starting tomorrow, are going to have to shift from a standard of medical codes known as ICD-9, to an updated version known as ICD-10.
Todd, can you give our listeners some background?
Campbell: Sure. I think the easiest way to explain this is just to think about it from the doctor's perspective. If you're a patient and you go in and you get treatment, your doctor looks at you and tells you what you can do to improve your condition and then sends you on your way.
But there's a lot of back-office things that occur at the doctor's office after that visit. That includes figuring out how they're going to get paid for providing that service to you. One of the ways they do that is by using a coding system based upon whatever it was you discussed with your doctor that day. Previously, until tomorrow, the U.S. was using ICD-9 and that was a very antiquated coding system. This has been around for almost 40 years.
Harjes: Yeah, it's been the standard since 1979.
Campbell: Yeah, getting very long in the tooth. People argue that it's an incredibly inefficient way to bill for services because it was put in place prior to all the technology that allows for online billing of an insurance company, or to Medicare, which is obviously the granddaddy for a lot of these providers and sources of income.
Harjes: Meanwhile, all the other countries have been using ICD-10, which is the new version of this coding system, for more than a decade and the U.S. is the only country in the industrialized world that's still holding out.
Campbell: We've absolutely been dragging our feet on this and it's much to the -- all these foreign countries are like "Come on!" They'll pull kicking and screaming and they want to be able to share data and come up with new findings as a result, but the U.S. has been reticent to disrupt how healthcare is provided. Obviously, switching over from a system that has less than 20,000 healthcare codes to a system that has 130,000 to 140,000 codes is no small feat.
It's also a pricey and time-consuming prospect. Hopefully, providers have taken the initiative and gotten on top of this because over the course of the last couple years as deadlines were approaching to get us switched over to ICD-10, providers continually pushed back and said they needed more time.
Harjes: This switchover was supposed to happen a long time ago and private insurers have signals that they're ready. They've said to bring it on and they want this updated version, but it's the providers themselves, the healthcare practices that are dragging their feet. Apparently, in October last year 82% of healthcare practices have said they're not quite ready for it and needed more time.
An entire year was given as an extension and we're now finally bumping up against the date, tomorrow, when the switch will finally be made.
Campbell: Doctors are pretty pressed for time as it is. I think a lot of them were looking at practicing medicine rather than dealing with the back-office nightmares that are likely to occur. The other issue is when you switch over from something so much more complex, something that is brand-new -- anyone who's coding in medical offices today has been using this ICD-9 for their entire career.
It's not like they've changed many times and this is just one more change. There are a lot of opportunities for error and in that error, if there is error; that could significantly derail the income stream for these practices. If you don't code correctly, the payer can deny the claim.
If the payer denies the claim, that means the doctor will then have to jump through many more hoops to provide the information necessary to that payer. That means there could be potential delays in receiving payment, it also means potentially never receiving payment depending on the certain situation.
There's a lot of reasons that doctors have basically put off getting things in place until the last minute. The vast majority should be OK. A study that was done in the middle of September showed that only 30% were ready to go as of September 15, but well over 80% said that they're most likely going to be ready and more than 90% said they'll probably be ready.
Harjes: "Probably" is the key word there. I've seen a lot of responses from different doctors in practices throwing it out there on different forums saying they'll probably be OK, but they're not sure. I saw once a group of physicians were polled and they said that 33% of them took out a line of credit to protect against the financial impact against potential delays.
Campbell: Yeah. That was a standard operating procedure recommendation from a lot of the companies that have been hired as consultants to come in and help practices prepare for this launch. Essentially, they'll need to protect their revenue stream by knowing you can tap into money if there are delays.
Harjes: As investors, what does this mean for us?
Campbell: There are a couple different takeaways. There could be some difficulties for hospitals, but most hospitals that are publicly traded are large institutions. They have tremendous resources, most likely the impact on them -- if any -- would be pretty small. Instead, a much bigger impact would probably come in the form of upside to healthcare IT companies whose software is being deployed to make it easier to collect the revenue from the patient, or the payer.
Also, the software that they're selling that's going to leverage all this new data -- think about all the opportunity that having so many more codes they provide, you'll now be able to parse that data in so many different ways and that could be used to help design treatment outcomes to evaluate the quality of care that's being provided, to better identify global threats of epidemics such as Ebola, or something else occurring in the future.
There are a lot of opportunities here for those companies that are going to be analyzing the data. I like Cerner , which is one of the companies in that space. They're a big player and the second largest in market share in many of these markets. I also like Athenahealth , which has a very big present in the private practices of doctor's offices and helping them get up to speed in the healthcare IT.
Harjes: You mentioned the granularity of the data and I totally agree that there's so much opportunity there, and in this new catalog of codes, you've got more than 200 different codes for diabetes alone, there's more than 100 different codes for gout. I think I even saw that the government's listed more than 30 different codes for industries caused by acts of terrorism.
You get really specific with this kind of data. The ability to analyze it just increases exponentially. I think that could be good news for insurers, too.
Campbell: Absolutely. As you're able to dig deeper into this data, you should be able to find cost savings. It increases efficiency, you should be able to design treatment protocols that work more effectively that would reduce readmissions or disease progression. All of those things could result in cost savings for payers like insurers.
Harjes: This does seem like this entire shift, even if it does cause some bumps in the road for small practices in the short term, healthcare IT is still going to be big. All these new waves of technology are going to continue to reform the industry and probably make it even more profitable, hopefully across the board.
Campbell: None of us probably wanted to upgrade our Windows software, but anybody who's trying to run Windows 3 right now is probably struggling.
Harjes: Exactly. Before we move on I'd like to announce a special offer that we have for you guys today. As a loyal Industry Focus listener you have access to a special discount on The Motley Fool's flagship stock-picking service called Stock Advisor . It works out to $129 for a full two-year subscription.
This is a really awesome product. If you'd like to take advantage of the offer, or even learn some more about the service, check out focus.fool.com. Again, this is just for you guys, our Industry Focus listeners -- focus.fool.com. I would highly recommend that you check it out.
Moving on, the most important PDUFA date of October is coming up at the end of the month. Todd, what's going on?
Campbell: One of the things I like to do -- and I think this is helpful for all investors who are listening, or watching on the program -- at the end of every month, go online and do a bit of due diligence and look and see what's on the calendar at the FDA because decisions that are coming out of the FDA can have a huge impact on the direction of a stock price in the near term.
While you shouldn't be investing over a period of weeks, you need to have a longer-term thesis, you can't ignore the potential impact of a new drug that could potentially be coming to market. Looking at the calendar for this coming month, the company that I think could really see the needle move on an approval would be Shire. Shire submitted an application for approval for a treatment for treating dry eye disease earlier this year.
One of the most common complaints of people going into eye doctors is the negative effects, and pain associated with dry eye. Shire has a drug that it believes will do a better job than anything that's currently out there at helping to relieve the symptoms of this condition. If so, Shire thinks this drug could be worth $1 billion a year in sales at some point.
Harjes: Care to take a stab at the pronunciation of this drug?
Campbell: Oh, boy. Lifitegrast. I always struggle because with the generic names of the drugs, it's either to-may-to or to-mah-to. Lifitegrast is what I'll go with today.
Harjes: OK. We can go with that. Lifitegrast.
Campbell: This is an intriguing drug. One of the reasons I'm so intrigued by it is that a dry eye typically occurs more frequently as you get older. As a long term investor, one of the trends I think investors should be focusing on is an ever larger, older population her in America. As baby boomers continue to get older, there's likely more baby boomers who are going to be going to their eye doctors and complaining about this condition.
If so, the demand for this drug could be strong. If it is strong and sales are strong, then it certainly helps propel Shire toward that goal they have of 10 billion in sales by 2020, which would roughly be a doubling from where they were when AbbVie was courting them as part of that failed merger.
Harjes: Right. I think one of the most promising signs for this drug and its upcoming potential approval is the fact that it received priority review. What exactly does that mean? Why is that so important?
Campbell: Typically speaking, when you have a drug in development coming through the works in the pipeline, it addresses a condition that is an "unmet need." The FDA will give you a perk. They will say that they understand that they're developing something for a condition that doesn't have a lot of effective therapies for.
What' they'll do is cut the amount of time that they spend in reviewing that application. In this case they're reducing the application review to 8 months from 12 months. In reducing that time and giving it priority review, that theoretically allows the drug maker to get that drug to the market more quickly and to capture those additional months of sales. For a $1 billion drug, that can be pretty substantial.
Harjes: Exactly. One of the things that's got people talking about this drug is that the phase 3 trials produced mixed results and there's already a drug developed by Allergan that's out there to treat this disease, but I think getting priority review for this drug from the FDA is a really good sign for it. There's got to be something there that the agency is seeing that could revolutionize this treatment space.
Campbell: Yeah. Again, that phase 3 trial does make it really interesting. That's another reason why we want to be watching this as investors this month. On the one hand it improved the symptoms of dry eye, but on the other hand key biomarkers that are used to evaluate dry eye didn't really improve. There's a bit of a disconnect on the efficacy side of this.
However, on the safety side, it did appear to fine. There were no real serious adverse events that led to mass discontinuation of this drug. I think what will probably happen is -- if I were going to handicap this -- the FDA will probably say they've got a safe drug for a condition that there aren't a lot of effective therapies for, and it works on the symptoms. Then they'll go ahead and approve it.
There is the risk that they approve it conditionally where they say they'll approve it but the company then has to come out with another study just to resolve that discrepancy in the primary outcomes data. If so, that would hinder the profitability of this drug for Shire because trials are expensive.
Harjes: Exactly. The other thing to keep in mind is that the 25th is a Sunday. I'd say it's more likely than not that we'll actually hear an answer before then. Definitely keep your eyes peeled. This will be a really interesting catalyst for Shire.
As always, people on this program may have interests in the stocks that they talk about, and The Motley Fool may have formal recommendations for or against those stocks. So, don't buy or sell anything based solely on what you hear on this program. Do your research on Shire and Allergan and everyone else that we've mentioned today. Keep your eyes out for this FDA decision coming up sometime prior even on October 25.
Todd, thanks as always for being here and folks, thanks for joining us today.
The article Healthcare's Trick or Treats: What We're Watching in October originally appeared on Fool.com.
Kristine Harjes has no position in any stocks mentioned. Todd Campbell has no position in any stocks mentioned. The Motley Fool recommends Athenahealth and Cerner. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | If it is strong and sales are strong, then it certainly helps propel Shire toward that goal they have of 10 billion in sales by 2020, which would roughly be a doubling from where they were when AbbVie was courting them as part of that failed merger. The highly anticipated switchover to ICD-10 medical coding kicks October off, and an FDA decision later in the month could move the needle at Shire Plc . Instead, a much bigger impact would probably come in the form of upside to healthcare IT companies whose software is being deployed to make it easier to collect the revenue from the patient, or the payer. | If it is strong and sales are strong, then it certainly helps propel Shire toward that goal they have of 10 billion in sales by 2020, which would roughly be a doubling from where they were when AbbVie was courting them as part of that failed merger. The highly anticipated switchover to ICD-10 medical coding kicks October off, and an FDA decision later in the month could move the needle at Shire Plc . People argue that it's an incredibly inefficient way to bill for services because it was put in place prior to all the technology that allows for online billing of an insurance company, or to Medicare, which is obviously the granddaddy for a lot of these providers and sources of income. | If it is strong and sales are strong, then it certainly helps propel Shire toward that goal they have of 10 billion in sales by 2020, which would roughly be a doubling from where they were when AbbVie was courting them as part of that failed merger. Harjes: You mentioned the granularity of the data and I totally agree that there's so much opportunity there, and in this new catalog of codes, you've got more than 200 different codes for diabetes alone, there's more than 100 different codes for gout. Campbell: One of the things I like to do -- and I think this is helpful for all investors who are listening, or watching on the program -- at the end of every month, go online and do a bit of due diligence and look and see what's on the calendar at the FDA because decisions that are coming out of the FDA can have a huge impact on the direction of a stock price in the near term. | If it is strong and sales are strong, then it certainly helps propel Shire toward that goal they have of 10 billion in sales by 2020, which would roughly be a doubling from where they were when AbbVie was courting them as part of that failed merger. Campbell: Doctors are pretty pressed for time as it is. There are a lot of opportunities here for those companies that are going to be analyzing the data. |
26832.0 | 2015-10-01 00:00:00 UTC | Novartis Announces Positive Data on Arthritis Drug Cosentyx | ABBV | https://www.nasdaq.com/articles/novartis-announces-positive-data-on-arthritis-drug-cosentyx-2015-10-01 | nan | nan | NovartisNVS announced results from a phase III study, FUTURE 1, on Cosentyx for the treatment of psoriatic arthritis.
The results were published in the New England Journal of Medicine .
The multi-center, randomized, placebo-controlled phase III study was conducted to evaluate the efficacy of Cosentyx in IL-17A inhibition in patients suffering from psoriatic arthritis. The study met its primary endpoint as Cosentyx demonstrated a 20% reduction in the American College of Rheumatology response criteria (ACR 20) at the end of week 24. The study showed that treatment with Cosentyx resulted in rapid and significant clinical improvements versus placebo.
Moreover, Cosentyx met all secondary endpoints, including improvements in skin and joint diseases, and joint structural damage progression. It was seen that approximately half of the patients in both Cosentyx-treated dose groups (150-mg and 75-mg) achieved an ACR 20 response as compared to only 17.3% in the placebo arm.
We remind investors that Cosentyx (at a dose of 300 mg) was approved in Europe as a first-line systemic treatment of moderate-to-severe plaque psoriasis in adult patients in Jan 2015. The drug was also approved in the U.S. as a treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy (light therapy).
Novartis made regulatory submissions across the world for the indication of psoriatic arthritis and ankylosing spondylitis. A potential label expansion of the drug will further boost its growth prospects.
We also note that Novartis had undertaken a series of actions to reorganize its portfolio in 2014 in order to focus on its core businesses of pharmaceuticals, eye care and generics. However, Novartis is expected to face headwinds this year in the form of generic competition for some products as well as negative currency movement.
Novartis currently carries a Zacks Rank #4 (Sell). Some better-ranked health care stocks are Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . All three carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked health care stocks are Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . Click to get this free report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. The multi-center, randomized, placebo-controlled phase III study was conducted to evaluate the efficacy of Cosentyx in IL-17A inhibition in patients suffering from psoriatic arthritis. | Click to get this free report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked health care stocks are Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . We remind investors that Cosentyx (at a dose of 300 mg) was approved in Europe as a first-line systemic treatment of moderate-to-severe plaque psoriasis in adult patients in Jan 2015. | Click to get this free report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked health care stocks are Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . NovartisNVS announced results from a phase III study, FUTURE 1, on Cosentyx for the treatment of psoriatic arthritis. | Click to get this free report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked health care stocks are Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . NovartisNVS announced results from a phase III study, FUTURE 1, on Cosentyx for the treatment of psoriatic arthritis. |
26833.0 | 2015-10-01 00:00:00 UTC | Celsion Begins Patient Enrollment in Ovarian Cancer Study | ABBV | https://www.nasdaq.com/articles/celsion-begins-patient-enrollment-in-ovarian-cancer-study-2015-10-01 | nan | nan | Celsion CorporationCLSN announced that it has enrolled the first patient in a phase Ib dose escalating clinical trial, OVATION.
The study will combine GEN-1, with the standard-of-care for the treatment of newly-diagnosed patients suffering from ovarian cancer, who will undergo neoadjuvant chemotherapy. GEN-1 is Celsion's DNA-based immunotherapy.
The study is being conducted to identify a safe, tolerable and therapeutically active dose of GEN-1 by recruiting and maximizing an immune response.
The trial will enroll three to six patients per dose level, and evaluate safety and efficacy of the therapy. It will also determine an optimal dose for a follow-on phase I/II study combining GEN-1 with Avastin and Doxil.
Moreover, the study aims to assess how cytokine-based compounds such as GEN-1 directly affects ovarian cancer cells and the tumor microenvironment in newly diagnosed patients.
Celsion plans to initiate the trial in two additional sites in the coming months. Interim results from the study are expected in the fourth quarter of 2015. Additionally, Celsion expects to continue the study into the first half of 2015 with higher doses of GEN-1.
Earlier, Celsion had reported positive safety and encouraging results from a phase I study with GEN-1, when given as monotherapy in patients with peritoneally metastasized ovarian cancer and in combination with PEGylated doxorubicin in patients suffering from platinum-resistant ovarian cancer.
Meanwhile, GEN-1 also showed preclinical activity in glioblastoma multiforme (brain cancer). Consequently, Celsion plans to initiate a phase I study.
We note that Celsion's lead program, ThermoDox, is currently in a phase III study for primary liver cancer and a phase II study for recurrent chest wall breast cancer.
Celsion currently carries a Zacks Rank #2 (Buy). Other favorably placed stocks in the health care sector include Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . All three carry the same rank as Celsion.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CELSION CORP (CLSN): Free Stock Analysis Report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other favorably placed stocks in the health care sector include Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . Click to get this free report CELSION CORP (CLSN): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Celsion CorporationCLSN announced that it has enrolled the first patient in a phase Ib dose escalating clinical trial, OVATION. | Click to get this free report CELSION CORP (CLSN): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Other favorably placed stocks in the health care sector include Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . Click to get this free report >> Want the latest recommendations from Zacks Investment Research? | Click to get this free report CELSION CORP (CLSN): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Other favorably placed stocks in the health care sector include Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . Earlier, Celsion had reported positive safety and encouraging results from a phase I study with GEN-1, when given as monotherapy in patients with peritoneally metastasized ovarian cancer and in combination with PEGylated doxorubicin in patients suffering from platinum-resistant ovarian cancer. | Click to get this free report CELSION CORP (CLSN): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Other favorably placed stocks in the health care sector include Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . Earlier, Celsion had reported positive safety and encouraging results from a phase I study with GEN-1, when given as monotherapy in patients with peritoneally metastasized ovarian cancer and in combination with PEGylated doxorubicin in patients suffering from platinum-resistant ovarian cancer. |
26834.0 | 2015-10-01 00:00:00 UTC | Infinity (INFI) Up, Set to Get Duvelisib Milestone Payment | ABBV | https://www.nasdaq.com/articles/infinity-infi-up-set-to-get-duvelisib-milestone-payment-2015-10-01 | nan | nan | Infinity Pharmaceuticals, Inc.INFI was up 6.6% after the company announced that the 120th patient has been enrolled in the phase II DYNAMO study. The global, open-label, single-arm study will evaluate the safety and efficacy of duvelisib in patients with refractory indolent non-Hodgkin lymphoma. The company expects to release top-line data from the DYNAMO study in the third quarter of 2016.
Completion of patient enrollment in the DYNAMO study has triggered a $130 million milestone payment from AbbVie Inc. ABBV , the company's worldwide development and commercialization partner for duvelisib in oncology. Infinity Pharma does not generate any product sales. In this scenario, the milestone payment is expected to provide the company with important financial resources.
So far, Infinity Pharma has received an upfront payment of $275 million and is set to receive the above mentioned milestone payment from AbbVie. Additionally, Infinity is eligible for regulatory and commercial milestones payments. While Infinity Pharma and AbbVie will jointly commercialize duvelisib and will share profits equally in the U.S., in ex-U.S. territories AbbVie will be responsible for the development and commercialization of duvelisib. Infinity will be eligible to receive tiered double-digit royalties on net product sales in ex-U.S. territories.
Apart from indolent non-Hodgkin lymphoma, duvelisib is also being evaluated for other indications including previously treated follicular lymphoma (DYNAMO+R - phase III study) and relapsed/refractory chronic lymphocytic leukemia (DUO - phase III study).
Both Infinity Pharma and AbbVie carry a Zacks Rank #2 (Buy). A couple of other well-ranked stocks in the health care sector include Anika Therapeutics Inc. ANIK and Regeneron Pharmaceuticals, Inc. REGN . Both stocks hold a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
REGENERON PHARM (REGN): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
INFINITY PHARMA (INFI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Completion of patient enrollment in the DYNAMO study has triggered a $130 million milestone payment from AbbVie Inc. ABBV , the company's worldwide development and commercialization partner for duvelisib in oncology. So far, Infinity Pharma has received an upfront payment of $275 million and is set to receive the above mentioned milestone payment from AbbVie. While Infinity Pharma and AbbVie will jointly commercialize duvelisib and will share profits equally in the U.S., in ex-U.S. territories AbbVie will be responsible for the development and commercialization of duvelisib. | Completion of patient enrollment in the DYNAMO study has triggered a $130 million milestone payment from AbbVie Inc. ABBV , the company's worldwide development and commercialization partner for duvelisib in oncology. Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report INFINITY PHARMA (INFI): Free Stock Analysis Report To read this article on Zacks.com click here. So far, Infinity Pharma has received an upfront payment of $275 million and is set to receive the above mentioned milestone payment from AbbVie. | Completion of patient enrollment in the DYNAMO study has triggered a $130 million milestone payment from AbbVie Inc. ABBV , the company's worldwide development and commercialization partner for duvelisib in oncology. While Infinity Pharma and AbbVie will jointly commercialize duvelisib and will share profits equally in the U.S., in ex-U.S. territories AbbVie will be responsible for the development and commercialization of duvelisib. Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report INFINITY PHARMA (INFI): Free Stock Analysis Report To read this article on Zacks.com click here. | Completion of patient enrollment in the DYNAMO study has triggered a $130 million milestone payment from AbbVie Inc. ABBV , the company's worldwide development and commercialization partner for duvelisib in oncology. Both Infinity Pharma and AbbVie carry a Zacks Rank #2 (Buy). So far, Infinity Pharma has received an upfront payment of $275 million and is set to receive the above mentioned milestone payment from AbbVie. |
26835.0 | 2015-09-30 00:00:00 UTC | The Zacks Analyst Blog Highlights: Express Scripts, AbbVie, Amgen, Anika Therapeutics and PDL BioPharma | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-express-scripts-abbvie-amgen-anika-therapeutics-and-pdl | nan | nan | For Immediate Release
Chicago, IL - September 30, 2015 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Express Scripts ( ESRX ), AbbVie Inc. ( ABBV ), Amgen ( AMGN ), Anika Therapeutics Inc. ( ANIK ) and PDL BioPharma, Inc. ( PDLI ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .
Here are highlights from Tuesday's Analyst Blog:
3 Compelling Biotech Stocks at Bargain Prices
Democratic Presidential candidate Hillary Clinton's "price gouging" tweet last week triggered a major sell-off in the biotech sector. With most biotech companies trading in the red since then, the NASDAQ Biotechnology Index and NYSE ARCA BIOTECH INDEX plunged 18.3% and 16.1%, respectively.
After Turing Pharmaceuticals hiked the price of its anti-parasitic drug Daraprim to $750 from $13.50 per tablet, Clinton tweeted that " Price gouging like this in the specialty drug market is outrageous. Tomorrow I'll lay out a plan to take it on. -H." This set the snowball rolling (read more: 5 Biotech Stocks Hit Hard by Hillary Clinton's Tweet ).
Pricing Concerns
Pricing concerns in the biotech sector are not new. High prices of biotech drugs have been on and off the limelight for some time now. Toward the end of last year, the sector had witnessed another sell-off when pharmacy benefit manager Express Scripts ( ESRX ) entered into an agreement with AbbVie Inc. ( ABBV ), adding the latter's lower priced Viekira Pak to its formulary, as an exclusive option for patients suffering from genotype 1 hepatitis C virus (HCV) infection. The PBM removed Gilead's high-priced Sovaldi and Harvoni and Johnson & Johnson's HCV drug Olysio from its National Preferred Formulary.
In the meantime, the first biosimilar, Zarxio, was launch by Sandoz in the U.S. Zarxio is a biosimilar version of Amgen's ( AMGN ) blockbuster drug, Neupogen. With several other companies including Pfizer, which acquired biosimilar maker Hospira, looking to introduce biosimilar drugs in the U.S., fresh bouts of speculation about pricing of branded drugs are not uncommon.
Trend Reversal in the Cards?
Despite conjectures and suppositions doing the rounds, the fundamental strength of the biotech sector remains intact. Product approvals, encouraging pipeline updates and a flurry of M&A activity should continue to make biotech a lucrative option. There are several catalysts that could lead to a trend reversal in the sector.
We have identified stocks that are trading below their inherent value. We have also narrowed down our choices with the help of the new Style Score System selecting stocks with a Value Style Score of "A" or "B," which when combined with a Zacks Rank #1 (Strong Buy) or Zacks Rank #2 (Buy) offer good investment opportunities.
These are stocks that have witnessed price depreciation last week in spite of their strong fundamentals. These attractive value stocks are trading at a bargain price and could fetch higher returns on market correction.
3 Cheap Value Picks
Our first pick is of course Amgen , a leading biotech company with a strong presence in the supportive cancer care, nephrology and autoimmune disease markets. Amgen's portfolio includes Enbrel, Kyprolis, Sensipar, Prolia and Xgeva among others. The company's PCSK9 inhibitor Repatha for cholesterol management is approved in both the U.S. and EU and has blockbuster potential.
This Thousand Oaks, CA-based company carries a Zacks Rank #2. The company has seen its price fall 12.2% since Clinton's tweet. Amgen currently has a Value Style Score of B.
Our second pick is Anika Therapeutics Inc. ( ANIK ). The Bedford, MA-based company is focused on developing and commercializing drugs for products for tissue protection, healing, and repair based on hyaluronic acid. The company markets over 20 products, primarily in Europe.
This Zacks Rank #1 stock has witnessed a price fall of 7.2% since Sep 21. Anika boasts a Value Style Score of A.
PDL BioPharma, Inc. ( PDLI ) is also looking attractive with a Zacks Rank #2 and a Value Style Score of A. The stock has fallen 4.7% since the controversy. Headquartered in Incline Village, NV, the company focuses on the management of intellectual property assets. PDL BioPharma is in collaboration with an established player like Roche and receives royalties on sales of humanized antibody products such as Avastin, Herceptin, Xolair, Kadcyla, Perjeta, Tysabri and Actemra.
What's Ahead?
Despite challenges like increasing competition, pricing pressure and the entry of biosimilars in the U.S., we believe that the key fundamentals in the biotech space are still intact. With the upcoming third-quarter earnings season and several product approvals and encouraging pipeline news, biotech remains a very happening corner of the investment world.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today . Find out What is happening in the stock market today on zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
AMGEN INC (AMGN): Free Stock Analysis Report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
PDL BIOPHARMA (PDLI): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include the Express Scripts ( ESRX ), AbbVie Inc. ( ABBV ), Amgen ( AMGN ), Anika Therapeutics Inc. ( ANIK ) and PDL BioPharma, Inc. ( PDLI ). Toward the end of last year, the sector had witnessed another sell-off when pharmacy benefit manager Express Scripts ( ESRX ) entered into an agreement with AbbVie Inc. ( ABBV ), adding the latter's lower priced Viekira Pak to its formulary, as an exclusive option for patients suffering from genotype 1 hepatitis C virus (HCV) infection. Click to get this free report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report PDL BIOPHARMA (PDLI): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include the Express Scripts ( ESRX ), AbbVie Inc. ( ABBV ), Amgen ( AMGN ), Anika Therapeutics Inc. ( ANIK ) and PDL BioPharma, Inc. ( PDLI ). Click to get this free report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report PDL BIOPHARMA (PDLI): Free Stock Analysis Report To read this article on Zacks.com click here. Toward the end of last year, the sector had witnessed another sell-off when pharmacy benefit manager Express Scripts ( ESRX ) entered into an agreement with AbbVie Inc. ( ABBV ), adding the latter's lower priced Viekira Pak to its formulary, as an exclusive option for patients suffering from genotype 1 hepatitis C virus (HCV) infection. | Click to get this free report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report PDL BIOPHARMA (PDLI): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include the Express Scripts ( ESRX ), AbbVie Inc. ( ABBV ), Amgen ( AMGN ), Anika Therapeutics Inc. ( ANIK ) and PDL BioPharma, Inc. ( PDLI ). Toward the end of last year, the sector had witnessed another sell-off when pharmacy benefit manager Express Scripts ( ESRX ) entered into an agreement with AbbVie Inc. ( ABBV ), adding the latter's lower priced Viekira Pak to its formulary, as an exclusive option for patients suffering from genotype 1 hepatitis C virus (HCV) infection. | Stocks recently featured in the blog include the Express Scripts ( ESRX ), AbbVie Inc. ( ABBV ), Amgen ( AMGN ), Anika Therapeutics Inc. ( ANIK ) and PDL BioPharma, Inc. ( PDLI ). Toward the end of last year, the sector had witnessed another sell-off when pharmacy benefit manager Express Scripts ( ESRX ) entered into an agreement with AbbVie Inc. ( ABBV ), adding the latter's lower priced Viekira Pak to its formulary, as an exclusive option for patients suffering from genotype 1 hepatitis C virus (HCV) infection. Click to get this free report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report PDL BIOPHARMA (PDLI): Free Stock Analysis Report To read this article on Zacks.com click here. |
26836.0 | 2015-09-30 00:00:00 UTC | Roche Presents Positive Data on Respiratory Drug Esbriet | ABBV | https://www.nasdaq.com/articles/roche-presents-positive-data-on-respiratory-drug-esbriet-2015-09-30 | nan | nan | RocheRHHBY announced positive data on idiopathic pulmonary fibrosis (IPF) drug, Esbriet from two phase III studies - ASCEND and CAPACITY. Data was presented at the European Respiratory Society congress in Amsterdam.
The results showed a 38% reduction in risk of death in patients suffering from IPF, who continued treatment with Esbriet for two years as compared with placebo.
The results reinforced the efficacy of Esbriet in reducing the risk of death in the long run in IPF patients. At the end of one year, the study had shown a 48%reduction in the risk of mortality after treatment with Esbriet.
Moreover, an ad-hoc analysis of the pooled data from ASCEND and CAPACITY showed that patients, who were hospitalized within the first six months of treatment, showed reduced risk of disease progression or death by more than two-thirds at one year on continued treatment with Esbriet.
We remind investors that Roche had added Esbriet to its respiratory portfolio following the acquisition of InterMune in Sep 2014. Esbriet was approved by the FDA in 2014 for the treatment of IPF. The drug was approved in Europe in 2011.
Roche's respiratory portfolio includes Xolair for severe asthma, Pulmozyme for cystic fibrosis, and Esbriet. The company also has a pipeline candidate - lebrikizumab - in phase III for severe uncontrolled asthma and targets IL-13. We are encouraged by Roche's efforts to broaden its drug portfolio beyond oncology.
Roche currently carries a Zacks Rank #3 (Hold). Some better-ranked health care stocks are Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . All three carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked health care stocks are Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. RocheRHHBY announced positive data on idiopathic pulmonary fibrosis (IPF) drug, Esbriet from two phase III studies - ASCEND and CAPACITY. | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked health care stocks are Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . RocheRHHBY announced positive data on idiopathic pulmonary fibrosis (IPF) drug, Esbriet from two phase III studies - ASCEND and CAPACITY. | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked health care stocks are Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . Moreover, an ad-hoc analysis of the pooled data from ASCEND and CAPACITY showed that patients, who were hospitalized within the first six months of treatment, showed reduced risk of disease progression or death by more than two-thirds at one year on continued treatment with Esbriet. | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked health care stocks are Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . Esbriet was approved by the FDA in 2014 for the treatment of IPF. |
26837.0 | 2015-09-30 00:00:00 UTC | Incyte & Eli Lilly Post Positive Phase III Data on Baricitinib | ABBV | https://www.nasdaq.com/articles/incyte-eli-lilly-post-positive-phase-iii-data-on-baricitinib-2015-09-30 | nan | nan | Incyte CorporationINCY and its partner Eli Lilly and Company LLY announced encouraging top-line data from the third phase III study - RA-BEGIN - evaluating the safety and efficacy of baricitinib in patients with moderately to severely active rheumatoid arthritis (RA). Incyte shares were up 4.7% on the news.
In the RA-BEGIN study, baricitinib was found to be non-inferior to methotrexate based on the ACR20 response rate after 24 weeks of treatment, thereby meeting the primary objective. Methotrexate is a widely used drug for RA. In fact, based on ACR20 response, baricitinib was found to be superior to methotrexate.
Meanwhile, the incidence of treatment-emergent adverse events and serious adverse events were similar in both the baricitinib and methotrexate arms.
We note that baricitinib has consistently fared well in all phase III studies reported so far. The companies had reported positive data from the first phase III study (RA-BEACON) on baricitinib in Dec 2014 and the second phase III study (RA-BUILD) in Feb 2015.
The companies are conducting a fourth phase III study, RA-BEAM, on baricitinib. Data from this study is expected to be released later this year.
As per WHO Global Burden of Disease Report, over 23 million people suffer from RA worldwide. Currently available treatments include AbbVie's ABBV Humira.
Apart from RA, Incyte and Eli Lilly are also evaluating baricitinib for psoriasis (phase II) and diabetic nephropathy (phase II).
Incyte is a Zacks Rank #3 (Hold) stock, while Eli Lilly carries a Zacks Rank #2 (Buy). Other well-ranked stocks in the health care sector are Bayer BAYRY and AbbVie, both carrying the same Zacks Rank as Eli Lilly.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BAYER A G -ADR (BAYRY): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis Report
INCYTE CORP (INCY): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other well-ranked stocks in the health care sector are Bayer BAYRY and AbbVie, both carrying the same Zacks Rank as Eli Lilly. Currently available treatments include AbbVie's ABBV Humira. Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report INCYTE CORP (INCY): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report INCYTE CORP (INCY): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Currently available treatments include AbbVie's ABBV Humira. Other well-ranked stocks in the health care sector are Bayer BAYRY and AbbVie, both carrying the same Zacks Rank as Eli Lilly. | Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report INCYTE CORP (INCY): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Currently available treatments include AbbVie's ABBV Humira. Other well-ranked stocks in the health care sector are Bayer BAYRY and AbbVie, both carrying the same Zacks Rank as Eli Lilly. | Currently available treatments include AbbVie's ABBV Humira. Other well-ranked stocks in the health care sector are Bayer BAYRY and AbbVie, both carrying the same Zacks Rank as Eli Lilly. Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report INCYTE CORP (INCY): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. |
26838.0 | 2015-09-28 00:00:00 UTC | Can AbbVie Rebound Before Year's End? | ABBV | https://www.nasdaq.com/articles/can-abbvie-rebound-years-end-2015-09-28 | nan | nan | AbbVie 's stock has definitely had an off year. Prior to 2015, AbbVie's shares had appreciated an astounding 83% since the company was spun off from its parent company, Abbott Laboratories , in 2013:
However, this year has been a different story altogether, with the drugmaker's shares falling by double digits, outpacing even the downturn in the broader markets:
The underlying reason behind AbbVie's rough year is no secret. Put simply, investors are deeply concerned that the upcoming patent expiration for the company's flagship anti-inflammatory drug, Humira, will cause revenues to plummet within the next two years.
After all, Humira does tend to make up over 60% of the drugmaker's quarterly revenues, and several competitors are attempting to bring a biosimilar (generic) version of the drug to market when it loses patent protection in the U.S. at the end of 2016.
The odd part of AbbVie's story, though, is that the average price target among 12 different analysts surveyed by S&P Capital IQ stands a whopping 34% higher than today's price, or $76 a share. Given that the market obviously disagrees with this figure, at least right now, let's consider if AbbVie indeed has what it takes to break out of this recent slump and head higher going into the end of the year.
Brighter days ahead?
Before we peak into AbbVie's future, I think it's important to sum up the drugmaker's 2015. At present, AbbVie is on track to post a 15% increase in product sales and a healthy 28% rise in EPS, year over year.
Those numbers are critical to note at this juncture, because they show that AbbVie's share price isn't lagging because of any major problem with its top or bottom lines. In fact, AbbVie's shares are currently trading at around 4.6 times trailing-12-month revenue -- a figure markedly lower than those of many of its peers.
Taking a look ahead, the bull case for AbbVie definitely picks up steam if we consider the Street's forecast for 2016. Specifically, AbbVie should see yet another 15% rise in annual revenue, and an 18% increase in EPS, relative to 2015's final figures.
The good news is that these double-digit projections do look realistic for a couple of reasons. First, AbbVie recently secured another label expansion for Humira, this time for the treatment of moderate to severe hidradenitis suppurativa. Most importantly, though, the drugmaker has made steady progress advancing its broader clinical pipeline, helping to bring important new drugs and revenue sources, like the intestinal gel Duopa for Parkinson's disease, into the fold.
Source: AbbVie.
So, while the concerns over Humira's exclusivity shouldn't be brushed aside, I think investors may want to keep in mind that this isn't an issue that will have any impact whatsoever on the drugmaker in 2016. In other words, the market appears to be hitting the panic button over an issue that is at least a year away from mattering, and perhaps much longer, depending on how long it takes a biosimilar to gain a regulatory approval.
Is AbbVie a buy right now?
Like many investors, I've recently grown somewhat cautious of AbbVie because of the glaring mismatch between its fundamentals and the market's perception of the company's future growth prospects. In short, the market has blatantly ignored the drugmaker's top-notch levels of growth this year, instead letting fear overcome common sense.
As AbbVie's shares are now trading at a forward price to earnings ratio of around 11, though, I do have a hard time believing they will go much lower at this point. Basically, the stock isn't garnering much of a premium to speak of, especially for a company that is leading the pack in terms of industrywide growth.
So, my hunch is that once the storm clouds dissipate over stocks in general, and healthcare stocks in particular, AbbVie is going to be one of the first to rebound. I'm thus cautiously optimistic that AbbVie is nearing an inflection point in terms of its stock price, perhaps making now a good time to pick up some shares.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early, in-the-know investors! To be one of them, just click here .
The article Can AbbVie Rebound Before Year's End? originally appeared on Fool.com.
George Budwell owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie 's stock has definitely had an off year. Prior to 2015, AbbVie's shares had appreciated an astounding 83% since the company was spun off from its parent company, Abbott Laboratories , in 2013: However, this year has been a different story altogether, with the drugmaker's shares falling by double digits, outpacing even the downturn in the broader markets: The underlying reason behind AbbVie's rough year is no secret. The odd part of AbbVie's story, though, is that the average price target among 12 different analysts surveyed by S&P Capital IQ stands a whopping 34% higher than today's price, or $76 a share. | I'm thus cautiously optimistic that AbbVie is nearing an inflection point in terms of its stock price, perhaps making now a good time to pick up some shares. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AbbVie 's stock has definitely had an off year. | AbbVie 's stock has definitely had an off year. Prior to 2015, AbbVie's shares had appreciated an astounding 83% since the company was spun off from its parent company, Abbott Laboratories , in 2013: However, this year has been a different story altogether, with the drugmaker's shares falling by double digits, outpacing even the downturn in the broader markets: The underlying reason behind AbbVie's rough year is no secret. I'm thus cautiously optimistic that AbbVie is nearing an inflection point in terms of its stock price, perhaps making now a good time to pick up some shares. | AbbVie 's stock has definitely had an off year. I'm thus cautiously optimistic that AbbVie is nearing an inflection point in terms of its stock price, perhaps making now a good time to pick up some shares. Prior to 2015, AbbVie's shares had appreciated an astounding 83% since the company was spun off from its parent company, Abbott Laboratories , in 2013: However, this year has been a different story altogether, with the drugmaker's shares falling by double digits, outpacing even the downturn in the broader markets: The underlying reason behind AbbVie's rough year is no secret. |
26839.0 | 2015-09-28 00:00:00 UTC | AbbVie Updates on Viekirax and Rheumatoid Arthritis Pipeline | ABBV | https://www.nasdaq.com/articles/abbvie-updates-on-viekirax-and-rheumatoid-arthritis-pipeline-2015-09-28 | nan | nan | AbbVie Inc.ABBV announced a series of regulatory/pipeline updates. The company's Viekirax has been approved by the Japanese Ministry of Health, Labour and Welfare as a new interferon and ribavirin-free treatment option for patients suffering from chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis. Viekirax (with or without ribavirin) is already approved in Europe in combination with Exviera for the treatment of GT1 chronic HCV patients, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients. Additionally, Viekirax is approved in the EU for use with ribavirin in genotype 4 chronic hepatitis C patients.
Additionally, the company announced positive results from two double-blind, placebo-controlled, dose-ranging phase II studies (BALANCE-I and BALANCE-II) on its rheumatoid arthritis candidate, ABT-494. Both studies evaluated patients suffering from moderate-to-severe rheumatoid arthritis, who responded inadequately to prior anti-TNF (TNF-IR) or methotrexate (MTX-IR) treatment, respectively. The primary endpoint of both studies was the percentage of patients achieving an ACR20 response after 12 weeks of treatment.
AbbVie stated that both studies achieved impressive levels of ACR20 at week 12 across all doses of ABT-494, except the lowest dose in the BALANCE-II study. In the TNF-inadequate responder population, ACR20 responses were up to 73%, while that in the MTX-inadequate responder population was up to 82%. The company intends to advance the once-daily formulation of ABT-494 to phase III studies for the treatment of rheumatoid arthritis by 2015 end.
AbbVie is also evaluating ABT-494 in a phase II study for the treatment of Crohn's disease.
Meanwhile, following a thorough review of available data, AbbVie decided not to exercise its right to in-license a JAK1 inhibitor, filgotinib, from Galapagos NV GLPG and terminated its agreement with the company for the development of filgotinib. Galapagos will advance filgotinib to phase III development for rheumatoid arthritis in early 2016.
AbbVie currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the health care sector are Eli Lilly and Company LLY and Abbott Laboratories ABT . Both carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
LILLY ELI & CO (LLY): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
GALAPAGOS -ADR (GLPG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc.ABBV announced a series of regulatory/pipeline updates. AbbVie stated that both studies achieved impressive levels of ACR20 at week 12 across all doses of ABT-494, except the lowest dose in the BALANCE-II study. AbbVie is also evaluating ABT-494 in a phase II study for the treatment of Crohn's disease. | Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report GALAPAGOS -ADR (GLPG): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV announced a series of regulatory/pipeline updates. AbbVie stated that both studies achieved impressive levels of ACR20 at week 12 across all doses of ABT-494, except the lowest dose in the BALANCE-II study. | Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report GALAPAGOS -ADR (GLPG): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV announced a series of regulatory/pipeline updates. AbbVie stated that both studies achieved impressive levels of ACR20 at week 12 across all doses of ABT-494, except the lowest dose in the BALANCE-II study. | AbbVie Inc.ABBV announced a series of regulatory/pipeline updates. AbbVie stated that both studies achieved impressive levels of ACR20 at week 12 across all doses of ABT-494, except the lowest dose in the BALANCE-II study. AbbVie is also evaluating ABT-494 in a phase II study for the treatment of Crohn's disease. |
26840.0 | 2015-09-26 00:00:00 UTC | The Best-Selling Drugs in the World By 2020 | ABBV | https://www.nasdaq.com/articles/best-selling-drugs-world-2020-2015-09-26 | nan | nan | Source: Pictures of Money via Flickr.
Last year global pharmaceutical sales topped the $1 trillion mark for the first time ever. By 2018, the Intellectual Property and Sciences Business of Thomson Reuters predicts sales will rise by another 30% to $1.3 trillion. This is a major growth opportunity for investors, but only if they understand what blockbuster drugs are on their ascent, and which ones could be on the decline.
As it stands now, AbbVie 's anti-inflammatory drug Humira is the best-selling drug in the world. While it hasn't eclipsed the $13 billion-plus that cholesterol-lowering drug Lipitor brought in during its heyday, Humira generated $12.54 billion in sales in 2014, representing 19% operational growth year-over-year. Through the first two quarters of 2015, Humira's sales totaled $6.65 billion, putting it on pace to log the highest sales total ever for a prescription drug in a calendar year.
Unfortunately for AbbVie and its investors, Humira's time as a protected drug is nearly up. In 2016 Humira will begin to lose exclusivity on certain patents and be exposed to generic competition, with biosimilar competition projected to enter the market by 2018. Long story short, Humira's run as the best-selling drug in the world is likely going to come to an end in the next couple of years.
The world's best-selling drugs by 2020
What drug could wind up taking its place? While it's nothing more than a guess at this point because so many variables can play into the total annual sales of a drug -- including drug development, competition, drug pricing, launch success, and marketing -- I'd keep my eye on a handful of therapies to step up as the best-selling drugs in the world by 2020.
Source: Gilead Sciences.
Harvoni
The most logical choice to ascend to the title of "best-selling drug in the world" would be Harvoni, the hepatitis C medication from Gilead Sciences that's designed to treat genotype 1 patients. Genotype 1 is the hardest to treat, but it's also the most common, comprising about 70% of all HCV cases.
Harvoni is a step up from previous HCV therapies in two big ways. First, it's extremely convenient. It's a once-daily pill that has minimal side effects. Compare this to prior-generation therapies that may have required interferon and a ribavirin, which came with the added side effects of flu-like symptoms and potential anemia.
Source: Gilead Sciences.
Secondly, Harvoni dramatically improved SVR rates, or the rate at which no detectable level of hepatitis C virus could be detected after however many weeks of treatment (typically 12). The treatment-naïve group demonstrated a 94% cure rate after just eight weeks (prior treatments could have been 24 weeks to 48 weeks long), while treatment-naïve and treatment-experienced genotype 1 patients, both with liver cirrhosis, demonstrated SVRs of 97% and 94%-99%, respectively, in the three ION trials that led to Harvoni's approval.
With little room left for efficacy improvements, and Gilead willing to go to bat on price, perhaps the only way left to unseat Gilead's dominance in this space is to find a therapy that can be effective in fewer than eight weeks. Until such time, I believe Harvoni could regularly generate $10 billion to $12 billion in annual sales.
Revlimid
Cancer drugs accounted for $100 billion of the $1 trillion in global sales in 2014, and they should arguably grow at a faster pace than other indications in the coming years given the seriousness of most cancers and a rise in the global rate of cancer occurrence. With that in mind, I'd opine that Celgene 's blood cancer drug Revlimid could make a serious run at the best-selling drug in the world by 2020.
Source: Celgene.
Revlimid's bread and butter is its indication for multiple myeloma in newly diagnosed and relapsed patients. However, Celgene is testing Revlimid in eight additional label indications, which could effectively double its sales potential by 2020 from what it reported in 2014. Revlimid is being studied as a maintenance therapy for multiple myeloma, as a treatment for diffuse large B-cell lymphoma (in first-line therapy for ABC-subtype and as a maintenance therapy), and for first-line follicular lymphoma, to name a few. It has a long patent life, which should help protect it from generic competition for years to come.
What's worth watching here is how other multiple myeloma therapies fare in clinical studies and post-launch. For instance, Kyprolis was recently approved by the FDA for second-line multiple myeloma indications. Revlimid held its market share in second-line multiple myeloma in the early going following the approval, but competition or label expansion in the indication seems inevitable over the next five years.
Even with this added competition, if Revlimid can land another four to eight label indications, it could, along with regular price increases, potentially push to the $10 billion sales mark by 2020. For context, Revlimid is expected to bring in $5.6 billion to $5.7 billion in sales in fiscal 2015.
Aducanumab *
Lastly, we have the wild card of the bunch, aducanumab, which has the asterisk next to its name because it's still an experimental therapy .
Source: Centers for Disease Control and Prevention.
Aducanumab is a potential treatment for Alzheimer's disease being developed by Biogen . The company gained incredible press late last year after announcing that aducanumab (previously known as BIIB-037) would skip midstage studies and dive right into phase 3 studies after demonstrating surprising efficacy in early-stage Alzheimer's patients in phase 1 studies. Not only did aducanumab lead to a decrease in beta-amyloid, a substance that has been attributed to cognitive decline due to its ability to "stick" to neurons, but it led to cognitive improvement for those in the earlier stages of the disease.
A more thorough analysis emerged from the phase 1b study in 2015, showing that in the 30-point mental acuity test the 3 mg and 10 mg doses of aducanumab led to a reduction of just 0.75 points and 0.58 points, respectively, compared to a 3.14-point decline for the placebo group. Similar efficacy was witnessed in the 18-point Clinical Dementia Rating.
The concern here is that drugs targeting the brain and neurological disorders in general have a very high failure rate. We've witnessed promising therapies succeed in phase 1 and/or phase 2 trials only to fall flat on their faces in phase 3. Thus, there's no guarantee of success for aducanumab in phase 3 trials.
However, in the event that it does succeed, the perfect storm of profitability could await. There are an estimated 600,000 mild cases of Alzheimer's disease within the U.S., and if it can attain 65% of market share at a price of $20,000 per year, according to ISI Group analyst Mark Schoenebaum, it could become an $8 billion per year drug. Note, the $20,000 per year price tag is lower than lesser-effective drugs already on the market -- thus this could be a very conservative estimate. My guess is if aducanumab's data holds consistent in phase 3 studies and is approved, it could possibly push the $10 billion sales mark by 2020.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article The Best-Selling Drugs in the World By 2020 originally appeared on Fool.com.
Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen nameTMFUltraLong, track every pick he makes under the screen nameTrackUltraLong, and check him out on Twitter, where he goes by the handle@TMFUltraLong.The Motley Fool owns and recommends Celgene and Gilead Sciences. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As it stands now, AbbVie 's anti-inflammatory drug Humira is the best-selling drug in the world. Unfortunately for AbbVie and its investors, Humira's time as a protected drug is nearly up. While it hasn't eclipsed the $13 billion-plus that cholesterol-lowering drug Lipitor brought in during its heyday, Humira generated $12.54 billion in sales in 2014, representing 19% operational growth year-over-year. | As it stands now, AbbVie 's anti-inflammatory drug Humira is the best-selling drug in the world. Unfortunately for AbbVie and its investors, Humira's time as a protected drug is nearly up. While it's nothing more than a guess at this point because so many variables can play into the total annual sales of a drug -- including drug development, competition, drug pricing, launch success, and marketing -- I'd keep my eye on a handful of therapies to step up as the best-selling drugs in the world by 2020. | As it stands now, AbbVie 's anti-inflammatory drug Humira is the best-selling drug in the world. Unfortunately for AbbVie and its investors, Humira's time as a protected drug is nearly up. While it's nothing more than a guess at this point because so many variables can play into the total annual sales of a drug -- including drug development, competition, drug pricing, launch success, and marketing -- I'd keep my eye on a handful of therapies to step up as the best-selling drugs in the world by 2020. | As it stands now, AbbVie 's anti-inflammatory drug Humira is the best-selling drug in the world. Unfortunately for AbbVie and its investors, Humira's time as a protected drug is nearly up. While it's nothing more than a guess at this point because so many variables can play into the total annual sales of a drug -- including drug development, competition, drug pricing, launch success, and marketing -- I'd keep my eye on a handful of therapies to step up as the best-selling drugs in the world by 2020. |
26841.0 | 2015-09-25 00:00:00 UTC | Pharmaceutical ETF Experiences Big Outflow | ABBV | https://www.nasdaq.com/articles/pharmaceutical-etf-experiences-big-outflow-2015-09-25 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Pharmaceutical ETF (Symbol: PPH) where we have detected an approximate $19.7 million dollar outflow -- that's a 5.6% decrease week over week (from 5,388,138 to 5,088,138). Among the largest underlying components of PPH, in trading today Novartis (Symbol: NVS) is up about 2.1%, Novo-Nordisk A/S (Symbol: NVO) is up about 1.7%, and AbbVie Inc. (Symbol: ABBV) is lower by about 0.1%. For a complete list of holdings, visit the PPH Holdings page » The chart below shows the one year price performance of PPH, versus its 200 day moving average:
Looking at the chart above, PPH's low point in its 52 week range is $45.23 per share, with $74.97 as the 52 week high point - that compares with a last trade of $65.65. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of PPH, in trading today Novartis (Symbol: NVS) is up about 2.1%, Novo-Nordisk A/S (Symbol: NVO) is up about 1.7%, and AbbVie Inc. (Symbol: ABBV) is lower by about 0.1%. For a complete list of holdings, visit the PPH Holdings page » The chart below shows the one year price performance of PPH, versus its 200 day moving average: Looking at the chart above, PPH's low point in its 52 week range is $45.23 per share, with $74.97 as the 52 week high point - that compares with a last trade of $65.65. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of PPH, in trading today Novartis (Symbol: NVS) is up about 2.1%, Novo-Nordisk A/S (Symbol: NVO) is up about 1.7%, and AbbVie Inc. (Symbol: ABBV) is lower by about 0.1%. For a complete list of holdings, visit the PPH Holdings page » The chart below shows the one year price performance of PPH, versus its 200 day moving average: Looking at the chart above, PPH's low point in its 52 week range is $45.23 per share, with $74.97 as the 52 week high point - that compares with a last trade of $65.65. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of PPH, in trading today Novartis (Symbol: NVS) is up about 2.1%, Novo-Nordisk A/S (Symbol: NVO) is up about 1.7%, and AbbVie Inc. (Symbol: ABBV) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Pharmaceutical ETF (Symbol: PPH) where we have detected an approximate $19.7 million dollar outflow -- that's a 5.6% decrease week over week (from 5,388,138 to 5,088,138). For a complete list of holdings, visit the PPH Holdings page » The chart below shows the one year price performance of PPH, versus its 200 day moving average: Looking at the chart above, PPH's low point in its 52 week range is $45.23 per share, with $74.97 as the 52 week high point - that compares with a last trade of $65.65. | Among the largest underlying components of PPH, in trading today Novartis (Symbol: NVS) is up about 2.1%, Novo-Nordisk A/S (Symbol: NVO) is up about 1.7%, and AbbVie Inc. (Symbol: ABBV) is lower by about 0.1%. For a complete list of holdings, visit the PPH Holdings page » The chart below shows the one year price performance of PPH, versus its 200 day moving average: Looking at the chart above, PPH's low point in its 52 week range is $45.23 per share, with $74.97 as the 52 week high point - that compares with a last trade of $65.65. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
26842.0 | 2015-09-25 00:00:00 UTC | AbbVie's "Life After Humira" Preparations Advance | ABBV | https://www.nasdaq.com/articles/abbvies-life-after-humira-preparations-advance-2015-09-25 | nan | nan | Source: AbbVie.
AbbVie 's is reporting positive study results from phase 2 trials evaluating its next-generation oral therapy for rheumatoid arthritis and based on those results, the company plans to move ABT-494 into late-stage trials by the end of 2015.
The positive results from this trial and the company's decision to move ABT-494 quickly into phase 3 could mean that it is better positioned to maintain its market share in this indication after Humira's patent expires at the end of 2016.
Protecting its moat
AbbVie's Humira has been the planet's top-selling drug for years and its best-in-class status is due at least in part to its widespread use in the treatment of rheumatoid arthritis, an autoimmune disease that afflicts 1.3 million Americans.
Humira isn't a cure for rheumatoid arthritis, but it does help patients more effectively control the symptoms of this condition. During phase 3 trials, up to 53.4% of patients receiving Humira after failing to improve on DMARDs achieved a 20% or greater improvement in ACR criteria, or ACR20.
Because of Humira's efficacy and the fact that it's a complex biologic, AbbVie charges as much as $60,000 per year for it, depending on patient weight and dosing frequency. As a result, Humira represents the lion's share of AbbVie's total annual sales. In the first quarter, Humira accounted for $3.54 billion of AbbVie's $5.48 billion in sales.
Given Humira's importance to AbbVie, it's not too surprising that it is investing heavily in a new generation of rheumatoid arthritis drugs in an attempt to maintain its market share when Humira's patent protection ends.
Advancing its pipeline
ABT-494 is one of AbbVie's most promising Humira successors. The drug could potentially offer significant benefits to Humira that could allow it to become a top seller if its phase 3 results back up its phase 2 performance.
In its phase 2 Balance II trials, which evaluated patients whose disease wasn't controlled by methotrexate, a common therapy for RA in the DMARD class of drugs, 82% of patients taking a 24 mg dose of ABT-494 once daily achieved ACR20 and 44% of patients achieved ACR50.
In its Balance 1 trial, which evaluated patients that inadequately responded to TNF-inhibitors like Humira, 71% of patients taking 18 mg twice a day achieved ACR20 and 40% achieved ACR50.
Importantly, the safety results from ABT-494's studies were also solid, with the most common adverse event being headache, which occurred in less than 5% of patients. There were two cases of serious infection; however, only one of those two cases occurred in the ABT-494 arm of the study.
Based on the findings, AbbVie plans to kick off a phase 3 study that will further evaluate the efficacy and safety of a once-daily formulation.
Why this drug could be a winner
What makes ABT-494 so intriguing is that it could significantly improve patient dosing and adherence because it's taken orally, rather than injected weekly or every two weeks like Humira.
Also, because ABT-494, a JAK1 inhibitor, has a different mechanism of action than Humira, a TNF inhibitor, its potentially better safety profile could make it a best-in-category choice for doctors given that TNF inhibitors carry a black-box warning of serious infection, including tuberculosis and reported cases of lymphoma.
If ABT-494 can continue to deliver efficacy that is arguably better than TNF inhibitors with a better safety profile, then it could maintain AbbVie's Humira market share and win away sales from other multibillion-dollar blockbuster TNF inhibitors, too. However, a lot of work needs to be done in phase 3 before investors will know for sure if that's likely and that means that AbbVie investors should remain cautiously optimistic about the phase 2 results until phase 3 data is eventually reported.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article AbbVie's "Life After Humira" Preparations Advance originally appeared on Fool.com.
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Protecting its moat AbbVie's Humira has been the planet's top-selling drug for years and its best-in-class status is due at least in part to its widespread use in the treatment of rheumatoid arthritis, an autoimmune disease that afflicts 1.3 million Americans. Because of Humira's efficacy and the fact that it's a complex biologic, AbbVie charges as much as $60,000 per year for it, depending on patient weight and dosing frequency. Based on the findings, AbbVie plans to kick off a phase 3 study that will further evaluate the efficacy and safety of a once-daily formulation. | AbbVie 's is reporting positive study results from phase 2 trials evaluating its next-generation oral therapy for rheumatoid arthritis and based on those results, the company plans to move ABT-494 into late-stage trials by the end of 2015. Given Humira's importance to AbbVie, it's not too surprising that it is investing heavily in a new generation of rheumatoid arthritis drugs in an attempt to maintain its market share when Humira's patent protection ends. Source: AbbVie. | AbbVie 's is reporting positive study results from phase 2 trials evaluating its next-generation oral therapy for rheumatoid arthritis and based on those results, the company plans to move ABT-494 into late-stage trials by the end of 2015. Given Humira's importance to AbbVie, it's not too surprising that it is investing heavily in a new generation of rheumatoid arthritis drugs in an attempt to maintain its market share when Humira's patent protection ends. Source: AbbVie. | AbbVie 's is reporting positive study results from phase 2 trials evaluating its next-generation oral therapy for rheumatoid arthritis and based on those results, the company plans to move ABT-494 into late-stage trials by the end of 2015. Given Humira's importance to AbbVie, it's not too surprising that it is investing heavily in a new generation of rheumatoid arthritis drugs in an attempt to maintain its market share when Humira's patent protection ends. Source: AbbVie. |
26843.0 | 2015-09-25 00:00:00 UTC | Health Care Sector Update for 09/25/2015: GLPG,ABBV,BLPH,PETX | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-09252015-glpgabbvblphpetx-2015-09-25 | nan | nan | Top Health Care Stocks
JNJ +0.22%
PZE -0.80%
MRK -0.79%
ABT -0.56%
AMGN -0.49%
Health care stocks have turned lower Friday afternoon, with the NYSE Health Care Sector Index giving back a small gain earlier in today's session and more recently slipping about 0.1% while shares of health care companies in the S&P 500 were slipping about 0.2% as a group.
In company news, Galapagos NV ( GLPG ) tumbled to a record low Friday after the Belgian biotech company said AbbVie ( ABBV ) will not be exercising its right to in-license Galapagos' ABT-494 drug candidate to treat rheumatoid arthritis.
The decision follows AbbVie Friday morning saying ABT-494 reached its primary endpoint of at least 20% improvement in tender or swollen joints during two Phase II trials. Galapagos today said it still intends to move the JAK1 inhibitor to Phase III testing earlier next year.
GLPG American depository shares were down almost 26% at $44.73 each, earlier dropping to a post-IPO low of $44.32 a share. Since pricing its initial public offering of stock at $42.05 a share on June 16, the stock had climbed more than 46% through Thursday's close.
ABBV shares were slightly lower this afternoon, falling about 0.1% to $56.47 apiece.
In other sector news,
(+) BLPH, (+95.2%) Reports positive interim data from long-term, Phase II extension study of its INOpulse drug candidate to treat pulmonary arterial hypertension. FDA also signs off on Phase III trial.
(-) PETX, (-28.2%) Said it does not believe its AT-004 or AT-005 drug candidates will capture the desired lymphoma market opportunity in their current, first-generation forms.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The decision follows AbbVie Friday morning saying ABT-494 reached its primary endpoint of at least 20% improvement in tender or swollen joints during two Phase II trials. In company news, Galapagos NV ( GLPG ) tumbled to a record low Friday after the Belgian biotech company said AbbVie ( ABBV ) will not be exercising its right to in-license Galapagos' ABT-494 drug candidate to treat rheumatoid arthritis. ABBV shares were slightly lower this afternoon, falling about 0.1% to $56.47 apiece. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In company news, Galapagos NV ( GLPG ) tumbled to a record low Friday after the Belgian biotech company said AbbVie ( ABBV ) will not be exercising its right to in-license Galapagos' ABT-494 drug candidate to treat rheumatoid arthritis. The decision follows AbbVie Friday morning saying ABT-494 reached its primary endpoint of at least 20% improvement in tender or swollen joints during two Phase II trials. | In company news, Galapagos NV ( GLPG ) tumbled to a record low Friday after the Belgian biotech company said AbbVie ( ABBV ) will not be exercising its right to in-license Galapagos' ABT-494 drug candidate to treat rheumatoid arthritis. The decision follows AbbVie Friday morning saying ABT-494 reached its primary endpoint of at least 20% improvement in tender or swollen joints during two Phase II trials. ABBV shares were slightly lower this afternoon, falling about 0.1% to $56.47 apiece. | In company news, Galapagos NV ( GLPG ) tumbled to a record low Friday after the Belgian biotech company said AbbVie ( ABBV ) will not be exercising its right to in-license Galapagos' ABT-494 drug candidate to treat rheumatoid arthritis. The decision follows AbbVie Friday morning saying ABT-494 reached its primary endpoint of at least 20% improvement in tender or swollen joints during two Phase II trials. ABBV shares were slightly lower this afternoon, falling about 0.1% to $56.47 apiece. |
26844.0 | 2015-09-25 00:00:00 UTC | Friday's ETF with Unusual Volume: XBI | ABBV | https://www.nasdaq.com/articles/fridays-etf-unusual-volume-xbi-2015-09-25 | nan | nan | The SPDR S&P Biotech ETF ( XBI ) is seeing unusually high volume in afternoon trading Friday, with over 3.5 million shares traded versus three month average volume of about 1.1 million. Shares of XBI were down about 3.9% on the day.
Components of that ETF with the highest volume on Friday were Gilead Sciences ( GILD ), trading trading flat with over 5.2 million shares changing hands so far this session, and Opko Health ( OPK ), down about 4.8% on volume of over 4.9 million shares. Abbvie ( ABBV ) is the component faring the best Friday, up by about 0.3% on the day, while Agenus ( AGEN ) is lagging other components of the SPDR S&P Biotech ETF, trading lower by about 12.2%.
VIDEO: Friday's ETF with Unusual Volume: XBI
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbvie ( ABBV ) is the component faring the best Friday, up by about 0.3% on the day, while Agenus ( AGEN ) is lagging other components of the SPDR S&P Biotech ETF, trading lower by about 12.2%. The SPDR S&P Biotech ETF ( XBI ) is seeing unusually high volume in afternoon trading Friday, with over 3.5 million shares traded versus three month average volume of about 1.1 million. Components of that ETF with the highest volume on Friday were Gilead Sciences ( GILD ), trading trading flat with over 5.2 million shares changing hands so far this session, and Opko Health ( OPK ), down about 4.8% on volume of over 4.9 million shares. | Abbvie ( ABBV ) is the component faring the best Friday, up by about 0.3% on the day, while Agenus ( AGEN ) is lagging other components of the SPDR S&P Biotech ETF, trading lower by about 12.2%. The SPDR S&P Biotech ETF ( XBI ) is seeing unusually high volume in afternoon trading Friday, with over 3.5 million shares traded versus three month average volume of about 1.1 million. VIDEO: Friday's ETF with Unusual Volume: XBI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbvie ( ABBV ) is the component faring the best Friday, up by about 0.3% on the day, while Agenus ( AGEN ) is lagging other components of the SPDR S&P Biotech ETF, trading lower by about 12.2%. The SPDR S&P Biotech ETF ( XBI ) is seeing unusually high volume in afternoon trading Friday, with over 3.5 million shares traded versus three month average volume of about 1.1 million. Components of that ETF with the highest volume on Friday were Gilead Sciences ( GILD ), trading trading flat with over 5.2 million shares changing hands so far this session, and Opko Health ( OPK ), down about 4.8% on volume of over 4.9 million shares. | Abbvie ( ABBV ) is the component faring the best Friday, up by about 0.3% on the day, while Agenus ( AGEN ) is lagging other components of the SPDR S&P Biotech ETF, trading lower by about 12.2%. The SPDR S&P Biotech ETF ( XBI ) is seeing unusually high volume in afternoon trading Friday, with over 3.5 million shares traded versus three month average volume of about 1.1 million. Shares of XBI were down about 3.9% on the day. |
26845.0 | 2015-09-21 00:00:00 UTC | 10 Stocks That Even the Pope Could Love | ABBV | https://www.nasdaq.com/articles/10-stocks-even-pope-could-love-2015-09-21 | nan | nan | Comfort the sick; feed and clothe the poor; provide shelter for the homeless. Pope Francis, who begins his first visit to the U.S. on September 22, has focused on issues of social justice since being named to the Catholic Church's top slot in 2013. But even before Francis became pope, several mutual funds applied the teachings of the church to their selection of stocks and bonds. In light of the pope's visit, we've taken a look at the stock holdings of three Catholic values fund families--Ave Maria, LKCM Aquinas and Epiphany FFV (FFV stands for Faith and Family Values)--which all base their investment choices on the ecumenical constraints of the church. That means barring investments in companies that facilitate abortions or produce pornography, among other things.
Even with these exclusions, Catholic values funds have plenty of companies to choose from. So we took a look at their top holdings in search of attractive stocks. Here are 10 that savvy investors--and even the pope--could love. (Share prices and related figures are as of September 18.)
Health care
Spun off from Abbott Labs in January 2013, drugmaker AbbVie (symbol ABBV , $61.22) is owned by two of the three fund companies that specialize in Catholic causes: LKCM's Aquinas Growth ( AQEGX ) and Epiphany FFV ( EPVNX ). AbbVie is best known for its blockbuster autoimmune drug, Humira, which is used to treat arthritis, Crohn's disease and psoriasis. The stock, which has climbed 74% since AbbVie began trading as a separate entity, has hit a rough patch lately, partly due to worries that the company could lose protection for some of its Humira patents next year. But analysts say that Humira won't be easy to replicate and, in any case, AbbVie has an impressive list of new medications, treating everything from fibroid tumors to hepatitis C and leukemia, working their way through its labs. Thanks in part to the recent pullback--the stock has dropped 13% since mid-July--the shares sell for just 13 times estimated year-ahead earnings. Plus, the stock yields a healthy 3.3%. By comparison, Standard & Poor's 500-stock index sells for 16 times estimated year-ahead profits and yields 2.2%. UBS analyst Marc Goodman rates AbbVie a buy, with a one-year price target of $81.
AbbVie's former parent, Abbott Labs ( ABT , $43.33) is a top holding in both Ave Maria Growth ( AVEGX ) and Ave Maria Rising Dividend ( AVEDX ) funds. When Abbott spun off its brand-name drug enterprise in AbbVie, it kept its generic pharmaceutical and medical device businesses, which have continued to grow rapidly. Because of the strong dollar, Abbott expects earnings to dip slightly this year. But analysts see profits rebounding by 11.5% next year. The stock trades for 19 times estimated year-ahead earnings and yields 2.2%. William Blair analyst Margaret Kaczor believes the company's profit estimates are conservative and that the stock is likely to outperform the market over the next year.
St. Jude Medical ( STJ , $67.31), which makes heart devices, is among the top holdings of the Ave Maria Catholic Values Fund ( AVEMX ). St. Jude, fresh off a restructuring aimed at consolidating its manufacturing and supply-chain operations, is expected to post flat earnings in 2015, then see profits rise by 9% next year. But what makes the shares especially compelling, says William Blair analyst Ben Andrew, is St. Jude's planned $3.4 billion purchase of Thoratec, a company that makes medical devices designed for patients with advanced heart failure. Andrew says the deal gives St. Jude entrée to a business with annual sales of $1 billion. That will boost St. Jude's revenues, he says, and revive the stock, which has slumped 13% since mid-July.
Other well-regarded health care stocks that find a place in these ecumenical funds include CVS Health ( CVS , $99.03), which runs drugstores and provides pharmacy-benefits management services; CVS's benefits management rival Express Scripts ( ESRX , $83.92); and medical testing giant Laboratory Corp. of America ( LH , $119.40).
Food and clothing
Coca-Cola Corp. ( KO ) and Costco ( COST ) are key holdings in the Epiphany funds, but the shares are tough to recommend at today's prices. Coke and Costco shares sell for 19 and 26 times projected year-ahead earnings, respectively. But neither company's earnings are expanding quickly enough to justify those P/E ratios. On the surface, Yum Brands ( YUM ), $80.15), which owns the KFC, Pizza Hut and Taco Bell restaurant chains, also looks expensive, trading at 21 times estimated year-ahead earnings. But the stock looks more defensible in light of analyst projections that Yum will deliver double-digit-percentage earnings gains this year and next. Yum is a big player in China, which accounts for 52% of its annual revenues. UBS analyst Keith Siegner says Yum's sales in China are picking up despite the country's slowing economy, and he thinks the stock could reach $116 within a year.
The Ave Maria Growth and Rising Dividend funds own shares in cut-rate clothing retailer Ross Stores ( ROST , $49.12). The stock, which is down about 13% since midAugust, is now reasonably priced, says William Blair analyst Daniel Hofkin. Investors are worried about Ross's rising inventory levels and relatively modest earnings projections. But Hofkin says that Ross boosted inventory this summer because it was able to get closeout merchandise at bargain prices. The company has a long history of successfully unloading its opportunistic buys. Indeed, Hofkin expects the rising inventory level to simply lead to stronger sales in coming quarters.
Housing
The stocks of home-improvement retailers Home Depot ( HD , $115.12) and Lowe's ( LOW , $68.19) are owned by the Aquinas Growth and Ave Maria Rising Dividend funds, respectively. Although the stocks aren't cheap--Home Depot sells for 20 times year-ahead earnings, while Lowe's sells for 19 times projected earnings--UBS analyst Michael Lasser says both are attractive because the companies are experiencing growth spurts. Analysts on average expect Home Depot's earnings to increase 16% in the fiscal year that ends in January and 15% in the following fiscal year, and they project that Lowe's earnings will rise by 22% in the January 2016 fiscal year and 20% the following year.
See Also: 10 Stocks for Socially Conscious Investors
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Health care Spun off from Abbott Labs in January 2013, drugmaker AbbVie (symbol ABBV , $61.22) is owned by two of the three fund companies that specialize in Catholic causes: LKCM's Aquinas Growth ( AQEGX ) and Epiphany FFV ( EPVNX ). The stock, which has climbed 74% since AbbVie began trading as a separate entity, has hit a rough patch lately, partly due to worries that the company could lose protection for some of its Humira patents next year. But analysts say that Humira won't be easy to replicate and, in any case, AbbVie has an impressive list of new medications, treating everything from fibroid tumors to hepatitis C and leukemia, working their way through its labs. | Health care Spun off from Abbott Labs in January 2013, drugmaker AbbVie (symbol ABBV , $61.22) is owned by two of the three fund companies that specialize in Catholic causes: LKCM's Aquinas Growth ( AQEGX ) and Epiphany FFV ( EPVNX ). AbbVie is best known for its blockbuster autoimmune drug, Humira, which is used to treat arthritis, Crohn's disease and psoriasis. The stock, which has climbed 74% since AbbVie began trading as a separate entity, has hit a rough patch lately, partly due to worries that the company could lose protection for some of its Humira patents next year. | Health care Spun off from Abbott Labs in January 2013, drugmaker AbbVie (symbol ABBV , $61.22) is owned by two of the three fund companies that specialize in Catholic causes: LKCM's Aquinas Growth ( AQEGX ) and Epiphany FFV ( EPVNX ). AbbVie is best known for its blockbuster autoimmune drug, Humira, which is used to treat arthritis, Crohn's disease and psoriasis. The stock, which has climbed 74% since AbbVie began trading as a separate entity, has hit a rough patch lately, partly due to worries that the company could lose protection for some of its Humira patents next year. | Health care Spun off from Abbott Labs in January 2013, drugmaker AbbVie (symbol ABBV , $61.22) is owned by two of the three fund companies that specialize in Catholic causes: LKCM's Aquinas Growth ( AQEGX ) and Epiphany FFV ( EPVNX ). AbbVie is best known for its blockbuster autoimmune drug, Humira, which is used to treat arthritis, Crohn's disease and psoriasis. The stock, which has climbed 74% since AbbVie began trading as a separate entity, has hit a rough patch lately, partly due to worries that the company could lose protection for some of its Humira patents next year. |
26846.0 | 2015-09-18 00:00:00 UTC | The Under-the-Radar Reason Why This Correction Could Be Trouble for Big Pharma and Biotech | ABBV | https://www.nasdaq.com/articles/under-radar-reason-why-correction-could-be-trouble-big-pharma-and-biotech-2015-09-18 | nan | nan | Source: U.S. Food and Drug Administration.
Unless you're a short-seller, the correction during the past couple of weeks has probably been a bit of an unwelcome surprise. However, it's also important to understand that corrections are a natural part of the stock-market cycle, and that over the long run, stocks have a tendency to generate real wealth for investors who seek out high-quality stocks.
Unfortunately, when a correction does occur, it can expose certain sectors more than others. Among the sectors that stands to be hit the hardest, arguably, is healthcare. Why healthcare?
Unlike the vast majority of companies that can be compared based on their growth prospects and fundamentals, a large number of healthcare companies aren't profitable. In other words, trying to use traditional fundamental metrics like price-to-book and price-to-earnings on companies in the biotech sector would be somewhat pointless.
Instead, healthcare stocks, especially those still losing money and/or in the clinical-development stage of their product lines, are valued based on an investor's perception of the potential of the company's product line and eventual profitability. It means that, when a correction does come around, these perception-led stocks tend to be among the most volatile.
However, Big Pharma and blue-chip biotech stocks may have other problems on their hands beyond just investor sentiment.
Source: Flickr user Nguyen Hung Vu.
A deal a day keeps the short-seller away
Whether you've been monitoring the pharmaceutical and biotech sector like a hawk or not, you're probably well aware of the multitude of mergers and acquisitions we've witnessed during the last couple of quarters. According to research firm DealLogic, through mid-August, M&A activity in the biotech sector had hit a total deal value of $270.9 billion.
For added context, $277.4 billion is the highest total deal value ever recorded for a full year , and it happened in 2014. It would appear we're well on our way to smashing this record in 2015.
Why are Big Pharma and blue-chip biotech stocks so eager for M&A? Although the reasons can vary on a company-to-company basis, it boils down to three main factors.
First, combining two businesses results in the removal of overlapping departments, and thus cost synergies that translate into improved margins and profitability. Secondly, M&A activity allows a combined business to potentially improve its market share in select indications. In short, being No. 1 or No. 2 in cancer sales, or cardiovascular products, could dramatically improve a company's pricing power, or the way investors view a company's growth prospects.
Finally, Big Pharma has been especially guilty of paring back their research and development expenses in order to buoy their EPS during the patent cliff. The result has been a slowdown in new product development that many pharmaceutical companies are solving by purchasing complementary pipelines.
Source: Flickr user Mike Poresky.
M&A could be about to backfire big time on Big Pharma and biotech
Yet this wave of increased M&A could wind up burning a lot of the acquiring Big Pharma and biotech companies. Wharton School of Business emeritus professor of management Lawrence Hrebiniak perhaps summed up the biggest concerns of the industry best in May 2014 when he had this say:
In other words, we've witnessed everything from bidding wars (see Allergan ) that have pumped up proposed buyout valuations to just enormous premiums being offered, such as Merck 's acquisition of clinical-stage hepatitis C drugmaker Idenix Pharmaceuticals for $3.85 billion, a nearly 240% premium to its prior-day closing value. With the understanding that Big Pharma and blue-chip biotech stocks were willing to pay quite the premium to acquire first-in-class, or complementary product portfolios and pipelines, small-, mid-, and even smaller large-cap biotech companies have maintained the upper hand. Now it appears that it could be Big Pharma and blue-chip biotech companies that reap the nasty side effects of this correction.
Although we've witnessed some clinical-stage biotech valuations deflating during the past couple of weeks, this doesn't do much good for the high-premium deals that have already occurred. It's also concerning if these deals aren't being conducted by the Big Pharma and biotech management with a long-term focus in mind.
A possible textbook example of overzealous M&A
For example, AbbVie (NYSE: ABBV) ponied up a whopping $21 billion for cancer drug company Pharmacyclics earlier this year, or $261.25 per share. Nonetheless, Pharmacyclics does have a potential blockbuster in its front pocket in Imbruvica, which is currently approved by the Food and Drug Administration to treat patients with a select type of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. Peak annual sales estimates for the drug typically fall around $5 billion and $7 billion, depending on its label expansion.
Source: Johnson & Johnson.
But Imbruvica's revenue stream isn't wholly owned by AbbVie. It shares sales and profits with Imbruvica's development partner Janssen Pharmaceuticals, a division of Johnson & Johnson . Thus, it could take another five-plus years for Imbruvica to realize its full potential.
Though the deal does help AbbVie diversify away from its heavy reliance on Humira, currently the best-selling drug in the world, the common stock issued by AbbVie to raise the $109 per share in cash offered in the cash-stock deal could counteract any near-term revenue and EPS gains. Furthermore, Andrew Baum, the covering analyst at Citigroup , has implied that AbbVie would need to find as much as $5 billion in revenue beyond just Imbruvica to make the acquisition pay off for AbbVie over the long run.
Stay vigilant
Make no mistake, AbbVie isn't alone. There are other potential zombie M&A deals out there that could weigh on the profitability of Big Pharma and blue-chip biotech stocks in the coming years, and become readily apparent if healthcare valuations continue to deflate.
What you need to do as an investor is stay vigilant. This isn't to say that AbbVie, or any other acquirer isn't worth owning, or that all deals made during the last couple of years were bad, because that's just not the case. Instead, it means taking the gloves off and digging into what an M&A deal might mean for your stock holdings.
It means understanding what sort of synergies can be expected, and whether there is a genuine bargain over the long run for the acquisition in question. If the deal doesn't look as if it makes sense, it could be time to reconsider your investment.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article The Under-the-Radar Reason Why This Correction Could Be Trouble for Big Pharma and Biotech originally appeared on Fool.com.
Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen nameTMFUltraLong, track every pick he makes under the screen nameTrackUltraLong, and check him out on Twitter, where he goes by the handle@TMFUltraLong.The Motley Fool recommends Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A possible textbook example of overzealous M&A For example, AbbVie (NYSE: ABBV) ponied up a whopping $21 billion for cancer drug company Pharmacyclics earlier this year, or $261.25 per share. But Imbruvica's revenue stream isn't wholly owned by AbbVie. Though the deal does help AbbVie diversify away from its heavy reliance on Humira, currently the best-selling drug in the world, the common stock issued by AbbVie to raise the $109 per share in cash offered in the cash-stock deal could counteract any near-term revenue and EPS gains. | A possible textbook example of overzealous M&A For example, AbbVie (NYSE: ABBV) ponied up a whopping $21 billion for cancer drug company Pharmacyclics earlier this year, or $261.25 per share. But Imbruvica's revenue stream isn't wholly owned by AbbVie. Though the deal does help AbbVie diversify away from its heavy reliance on Humira, currently the best-selling drug in the world, the common stock issued by AbbVie to raise the $109 per share in cash offered in the cash-stock deal could counteract any near-term revenue and EPS gains. | A possible textbook example of overzealous M&A For example, AbbVie (NYSE: ABBV) ponied up a whopping $21 billion for cancer drug company Pharmacyclics earlier this year, or $261.25 per share. But Imbruvica's revenue stream isn't wholly owned by AbbVie. Though the deal does help AbbVie diversify away from its heavy reliance on Humira, currently the best-selling drug in the world, the common stock issued by AbbVie to raise the $109 per share in cash offered in the cash-stock deal could counteract any near-term revenue and EPS gains. | A possible textbook example of overzealous M&A For example, AbbVie (NYSE: ABBV) ponied up a whopping $21 billion for cancer drug company Pharmacyclics earlier this year, or $261.25 per share. But Imbruvica's revenue stream isn't wholly owned by AbbVie. Though the deal does help AbbVie diversify away from its heavy reliance on Humira, currently the best-selling drug in the world, the common stock issued by AbbVie to raise the $109 per share in cash offered in the cash-stock deal could counteract any near-term revenue and EPS gains. |
26847.0 | 2015-09-18 00:00:00 UTC | TG Therapeutics Up on FDA Consent for Leukemia Study | ABBV | https://www.nasdaq.com/articles/tg-therapeutics-up-on-fda-consent-for-leukemia-study-2015-09-18 | nan | nan | TG Therapeutics, Inc.TGTX announced an agreement with the FDA related to a Special Protocol Assessment (SPA) of the design of a phase III study (UNITY-CLL) on TG-1101 (ublituximab) in combination with TGR-1202 (the combination referred to as 1303) for the treatment of chronic lymphocytic leukemia (CLL). TG Therapeutics' shares surged 22.6% on the news.
UNITY-CLL will be a randomized and controlled study with two primary objectives - to define the contribution made by each agent (TG-1101 and TGR-1202) in the TG-1101 plus TGR-1202 combination regimen and to evaluate the superiority of the combination in terms of progression-free survival over standard-of-care therapies.
TG Therapeutics intends to conduct an early interim analysis to evaluate the individual contribution of each agent to the combination regimen. If the analysis reveals positive results, both single-agent arms of the study will be terminated. A second interim analysis will be conducted once the study has been fully enrolled.
This was an important milestone for TG Therapeutics. If the study achieves its objectives, the company will be eligible to file for approval of the TG-1101 plus TGR-1202 combination regimen for the treatment of CLL.
We note that the TG-1101 plus TGR-1202 combination is a non-chemotherapy regimen for the potential treatment of patients suffering from CLL. Upon successful development, it will offer a new treatment option for the patients. Moreover, the company believes that the TG-1101 plus TGR-1202 combination regimen may gain a broad label in the treatment of CLL.
Meanwhile, TG Therapeutics is comparing TG-1101 in combination with AbbVie ABBV /Johnson & Johnson's JNJ Imbruvica to Imbruvica alone in a phase III study (GENUINE) for the treatment of treatment-experienced CLL patients suffering from high-risk cytogenetics.
Being a development-stage company, TG Therapeutics does not have any approved product in its portfolio yet. The company depends heavily on the development of TG-1101 and TGR-1202 for future growth.
TG Therapeutics carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector is Eli Lilly and Company LLY , carrying a Zacks Rank #2 (Buy). J&J carries the same Zacks Rank as Lilly.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
LILLY ELI & CO (LLY): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
TG THERAPEUTICS (TGTX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Meanwhile, TG Therapeutics is comparing TG-1101 in combination with AbbVie ABBV /Johnson & Johnson's JNJ Imbruvica to Imbruvica alone in a phase III study (GENUINE) for the treatment of treatment-experienced CLL patients suffering from high-risk cytogenetics. Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report TG THERAPEUTICS (TGTX): Free Stock Analysis Report To read this article on Zacks.com click here. TG Therapeutics intends to conduct an early interim analysis to evaluate the individual contribution of each agent to the combination regimen. | Meanwhile, TG Therapeutics is comparing TG-1101 in combination with AbbVie ABBV /Johnson & Johnson's JNJ Imbruvica to Imbruvica alone in a phase III study (GENUINE) for the treatment of treatment-experienced CLL patients suffering from high-risk cytogenetics. Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report TG THERAPEUTICS (TGTX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Meanwhile, TG Therapeutics is comparing TG-1101 in combination with AbbVie ABBV /Johnson & Johnson's JNJ Imbruvica to Imbruvica alone in a phase III study (GENUINE) for the treatment of treatment-experienced CLL patients suffering from high-risk cytogenetics. Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report TG THERAPEUTICS (TGTX): Free Stock Analysis Report To read this article on Zacks.com click here. TG Therapeutics, Inc.TGTX announced an agreement with the FDA related to a Special Protocol Assessment (SPA) of the design of a phase III study (UNITY-CLL) on TG-1101 (ublituximab) in combination with TGR-1202 (the combination referred to as 1303) for the treatment of chronic lymphocytic leukemia (CLL). | Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report TG THERAPEUTICS (TGTX): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, TG Therapeutics is comparing TG-1101 in combination with AbbVie ABBV /Johnson & Johnson's JNJ Imbruvica to Imbruvica alone in a phase III study (GENUINE) for the treatment of treatment-experienced CLL patients suffering from high-risk cytogenetics. If the study achieves its objectives, the company will be eligible to file for approval of the TG-1101 plus TGR-1202 combination regimen for the treatment of CLL. |
26848.0 | 2015-09-18 00:00:00 UTC | Best Stock to Buy on Anheuser-Miller Deal is Altria | ABBV | https://www.nasdaq.com/articles/best-stock-buy-anheuser-miller-deal-altria-2015-09-18 | nan | nan | The world needs rivals. Ford versus Chevy. Coke versus Pepsi. Me versus the Brawny Paper Towel guy. Sometimes it all boils down to a matter of preference and the difference is very subtle. Other times there's a clear cut king of the mountain and challenger trying to rise to the top.
Earlier this week Anheuser-Busch InBev ( BUD ) proposed a takeover of SABMiller ( SBMRY ) . The merger would combine Budweiser and Miller beers. I never even put Budweiser and MGD in the same refrigerator. It's madness!
Here I thought the whole argument was great taste or less filling. Never mind the bottles versus cans dilemma. I wonder what Miller Lite Spokesmodel Kitana Baker has to say about all this. Are they going to make commercials with her riding in on the Clydesdales? I thought she was allergic. Can she even ride a horse? Kitana! (Call me)
Everybody here in Chicago knows that Budweiser is really just a byproduct of our waste water. Where do you think that river runs Cardinal fans? That's right, down the Illinois River, through the amber waves of grain, into the mighty Mississippi and directly into your twelve ounces of disappointment. Sorry Anheuser-Busch but I'm still a little miffed by what you did to Goose Island. My boy Eric behind the scenes agrees.
Let's not forget the big winners in this potential deal. When the news broke, SABMiller shares shot up 20%. That move was huge for Altria ( MO ) who owns a 27% stake in Miller. That's right, Altria and Miller together like drinking and cigarettes. Ironic, I know. Throw in Rick's Cabaret ( RICK ) and Vicodin maker Abbvie ( ABBV ) and you've got perfect storm of vice.
Anheuser is looking for some way to get analysts fired up about their prospects. This Zacks Rank #5 (Strong Sell) has seen earnings estimates fall like the ninety-ninth bottle of beer on the wall, the ninety-ninth bottle of beer. With four analysts dropping their estimates for the current year, our Zacks Consensus Estimate has gone from $5.49 to $5.18. Maybe they could find one of those "Real men of genius" from the radio spot to come help them out.
Honestly, I think the way to play this deal is to go with Altria. They are a Zacks Rank #2 (Buy) in an industry that's in the Top 28% of the 265 industries we rank with our Zacks Industry Rank. Looking at the chart shares of MO have carved out a good range here from $47 to $56.50. An overbought Commodity Channel Index with shares trading in the mid-$50s is a little bearish. I'm hoping a pullback to the 25-day moving average is met with renewed buying. Volumes have ticked up here a bit as well.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ANHEUSER-BU ADR (BUD): Free Stock Analysis Report
SABMILLER PLC (SBMRY): Free Stock Analysis Report
ALTRIA GROUP (MO): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Throw in Rick's Cabaret ( RICK ) and Vicodin maker Abbvie ( ABBV ) and you've got perfect storm of vice. Click to get this free report ANHEUSER-BU ADR (BUD): Free Stock Analysis Report SABMILLER PLC (SBMRY): Free Stock Analysis Report ALTRIA GROUP (MO): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Other times there's a clear cut king of the mountain and challenger trying to rise to the top. | Click to get this free report ANHEUSER-BU ADR (BUD): Free Stock Analysis Report SABMILLER PLC (SBMRY): Free Stock Analysis Report ALTRIA GROUP (MO): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Throw in Rick's Cabaret ( RICK ) and Vicodin maker Abbvie ( ABBV ) and you've got perfect storm of vice. They are a Zacks Rank #2 (Buy) in an industry that's in the Top 28% of the 265 industries we rank with our Zacks Industry Rank. | Click to get this free report ANHEUSER-BU ADR (BUD): Free Stock Analysis Report SABMILLER PLC (SBMRY): Free Stock Analysis Report ALTRIA GROUP (MO): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Throw in Rick's Cabaret ( RICK ) and Vicodin maker Abbvie ( ABBV ) and you've got perfect storm of vice. This Zacks Rank #5 (Strong Sell) has seen earnings estimates fall like the ninety-ninth bottle of beer on the wall, the ninety-ninth bottle of beer. | Throw in Rick's Cabaret ( RICK ) and Vicodin maker Abbvie ( ABBV ) and you've got perfect storm of vice. Click to get this free report ANHEUSER-BU ADR (BUD): Free Stock Analysis Report SABMILLER PLC (SBMRY): Free Stock Analysis Report ALTRIA GROUP (MO): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. The merger would combine Budweiser and Miller beers. |
26849.0 | 2015-09-17 00:00:00 UTC | S&P 500 Analyst Moves: ABBV | ABBV | https://www.nasdaq.com/articles/sp-500-analyst-moves-abbv-2015-09-17 | nan | nan | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, AbbVie ( ABBV ) is now the #34 analyst pick, moving up by 1 spot.
This rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those average opinion values.
Looking at the stock price movement year to date, AbbVie ( ABBV ) is lower by about 9.1%.
VIDEO: S&P 500 Analyst Moves: ABBV
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, AbbVie ( ABBV ) is now the #34 analyst pick, moving up by 1 spot. Looking at the stock price movement year to date, AbbVie ( ABBV ) is lower by about 9.1%. VIDEO: S&P 500 Analyst Moves: ABBV The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | VIDEO: S&P 500 Analyst Moves: ABBV The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, AbbVie ( ABBV ) is now the #34 analyst pick, moving up by 1 spot. Looking at the stock price movement year to date, AbbVie ( ABBV ) is lower by about 9.1%. | VIDEO: S&P 500 Analyst Moves: ABBV The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, AbbVie ( ABBV ) is now the #34 analyst pick, moving up by 1 spot. Looking at the stock price movement year to date, AbbVie ( ABBV ) is lower by about 9.1%. | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, AbbVie ( ABBV ) is now the #34 analyst pick, moving up by 1 spot. Looking at the stock price movement year to date, AbbVie ( ABBV ) is lower by about 9.1%. VIDEO: S&P 500 Analyst Moves: ABBV The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
26850.0 | 2015-09-16 00:00:00 UTC | Vanguard Growth ETF Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/vanguard-growth-etf-experiences-big-inflow-2015-09-16 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Growth ETF (Symbol: VUG) where we have detected an approximate $214.5 million dollar inflow -- that's a 1.1% increase week over week in outstanding units (from 182,547,722 to 184,599,175). Among the largest underlying components of VUG, in trading today Visa Inc (Symbol: V) is down about 0.3%, Oracle Corp. (Symbol: ORCL) is up about 0.9%, and AbbVie Inc. (Symbol: ABBV) is lower by about 0.7%. For a complete list of holdings, visit the VUG Holdings page » The chart below shows the one year price performance of VUG, versus its 200 day moving average:
Looking at the chart above, VUG's low point in its 52 week range is $91.80 per share, with $111.92 as the 52 week high point - that compares with a last trade of $104.72. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VUG, in trading today Visa Inc (Symbol: V) is down about 0.3%, Oracle Corp. (Symbol: ORCL) is up about 0.9%, and AbbVie Inc. (Symbol: ABBV) is lower by about 0.7%. For a complete list of holdings, visit the VUG Holdings page » The chart below shows the one year price performance of VUG, versus its 200 day moving average: Looking at the chart above, VUG's low point in its 52 week range is $91.80 per share, with $111.92 as the 52 week high point - that compares with a last trade of $104.72. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VUG, in trading today Visa Inc (Symbol: V) is down about 0.3%, Oracle Corp. (Symbol: ORCL) is up about 0.9%, and AbbVie Inc. (Symbol: ABBV) is lower by about 0.7%. For a complete list of holdings, visit the VUG Holdings page » The chart below shows the one year price performance of VUG, versus its 200 day moving average: Looking at the chart above, VUG's low point in its 52 week range is $91.80 per share, with $111.92 as the 52 week high point - that compares with a last trade of $104.72. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VUG, in trading today Visa Inc (Symbol: V) is down about 0.3%, Oracle Corp. (Symbol: ORCL) is up about 0.9%, and AbbVie Inc. (Symbol: ABBV) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Growth ETF (Symbol: VUG) where we have detected an approximate $214.5 million dollar inflow -- that's a 1.1% increase week over week in outstanding units (from 182,547,722 to 184,599,175). For a complete list of holdings, visit the VUG Holdings page » The chart below shows the one year price performance of VUG, versus its 200 day moving average: Looking at the chart above, VUG's low point in its 52 week range is $91.80 per share, with $111.92 as the 52 week high point - that compares with a last trade of $104.72. | Among the largest underlying components of VUG, in trading today Visa Inc (Symbol: V) is down about 0.3%, Oracle Corp. (Symbol: ORCL) is up about 0.9%, and AbbVie Inc. (Symbol: ABBV) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Growth ETF (Symbol: VUG) where we have detected an approximate $214.5 million dollar inflow -- that's a 1.1% increase week over week in outstanding units (from 182,547,722 to 184,599,175). For a complete list of holdings, visit the VUG Holdings page » The chart below shows the one year price performance of VUG, versus its 200 day moving average: Looking at the chart above, VUG's low point in its 52 week range is $91.80 per share, with $111.92 as the 52 week high point - that compares with a last trade of $104.72. |
26851.0 | 2015-09-15 00:00:00 UTC | AbbVie a Top Ranked SAFE Dividend Stock With 3.5% Yield | ABBV | https://www.nasdaq.com/articles/abbvie-top-ranked-safe-dividend-stock-35-yield-2015-09-15 | nan | nan | AbbVie Inc. (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. 25'' list, signifying a stock with above-average ''DividendRank'' statistics including a strong 3.5% yield, as well as a superb track record of at least two decades of dividend growth, according to the most recent ''DividendRank'' report.
According to the ETF Finder at ETF Channel , AbbVie Inc. is a member of the iShares S&P 1500 Index ETF ( ITOT ), and is also an underlying holding representing 1.22% of the SPDR S&P Dividend ETF ( SDY ), which holds $147,754,182 worth of ABBV shares.
AbbVie Inc. (Symbol: ABBV) made the "Dividend Channel S.A.F.E. 25" list because of these qualities: S . Solid return - hefty yield and strong DividendRank characteristics; A. Accelerating amount - consistent dividend increases over time; F . Flawless history - never a missed or lowered dividend; E. Enduring - at least two decades of dividend payments.
The annualized dividend paid by AbbVie Inc. is $2.04/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 10/13/2015. Below is a long-term dividend history chart for ABBV, which the report stressed as being of key importance.
ABBV operates in the Drugs & Pharmaceuticals sector, among companies like Johnson & Johnson ( JNJ ), and Novartis ( NVS ).
Top 25 S.A.F.E. Dividend Stocks Increasing Payments For Decades »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is a long-term dividend history chart for ABBV, which the report stressed as being of key importance. AbbVie Inc. (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. According to the ETF Finder at ETF Channel , AbbVie Inc. is a member of the iShares S&P 1500 Index ETF ( ITOT ), and is also an underlying holding representing 1.22% of the SPDR S&P Dividend ETF ( SDY ), which holds $147,754,182 worth of ABBV shares. | AbbVie Inc. (Symbol: ABBV) made the "Dividend Channel S.A.F.E. AbbVie Inc. (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. According to the ETF Finder at ETF Channel , AbbVie Inc. is a member of the iShares S&P 1500 Index ETF ( ITOT ), and is also an underlying holding representing 1.22% of the SPDR S&P Dividend ETF ( SDY ), which holds $147,754,182 worth of ABBV shares. | According to the ETF Finder at ETF Channel , AbbVie Inc. is a member of the iShares S&P 1500 Index ETF ( ITOT ), and is also an underlying holding representing 1.22% of the SPDR S&P Dividend ETF ( SDY ), which holds $147,754,182 worth of ABBV shares. AbbVie Inc. (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. AbbVie Inc. (Symbol: ABBV) made the "Dividend Channel S.A.F.E. | AbbVie Inc. (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. According to the ETF Finder at ETF Channel , AbbVie Inc. is a member of the iShares S&P 1500 Index ETF ( ITOT ), and is also an underlying holding representing 1.22% of the SPDR S&P Dividend ETF ( SDY ), which holds $147,754,182 worth of ABBV shares. AbbVie Inc. (Symbol: ABBV) made the "Dividend Channel S.A.F.E. |
26852.0 | 2015-09-13 00:00:00 UTC | Is It Time to Kick These Healthcare Laggards Out of Your Portfolio? | ABBV | https://www.nasdaq.com/articles/it-time-kick-these-healthcare-laggards-out-your-portfolio-2015-09-13 | nan | nan | I ( Brian Feroldi here!) know firsthand just how painful it can be to sell a stock that has lost you money. And whenever it happens I get that nagging feeling in the back of my mind that if I just hang in there, the stock will come back and I will sell then. Unfortunately, the stock market doesn't work like that; the market doesn't care how much you paid to own a stock, so it's under no obligation to move higher just because you don't want to accept a loss.
Parting ways with a stock can be tough, so it can be helpful to have a really good concrete reason to finally say goodbye. Our team of Motley Fool healthcare contributors was asked to pick a healthcare stock that we each believe might be a good candidate to say goodbye to right now. Read below why now might be a good time to kick Isis Pharmaceuticals , MannKind , and AbbVie out of your portfolio.
Todd Campbell : Isis Pharmaceuticals is posting disappointing returns this year, but that may not mean it's the right time to toss it aside.
So far, Isis Pharmaceuticals' shares have lost 12% of their value in 2015, and while that's significantly worse than its peers and the broader S&P 500 market, there's reason to think that better times may be coming. The company has 38 drugs in its pipeline in various stages of development, it counts some of the planet's biggest drug developers as collaborators, and its balance sheet includes $815 million in cash.
Of the 38 drug programs under way at Isis Pharmaceuticals, five are in phase 3 trials, and that means data may be coming that could help Isis Pharmaceuticals transition into a profitable company. If all goes well, then investors will cheer -- particularly because Isis Pharmaceuticals' track record is admittedly mixed. While the company has successfully launched Kynamro as a therapy for a rare form of high cholesterol, its sales have been tepid. Also, while Kynamro successfully made its way to market, many of Isis Pharmaceuticals' other drug programs have fizzled out during studies.
Because Isis Pharmaceuticals' future is tied tightly to its clinical-stage drugs, its shares are risky enough that they might not be right for everyone to own. If you're the kind of investor that abhors biotech's pop-and-drop nature, then Isis Pharmaceuticals probably shouldn't be in your portfolio, and it might be wise to sell so it doesn't keep you up at night. However, if you're a risk-tolerant investor who owns Isis Pharmaceuticals as part of a well-diversified portfolio, then it might be worth sticking with the stock in spite of its performance this year.
Brian Feroldi : Taking a drug all the way from an initial idea to a product that is on the market and producing revenue is a long, expensive process that's fraught with hurdles. Even the best of ideas can flame out at any point, even after they've cleared all the clinical and regulatory hurdles.
While it is still too early to know for sure, I'd say the odds are quite good that MannKind's inhaled insulin Afrezza will end up as a bust. The drug has been on the market for only about 6 months now, but the early results look ugly as its marketing partner, Sanofi , has only been able to sell about $3.3 million worth of the drug during its first two quarters on the market. For a drug that supposedly holds blockbuster potential , that's a discouraging number.
MannKind's management team offered plenty of reasons why sales out of the gate have been so slow, and they are actively working to knock down the barriers in an attempt to spark demand, but Wall Street is extremely skeptical of the company's prospects as this point -- and I think you should be, too.
MannKind has been a tough stock to own for more than a decade now as investors have patiently waited for the promise of Afrezza to finally pay off. Given the rough start for this drug, I'm skeptical that the big payday will ever come, so I'd say it's time to kick this laggard out of your portfolio and put the money in a more promising name.
George Budwell : AbbVie is a large cap biopharma stock that I've owned pretty much since the company was spun off from Abbott Laboratories in 2013. In many ways, this stock has been a great pick both in terms of its stable dividend payout and its overall return on investment.
That said, AbbVie has been stuck in a rut in 2015, and nothing seems to be able to break it free. In the second quarter, for example, the company posted an 11.1% rise in global sales year over year, continuing its tradition of generating double-digit sales growth. Yet the stock has fallen nearly 7% year to date.
Global economic turmoil and general stock market volatility aside, AbbVie's core problem at the moment appears to be the looming patent expiration in the U.S. for its flagship anti-inflammatory drug Humira in December 2016. Humira presently makes up over 60% of the drugmaker's total revenues, so the potential introduction of a biosimilar is weighing heavily on its shares this year.
Complicating matters, investors were hoping AbbVie's hepatitis C therapy, Viekira Pak, could help offset any drop in revenue, but this new growth product is facing its own problems competing in an increasingly crowded market.
To management's credit, they have provided a fairly convincing outline for how they plan on protecting Humira after it loses patent protection. But the market just doesn't seem to care or to be listening right now.
That's why I'm having a hard time seeing how this stock can push past the market's perhaps overly pessimistic view anytime soon. Therefore, AbbVie appears to be locked into a holding pattern until Humira goes off patent and the company's defense strategy proves capable of keeping disaster at bay. As such, I'm currently mulling the idea of finally relinquishing some, or maybe even all, of my shares of this healthcare laggard.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article Is It Time to Kick These Healthcare Laggards Out of Your Portfolio? originally appeared on Fool.com.
Brian Feroldi has no position in any stocks mentioned. George Budwell owns shares of AbbVie Inc. and Isis Pharmaceuticals. Todd Campbell has no position in any stocks mentioned. The Motley Fool recommends Isis Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Global economic turmoil and general stock market volatility aside, AbbVie's core problem at the moment appears to be the looming patent expiration in the U.S. for its flagship anti-inflammatory drug Humira in December 2016. Complicating matters, investors were hoping AbbVie's hepatitis C therapy, Viekira Pak, could help offset any drop in revenue, but this new growth product is facing its own problems competing in an increasingly crowded market. Read below why now might be a good time to kick Isis Pharmaceuticals , MannKind , and AbbVie out of your portfolio. | Read below why now might be a good time to kick Isis Pharmaceuticals , MannKind , and AbbVie out of your portfolio. George Budwell owns shares of AbbVie Inc. and Isis Pharmaceuticals. George Budwell : AbbVie is a large cap biopharma stock that I've owned pretty much since the company was spun off from Abbott Laboratories in 2013. | Read below why now might be a good time to kick Isis Pharmaceuticals , MannKind , and AbbVie out of your portfolio. George Budwell : AbbVie is a large cap biopharma stock that I've owned pretty much since the company was spun off from Abbott Laboratories in 2013. That said, AbbVie has been stuck in a rut in 2015, and nothing seems to be able to break it free. | Read below why now might be a good time to kick Isis Pharmaceuticals , MannKind , and AbbVie out of your portfolio. George Budwell : AbbVie is a large cap biopharma stock that I've owned pretty much since the company was spun off from Abbott Laboratories in 2013. That said, AbbVie has been stuck in a rut in 2015, and nothing seems to be able to break it free. |
26853.0 | 2015-09-11 00:00:00 UTC | AbbVie's Humira Gains FDA Approval for Label Expansion | ABBV | https://www.nasdaq.com/articles/abbvies-humira-gains-fda-approval-for-label-expansion-2015-09-11 | nan | nan | AbbVie Inc . ABBV announced a label expansion for its anti-inflammatory drug, Humira, in the U.S. With the label expansion, Humira can now be used for the treatment of patients suffering from moderate-to-severe hidradenitis suppurativa (HS). Approval makes Humira the first and only FDA-approved treatment for this indication.
The U.S. approval comes after Humira gained approval in the EU in Jul 2015 for the treatment of active moderate-to-severe HS in adults who have had an inadequate response to conventional systemic HS treatment.
We note that this is the ninth FDA approval for Humira over a period of 12 years. Humira is currently approved for several indications including reduction of the signs and symptoms of psoriatic arthritis, ankylosing spondylitis, moderate-to-severe rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, Crohn's disease (CD), ulcerative colitis and chronic plaque psoriasis arthritis in the U.S. It is also approved for the treatment of moderate-to-severe CD in children 6 years of age and older.
Humira has orphan drug status for the treatment of moderate-to-severe HS (Hurley stage II and Hurley stage III disease). The orphan drug status should now make Humira eligible for seven years of market exclusivity for this indication.
We are encouraged by the label expansion of Humira. Humira is the key growth driver at AbbVie. In the first half of 2015, Humira generated global revenues of $6.6 billion, an increase of 12.2% year over year. Label expansion should boost the drug's sales further.
Meanwhile, AbbVie is working on expanding Humira's label further. The company is evaluating Humira for the treatment of adults with uveitis. Regulatory applications in the U.S. and EU are planned for the second half of 2015.
AbbVie currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Dr. Reddy's Laboratories Ltd. RDY , Gilead Sciences Inc. GILD and Regeneron Pharmaceuticals, Inc. REGN . All three carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
DOCTOR REDDYS (RDY): Free Stock Analysis Report
REGENERON PHARM (REGN): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc . ABBV announced a label expansion for its anti-inflammatory drug, Humira, in the U.S. With the label expansion, Humira can now be used for the treatment of patients suffering from moderate-to-severe hidradenitis suppurativa (HS). Humira is the key growth driver at AbbVie. | Click to get this free report DOCTOR REDDYS (RDY): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc . ABBV announced a label expansion for its anti-inflammatory drug, Humira, in the U.S. With the label expansion, Humira can now be used for the treatment of patients suffering from moderate-to-severe hidradenitis suppurativa (HS). | ABBV announced a label expansion for its anti-inflammatory drug, Humira, in the U.S. With the label expansion, Humira can now be used for the treatment of patients suffering from moderate-to-severe hidradenitis suppurativa (HS). Click to get this free report DOCTOR REDDYS (RDY): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc . | Meanwhile, AbbVie is working on expanding Humira's label further. Click to get this free report DOCTOR REDDYS (RDY): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc . |
26854.0 | 2015-09-11 00:00:00 UTC | Why is Gilead (GILD) Raising a Whopping $10 Billion? | ABBV | https://www.nasdaq.com/articles/why-is-gilead-gild-raising-a-whopping-%2410-billion-2015-09-11 | nan | nan | Gilead Sciences, Inc.GILD was up 3.3% after the company announced the successful pricing of its senior note offering worth $10 billion in aggregate principal amount. The company is offering six tranches of senior notes maturing between 2018 and 2046 with interest rate ascending from 1.85% to 4.75%. The offering will close on Sep 14, 2015, subject to the satisfaction of customary closing conditions.
The company intends to use the net proceeds from the senior notes offering for general corporate purposes including the repayment of debt, working capital, payment of dividends and the repurchase of its outstanding common stock pursuant to its authorized share repurchase program. The timing for Gilead to lock in current rates with its senior notes offering is favorable, considering that the U.S. Federal Reserve might hike rates in the near term.
Gilead's revenues received a major boost with the launch of hepatitis C virus (HCV) drugs Sovaldi (Dec 2013) and Harvoni (Oct 2014). Although Sovaldi and Harvoni sales have been impressive, Sovaldi sales are already weakening owing to availability of newer HCV therapies. Other approved HCV therapies include Johnson & Johnson's JNJ Olysio and AbbVie's ABBV Viekira Pak. Pricing measures in the form of rebates and discounts could lead to a slowdown in Harvoni sales. With uncertainty surrounding the future of its blockbuster HCV drugs, Gilead must be looking to augment its portfolio.
Gilead has a history of boosting its portfolio and pipeline by entering into licensing and acquisition agreements. In fact, the blockbuster HCV therapy, Sovaldi, was added to Gilead's portfolio through the Pharmasset acquisition in 2012. In May 2015, Gilead acquired privately held Danish company, EpiTherapeutics ApS, for $65 million gaining access to the latter's library of first-in-class, selective small molecule inhibitors of epigenetic regulation of gene transcription, in particular histone demethylases. Earlier this year, the company acquired a privately held biotechnology company, Phenex, to develop treatments for liver diseases including nonalcoholic steatohepatitis (NASH). Thus, we can see more such acquisitions from Gilead in the near term.
Gilead carries a Zacks Rank #1 (Strong Buy). Regeneron Pharmaceuticals, Inc. REGN is another favorably ranked stock in the health care sector carrying the same Zacks Rank as Gilead.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
REGENERON PHARM (REGN): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other approved HCV therapies include Johnson & Johnson's JNJ Olysio and AbbVie's ABBV Viekira Pak. Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Gilead Sciences, Inc.GILD was up 3.3% after the company announced the successful pricing of its senior note offering worth $10 billion in aggregate principal amount. | Other approved HCV therapies include Johnson & Johnson's JNJ Olysio and AbbVie's ABBV Viekira Pak. Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Other approved HCV therapies include Johnson & Johnson's JNJ Olysio and AbbVie's ABBV Viekira Pak. The company intends to use the net proceeds from the senior notes offering for general corporate purposes including the repayment of debt, working capital, payment of dividends and the repurchase of its outstanding common stock pursuant to its authorized share repurchase program. | Other approved HCV therapies include Johnson & Johnson's JNJ Olysio and AbbVie's ABBV Viekira Pak. Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. The company is offering six tranches of senior notes maturing between 2018 and 2046 with interest rate ascending from 1.85% to 4.75%. |
26855.0 | 2015-09-10 00:00:00 UTC | Why Shares of AbbVie Inc. Dropped 10% in August | ABBV | https://www.nasdaq.com/articles/why-shares-abbvie-inc-dropped-10-august-2015-09-10 | nan | nan | What: Global pharmaceutical giant AbbVie got caught up in the market's madness during August as the company's stock lost more than 10% of its value during the month, according to S&P Capital IQ .
So what: Even though shares managed to slide in August, that doesn't mean anything bad happened. In fact, the company is in terrific financial shape, with its reported second-quarter results exceeding analysts' expectations. Revenue during the quarter was more than $5.4 billion, up a strong 19% over the year-ago period. Adjusted earnings for the quarter, which excludes some of the one-time costs related to its huge $21 billion Pharmacyclics acquisition, were $1.08, up a strong 31% over the year-ago period.
Looking at AbbVie's individual products, sales of the company's flagship anti-inflammatory drug Humira increased 7.6% around the world to $3.5 billion and would have been much higher if not for currency headwinds. Sales of Viekira Pak, AbbVie's recently-launched hepatitis C treatment, landed at $385 million, and this figure is expected to continue to grow strongly throughout the rest of the year. Sales of Imbruvica, the company's chronic lymphocytic leukemia treatment that was recently added to its portfolio through the Pharmacyclics acquisition, landed at $234 million, though the company was only allowed a portion of that revenue on its books, as the acquisition was finalized during the quarter.
This strong sales growth coupled with the amounts booked in the first quarter have management expecting adjusted earnings for the year to land between $4.10 and $4.30 per share .
Now what: Although shares of this behemoth are down since the start of the year, I think there are a lot of reasons to be bullish on AbbVie's stock form here. While the sheer size of the Pharmacyclics acquisition may put some temporary pressure on reported results, AbbVie's management team expects the deal to be accretive by around $0.60 per share by 2017. The acquisition also helps to diversify the company's revenue base away from Humira, from which AbbVie still derives the bulk of its revenue.
Looking a few years out, analysts expect profits to grow by 17% per year, which is a quite a rapid pace for a company that's only trading for around 12 times expected 2016 earnings. When you combine its juicy 3.4% dividend yield to the mix, it might be a great time for opportunistic investors to add this dividend dynamo to their portfolios.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article Why Shares of AbbVie Inc. Dropped 10% in August originally appeared on Fool.com.
Brian Feroldi has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at AbbVie's individual products, sales of the company's flagship anti-inflammatory drug Humira increased 7.6% around the world to $3.5 billion and would have been much higher if not for currency headwinds. Sales of Viekira Pak, AbbVie's recently-launched hepatitis C treatment, landed at $385 million, and this figure is expected to continue to grow strongly throughout the rest of the year. While the sheer size of the Pharmacyclics acquisition may put some temporary pressure on reported results, AbbVie's management team expects the deal to be accretive by around $0.60 per share by 2017. | While the sheer size of the Pharmacyclics acquisition may put some temporary pressure on reported results, AbbVie's management team expects the deal to be accretive by around $0.60 per share by 2017. What: Global pharmaceutical giant AbbVie got caught up in the market's madness during August as the company's stock lost more than 10% of its value during the month, according to S&P Capital IQ . Looking at AbbVie's individual products, sales of the company's flagship anti-inflammatory drug Humira increased 7.6% around the world to $3.5 billion and would have been much higher if not for currency headwinds. | What: Global pharmaceutical giant AbbVie got caught up in the market's madness during August as the company's stock lost more than 10% of its value during the month, according to S&P Capital IQ . Looking at AbbVie's individual products, sales of the company's flagship anti-inflammatory drug Humira increased 7.6% around the world to $3.5 billion and would have been much higher if not for currency headwinds. Sales of Viekira Pak, AbbVie's recently-launched hepatitis C treatment, landed at $385 million, and this figure is expected to continue to grow strongly throughout the rest of the year. | What: Global pharmaceutical giant AbbVie got caught up in the market's madness during August as the company's stock lost more than 10% of its value during the month, according to S&P Capital IQ . Looking at AbbVie's individual products, sales of the company's flagship anti-inflammatory drug Humira increased 7.6% around the world to $3.5 billion and would have been much higher if not for currency headwinds. Sales of Viekira Pak, AbbVie's recently-launched hepatitis C treatment, landed at $385 million, and this figure is expected to continue to grow strongly throughout the rest of the year. |
26856.0 | 2015-09-08 00:00:00 UTC | Whipsaw the Market Right Back with These Three Tech Investing Plays | ABBV | https://www.nasdaq.com/articles/whipsaw-market-right-back-these-three-tech-investing-plays-2015-09-08 | nan | nan | MoneyMorning.com Report - Last Thursday, I showed you why a strong U.S economy should give you confidence about tech investing .
While others get distracted by the noise on Wall Street, we're staying focused on our long-term objective of building wealth through tech investing.
I also said I'd bring you three stocks that can beat this whipsawed market . And in a moment, I'm going to do just that...
But first, let's me address something no one else in the mainstream media is covering - tech is still performing better than the overall market.
So far this year, the Dow Jones Industrial Average is down nearly 8%, and the Standard & Poor's 500 Index is off about 5%. By contrast, the Nasdaq Composite is just above breakeven.
Tech will continue to outperform this choppy market.
And these three tech stocks will lead the pack...
Getting Revved Up
You can be sure that Wall Street is keeping all eyes on Sept. 16-17, when the U.S. Federal Reserve holds its next policy meeting.
Fed Chairwoman Janet Yellen is scheduled to meet with reporters on Sept. 16 to explain the central bank's policy stance. The Wall Street Journal says 82% of forecasters polled expect a rate increase at the September meeting.
I mention that to make sure you know I've factored a possible Fed-driven market retreat into my investment thesis.
Now that that's out of the way, let's take a look at why these three stocks are the ones you should add whenever Wall Street goes on sale...
Tech Investing Pick No. 1: Gilead Sciences Inc.
There's never been anything like the success Gilead (Nasdaq: GILD) has had with Sovaldi. This highly effective treatment for the blood-borne disease hepatitis C racked up $10.3 billion in sales last year - its first full year on the market.
But there's more to the story. Gilead launched a second hepatitis C drug, Harvoni, at the end of 2014 that did $2.1 billion in sales. That combined $12.4 billion is just slightly less than the $12.5 that AbbVie Inc. (NYSE: ABBV) brought in last year for Humira, an anti-inflammatory that is the best-selling drug ever.
Some investors are worried about Gilead's stock because the company is facing competition for hepatitis C drugs.
But Harvoni ranks as the most effective drug in its class and is targeting a large market. The Centers for Disease Control and Prevention recommend that all 76.5 million U.S. baby boomers get tested for hepatitis C.
Moreover, the company has at least 36 new drugs in its clinical pipeline, including three that are close to getting approval from the U.S. Food and Drug Administration.
The stock trades at $102, giving it a $158 billion market cap - and it offers sterling financials. It reported triple-digit earnings gains in four of the past six quarters. Over the past three years, it has grown per-share earnings by an average 91% and boasts a 99% return on stockholders' equity.
This next "whipsawed market" play is making rapid gains in the wearable tech sector...
Tech Investing Pick No. 2: Apple Inc.
Mention "wearable tech" and most investors immediately think of Fitbit Inc. (NYSE: FIT) and its health-focused wristbands. In the second quarter, Fitbit led the world in "wearables" shipments with 4.4 million units.
But there is a global tech leader that is quickly caching up. Apple (Nasdaq: AAPL) only entered the wearable-tech market in April with the release of its smart watch and is already in second place.
New data compiled by IDC says the iDevice King shipped 3.6 million Apple Watches in the period, just 18% behind Fitbit. Considering that Fitbit was founded in 2007, Apple is clearly the fast mover in this market.
And this is a lucrative move for Apple. IDC says the wearables sector saw a 223% increase in second-quarter shipments to 18.1 million.
Of course, that's far from the only market the Silicon Valley legend dominates. It remains the world's most profitable maker of smartphones, registering sales of 47.5 million units in the June period, a 35% gain.
It's set to launch an updated version of the iPhone, the iPhone 6S, on Sept. 9. The phone is already getting rave reviews from the tech trades for having double the amount of memory, a faster processing chip, and a video camera that can film in the new ultra-high-def format known as 4K.
The stock has come under pressure in the last several weeks as Wall Street discounts the price based on what I believe are exaggerated concerns about iPhone sales in China.
Savvy long-term investors can turn this to their advantage. Apple trades at just 10.8 times forward earnings, or 40% less than that of the S&P 500 and 45% less than the Nasdaq 100.
Trading at about $110, Apple has a market cap of $646 billion. It has 30% operating margins and a 41% return on equity.
Tech Investing Pick No. 3: Google Inc.
Until early July, Google Inc. (Nasdaq: GOOG, GOOGL) had been lagging the broader market over the past year simply because Wall Street didn't understand the company's long-term approach.
After all, this is a company that signed a 60-year lease at a NASA facility in Silicon Valley where it's pursuing such cutting-edge areas as robotics, space exploration, and driverless cars.
Google also is investing up to $1.5 billion in drug research for antiaging. It has logged 2 million miles for its fleet of driverless cars and has purchased at least six robotics firms in recent years.
None of these seemed directly related to its perceived core missions of web search and the Android operating system for mobile devices.
But when it recently announced a broad realignment into Alphabet, Google got the support of Wall Street for its bold new vision - to build the tech conglomerate of the 21st century.
Under the Alphabet plan, Google intends to prove it can pursue futuristic tech while remaining focused on the bottom line.
Alphabet will hold the firm's cutting-edge research via such holdings as Boston Robotics, California Life Sciences (Calico), and Google X. Google itself will retain its web and mobile businesses.
From a financial standpoint, the company is on a roll. In the second quarter, sales rose 11% to $17.7 billion as earnings per share climbed nearly 32%. Trading at $637, the company has a $452 billion market cap - in addition to 25% operating margins and a 14% return on equity.
Each of these tech leaders is poised to outgrow the economy for years to come.
And that makes them great foundational plays. You can count on them to keep you on the road to wealth no matter what the markets throw our way.
Follow us on Twitter @moneymorning.
It's in the Numbers:Despite this year's stock market volatility, the U.S. economy is standing steady. The Commerce Department recently issued an upward GDP growth revision, bolstered by hearty home and auto sales.It's the perfect time to take advantage of recent market dips and buy into the tech sector - these numbers prove it...
To get full access to all Money Morning content including our latest Premium Report, "How to Make 2015 Your Wealthiest Year Ever," click here
About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience - for free . Our experts - who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV - deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.
Disclaimer: © 2015 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | That combined $12.4 billion is just slightly less than the $12.5 that AbbVie Inc. (NYSE: ABBV) brought in last year for Humira, an anti-inflammatory that is the best-selling drug ever. The phone is already getting rave reviews from the tech trades for having double the amount of memory, a faster processing chip, and a video camera that can film in the new ultra-high-def format known as 4K. Our experts - who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV - deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. | That combined $12.4 billion is just slightly less than the $12.5 that AbbVie Inc. (NYSE: ABBV) brought in last year for Humira, an anti-inflammatory that is the best-selling drug ever. This next "whipsawed market" play is making rapid gains in the wearable tech sector... Tech Investing Pick No. Alphabet will hold the firm's cutting-edge research via such holdings as Boston Robotics, California Life Sciences (Calico), and Google X. Google itself will retain its web and mobile businesses. | That combined $12.4 billion is just slightly less than the $12.5 that AbbVie Inc. (NYSE: ABBV) brought in last year for Humira, an anti-inflammatory that is the best-selling drug ever. This next "whipsawed market" play is making rapid gains in the wearable tech sector... Tech Investing Pick No. 3: Google Inc. Until early July, Google Inc. (Nasdaq: GOOG, GOOGL) had been lagging the broader market over the past year simply because Wall Street didn't understand the company's long-term approach. | That combined $12.4 billion is just slightly less than the $12.5 that AbbVie Inc. (NYSE: ABBV) brought in last year for Humira, an anti-inflammatory that is the best-selling drug ever. And these three tech stocks will lead the pack... Getting Revved Up You can be sure that Wall Street is keeping all eyes on Sept. 16-17, when the U.S. Federal Reserve holds its next policy meeting. Gilead launched a second hepatitis C drug, Harvoni, at the end of 2014 that did $2.1 billion in sales. |
26857.0 | 2015-09-07 00:00:00 UTC | 5 Low-Risk Stocks for Dividend Investors | ABBV | https://www.nasdaq.com/articles/5-low-risk-stocks-dividend-investors-2015-09-07 | nan | nan | The overall trend for the broader markets is up, especially when factoring dividend payments into the equation. So it might be a wise move to start moving some money into less risky types of stocks, and into, perhaps, stable large-cap companies with sustainable dividend payments.
Keeping with this theme, I'm favoring top healthcare stocks AbbVie , Bristol-Myers Squibb , Gilead Sciences , Johnson & Johnson , and Pfizer right now. Here's why.
AbbVie is a top dividend stock primed for long-term growth
AbbVie's stated goal is nothing less than to serve up industry-leading growth, and so far, it's fulfilling that goal in spades. In the second quarter, for instance, the drugmaker generated $5.475 billion in revenue, a 19.4% rise over a year ago, on an operational basis. That kind of double-digit revenue growth is nearly unheard of among big pharmas, but it has essentially been an AbbVie hallmark since Abbott Laboratories spun off the company in 2013.
Source: AbbVie.
This strong revenue growth has enabled the company to up its dividend several times over the past two years, giving it one of the highest yields in the healthcare sector -- 3.23% at current levels. That said, AbbVie does sport a 12-month, trailing dividend payout ratio of 73% (expressed as annual dividend per share divided by free cash flow per share), suggesting that further increases are unlikely in the near-term.
Turning to AbbVie's long-term outlook, management believes its recent acquisition of Pharmacyclics will begin to add to AbbVie's earnings in a meaningful way by 2017 and potentially drive earnings to more than double by 2020 -- depending, perhaps heavily so, on how the patent expiration for its flagship anti-inflammatory drug Humira plays out in terms of the timing and impact of biosimilars hitting the market.
Bristol-Myers' new immuno-oncology drug, Opdivo, is a game-changer
Bristol-Myers is starting to emerge from the patent cliff thanks to its PD-1 inhibitor Opdivo that's proving to be a major advancement in the fight against cancer. Although the drug has garnered only two regulatory approvals as a monotherapy in the U.S. thus far -- for advanced melanoma and metastatic squamous non-small-cell lung cancer, respectively -- its sales rose more than 300% in the second quarter to $122 million, just from the first quarter alone. Furthermore, the drug is on track to rack up several additional approvals in the U.S. and EU in the coming months, and that should ratchet up sales even further.
Given that Opdivo's peak sales could reach into the $8 billion stratosphere according to some analysts, and that Bristol already sports over $10 billion in cash, the company's sector average dividend yield of 2.47% looks, to me, to be sustainable for the long term. Even so, it is important to note that Bristol has one of the highest cash payout ratios in the sector at a noteworthy 154%, resulting, in part, from the loss of patent protection for former top selling drugs and the sale of its diabetes assets to AstraZeneca .
Gilead has plenty of dry powder to fund its significant shareholder rewards
Gilead isn't known for its dividend, because it only recently initiated a payout. But with over $14 billion in cash at the end of the second quarter and a history of staying away from bank-breaking acquisitions (with the one exception of the brilliant $11 billion deal that netted blockbuster hepatitis C drug Sovaldi), Gilead is probably going to significantly ramp up its meager yield that currently sits at 1.6%.
What makes this stock "low-risk," though, goes beyond its strong financial position and has everything to do with management's rock star-like ability to identify promising clinical candidates and subsequently bringing them to market in record time.
Right now, Gilead has several intriguing experimental products aimed at liver diseases, infectious diseases, and various cancers that haven't gotten much respect from the Street. In fact, the stock is currently trading at a highly compressed P/E ratio of 11.2, relative to its biotech peers. As history has repeatedly shown, however, Gilead's pipeline is one of the most productive in all of big pharma and big biotech, giving investors good reason to feel comfortable holding this stock for the long term.
Johnson & Johnson takes care of its shareholders -- in good times and bad
Aside from it being a Dividend Aristocrat, J&J is a favorite name among income investors because the company has returned the bulk of its cash to shareholders through share repurchases and dividend increases, and its total gains (including dividends) have beaten the broader markets for two decades running.
J&J's safety factor nevertheless comes from its industry-leading pharma pipeline. Not only did the IDEA Pharma Productive Innovation Index for 2015 recently rank J&J's pipeline as No. 1, but the Big Pharma is also on track to potentially bring another 10 blockbusters to market in the next three years. Adding to its safety factor during turbulent times, J&J has one of the strongest balance sheets in the industry, with over $10 billion in cash and cash equivalents at the end of the second quarter.
Given its strong balance sheet, clinical pipeline, and reasonable cash payout ratio of 60%, J&J's sector-beating yield of 3% therefore looks safe for the long-term.
Pfizer's return to growth is finally taking shape
Pfizer has long been a favorite name among income investors, but it hasn't attracted many folks seeking growth because of its nasty run-in with the patent cliff. Put plainly, Pfizer's stock has struggled mightily for the better part of a decade as a result of exclusivity periods expiring on its key drugs. That said, the drugmaker's newer products, such as its breast cancer drug Ibrance and its pneumococcal pneumonia vaccine Prevnar 13, are starting to help it turn the corner in terms of top-line growth. Looking a bit further down the line, Pfizer is also building out a potentially game-changing immuno-oncology pipeline, and its experimental PCSK9 products aimed at lowering bad cholesterol could also be future blockbusters for the drugmaker.
Source: Pfizer.
Now, Pfizer does have a problem with its legacy product portfolio, and this issue is only going to get worse as generic competitors continue to clobber key products such as Celebrex. But keep in mind that Pfizer has over $30 billion in liquid assets alone that it could put to work to acquire another drugmaker with better growth prospects. This mountain of cash, and a cash payout ratio that presently stands at 50%, also suggests that its sector-beating dividend yield of 3.45% is safe.
Should you pick up these stocks right now?
I think all five of these stocks would be great pickups for investors looking for relatively safe plays in such a violent market. While the sustainability of some of their dividends may look questionable at present (especially AbbVie and Bristol), their strong cash flows, balance sheets, and emerging clinical pipelines all give them a comfortable economic moat -- even in a worst-case scenario where global economic conditions continue to deteriorate. And in sunnier times, these dividend stocks should continue to provide market-beating returns because of their top-notch clinical portfolios that provide deep value for investors with a long-term outlook.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article 5 Low-Risk Stocks for Dividend Investors originally appeared on Fool.com.
George Budwell owns shares of AbbVie and Gilead Sciences. The Motley Fool owns and recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Keeping with this theme, I'm favoring top healthcare stocks AbbVie , Bristol-Myers Squibb , Gilead Sciences , Johnson & Johnson , and Pfizer right now. AbbVie is a top dividend stock primed for long-term growth AbbVie's stated goal is nothing less than to serve up industry-leading growth, and so far, it's fulfilling that goal in spades. That kind of double-digit revenue growth is nearly unheard of among big pharmas, but it has essentially been an AbbVie hallmark since Abbott Laboratories spun off the company in 2013. | Keeping with this theme, I'm favoring top healthcare stocks AbbVie , Bristol-Myers Squibb , Gilead Sciences , Johnson & Johnson , and Pfizer right now. While the sustainability of some of their dividends may look questionable at present (especially AbbVie and Bristol), their strong cash flows, balance sheets, and emerging clinical pipelines all give them a comfortable economic moat -- even in a worst-case scenario where global economic conditions continue to deteriorate. AbbVie is a top dividend stock primed for long-term growth AbbVie's stated goal is nothing less than to serve up industry-leading growth, and so far, it's fulfilling that goal in spades. | AbbVie is a top dividend stock primed for long-term growth AbbVie's stated goal is nothing less than to serve up industry-leading growth, and so far, it's fulfilling that goal in spades. That said, AbbVie does sport a 12-month, trailing dividend payout ratio of 73% (expressed as annual dividend per share divided by free cash flow per share), suggesting that further increases are unlikely in the near-term. Keeping with this theme, I'm favoring top healthcare stocks AbbVie , Bristol-Myers Squibb , Gilead Sciences , Johnson & Johnson , and Pfizer right now. | Keeping with this theme, I'm favoring top healthcare stocks AbbVie , Bristol-Myers Squibb , Gilead Sciences , Johnson & Johnson , and Pfizer right now. AbbVie is a top dividend stock primed for long-term growth AbbVie's stated goal is nothing less than to serve up industry-leading growth, and so far, it's fulfilling that goal in spades. That kind of double-digit revenue growth is nearly unheard of among big pharmas, but it has essentially been an AbbVie hallmark since Abbott Laboratories spun off the company in 2013. |
26858.0 | 2015-09-04 00:00:00 UTC | Noteworthy ETF Outflows: IYH, ABBV, MDT, BIIB | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-outflows-iyh-abbv-mdt-biib-2015-09-04 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $119.5 million dollar outflow -- that's a 5.2% decrease week over week (from 15,350,000 to 14,550,000). Among the largest underlying components of IYH, in trading today AbbVie Inc. (Symbol: ABBV) is down about 2%, Medtronic PLC (Symbol: MDT) is down about 1.7%, and Biogen Inc (Symbol: BIIB) is lower by about 0.2%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average:
Looking at the chart above, IYH's low point in its 52 week range is $108.00 per share, with $164.98 as the 52 week high point - that compares with a last trade of $147.32. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IYH, in trading today AbbVie Inc. (Symbol: ABBV) is down about 2%, Medtronic PLC (Symbol: MDT) is down about 1.7%, and Biogen Inc (Symbol: BIIB) is lower by about 0.2%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $108.00 per share, with $164.98 as the 52 week high point - that compares with a last trade of $147.32. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IYH, in trading today AbbVie Inc. (Symbol: ABBV) is down about 2%, Medtronic PLC (Symbol: MDT) is down about 1.7%, and Biogen Inc (Symbol: BIIB) is lower by about 0.2%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $108.00 per share, with $164.98 as the 52 week high point - that compares with a last trade of $147.32. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IYH, in trading today AbbVie Inc. (Symbol: ABBV) is down about 2%, Medtronic PLC (Symbol: MDT) is down about 1.7%, and Biogen Inc (Symbol: BIIB) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $119.5 million dollar outflow -- that's a 5.2% decrease week over week (from 15,350,000 to 14,550,000). For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $108.00 per share, with $164.98 as the 52 week high point - that compares with a last trade of $147.32. | Among the largest underlying components of IYH, in trading today AbbVie Inc. (Symbol: ABBV) is down about 2%, Medtronic PLC (Symbol: MDT) is down about 1.7%, and Biogen Inc (Symbol: BIIB) is lower by about 0.2%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $108.00 per share, with $164.98 as the 52 week high point - that compares with a last trade of $147.32. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
26859.0 | 2015-08-31 00:00:00 UTC | After Hours Most Active for Aug 31, 2015 : TV, MSFT, QQQ, ABBV, GE, INTC, EXEL, FTR, T, PFE, FB, F | ABBV | https://www.nasdaq.com/articles/after-hours-most-active-aug-31-2015-tv-msft-qqq-abbv-ge-intc-exel-ftr-t-pfe-fb-f-2015-08 | nan | nan | The NASDAQ 100 After Hours Indicator is down -2.33 to 4,272.25. The total After hours volume is currently 61,953,900 shares traded.
The following are the most active stocks for the after hours session :
Grupo Televisa S.A. ( TV ) is unchanged at $30.56, with 3,043,910 shares traded. TV's current last sale is 76.4% of the target price of $40.
Microsoft Corporation ( MSFT ) is -0.003 at $43.52, with 2,692,215 shares traded. MSFT's current last sale is 82.89% of the target price of $52.5.
PowerShares QQQ Trust, Series 1 ( QQQ ) is -0.15 at $104.16, with 2,403,253 shares traded. This represents a 22.92% increase from its 52 Week Low.
AbbVie Inc. ( ABBV ) is unchanged at $62.41, with 2,185,824 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range".
General Electric Company ( GE ) is unchanged at $24.82, with 2,067,338 shares traded. GE's current last sale is 82.73% of the target price of $30.
Intel Corporation ( INTC ) is -0.003 at $28.54, with 1,821,141 shares traded. INTC's current last sale is 79.27% of the target price of $36.
Exelixis, Inc. ( EXEL ) is -0.003 at $5.95, with 1,712,872 shares traded. As reported in the last short interest update the days to cover for EXEL is 7.378266; this calculation is based on the average trading volume of the stock.
Frontier Communications Corporation ( FTR ) is -0.003 at $5.07, with 1,644,306 shares traded. As reported by Zacks, the current mean recommendation for FTR is in the "buy range".
AT&T Inc. ( T ) is -0.02 at $33.18, with 1,570,088 shares traded. Over the last four weeks they have had 5 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2015. The consensus EPS forecast is $0.68. As reported by Zacks, the current mean recommendation for T is in the "buy range".
Pfizer, Inc. ( PFE ) is unchanged at $32.22, with 1,497,607 shares traded. As reported by Zacks, the current mean recommendation for PFE is in the "buy range".
Facebook, Inc. ( FB ) is -0.18 at $89.25, with 1,481,069 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2015. The consensus EPS forecast is $0.35. As reported by Zacks, the current mean recommendation for FB is in the "buy range".
Ford Motor Company ( F ) is -0.05 at $13.82, with 1,373,075 shares traded. F's current last sale is 81.29% of the target price of $17.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc. ( ABBV ) is unchanged at $62.41, with 2,185,824 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". The following are the most active stocks for the after hours session : Grupo Televisa S.A. ( TV ) is unchanged at $30.56, with 3,043,910 shares traded. | AbbVie Inc. ( ABBV ) is unchanged at $62.41, with 2,185,824 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". The total After hours volume is currently 61,953,900 shares traded. | AbbVie Inc. ( ABBV ) is unchanged at $62.41, with 2,185,824 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". AT&T Inc. ( T ) is -0.02 at $33.18, with 1,570,088 shares traded. | AbbVie Inc. ( ABBV ) is unchanged at $62.41, with 2,185,824 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". The following are the most active stocks for the after hours session : Grupo Televisa S.A. ( TV ) is unchanged at $30.56, with 3,043,910 shares traded. |
26860.0 | 2015-08-27 00:00:00 UTC | After Hours Most Active for Aug 27, 2015 : FCX, QQQ, ODP, GM, JPM, C, AAPL, YHOO, ON, KMI, ABBV, MSFT | ABBV | https://www.nasdaq.com/articles/after-hours-most-active-aug-27-2015-fcx-qqq-odp-gm-jpm-c-aapl-yhoo-kmi-abbv-msft-2015-08 | nan | nan | The NASDAQ 100 After Hours Indicator is down -1.57 to 4,323.25. The total After hours volume is currently 32,555,668 shares traded.
The following are the most active stocks for the after hours session :
Freeport-McMoran, Inc. ( FCX ) is +1.91 at $12.10, with 5,483,923 shares traded. As reported by Zacks, the current mean recommendation for FCX is in the "buy range".
PowerShares QQQ Trust, Series 1 ( QQQ ) is +0.06 at $105.70, with 4,996,065 shares traded. This represents a 24.73% increase from its 52 Week Low.
Office Depot, Inc. ( ODP ) is unchanged at $7.88, with 1,577,758 shares traded. ODP's current last sale is 71.64% of the target price of $11.
General Motors Company ( GM ) is +0.08 at $28.66, with 1,575,525 shares traded. GM's current last sale is 77.46% of the target price of $37.
J P Morgan Chase & Co ( JPM ) is unchanged at $64.48, with 1,565,693 shares traded. As reported by Zacks, the current mean recommendation for JPM is in the "buy range".
Citigroup Inc. ( C ) is unchanged at $53.44, with 1,508,332 shares traded. As reported by Zacks, the current mean recommendation for C is in the "buy range".
Apple Inc. ( AAPL ) is -0.34 at $112.58, with 1,323,382 shares traded. As reported by Zacks, the current mean recommendation for AAPL is in the "buy range".
Yahoo! Inc. ( YHOO ) is unchanged at $33.69, with 993,185 shares traded. As reported by Zacks, the current mean recommendation for YHOO is in the "buy range".
ON Semiconductor Corporation ( ON ) is unchanged at $9.79, with 987,213 shares traded. ON's current last sale is 72.52% of the target price of $13.5.
Kinder Morgan, Inc. ( KMI ) is unchanged at $32.00, with 829,127 shares traded. As reported by Zacks, the current mean recommendation for KMI is in the "buy range".
AbbVie Inc. ( ABBV ) is unchanged at $64.51, with 745,702 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range".
Microsoft Corporation ( MSFT ) is unchanged at $43.90, with 708,629 shares traded. MSFT's current last sale is 83.62% of the target price of $52.5.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc. ( ABBV ) is unchanged at $64.51, with 745,702 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". The following are the most active stocks for the after hours session : Freeport-McMoran, Inc. ( FCX ) is +1.91 at $12.10, with 5,483,923 shares traded. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AbbVie Inc. ( ABBV ) is unchanged at $64.51, with 745,702 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". | AbbVie Inc. ( ABBV ) is unchanged at $64.51, with 745,702 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". As reported by Zacks, the current mean recommendation for AAPL is in the "buy range". | AbbVie Inc. ( ABBV ) is unchanged at $64.51, with 745,702 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". The NASDAQ 100 After Hours Indicator is down -1.57 to 4,323.25. |
26861.0 | 2015-08-25 00:00:00 UTC | iShares Core S&P 500 ETF Experiences Big Outflow | ABBV | https://www.nasdaq.com/articles/ishares-core-sp-500-etf-experiences-big-outflow-2015-08-25 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P 500 ETF (Symbol: IVV) where we have detected an approximate $99.3 million dollar outflow -- that's a 0.1% decrease week over week (from 333,900,000 to 333,400,000). Among the largest underlying components of IVV, in trading today Bank of America Corp. (Symbol: BAC) is up about 4.6%, PepsiCo Inc. (Symbol: PEP) is up about 0.8%, and AbbVie Inc. (Symbol: ABBV) is higher by about 0.5%. For a complete list of holdings, visit the IVV Holdings page » The chart below shows the one year price performance of IVV, versus its 200 day moving average:
Looking at the chart above, IVV's low point in its 52 week range is $147.21 per share, with $215.23 as the 52 week high point - that compares with a last trade of $194.41. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IVV, in trading today Bank of America Corp. (Symbol: BAC) is up about 4.6%, PepsiCo Inc. (Symbol: PEP) is up about 0.8%, and AbbVie Inc. (Symbol: ABBV) is higher by about 0.5%. For a complete list of holdings, visit the IVV Holdings page » The chart below shows the one year price performance of IVV, versus its 200 day moving average: Looking at the chart above, IVV's low point in its 52 week range is $147.21 per share, with $215.23 as the 52 week high point - that compares with a last trade of $194.41. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IVV, in trading today Bank of America Corp. (Symbol: BAC) is up about 4.6%, PepsiCo Inc. (Symbol: PEP) is up about 0.8%, and AbbVie Inc. (Symbol: ABBV) is higher by about 0.5%. For a complete list of holdings, visit the IVV Holdings page » The chart below shows the one year price performance of IVV, versus its 200 day moving average: Looking at the chart above, IVV's low point in its 52 week range is $147.21 per share, with $215.23 as the 52 week high point - that compares with a last trade of $194.41. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IVV, in trading today Bank of America Corp. (Symbol: BAC) is up about 4.6%, PepsiCo Inc. (Symbol: PEP) is up about 0.8%, and AbbVie Inc. (Symbol: ABBV) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P 500 ETF (Symbol: IVV) where we have detected an approximate $99.3 million dollar outflow -- that's a 0.1% decrease week over week (from 333,900,000 to 333,400,000). For a complete list of holdings, visit the IVV Holdings page » The chart below shows the one year price performance of IVV, versus its 200 day moving average: Looking at the chart above, IVV's low point in its 52 week range is $147.21 per share, with $215.23 as the 52 week high point - that compares with a last trade of $194.41. | Among the largest underlying components of IVV, in trading today Bank of America Corp. (Symbol: BAC) is up about 4.6%, PepsiCo Inc. (Symbol: PEP) is up about 0.8%, and AbbVie Inc. (Symbol: ABBV) is higher by about 0.5%. For a complete list of holdings, visit the IVV Holdings page » The chart below shows the one year price performance of IVV, versus its 200 day moving average: Looking at the chart above, IVV's low point in its 52 week range is $147.21 per share, with $215.23 as the 52 week high point - that compares with a last trade of $194.41. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
26862.0 | 2015-08-24 00:00:00 UTC | Notable Two Hundred Day Moving Average Cross - ABBV | ABBV | https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-abbv-2015-08-24 | nan | nan | In trading on Monday, shares of AbbVie Inc. (Symbol: ABBV) crossed below their 200 day moving average of $64.71, changing hands as low as $53.87 per share. AbbVie Inc. shares are currently trading down about 3.5% on the day. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average:
Looking at the chart above, ABBV's low point in its 52 week range is $52.06 per share, with $71.60 as the 52 week high point - that compares with a last trade of $63.56. According to the ETF Finder at ETF Channel, ABBV makes up 9.80% of the First Trust US IPO Index Fund ETF (Symbol: FPX) which is trading lower by about 4% on the day Monday.
Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Monday, shares of AbbVie Inc. (Symbol: ABBV) crossed below their 200 day moving average of $64.71, changing hands as low as $53.87 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week range is $52.06 per share, with $71.60 as the 52 week high point - that compares with a last trade of $63.56. AbbVie Inc. shares are currently trading down about 3.5% on the day. | In trading on Monday, shares of AbbVie Inc. (Symbol: ABBV) crossed below their 200 day moving average of $64.71, changing hands as low as $53.87 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week range is $52.06 per share, with $71.60 as the 52 week high point - that compares with a last trade of $63.56. AbbVie Inc. shares are currently trading down about 3.5% on the day. | In trading on Monday, shares of AbbVie Inc. (Symbol: ABBV) crossed below their 200 day moving average of $64.71, changing hands as low as $53.87 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week range is $52.06 per share, with $71.60 as the 52 week high point - that compares with a last trade of $63.56. AbbVie Inc. shares are currently trading down about 3.5% on the day. | In trading on Monday, shares of AbbVie Inc. (Symbol: ABBV) crossed below their 200 day moving average of $64.71, changing hands as low as $53.87 per share. According to the ETF Finder at ETF Channel, ABBV makes up 9.80% of the First Trust US IPO Index Fund ETF (Symbol: FPX) which is trading lower by about 4% on the day Monday. AbbVie Inc. shares are currently trading down about 3.5% on the day. |
26863.0 | 2015-08-24 00:00:00 UTC | AbbVie is Oversold | ABBV | https://www.nasdaq.com/articles/abbvie-oversold-2015-08-24 | nan | nan | The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks , according to a proprietary formula designed to identify those stocks that combine two important characteristics - strong fundamentals and a valuation that looks inexpensive. AbbVie Inc. (Symbol: ABBV) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.
But making AbbVie Inc. an even more interesting and timely stock to look at, is the fact that in trading on Monday, shares of ABBV entered into oversold territory, changing hands as low as $53.87 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In the case of AbbVie Inc., the RSI reading has hit 29.0 - by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 31.9. A falling stock price - all else being equal - creates a better opportunity for dividend investors to capture a higher yield. Indeed, ABBV's recent annualized dividend of 2.04/share (currently paid in quarterly installments) works out to an annual yield of 3.10% based upon the recent $65.90 share price. A bullish investor could look at ABBV's 29.0 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on ABBV is its dividend history. In general, dividends are not always predictable; but, looking at the history chart below can help in judging whether the most recent dividend is likely to continue. According to the ETF Finder at ETF Channel, ABBV makes up 9.80% of the First Trust US IPO Index Fund ETF (Symbol: FPX) which is trading lower by about 2.5% on the day Monday.
Click here to find out what 9 other oversold dividend stocks you need to know about »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A bullish investor could look at ABBV's 29.0 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. AbbVie Inc. (Symbol: ABBV) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making AbbVie Inc. an even more interesting and timely stock to look at, is the fact that in trading on Monday, shares of ABBV entered into oversold territory, changing hands as low as $53.87 per share. | Indeed, ABBV's recent annualized dividend of 2.04/share (currently paid in quarterly installments) works out to an annual yield of 3.10% based upon the recent $65.90 share price. AbbVie Inc. (Symbol: ABBV) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making AbbVie Inc. an even more interesting and timely stock to look at, is the fact that in trading on Monday, shares of ABBV entered into oversold territory, changing hands as low as $53.87 per share. | In the case of AbbVie Inc., the RSI reading has hit 29.0 - by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 31.9. AbbVie Inc. (Symbol: ABBV) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making AbbVie Inc. an even more interesting and timely stock to look at, is the fact that in trading on Monday, shares of ABBV entered into oversold territory, changing hands as low as $53.87 per share. | In the case of AbbVie Inc., the RSI reading has hit 29.0 - by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 31.9. Indeed, ABBV's recent annualized dividend of 2.04/share (currently paid in quarterly installments) works out to an annual yield of 3.10% based upon the recent $65.90 share price. AbbVie Inc. (Symbol: ABBV) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. |
26864.0 | 2015-08-22 00:00:00 UTC | A $25 Billion Hedge Fund Just Made AbbVie One of Its Biggest Bets | ABBV | https://www.nasdaq.com/articles/25-billion-hedge-fund-just-made-abbvie-one-its-biggest-bets-2015-08-22 | nan | nan | Source: AbbVie.
Expiring patents on Humira, the world's top-selling medicine, could significantly dent AbbVie 's revenue stream in 2017, but that risk doesn't seem to be fazing Glenview Capital Management, a hedge fund managing $25 billion in equities.
In the second quarter, Glenview, which invests based on a growth at a reasonable price methodology, made AbbVie its third-largest position when it increased the number of shares it owns by a whopping 630%.
Glenview's confidence in AbbVie indicates the hedge fund manager is confident that AbbVie can limit the amount of market share Humira may lose when its patent expires or blunt the impact of sales that are lost by launching and growing revenue for its other therapies.
In AbbVie's second-quarter conference call, the company made a point of reminding investors of its various efforts to offset Humira's risk. Those efforts include a new formulation of Humira that is less painful to inject and that may require less volume of the medicine to be used. Those advantages could result in some number of Humira patients switching over to it, allowing AbbVie to outmaneuver revenue risk tied to potential biosimilars for its original formulation.
AbbVie is also developing a next generation of autoimmune drugs to supplant Humira, including a JAK-1 inhibitor, ABT-494, that is in phase 2 trials as a treatment for rheumatoid arthritis. Additional immunology drugs that could insulate AbbVie's autoimmune disease market share down the road include ALX-0061, an anti-IL-6 nanobody, and ABT-122, a drug that combines an anti-TNF like Humira with an anti-IL-17 therapy. Results from ABT-122's mid-stage study are expected next year.
Even if AbbVie's R&D efforts in autoimmune disease come up short, AbbVie could still make up for any lost sales with other drugs in its product lineup.
Source: AbbVie.
For instance, AbbVie's recent Pharmacyclics acquisition landed the company the fast-growing cancer drug Imbruvica.
Imbruvica had sales of $492 million last year and prior to its acquisition, Pharmacyclics had offered up guidance for $1 billion in sales for the drug this year. Because Imbruvica is involved in a deep slate of trials evaluating expanding its use, industry watchers estimate that it could have peak annual sales of $3.6 billion some day.
Obviously, Imbruvica could go a long way toward filling any gap caused by Humira facing off against biosimilars, but it may not have to do it alone. AbbVie could end up winning regulatory approval for the CLL drug venetoclax, the multiple myeloma drug elotuzumab, and the MS drug Zinbryta within the next year to 18 months.
In addition to those drugs, an argument could also be made that AbbVie's hepatitis C pipeline could still be generating significant sales when Humira's patent expires. Currently, AbbVie's Viekira Pak is the second most prescribed therapy for treating genotype 1 hepatitis C and as a result, Viekira Pak's sales totaled $385 million in the second quarter.
AbbVie expects Viekira Pak to exit 2015 with a $3 billion annualized revenue run rate, but given how quickly hep C drug development is progressing, it's more likely that AbbVie's hep C pipeline drugs ABT-493 and ABT-530 will be counted on to offset Humira's risk, not Viekira Pak itself. Of course, that will only have a chance of happening if that once-daily pan-genotype approach proves itself in future trials.
Tying it together
Because of Glenview's growth and value blended approach, it's likely they believe AbbVie's various levers are being underappreciated by investors. That could be true. Despite AbbVie's shares rising 8% this year to new highs, its P/E-to-growth ratio is just 0.95 and it's still only trading at less than 14 times next year's estimated earnings per share. With a reasonable valuation and an opportunity to sidestep some of the risk to Humira, AbbVie might be a company worth considering again in portfolios.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article A $25 Billion Hedge Fund Just Made AbbVie One of Its Biggest Bets originally appeared on Fool.com.
Todd Campbell has no position in any stocks mentioned. Todd owns the independent equity research firm E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Source: AbbVie. In the second quarter, Glenview, which invests based on a growth at a reasonable price methodology, made AbbVie its third-largest position when it increased the number of shares it owns by a whopping 630%. Those advantages could result in some number of Humira patients switching over to it, allowing AbbVie to outmaneuver revenue risk tied to potential biosimilars for its original formulation. | Source: AbbVie. Expiring patents on Humira, the world's top-selling medicine, could significantly dent AbbVie 's revenue stream in 2017, but that risk doesn't seem to be fazing Glenview Capital Management, a hedge fund managing $25 billion in equities. Glenview's confidence in AbbVie indicates the hedge fund manager is confident that AbbVie can limit the amount of market share Humira may lose when its patent expires or blunt the impact of sales that are lost by launching and growing revenue for its other therapies. | Source: AbbVie. Expiring patents on Humira, the world's top-selling medicine, could significantly dent AbbVie 's revenue stream in 2017, but that risk doesn't seem to be fazing Glenview Capital Management, a hedge fund managing $25 billion in equities. Glenview's confidence in AbbVie indicates the hedge fund manager is confident that AbbVie can limit the amount of market share Humira may lose when its patent expires or blunt the impact of sales that are lost by launching and growing revenue for its other therapies. | Source: AbbVie. In addition to those drugs, an argument could also be made that AbbVie's hepatitis C pipeline could still be generating significant sales when Humira's patent expires. Expiring patents on Humira, the world's top-selling medicine, could significantly dent AbbVie 's revenue stream in 2017, but that risk doesn't seem to be fazing Glenview Capital Management, a hedge fund managing $25 billion in equities. |
26865.0 | 2015-08-21 00:00:00 UTC | Did AbbVie Just Make an Incredibly Brilliant Decision? | ABBV | https://www.nasdaq.com/articles/did-abbvie-just-make-incredibly-brilliant-decision-2015-08-21 | nan | nan | Picking up the pace in HCV
Personally, it wouldn't surprise me if the company used the voucher to accelerate approval of its pan-genotype, once-daily, next-generation drug for hepatitis C.
The company is studying the efficacy and safety of combining the protease inhibitor ABT-493 with the NS5A inhibitor ABT-530 in phase 3 studies and in phase 2 studies, and the duo achieved a functional cure in 99% of genotype 1 patients without the co-administration of ribavirin.
AbbVie believes that the ABT-493/ABT-530 co-therapy could be used across various genotypes of HCV and that it could prove to be effective over a dosing period of as little as eight weeks. If so, then it could pose a much larger threat to market-share leader Gilead Sciences ' Sovaldi and Harvoni than its current HCV drug, Viekira Pak, which is approved for genotype 1 HCV, requires multiple doses daily for 12 weeks, and is often dosed with ribavirin.
Additional results from AbbVie's ABT-493/ABT-530 midstage studies should trickle out later this year and phase 3 results should come in 2016, but given that Gilead Sciences is already working on its own pan-genotype, next-generation approach and that Gilead Sciences expects to announce phase 3 data from its studies shortly, pressure to get ABT-493/ABT-530 to market quickly will be high.
Looking ahead
Because millions of patients remain untreated and therapies are expensive, the market for hepatitis C treatment has become incredibly lucrative. In the second quarter, Gilead Sciences reports total HCV drug sales that are running at an annualized clip of nearly $20 billion and AbbVie's Viekira Pak posted $385 million in sales, leading to AbbVie reiterating its expectations to exit 2015 with annualized Viekira Pak sales of $3 billion. Given the amount of money at stake, a $350 million investment for a voucher that can reduce approval time by four months could end up proving to be a very good investment.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article Did AbbVie Just Make an Incredibly Brilliant Decision? originally appeared on Fool.com.
Todd Campbell owns shares of Gilead Sciences. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. he Motley Fool recommends Gilead Sciences. The Motley Fool owns shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Additional results from AbbVie's ABT-493/ABT-530 midstage studies should trickle out later this year and phase 3 results should come in 2016, but given that Gilead Sciences is already working on its own pan-genotype, next-generation approach and that Gilead Sciences expects to announce phase 3 data from its studies shortly, pressure to get ABT-493/ABT-530 to market quickly will be high. AbbVie believes that the ABT-493/ABT-530 co-therapy could be used across various genotypes of HCV and that it could prove to be effective over a dosing period of as little as eight weeks. In the second quarter, Gilead Sciences reports total HCV drug sales that are running at an annualized clip of nearly $20 billion and AbbVie's Viekira Pak posted $385 million in sales, leading to AbbVie reiterating its expectations to exit 2015 with annualized Viekira Pak sales of $3 billion. | In the second quarter, Gilead Sciences reports total HCV drug sales that are running at an annualized clip of nearly $20 billion and AbbVie's Viekira Pak posted $385 million in sales, leading to AbbVie reiterating its expectations to exit 2015 with annualized Viekira Pak sales of $3 billion. AbbVie believes that the ABT-493/ABT-530 co-therapy could be used across various genotypes of HCV and that it could prove to be effective over a dosing period of as little as eight weeks. Additional results from AbbVie's ABT-493/ABT-530 midstage studies should trickle out later this year and phase 3 results should come in 2016, but given that Gilead Sciences is already working on its own pan-genotype, next-generation approach and that Gilead Sciences expects to announce phase 3 data from its studies shortly, pressure to get ABT-493/ABT-530 to market quickly will be high. | Additional results from AbbVie's ABT-493/ABT-530 midstage studies should trickle out later this year and phase 3 results should come in 2016, but given that Gilead Sciences is already working on its own pan-genotype, next-generation approach and that Gilead Sciences expects to announce phase 3 data from its studies shortly, pressure to get ABT-493/ABT-530 to market quickly will be high. In the second quarter, Gilead Sciences reports total HCV drug sales that are running at an annualized clip of nearly $20 billion and AbbVie's Viekira Pak posted $385 million in sales, leading to AbbVie reiterating its expectations to exit 2015 with annualized Viekira Pak sales of $3 billion. AbbVie believes that the ABT-493/ABT-530 co-therapy could be used across various genotypes of HCV and that it could prove to be effective over a dosing period of as little as eight weeks. | AbbVie believes that the ABT-493/ABT-530 co-therapy could be used across various genotypes of HCV and that it could prove to be effective over a dosing period of as little as eight weeks. Additional results from AbbVie's ABT-493/ABT-530 midstage studies should trickle out later this year and phase 3 results should come in 2016, but given that Gilead Sciences is already working on its own pan-genotype, next-generation approach and that Gilead Sciences expects to announce phase 3 data from its studies shortly, pressure to get ABT-493/ABT-530 to market quickly will be high. In the second quarter, Gilead Sciences reports total HCV drug sales that are running at an annualized clip of nearly $20 billion and AbbVie's Viekira Pak posted $385 million in sales, leading to AbbVie reiterating its expectations to exit 2015 with annualized Viekira Pak sales of $3 billion. |
26866.0 | 2015-08-20 00:00:00 UTC | United Therapeutics to Sell Priority Review Voucher to AbbVie | ABBV | https://www.nasdaq.com/articles/united-therapeutics-to-sell-priority-review-voucher-to-abbvie-2015-08-20 | nan | nan | United Therapeutics CorporationUTHR announced its intention to sell a rare pediatric disease priority review voucher (PPRV) to a subsidiary of AbbVie Inc. ABBV for $350 million in cash.
We note that the FDA issues a PPRV to encourage the development of new drugs and biologics to prevent and treat rare pediatric diseases. A PPRV is received upon approval of a rare pediatric disease product and it might be sold or transferred without limitation. Moreover, the voucher can be used to obtain priority review for a new drug application or biologics license application submitted later. Priority review would shorten the review period of the candidate and could lead to speedy approval.
United Therapeutics was awarded the PPRV when Unituxin (dinutuximab) received FDA approval for the treatment of pediatric patients suffering from high-risk neuroblastoma (a rare pediatric disease) in Mar 2015.
Apart from United Therapeutics, quite a few companies have sold PRVs in the past and earned millions of dollars. While Knight Therapeutics sold its voucher to Gilead Sciences Inc. GILD for $125 million, BioMarin Pharmaceutical Inc. BMRN received $67.5 million for its voucher.
Meanwhile, United Therapeutics gained approval for Unituxin earlier this week in the EU for use in combination with granulocyte-macrophage colony-stimulating factor, interleukin-2 and isotretinoin for the treatment of pediatric patients (aged 12 months to 17 years) suffering from high-risk neuroblastoma, who have previously received induction chemotherapy and achieved at least a partial response followed by myeloablative therapy and autologous stem cell transplantation.
However, Unituxin's approval in the EU came with special warnings and precautions related to allergic reactions and capillary leak syndrome among others. The drug is subject to additional monitoring.
We are encouraged by the approval of Unituxin in the EU. According to the press release issued by the company, neuroblastoma is estimated to affect about 1,500 patients in the EU annually, half of whom fall in the high-risk category.
We note that Unituxin has already hit the U.S. markets in the current quarter. Approval in the EU would boost the drug's sales potential further. We expect investor focus to remain on the commercialization and sales ramp up of Unituxin.
United Therapeutics currently carries a Zacks Rank #3 (Hold). Gilead is a better-ranked stock in the health care sector carrying a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
UTD THERAPEUTIC (UTHR): Free Stock Analysis Report
BIOMARIN PHARMA (BMRN): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | United Therapeutics CorporationUTHR announced its intention to sell a rare pediatric disease priority review voucher (PPRV) to a subsidiary of AbbVie Inc. ABBV for $350 million in cash. Click to get this free report UTD THERAPEUTIC (UTHR): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, United Therapeutics gained approval for Unituxin earlier this week in the EU for use in combination with granulocyte-macrophage colony-stimulating factor, interleukin-2 and isotretinoin for the treatment of pediatric patients (aged 12 months to 17 years) suffering from high-risk neuroblastoma, who have previously received induction chemotherapy and achieved at least a partial response followed by myeloablative therapy and autologous stem cell transplantation. | Click to get this free report UTD THERAPEUTIC (UTHR): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. United Therapeutics CorporationUTHR announced its intention to sell a rare pediatric disease priority review voucher (PPRV) to a subsidiary of AbbVie Inc. ABBV for $350 million in cash. United Therapeutics was awarded the PPRV when Unituxin (dinutuximab) received FDA approval for the treatment of pediatric patients suffering from high-risk neuroblastoma (a rare pediatric disease) in Mar 2015. | Click to get this free report UTD THERAPEUTIC (UTHR): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. United Therapeutics CorporationUTHR announced its intention to sell a rare pediatric disease priority review voucher (PPRV) to a subsidiary of AbbVie Inc. ABBV for $350 million in cash. United Therapeutics was awarded the PPRV when Unituxin (dinutuximab) received FDA approval for the treatment of pediatric patients suffering from high-risk neuroblastoma (a rare pediatric disease) in Mar 2015. | United Therapeutics CorporationUTHR announced its intention to sell a rare pediatric disease priority review voucher (PPRV) to a subsidiary of AbbVie Inc. ABBV for $350 million in cash. Click to get this free report UTD THERAPEUTIC (UTHR): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. We note that the FDA issues a PPRV to encourage the development of new drugs and biologics to prevent and treat rare pediatric diseases. |
26867.0 | 2015-08-19 00:00:00 UTC | Insys Files CP; Dronabinol Oral Solution under FDA Review | ABBV | https://www.nasdaq.com/articles/insys-files-cp-dronabinol-oral-solution-under-fda-review-2015-08-19 | nan | nan | Insys Therapeutics, Inc.INSY filed a citizen petition with the Drug Enforcement Administration and requested the agency to move its synthetic pharmaceutical cannabidiol (CBD) from Schedule I to Schedule IV.
Meanwhile, earlier this week, Insys announced the acceptance of the new drug application, for its proprietary dronabinol oral solution, by the FDA. Insys is looking to get dronabinol oral solution approved for anorexia associated with weight loss in patients suffering from AIDS and chemotherapy-induced nausea and vomiting (CINV) in cancer patients who respond inadequately to conventional antiemetic treatments.
Insys expects a response from the FDA by Apr 1, 2016.
Dronabinol oral solution is an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol. We remind investors that Insys had received FDA approval for dronabinol soft gelatin (SG) capsules, a generic equivalent of AbbVie Inc.'s ABBV Marinol, for the second-line treatment of CINV and anorexia associated with weight loss in AIDS patients in Aug 2011.
Insys has an exclusive supply and distribution agreement with Mylan, Inc. MYL under which Mylan holds distribution rights to dronabinol SG capsules in the U.S.
We are encouraged by the company's progress with the dronabinol oral solution. The oral solution is expected to lead to faster onset of action along with less dose-to-dose variability as compared to capsules. Once approved, the oral formulation will provide patients with an additional treatment option and boost dronabinol's sales.
Insys has a pipeline of sublingual sprays and pharmaceutical CBD.
Insys carries a Zacks Rank #5 (Strong Sell). Gilead Sciences Inc. GILD is a better-ranked stock in the health care sector carrying a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
MYLAN NV (MYL): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
INSYS THERAP (INSY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We remind investors that Insys had received FDA approval for dronabinol soft gelatin (SG) capsules, a generic equivalent of AbbVie Inc.'s ABBV Marinol, for the second-line treatment of CINV and anorexia associated with weight loss in AIDS patients in Aug 2011. Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report INSYS THERAP (INSY): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, earlier this week, Insys announced the acceptance of the new drug application, for its proprietary dronabinol oral solution, by the FDA. | Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report INSYS THERAP (INSY): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that Insys had received FDA approval for dronabinol soft gelatin (SG) capsules, a generic equivalent of AbbVie Inc.'s ABBV Marinol, for the second-line treatment of CINV and anorexia associated with weight loss in AIDS patients in Aug 2011. Insys is looking to get dronabinol oral solution approved for anorexia associated with weight loss in patients suffering from AIDS and chemotherapy-induced nausea and vomiting (CINV) in cancer patients who respond inadequately to conventional antiemetic treatments. | Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report INSYS THERAP (INSY): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that Insys had received FDA approval for dronabinol soft gelatin (SG) capsules, a generic equivalent of AbbVie Inc.'s ABBV Marinol, for the second-line treatment of CINV and anorexia associated with weight loss in AIDS patients in Aug 2011. Insys is looking to get dronabinol oral solution approved for anorexia associated with weight loss in patients suffering from AIDS and chemotherapy-induced nausea and vomiting (CINV) in cancer patients who respond inadequately to conventional antiemetic treatments. | Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report INSYS THERAP (INSY): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that Insys had received FDA approval for dronabinol soft gelatin (SG) capsules, a generic equivalent of AbbVie Inc.'s ABBV Marinol, for the second-line treatment of CINV and anorexia associated with weight loss in AIDS patients in Aug 2011. Dronabinol oral solution is an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol. |
26868.0 | 2015-08-19 00:00:00 UTC | Biotech Stock Roundup: Kite Addresses Patient Death Concerns, Omeros Soars on Data | ABBV | https://www.nasdaq.com/articles/biotech-stock-roundup-kite-addresses-patient-death-concerns-omeros-soars-data-2015-08-19 | nan | nan | Several companies like Omeros OMER and AbbVie ABBV provided pipeline updates over the last few days. Kite Pharma KITE also remained in the news for a major part of last week due to concerns regarding a patient death in a study being conducted on its lead pipeline candidate.
Recap of the Week's Most Important Stories
1. Kite's shares have been under pressure ever since rumors about a patient death in an ongoing study on lead pipeline candidate, KTE-C19, surfaced. Earlier this week, the company issued a press release and held a conference call to dispel concerns regarding the patient death. While Kite confirmed the patient death, the company said that it was unrelated to treatment with KTE-C19.
Importantly, complete responses have been observed in the study and durability of treatment is being monitored. The company remains on track to report data later this year at ASH and if all goes well, KTE-C19 could reach the market in 2017 (Read more: Kite Pharma Provides Update, Death Not Related to KTE-C19 ).
2. AbbVie's experimental leukemia treatment, venetoclax, hit the primary endpoint in a phase II study. AbbVie and partner Roche will be using data from this study for the filing of regulatory applications in the U.S., EU and other territories. Relapsed/refractory chronic lymphocytic leukemia in patients who have 17p deletion has historically been difficult to treat. Venetoclax has Breakthrough Therapy Designation in the U.S. for this indication (Read more: AbbVie/Roche's Leukemia Drug Hits Phase II Primary Endpoint ).
3. AVEO Oncology's shares received a boost with the company signing an exclusive, worldwide license agreement with Novartis for the development and commercialization of AV-380 (cachexia) and related antibodies. The agreement will see AVEO receiving up to $326 million in the form of upfront and milestone payments as well as tiered royalties ranging from high single digits to a low double-digit on product sales.
Novartis will conduct as well as fund all development, manufacturing and commercialization activities related to the candidates covered by the agreement (Read more: AVEO Up on Novartis Collaboration for Cachexia Candidate ).
4. Omeros' shares shot up more than 72% on additional positive data from the company's mid-stage study on OMS721 for the treatment of thrombotic microangiopathies (TMAs). Given the encouraging data, the company said that it expects to enter into discussions with the FDA later this year regarding the phase III study design.
5. Avalanche's AAVL shares tumbled on news that the company will not be going ahead with a phase IIb study on AVA-101 for the potential treatment of wet age-related macular degeneration (wet AMD). The study was expected to commence in the second half of the year. AVA-101. Instead, the company is now looking to conduct additional preclinical studies on AVA-101 and AVA-201 versus standard of care anti-VEGF protein therapy before selecting the best gene therapy candidate for wet AMD to move back into the clinic.
Performance
Over the last five trading days, Alexion ALXN recorded a decline of 1.88% while Regeneron was the highest gainer (3.01%) among the major biotechs. Biogen BIIB lost 22.19% over the last six months with Regeneron being the highest gainer (47.04%) during this period as well.
The NASDAQ Biotechnology Index was down slightly (0.47%) over the last five trading days (see the last biotech stock roundup here: Baxalta Rejects Shire Bid, Amgen's Beat & Raise Quarter ).
What's Next in the Biotech World?
Amgen AMGN has an important regulatory event coming up with the FDA expected to decide on the approval status of Praluent, the company's PCSK9 inhibitor. Alkermes is also awaiting a response from the agency regarding the approval status of its experimental schizophrenia treatment, Aristada.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AMGEN INC (AMGN): Free Stock Analysis Report
BIOGEN INC (BIIB): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
OMEROS CORP (OMER): Free Stock Analysis Report
KITE PHARMA INC (KITE): Free Stock Analysis Report
AVALANCHE BIOT (AAVL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Several companies like Omeros OMER and AbbVie ABBV provided pipeline updates over the last few days. AbbVie's experimental leukemia treatment, venetoclax, hit the primary endpoint in a phase II study. AbbVie and partner Roche will be using data from this study for the filing of regulatory applications in the U.S., EU and other territories. | AbbVie's experimental leukemia treatment, venetoclax, hit the primary endpoint in a phase II study. Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report OMEROS CORP (OMER): Free Stock Analysis Report KITE PHARMA INC (KITE): Free Stock Analysis Report AVALANCHE BIOT (AAVL): Free Stock Analysis Report To read this article on Zacks.com click here. Several companies like Omeros OMER and AbbVie ABBV provided pipeline updates over the last few days. | Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report OMEROS CORP (OMER): Free Stock Analysis Report KITE PHARMA INC (KITE): Free Stock Analysis Report AVALANCHE BIOT (AAVL): Free Stock Analysis Report To read this article on Zacks.com click here. Several companies like Omeros OMER and AbbVie ABBV provided pipeline updates over the last few days. AbbVie's experimental leukemia treatment, venetoclax, hit the primary endpoint in a phase II study. | Several companies like Omeros OMER and AbbVie ABBV provided pipeline updates over the last few days. AbbVie's experimental leukemia treatment, venetoclax, hit the primary endpoint in a phase II study. AbbVie and partner Roche will be using data from this study for the filing of regulatory applications in the U.S., EU and other territories. |
26869.0 | 2015-08-19 00:00:00 UTC | Health Care Sector Update for 08/19/2015: CRBP, UTHR, PRQR, ABBV | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-08192015-crbp-uthr-prqr-abbv-2015-08-19 | nan | nan | Top Health-care stocks:
JNJ: flat
PFE: flat
ABT: flat
MRK: flat
AMGN: flat
Health-care shares were generally unchanged in pre-market trade Wednesday.
In health-care stocks news, Corbus Pharmaceuticals ( CRBP ) said it received FDA Fast Track status for Resunab for systemic sclerosis.
Shares in the company were trading 44.2% higher at $2.74 pre-bell. Over the past 52 weeks, the company has traded between $1.80 and $4.95.
Meanwhile, United Therapeutics ( UTHR ), a biotechnology company, said it has agreed to sell its Rare Pediatric Disease Priority Review Voucher to a subsidiary of AbbVie ( ABBV ), for US$350 million in cash.
Shares in the company were flat at $167.58 pre-bell. Over the past 52 weeks, the company has traded between $90.40 and $190.29.
And ProQR Therapeutics N.V. ( PRQR ), which focuses on RNA medicines for the treatment of severe diseases such as cystic fibrosis and Leber's congenital amaurosis, posted a wider Q2 loss as costs rose.
Shares in the company were flat at $16.30 pre-bell. Over the past 52 weeks, the company has traded between $11.00 and $27.60.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Meanwhile, United Therapeutics ( UTHR ), a biotechnology company, said it has agreed to sell its Rare Pediatric Disease Priority Review Voucher to a subsidiary of AbbVie ( ABBV ), for US$350 million in cash. In health-care stocks news, Corbus Pharmaceuticals ( CRBP ) said it received FDA Fast Track status for Resunab for systemic sclerosis. And ProQR Therapeutics N.V. ( PRQR ), which focuses on RNA medicines for the treatment of severe diseases such as cystic fibrosis and Leber's congenital amaurosis, posted a wider Q2 loss as costs rose. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Meanwhile, United Therapeutics ( UTHR ), a biotechnology company, said it has agreed to sell its Rare Pediatric Disease Priority Review Voucher to a subsidiary of AbbVie ( ABBV ), for US$350 million in cash. Top Health-care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health-care shares were generally unchanged in pre-market trade Wednesday. | Meanwhile, United Therapeutics ( UTHR ), a biotechnology company, said it has agreed to sell its Rare Pediatric Disease Priority Review Voucher to a subsidiary of AbbVie ( ABBV ), for US$350 million in cash. Top Health-care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health-care shares were generally unchanged in pre-market trade Wednesday. Shares in the company were flat at $167.58 pre-bell. | Meanwhile, United Therapeutics ( UTHR ), a biotechnology company, said it has agreed to sell its Rare Pediatric Disease Priority Review Voucher to a subsidiary of AbbVie ( ABBV ), for US$350 million in cash. Top Health-care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health-care shares were generally unchanged in pre-market trade Wednesday. Shares in the company were trading 44.2% higher at $2.74 pre-bell. |
26870.0 | 2015-08-18 00:00:00 UTC | 3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever | ABBV | https://www.nasdaq.com/articles/3-dividend-paying-healthcare-stocks-buy-and-hold-forever-2015-08-18 | nan | nan | Healthcare stocks have been getting crushed as the sector rolls out its second-quarter earnings. This spike in volatility nonetheless may represent a compelling buying opportunity for investors with a long-term outlook.
Source: Flickr via user NEC Corporation of America
After all, the sector contains many companies that not only pay dividends but offer investors high growth prospects for decades to come due to greater access to healthcare from Obamacare and the surge in overall demand stemming from the estimated 78 million baby boomers reaching retirement age right now.
Given the diversity of investing options, though, how does one go about selecting healthcare stocks to stash away for the long haul? My recommendation is to go with companies that have proven to be on the side of shareholders by committing to share buybacks, dividend increases, and deep clinical pipelines able to fuel long-term growth.
With this in mind, I think AbbVie , Gilead Sciences , and Johnson & Johnson stand out from the crowd. Here's a deeper look at why investors may want to consider buying these three healthcare giants to anchor their portfolios for the long haul.
AbbVie is committed to high growth and shareholder rewards
The Street has been throwing shade at AbbVie for some time now, in part because of the looming patent expiration of its flagship anti-inflammatory drug Humira, but also because of the drugmaker's recent $21 billion acquisition of Pharmacyclics for its best-in-class blood cancer drug Imbruvica. Put simply, the Street simply isn't buying management's rosy double-digit growth projections in the years ahead because of Humira's patent problems, and it seems to think that AbbVie vastly overpaid for Pharmacyclics. That's why the stock is currently trading at a forward price-to-earnings ratio of only 13.6 -- well below the sector average.
Source: AbbVie
A deeper look at AbbVie, though, shows a company committed to creating value for its shareholders. Since being spun-off from Abbott Laboratories in 2013, the drugmaker has raised its dividend by 28%, put a $10 billion share repurchase program in place, formed multiple partnerships to build out its pipeline, and aggressively developed its own clinical assets, leading to the regulatory approvals of key new drugs like Duopa and Viekira Pak, among others. The Imbruvica acquisition also puts the company's burgeoning hematology/oncology franchise on track to generate over $20 billion in peak sales, giving it more than enough potential to offset the expected revenue losses from Humira moving forward.
That being said, management has been working diligently to defend Humira against generic competition, with its multi-layered defense perhaps effectively extending the drug's exclusivity into the 2020s. Time will tell.
Gilead Sciences is perhaps the biggest innovator in biotech
When it comes to changing the healthcare game altogether, look no further than Gilead. Not only has the biotech revolutionized the treatment of HIV with its single-tablet regimen drugs, but it also brought the first effective cure -- in many cases, at least -- to market for hepatitis C. The biotech now has its sights set on curing HIV and bringing important new medicines to bear for hard-to-treat blood cancers and liver diseases.
This steady stream of ground-breaking innovation has led to an earnings bonanza for Gilead, which management promptly put to use by rewarding shareholders with a $15 billion increase in the company's share buyback program and instituting a dividend payment. With over $14 billion in the bank at last count, Gilead is also potentially gearing up to add to its embarrassment of riches by gobbling up other promising drugmakers -- or perhaps one large biotech or biopharma. All told, Gilead has a solid future ahead, making it a great stock to buy and never sell.
J&J is the Rock of Gibraltar of healthcare stocks
Despite the negative impacts of both a strong dollar and fierce competition, J&J remains as solid as ever. Underneath the healthcare behemoth's dismal second-quarter numbers, in which its total revenue dipped by 8.8% from a year ago, we learned that once you take out the effects of currency translation, the company is actually still growing at a decent clip. Specifically, J&J posted a 6.7% increase in operational earnings (excluding foreign exchange) year-over-year for the three month period. That speaks to the company's resilience during a time of transition for its pharma product portfolio and an extremely unfavorable currency environment.
If we zoom out on the timescale , though, the real reason J&J is a stock to hold forever becomes apparent. J&J has raised its dividend for 53 consecutive years in a row, and increased its adjusted earnings per share for 31 straight years. So yes, J&J is facing some serious headwinds, with the introduction of generic Remicade, as well as with Olysio getting clobbered by newer hepatitis C drugs. But the company's vast pipeline and long history of bringing new game-changing products to market strongly suggest it will continue to be as steady as the Rock of Gibraltar going forward.
Tying it altogether
There aren't many stocks that will truly give you peace of mind, but these three are probably the closest things you'll find, especially in the volatile healthcare sector. At the end of the day, they all have solid management teams that keep their shareholders' interest at the forefront of their minds, substantial and growing cash flows to support further increases in their dividends/share buyback programs, and, most importantly, first-rate clinical pipelines. In short, you may want to add all three stocks to your portfolio and hold them -- forever.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article 3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever originally appeared on Fool.com.
George Budwell owns shares of AbbVie and Gilead Sciences. The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | With this in mind, I think AbbVie , Gilead Sciences , and Johnson & Johnson stand out from the crowd. AbbVie is committed to high growth and shareholder rewards The Street has been throwing shade at AbbVie for some time now, in part because of the looming patent expiration of its flagship anti-inflammatory drug Humira, but also because of the drugmaker's recent $21 billion acquisition of Pharmacyclics for its best-in-class blood cancer drug Imbruvica. Put simply, the Street simply isn't buying management's rosy double-digit growth projections in the years ahead because of Humira's patent problems, and it seems to think that AbbVie vastly overpaid for Pharmacyclics. | AbbVie is committed to high growth and shareholder rewards The Street has been throwing shade at AbbVie for some time now, in part because of the looming patent expiration of its flagship anti-inflammatory drug Humira, but also because of the drugmaker's recent $21 billion acquisition of Pharmacyclics for its best-in-class blood cancer drug Imbruvica. Put simply, the Street simply isn't buying management's rosy double-digit growth projections in the years ahead because of Humira's patent problems, and it seems to think that AbbVie vastly overpaid for Pharmacyclics. With this in mind, I think AbbVie , Gilead Sciences , and Johnson & Johnson stand out from the crowd. | AbbVie is committed to high growth and shareholder rewards The Street has been throwing shade at AbbVie for some time now, in part because of the looming patent expiration of its flagship anti-inflammatory drug Humira, but also because of the drugmaker's recent $21 billion acquisition of Pharmacyclics for its best-in-class blood cancer drug Imbruvica. With this in mind, I think AbbVie , Gilead Sciences , and Johnson & Johnson stand out from the crowd. Put simply, the Street simply isn't buying management's rosy double-digit growth projections in the years ahead because of Humira's patent problems, and it seems to think that AbbVie vastly overpaid for Pharmacyclics. | AbbVie is committed to high growth and shareholder rewards The Street has been throwing shade at AbbVie for some time now, in part because of the looming patent expiration of its flagship anti-inflammatory drug Humira, but also because of the drugmaker's recent $21 billion acquisition of Pharmacyclics for its best-in-class blood cancer drug Imbruvica. With this in mind, I think AbbVie , Gilead Sciences , and Johnson & Johnson stand out from the crowd. Put simply, the Street simply isn't buying management's rosy double-digit growth projections in the years ahead because of Humira's patent problems, and it seems to think that AbbVie vastly overpaid for Pharmacyclics. |
26871.0 | 2015-08-17 00:00:00 UTC | iShares U.S. Healthcare ETF Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/ishares-us-healthcare-etf-experiences-big-inflow-2015-08-17 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $56.2 million dollar inflow -- that's a 2.2% increase week over week in outstanding units (from 15,950,000 to 16,300,000). Among the largest underlying components of IYH, in trading today Amgen Inc (Symbol: AMGN) is up about 0.5%, Allergan PLC (Symbol: AGN) is up about 0.7%, and AbbVie Inc. (Symbol: ABBV) is higher by about 0.8%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average:
Looking at the chart above, IYH's low point in its 52 week range is $124.28 per share, with $164.98 as the 52 week high point - that compares with a last trade of $160.86. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IYH, in trading today Amgen Inc (Symbol: AMGN) is up about 0.5%, Allergan PLC (Symbol: AGN) is up about 0.7%, and AbbVie Inc. (Symbol: ABBV) is higher by about 0.8%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $124.28 per share, with $164.98 as the 52 week high point - that compares with a last trade of $160.86. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IYH, in trading today Amgen Inc (Symbol: AMGN) is up about 0.5%, Allergan PLC (Symbol: AGN) is up about 0.7%, and AbbVie Inc. (Symbol: ABBV) is higher by about 0.8%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $124.28 per share, with $164.98 as the 52 week high point - that compares with a last trade of $160.86. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IYH, in trading today Amgen Inc (Symbol: AMGN) is up about 0.5%, Allergan PLC (Symbol: AGN) is up about 0.7%, and AbbVie Inc. (Symbol: ABBV) is higher by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $56.2 million dollar inflow -- that's a 2.2% increase week over week in outstanding units (from 15,950,000 to 16,300,000). For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $124.28 per share, with $164.98 as the 52 week high point - that compares with a last trade of $160.86. | Among the largest underlying components of IYH, in trading today Amgen Inc (Symbol: AMGN) is up about 0.5%, Allergan PLC (Symbol: AGN) is up about 0.7%, and AbbVie Inc. (Symbol: ABBV) is higher by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $56.2 million dollar inflow -- that's a 2.2% increase week over week in outstanding units (from 15,950,000 to 16,300,000). For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $124.28 per share, with $164.98 as the 52 week high point - that compares with a last trade of $160.86. |
26872.0 | 2015-08-17 00:00:00 UTC | After Hours Most Active for Aug 17, 2015 : ABBV, ABEV, SUNE, CCP$, TSM, HST, URBN, ESPR, CENX, QQQ, CAR, MSFT | ABBV | https://www.nasdaq.com/articles/after-hours-most-active-aug-17-2015-abbv-abev-sune-ccp-tsm-hst-urbn-espr-cenx-qqq-car-msft | nan | nan | The NASDAQ 100 After Hours Indicator is up .22 to 4,566.59. The total After hours volume is currently 19,071,913 shares traded.
The following are the most active stocks for the after hours session :
AbbVie Inc. ( ABBV ) is unchanged at $69.37, with 10,132,442 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range".
Ambev S.A. ( ABEV ) is +0.013 at $5.31, with 3,185,379 shares traded. As reported by Zacks, the current mean recommendation for ABEV is in the "buy range".
SunEdison, Inc. ( SUNE ) is +0.77 at $15.45, with 1,182,125 shares traded. As reported by Zacks, the current mean recommendation for SUNE is in the "buy range".
Care Capital Properties, Inc. (CCP$) is unchanged at $34.05, with 858,839 shares traded., following a 52-week high recorded in today's regular session.
Taiwan Semiconductor Manufacturing Company Ltd. ( TSM ) is unchanged at $20.28, with 571,398 shares traded. TSM's current last sale is 72.77% of the target price of $27.87.
Host Hotels & Resorts, Inc. ( HST ) is unchanged at $19.60, with 537,557 shares traded. HST's current last sale is 89.09% of the target price of $22.
Urban Outfitters, Inc. ( URBN ) is +1.87 at $34.10, with 486,649 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Jan 2016. The consensus EPS forecast is $0.73. RTT News Reports: Urban Outfitters Q2 Profit Tops Estimate
Esperion Therapeutics, Inc. ( ESPR ) is +7.48 at $82.99, with 392,396 shares traded. As reported by Zacks, the current mean recommendation for ESPR is in the "buy range".
Century Aluminum Company ( CENX ) is +0.0012 at $5.83, with 368,864 shares traded. As reported in the last short interest update the days to cover for CENX is 7.458827; this calculation is based on the average trading volume of the stock.
PowerShares QQQ Trust, Series 1 ( QQQ ) is +0.02 at $111.45, with 358,656 shares traded. This represents a 23.5% increase from its 52 Week Low.
Avis Budget Group, Inc. ( CAR ) is unchanged at $46.90, with 328,780 shares traded. CAR's current last sale is 78.17% of the target price of $60.
Microsoft Corporation ( MSFT ) is +0.01 at $47.33, with 318,838 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2015. The consensus EPS forecast is $0.58. MSFT's current last sale is 90.15% of the target price of $52.5.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The following are the most active stocks for the after hours session : AbbVie Inc. ( ABBV ) is unchanged at $69.37, with 10,132,442 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". Care Capital Properties, Inc. (CCP$) is unchanged at $34.05, with 858,839 shares traded., following a 52-week high recorded in today's regular session. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The following are the most active stocks for the after hours session : AbbVie Inc. ( ABBV ) is unchanged at $69.37, with 10,132,442 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". | The following are the most active stocks for the after hours session : AbbVie Inc. ( ABBV ) is unchanged at $69.37, with 10,132,442 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Jan 2016. | The following are the most active stocks for the after hours session : AbbVie Inc. ( ABBV ) is unchanged at $69.37, with 10,132,442 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". As reported by Zacks, the current mean recommendation for ABEV is in the "buy range". |
26873.0 | 2015-08-14 00:00:00 UTC | Why AbbVie is a Top 25 Dividend Giant (ABBV) | ABBV | https://www.nasdaq.com/articles/why-abbvie-top-25-dividend-giant-abbv-2015-08-14 | nan | nan | AbbVie Inc. (Symbol: ABBV) has been named as a Top 25 ''Dividend Giant'' by ETF Channel , with a staggering $4.24B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 2.98% yield, according to the most recent Dividend Channel''DividendRank'' report. The report noted a strong quarterly dividend history at AbbVie Inc., and favorable long-term multi-year growth rates in key fundamental data points.
The annualized dividend paid by AbbVie Inc. is $2.04/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 07/13/2015. Below is a long-term dividend history chart for ABBV, which the report stressed as being of key importance. Indeed, studying a company's past dividend history can be of good help in judging whether the most recent dividend is likely to continue.
25 Dividend Giants Widely Held By ETFs »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc. (Symbol: ABBV) has been named as a Top 25 ''Dividend Giant'' by ETF Channel , with a staggering $4.24B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 2.98% yield, according to the most recent Dividend Channel''DividendRank'' report. The report noted a strong quarterly dividend history at AbbVie Inc., and favorable long-term multi-year growth rates in key fundamental data points. Below is a long-term dividend history chart for ABBV, which the report stressed as being of key importance. | AbbVie Inc. (Symbol: ABBV) has been named as a Top 25 ''Dividend Giant'' by ETF Channel , with a staggering $4.24B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 2.98% yield, according to the most recent Dividend Channel''DividendRank'' report. The report noted a strong quarterly dividend history at AbbVie Inc., and favorable long-term multi-year growth rates in key fundamental data points. The annualized dividend paid by AbbVie Inc. is $2.04/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 07/13/2015. | AbbVie Inc. (Symbol: ABBV) has been named as a Top 25 ''Dividend Giant'' by ETF Channel , with a staggering $4.24B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 2.98% yield, according to the most recent Dividend Channel''DividendRank'' report. The annualized dividend paid by AbbVie Inc. is $2.04/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 07/13/2015. The report noted a strong quarterly dividend history at AbbVie Inc., and favorable long-term multi-year growth rates in key fundamental data points. | The report noted a strong quarterly dividend history at AbbVie Inc., and favorable long-term multi-year growth rates in key fundamental data points. The annualized dividend paid by AbbVie Inc. is $2.04/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 07/13/2015. AbbVie Inc. (Symbol: ABBV) has been named as a Top 25 ''Dividend Giant'' by ETF Channel , with a staggering $4.24B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 2.98% yield, according to the most recent Dividend Channel''DividendRank'' report. |
26874.0 | 2015-08-13 00:00:00 UTC | After Hours Most Active for Aug 13, 2015 : RIG, BAC, ETE, NBL, ABBV, FTR, NOV, HOLX, RELL, LOCO, CSCO, MPEL | ABBV | https://www.nasdaq.com/articles/after-hours-most-active-aug-13-2015-rig-bac-ete-nbl-abbv-ftr-nov-holx-rell-loco-csco-mpel | nan | nan | The NASDAQ 100 After Hours Indicator is up 1.37 to 4,520.69. The total After hours volume is currently 20,648,407 shares traded.
The following are the most active stocks for the after hours session :
Transocean Ltd. ( RIG ) is unchanged at $14.07, with 2,945,846 shares traded. Over the last four weeks they have had 7 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2015. The consensus EPS forecast is $0.52. As reported in the last short interest update the days to cover for RIG is 8.321585; this calculation is based on the average trading volume of the stock.
Bank of America Corporation ( BAC ) is +0.01 at $17.63, with 2,780,216 shares traded. Over the last four weeks they have had 6 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2015. The consensus EPS forecast is $0.36. As reported by Zacks, the current mean recommendation for BAC is in the "buy range".
Energy Transfer Equity, L.P. ( ETE ) is -0.1781 at $29.31, with 2,018,716 shares traded. As reported by Zacks, the current mean recommendation for ETE is in the "buy range".
Noble Energy Inc. ( NBL ) is unchanged at $36.30, with 1,391,689 shares traded. As reported by Zacks, the current mean recommendation for NBL is in the "buy range".
AbbVie Inc. ( ABBV ) is unchanged at $68.54, with 1,281,661 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range".
Frontier Communications Corporation ( FTR ) is unchanged at $5.35, with 1,185,501 shares traded. As reported by Zacks, the current mean recommendation for FTR is in the "buy range".
National Oilwell Varco, Inc. ( NOV ) is unchanged at $39.83, with 1,116,769 shares traded. Over the last four weeks they have had 7 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2015. The consensus EPS forecast is $0.57. NOV's current last sale is 82.98% of the target price of $48.
Hologic, Inc. ( HOLX ) is unchanged at $41.73, with 987,945 shares traded. Over the last four weeks they have had 8 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2015. The consensus EPS forecast is $0.42. HOLX's current last sale is 99.36% of the target price of $42.
Richardson Electronics, Ltd. ( RELL ) is +0.03 at $5.50, with 900,000 shares traded., following a 52-week high recorded in today's regular session.
El Pollo Loco Holdings, Inc. ( LOCO ) is -2.23 at $16.13, with 745,083 shares traded. As reported in the last short interest update the days to cover for LOCO is 8.638743; this calculation is based on the average trading volume of the stock.
Cisco Systems, Inc. ( CSCO ) is unchanged at $28.70, with 723,912 shares traded. As reported by Zacks, the current mean recommendation for CSCO is in the "buy range".
Melco Crown Entertainment Limited ( MPEL ) is -0.01 at $21.65, with 586,944 shares traded. MPEL's current last sale is 84.57% of the target price of $25.6.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc. ( ABBV ) is unchanged at $68.54, with 1,281,661 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". The following are the most active stocks for the after hours session : Transocean Ltd. ( RIG ) is unchanged at $14.07, with 2,945,846 shares traded. | AbbVie Inc. ( ABBV ) is unchanged at $68.54, with 1,281,661 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". Over the last four weeks they have had 7 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2015. | As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". AbbVie Inc. ( ABBV ) is unchanged at $68.54, with 1,281,661 shares traded. The following are the most active stocks for the after hours session : Transocean Ltd. ( RIG ) is unchanged at $14.07, with 2,945,846 shares traded. | AbbVie Inc. ( ABBV ) is unchanged at $68.54, with 1,281,661 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". The following are the most active stocks for the after hours session : Transocean Ltd. ( RIG ) is unchanged at $14.07, with 2,945,846 shares traded. |
26875.0 | 2015-08-13 00:00:00 UTC | AbbVie/Roche's Leukemia Drug Hits Phase II Primary Endpoint | ABBV | https://www.nasdaq.com/articles/abbvie-roches-leukemia-drug-hits-phase-ii-primary-endpoint-2015-08-13 | nan | nan | AbbVie Inc.ABBV and partner Roche RHHBY announced that their experimental leukemia candidate, venetoclax, achieved the primary endpoint - overall response rate - in a phase II study (M13-982). Data from the study will be presented at an upcoming medical conference.
The multicenter, open-label, single-arm study (n=157) was conducted to evaluate the efficacy and safety of venetoclax in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL) with 17p deletion. As per an independent review analysis, patients when treated with venetoclax witnessed a clinically meaningful reduction in the number of cancer cells thereby meeting the primary endpoint of the study. The safety profile of the candidate was found to be similar with earlier studies and no unexpected safety issues were reported.
Based on these results, AbbVie plans to submit regulatory applications for the candidate both in the U.S. and EU before year end. We note that venetoclax has been granted Breakthrough Therapy designation by the FDA for this indication, which will expedite its development process.
According to the press release issued by both AbbVie and Roche, CLL is the most common type of leukemia in adults. About 3-10% of CLL patients have the 17p deletion at the time of diagnosis but it is found in 30-50% of patients with relapsed/refractory CLL. The approval will provide significant benefit to patients suffering from this hard-to-treat type of CLL and holds significant commercial potential.
AbbVie is developing venetoclax either alone or in combination with other regimens under a collaboration agreement with Roche. Currently, the candidate is in several early- and mid-stage studies across multiple types of blood cancers like indolent non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, acute myeloid leukemia and multiple myeloma.
AbbVie currently holds a Zacks Rank #3 (Hold). Gilead Sciences Inc. GILD and AMAG Pharmaceuticals, Inc. AMAG are some better-ranked stocks in the health care sector, each carrying a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
AMAG PHARMA INC (AMAG): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc.ABBV and partner Roche RHHBY announced that their experimental leukemia candidate, venetoclax, achieved the primary endpoint - overall response rate - in a phase II study (M13-982). Based on these results, AbbVie plans to submit regulatory applications for the candidate both in the U.S. and EU before year end. According to the press release issued by both AbbVie and Roche, CLL is the most common type of leukemia in adults. | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV and partner Roche RHHBY announced that their experimental leukemia candidate, venetoclax, achieved the primary endpoint - overall response rate - in a phase II study (M13-982). Based on these results, AbbVie plans to submit regulatory applications for the candidate both in the U.S. and EU before year end. | AbbVie Inc.ABBV and partner Roche RHHBY announced that their experimental leukemia candidate, venetoclax, achieved the primary endpoint - overall response rate - in a phase II study (M13-982). Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Based on these results, AbbVie plans to submit regulatory applications for the candidate both in the U.S. and EU before year end. | AbbVie Inc.ABBV and partner Roche RHHBY announced that their experimental leukemia candidate, venetoclax, achieved the primary endpoint - overall response rate - in a phase II study (M13-982). Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Based on these results, AbbVie plans to submit regulatory applications for the candidate both in the U.S. and EU before year end. |
26876.0 | 2015-08-12 00:00:00 UTC | Here's Why Enanta Pharmaceuticals Stock Beat the Downtrend in July | ABBV | https://www.nasdaq.com/articles/heres-why-enanta-pharmaceuticals-stock-beat-downtrend-july-2015-08-12 | nan | nan | What : While many healthcare stocks were getting walloped in July as a result of the Greek financial crisis, Enanta Pharmaceuticals was among the few strong performers in the sector, with its share price actually climbing double digits last month:
ENTA data by YCharts
Enanta's ability to defy the weight of the global economic turmoil last month stemmed directly from the approval of AbbVie 's Technivie on July 24, a genotype 4 hepatitis C treatment co-prescribed with ribavirin and indicated for patients without cirrhosis of the liver. Enanta developed one of the two direct-acting antivirals, paritaprevir, which is used in Technivie, as well as AbbVie's other hep C combo therapy Viekira Pak, and it's therefore entitled to milestone and royalty payments on net sales of the drugs.
So what : According to AbbVie and Enanta, Technivie is the first all-oral, interferon-free, direct-acting antiviral treatment approved in the U.S. for adult patients with genotype 4 hepatitis C. Presently, Gilead 's wonder drug Sovaldi is approved in genotype 4 patients, but in combination with both peginterferon alfa and ribavirin.
Now what : As you might expect, Gilead is also closing in on all-oral, interferon- and ribavirin-free treatment regimen via its combo pill Harvoni. Last April, the biotech released intriguing data from a midstage study showing functional cure rates of 95% for genotype 4 patients after receiving Harvoni.
Perhaps most worrisome for AbbVie and Enanta's Technivie, Harvoni proved effective in patients with and without cirrhosis. So, while Technivie did have slightly higher functional cure rates in its pivotal late-stage trial (100%) in genotype 4 patients, Harvoni might come without the serious adverse effects induced by ribavirin (depending on its label for this indication), and could potentially be used in a wider patient population. Put plainly, Technivie's approval may not turn out to be much of long-term value driver for Enanta or its partner AbbVie. Stay tuned.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article Here's Why Enanta Pharmaceuticals Stock Beat the Downtrend in July originally appeared on Fool.com.
George Budwell owns shares of AbbVie and Gilead Sciences. The Motley Fool recommends Gilead Sciences. The Motley Fool owns shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What : While many healthcare stocks were getting walloped in July as a result of the Greek financial crisis, Enanta Pharmaceuticals was among the few strong performers in the sector, with its share price actually climbing double digits last month: ENTA data by YCharts Enanta's ability to defy the weight of the global economic turmoil last month stemmed directly from the approval of AbbVie 's Technivie on July 24, a genotype 4 hepatitis C treatment co-prescribed with ribavirin and indicated for patients without cirrhosis of the liver. Enanta developed one of the two direct-acting antivirals, paritaprevir, which is used in Technivie, as well as AbbVie's other hep C combo therapy Viekira Pak, and it's therefore entitled to milestone and royalty payments on net sales of the drugs. So what : According to AbbVie and Enanta, Technivie is the first all-oral, interferon-free, direct-acting antiviral treatment approved in the U.S. for adult patients with genotype 4 hepatitis C. Presently, Gilead 's wonder drug Sovaldi is approved in genotype 4 patients, but in combination with both peginterferon alfa and ribavirin. | What : While many healthcare stocks were getting walloped in July as a result of the Greek financial crisis, Enanta Pharmaceuticals was among the few strong performers in the sector, with its share price actually climbing double digits last month: ENTA data by YCharts Enanta's ability to defy the weight of the global economic turmoil last month stemmed directly from the approval of AbbVie 's Technivie on July 24, a genotype 4 hepatitis C treatment co-prescribed with ribavirin and indicated for patients without cirrhosis of the liver. So what : According to AbbVie and Enanta, Technivie is the first all-oral, interferon-free, direct-acting antiviral treatment approved in the U.S. for adult patients with genotype 4 hepatitis C. Presently, Gilead 's wonder drug Sovaldi is approved in genotype 4 patients, but in combination with both peginterferon alfa and ribavirin. Enanta developed one of the two direct-acting antivirals, paritaprevir, which is used in Technivie, as well as AbbVie's other hep C combo therapy Viekira Pak, and it's therefore entitled to milestone and royalty payments on net sales of the drugs. | What : While many healthcare stocks were getting walloped in July as a result of the Greek financial crisis, Enanta Pharmaceuticals was among the few strong performers in the sector, with its share price actually climbing double digits last month: ENTA data by YCharts Enanta's ability to defy the weight of the global economic turmoil last month stemmed directly from the approval of AbbVie 's Technivie on July 24, a genotype 4 hepatitis C treatment co-prescribed with ribavirin and indicated for patients without cirrhosis of the liver. So what : According to AbbVie and Enanta, Technivie is the first all-oral, interferon-free, direct-acting antiviral treatment approved in the U.S. for adult patients with genotype 4 hepatitis C. Presently, Gilead 's wonder drug Sovaldi is approved in genotype 4 patients, but in combination with both peginterferon alfa and ribavirin. Enanta developed one of the two direct-acting antivirals, paritaprevir, which is used in Technivie, as well as AbbVie's other hep C combo therapy Viekira Pak, and it's therefore entitled to milestone and royalty payments on net sales of the drugs. | So what : According to AbbVie and Enanta, Technivie is the first all-oral, interferon-free, direct-acting antiviral treatment approved in the U.S. for adult patients with genotype 4 hepatitis C. Presently, Gilead 's wonder drug Sovaldi is approved in genotype 4 patients, but in combination with both peginterferon alfa and ribavirin. What : While many healthcare stocks were getting walloped in July as a result of the Greek financial crisis, Enanta Pharmaceuticals was among the few strong performers in the sector, with its share price actually climbing double digits last month: ENTA data by YCharts Enanta's ability to defy the weight of the global economic turmoil last month stemmed directly from the approval of AbbVie 's Technivie on July 24, a genotype 4 hepatitis C treatment co-prescribed with ribavirin and indicated for patients without cirrhosis of the liver. Enanta developed one of the two direct-acting antivirals, paritaprevir, which is used in Technivie, as well as AbbVie's other hep C combo therapy Viekira Pak, and it's therefore entitled to milestone and royalty payments on net sales of the drugs. |
26877.0 | 2015-08-07 00:00:00 UTC | Health Care Select Sector SPDR Fund Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/health-care-select-sector-spdr-fund-experiences-big-inflow-2015-08-07 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $98.1 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 211,565,324 to 212,865,324). Among the largest underlying components of XLV, in trading today Allergan PLC (Symbol: AGN) is down about 0.7%, Amgen Inc (Symbol: AMGN) is off about 0.7%, and AbbVie Inc. (Symbol: ABBV) is lower by about 1.8%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $59.21 per share, with $77.40 as the 52 week high point - that compares with a last trade of $74.66. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today Allergan PLC (Symbol: AGN) is down about 0.7%, Amgen Inc (Symbol: AMGN) is off about 0.7%, and AbbVie Inc. (Symbol: ABBV) is lower by about 1.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $98.1 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 211,565,324 to 212,865,324). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today Allergan PLC (Symbol: AGN) is down about 0.7%, Amgen Inc (Symbol: AMGN) is off about 0.7%, and AbbVie Inc. (Symbol: ABBV) is lower by about 1.8%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $59.21 per share, with $77.40 as the 52 week high point - that compares with a last trade of $74.66. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. | Among the largest underlying components of XLV, in trading today Allergan PLC (Symbol: AGN) is down about 0.7%, Amgen Inc (Symbol: AMGN) is off about 0.7%, and AbbVie Inc. (Symbol: ABBV) is lower by about 1.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $98.1 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 211,565,324 to 212,865,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $59.21 per share, with $77.40 as the 52 week high point - that compares with a last trade of $74.66. | Among the largest underlying components of XLV, in trading today Allergan PLC (Symbol: AGN) is down about 0.7%, Amgen Inc (Symbol: AMGN) is off about 0.7%, and AbbVie Inc. (Symbol: ABBV) is lower by about 1.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $98.1 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 211,565,324 to 212,865,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $59.21 per share, with $77.40 as the 52 week high point - that compares with a last trade of $74.66. |
26878.0 | 2015-08-06 00:00:00 UTC | Commit To Purchase AbbVie At $60, Earn 5.4% Annualized Using Options | ABBV | https://www.nasdaq.com/articles/commit-purchase-abbvie-60-earn-54-annualized-using-options-2015-08-06 | nan | nan | Investors considering a purchase of AbbVie Inc. (Symbol: ABBV) stock, but cautious about paying the going market price of $69.83/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2016 put at the $60 strike, which has a bid at the time of this writing of $1.45. Collecting that bid as the premium represents a 2.4% return against the $60 commitment, or a 5.4% annualized rate of return (at Stock Options Channel we call this the YieldBoost ).
Selling a put does not give an investor access to ABBV's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $60 strike if doing so produced a better outcome than selling at the going market price. ( Do options carry counterparty risk? This and six other common options myths debunked ). So unless AbbVie Inc. sees its shares decline 14.3% and the contract is exercised (resulting in a cost basis of $58.55 per share before broker commissions, subtracting the $1.45 from $60), the only upside to the put seller is from collecting that premium for the 5.4% annualized rate of return.
Worth considering, is that the annualized 5.4% figure actually exceeds the 2.9% annualized dividend paid by AbbVie Inc. by 2.5%, based on the current share price of $69.83. And yet, if an investor was to buy the stock at the going market price in order to collect the dividend, there is greater downside because the stock would have to fall 14.26% to reach the $60 strike price.
Always important when discussing dividends is the fact that, in general, dividend amounts are not always predictable and tend to follow the ups and downs of profitability at each company. In the case of AbbVie Inc., looking at the dividend history chart for ABBV below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2.9% annualized dividend yield.
Below is a chart showing the trailing twelve month trading history for AbbVie Inc., and highlighting in green where the $60 strike is located relative to that history:
The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2016 put at the $60 strike for the 5.4% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for AbbVie Inc. (considering the last 252 trading day closing values as well as today's price of $69.83) to be 26%. For other put options contract ideas at the various different available expirations, visit the ABBV Stock Options page of StockOptionsChannel.com.
In mid-afternoon trading on Thursday, the put volume among S&P 500 components was 1.02M contracts, with call volume at 1.08M, for a put:call ratio of 0.95 so far for the day, which is unusually high compared to the long-term median put:call ratio of .65. In other words, there are lots more put buyers out there in options trading so far today than would normally be seen, as compared to call buyers. Find out which 15 call and put options traders are talking about today .
Top YieldBoost Puts of Stocks Analysts Like »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors considering a purchase of AbbVie Inc. (Symbol: ABBV) stock, but cautious about paying the going market price of $69.83/share, might benefit from considering selling puts among the alternative strategies at their disposal. Below is a chart showing the trailing twelve month trading history for AbbVie Inc., and highlighting in green where the $60 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2016 put at the $60 strike for the 5.4% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for AbbVie Inc. (considering the last 252 trading day closing values as well as today's price of $69.83) to be 26%. | Below is a chart showing the trailing twelve month trading history for AbbVie Inc., and highlighting in green where the $60 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2016 put at the $60 strike for the 5.4% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for AbbVie Inc. (considering the last 252 trading day closing values as well as today's price of $69.83) to be 26%. Investors considering a purchase of AbbVie Inc. (Symbol: ABBV) stock, but cautious about paying the going market price of $69.83/share, might benefit from considering selling puts among the alternative strategies at their disposal. | Selling a put does not give an investor access to ABBV's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. Below is a chart showing the trailing twelve month trading history for AbbVie Inc., and highlighting in green where the $60 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2016 put at the $60 strike for the 5.4% annualized rate of return represents good reward for the risks. Investors considering a purchase of AbbVie Inc. (Symbol: ABBV) stock, but cautious about paying the going market price of $69.83/share, might benefit from considering selling puts among the alternative strategies at their disposal. | In the case of AbbVie Inc., looking at the dividend history chart for ABBV below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2.9% annualized dividend yield. Below is a chart showing the trailing twelve month trading history for AbbVie Inc., and highlighting in green where the $60 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2016 put at the $60 strike for the 5.4% annualized rate of return represents good reward for the risks. Investors considering a purchase of AbbVie Inc. (Symbol: ABBV) stock, but cautious about paying the going market price of $69.83/share, might benefit from considering selling puts among the alternative strategies at their disposal. |
26879.0 | 2015-08-05 00:00:00 UTC | Noteworthy Wednesday Option Activity: AZO, CBS, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-azo-cbs-abbv-2015-08-05 | nan | nan | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AutoZone, Inc. (Symbol: AZO), where a total of 1,847 contracts have traded so far, representing approximately 184,700 underlying shares. That amounts to about 106.8% of AZO's average daily trading volume over the past month of 172,955 shares. Especially high volume was seen for the $700 strike call option expiring August 21, 2015 , with 302 contracts trading so far today, representing approximately 30,200 underlying shares of AZO. Below is a chart showing AZO's trailing twelve month trading history, with the $700 strike highlighted in orange:
CBS Corp (Symbol: CBS) saw options trading volume of 41,785 contracts, representing approximately 4.2 million underlying shares or approximately 100.6% of CBS's average daily trading volume over the past month, of 4.2 million shares. Particularly high volume was seen for the $50.50 strike put option expiring August 07, 2015 , with 5,501 contracts trading so far today, representing approximately 550,100 underlying shares of CBS. Below is a chart showing CBS's trailing twelve month trading history, with the $50.50 strike highlighted in orange:
And AbbVie Inc. (Symbol: ABBV) options are showing a volume of 71,072 contracts thus far today. That number of contracts represents approximately 7.1 million underlying shares, working out to a sizeable 90.1% of ABBV's average daily trading volume over the past month, of 7.9 million shares. Particularly high volume was seen for the $65 strike call option expiring September 18, 2015 , with 57,929 contracts trading so far today, representing approximately 5.8 million underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $65 strike highlighted in orange:
For the various different available expirations for AZO options , CBS options , or ABBV options , visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Particularly high volume was seen for the $65 strike call option expiring September 18, 2015 , with 57,929 contracts trading so far today, representing approximately 5.8 million underlying shares of ABBV. Below is a chart showing CBS's trailing twelve month trading history, with the $50.50 strike highlighted in orange: And AbbVie Inc. (Symbol: ABBV) options are showing a volume of 71,072 contracts thus far today. That number of contracts represents approximately 7.1 million underlying shares, working out to a sizeable 90.1% of ABBV's average daily trading volume over the past month, of 7.9 million shares. | Below is a chart showing CBS's trailing twelve month trading history, with the $50.50 strike highlighted in orange: And AbbVie Inc. (Symbol: ABBV) options are showing a volume of 71,072 contracts thus far today. That number of contracts represents approximately 7.1 million underlying shares, working out to a sizeable 90.1% of ABBV's average daily trading volume over the past month, of 7.9 million shares. Particularly high volume was seen for the $65 strike call option expiring September 18, 2015 , with 57,929 contracts trading so far today, representing approximately 5.8 million underlying shares of ABBV. | Particularly high volume was seen for the $65 strike call option expiring September 18, 2015 , with 57,929 contracts trading so far today, representing approximately 5.8 million underlying shares of ABBV. Below is a chart showing CBS's trailing twelve month trading history, with the $50.50 strike highlighted in orange: And AbbVie Inc. (Symbol: ABBV) options are showing a volume of 71,072 contracts thus far today. That number of contracts represents approximately 7.1 million underlying shares, working out to a sizeable 90.1% of ABBV's average daily trading volume over the past month, of 7.9 million shares. | Particularly high volume was seen for the $65 strike call option expiring September 18, 2015 , with 57,929 contracts trading so far today, representing approximately 5.8 million underlying shares of ABBV. Below is a chart showing CBS's trailing twelve month trading history, with the $50.50 strike highlighted in orange: And AbbVie Inc. (Symbol: ABBV) options are showing a volume of 71,072 contracts thus far today. That number of contracts represents approximately 7.1 million underlying shares, working out to a sizeable 90.1% of ABBV's average daily trading volume over the past month, of 7.9 million shares. |
26880.0 | 2015-08-03 00:00:00 UTC | After Hours Most Active for Aug 3, 2015 : VER, QQQ, MCRL, LOW, ABBV, CLV, RMP, HTZ, CG, AAPL, FTR, FKU | ABBV | https://www.nasdaq.com/articles/after-hours-most-active-aug-3-2015-ver-qqq-mcrl-low-abbv-clv-rmp-htz-cg-aapl-ftr-fku-2015 | nan | nan | The NASDAQ 100 After Hours Indicator is down -1.4 to 4,579.06. The total After hours volume is currently 20,512,579 shares traded.
The following are the most active stocks for the after hours session :
VEREIT Inc. ( VER ) is unchanged at $8.83, with 2,154,708 shares traded.VER is scheduled to provide an earnings report on 8/6/2015, for the fiscal quarter ending Jun2015. The consensus earnings per share forecast is 0.21 per share, which represents a 24 percent increase over the EPS one Year Ago
PowerShares QQQ Trust, Series 1 ( QQQ ) is +0.04 at $111.64, with 1,709,154 shares traded. This represents a 23.71% increase from its 52 Week Low.
Micrel, Incorporated ( MCRL ) is unchanged at $13.86, with 1,232,346 shares traded.MCRL is scheduled to provide an earnings report on 8/6/2015, for the fiscal quarter ending Jun2015. The consensus earnings per share forecast is 0.05 per share, which represents a 6 percent increase over the EPS one Year Ago
Lowe's Companies, Inc. ( LOW ) is unchanged at $68.91, with 821,611 shares traded. As reported by Zacks, the current mean recommendation for LOW is in the "buy range".
AbbVie Inc. ( ABBV ) is unchanged at $69.73, with 681,826 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range".
Cliffs Natural Resources Inc. ( CLV ) is +0.05 at $2.50, with 615,000 shares traded.
Rice Midstream Partners LP ( RMP ) is -0.05 at $16.50, with 600,000 shares traded.RMP is scheduled to provide an earnings report on 8/6/2015, for the fiscal quarter ending Jun2015. The consensus earnings per share forecast is 0.18 per share, which represents a 99,900 percent increase over the EPS one Year Ago
Hertz Global Holdings, Inc ( HTZ ) is +0.15 at $16.70, with 573,736 shares traded. HTZ's current last sale is 64.23% of the target price of $26.
The Carlyle Group L.P. ( CG ) is -0.4 at $25.65, with 545,197 shares traded. As reported by Zacks, the current mean recommendation for CG is in the "buy range".
Apple Inc. ( AAPL ) is -0.13 at $118.31, with 388,052 shares traded. Over the last four weeks they have had 10 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2015. The consensus EPS forecast is $1.87. As reported by Zacks, the current mean recommendation for AAPL is in the "buy range".
Frontier Communications Corporation ( FTR ) is -0.0006 at $5.15, with 382,254 shares traded. RTT News Reports: Frontier Communications Q2 Profit Matches Estimates - Quick Facts
First Trust United Kingdom AlphaDEX Fund ( FKU ) is -0.0124 at $43.49, with 327,091 shares traded. This represents a 24.04% increase from its 52 Week Low.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc. ( ABBV ) is unchanged at $69.73, with 681,826 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". The following are the most active stocks for the after hours session : VEREIT Inc. ( VER ) is unchanged at $8.83, with 2,154,708 shares traded.VER is scheduled to provide an earnings report on 8/6/2015, for the fiscal quarter ending Jun2015. | AbbVie Inc. ( ABBV ) is unchanged at $69.73, with 681,826 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". The consensus earnings per share forecast is 0.21 per share, which represents a 24 percent increase over the EPS one Year Ago PowerShares QQQ Trust, Series 1 ( QQQ ) is +0.04 at $111.64, with 1,709,154 shares traded. | AbbVie Inc. ( ABBV ) is unchanged at $69.73, with 681,826 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". The consensus earnings per share forecast is 0.21 per share, which represents a 24 percent increase over the EPS one Year Ago PowerShares QQQ Trust, Series 1 ( QQQ ) is +0.04 at $111.64, with 1,709,154 shares traded. | AbbVie Inc. ( ABBV ) is unchanged at $69.73, with 681,826 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". The following are the most active stocks for the after hours session : VEREIT Inc. ( VER ) is unchanged at $8.83, with 2,154,708 shares traded.VER is scheduled to provide an earnings report on 8/6/2015, for the fiscal quarter ending Jun2015. |
26881.0 | 2015-07-31 00:00:00 UTC | Seattle Genetics (SGEN) Loss Widens in Q2, Ups 2015 View - Analyst Blog | ABBV | https://www.nasdaq.com/articles/seattle-genetics-sgen-loss-widens-in-q2-ups-2015-view-analyst-blog-2015-07-31 | nan | nan | Seattle Genetics, Inc.SGEN reported a loss of 38 cents per share, wider than the Zacks Consensus Estimate of a loss of 23 cents and the year-ago loss of 14 cents.
Seattle Genetics Inc. - Earnings Surprise | FindTheBest
Revenues increased 12.9% from the year-ago quarter to $77.1 million but missed the Zacks Consensus Estimate of $78 million. The increase in revenues was primarily driven by higher Adcetris sales.
The Quarter in Detail
Total revenue comprised product revenues, collaboration and license agreement revenues, and royalties. Adcetris, the only marketed product at Seattle Genetics, generated revenues of $55.1 million (in the U.S. and Canada), up 23% year over year.
Collaboration and license agreement revenues, and royalty revenues were $14.4 million (down 11.2% year over year) and $7.6 million (up 3.8% year over year), respectively. Collaboration revenues included revenues earned from the company's Adcetris collaboration with Takeda Pharmaceutical TKPYY as well as other antibody drug conjugate (ADC) collaborations.
During the quarter, Seattle Genetics entered into a strategic collaboration and license agreement with Unum Therapeutics for the development and commercialization of novel antibody-coupled T-cell receptor therapies for cancer. Per the deal, Seattle Genetics made an upfront payment of $25 million to Unum and an equity investment of $5 million in the company.
On the other hand, Seattle Genetics received a milestone payment from AbbVie ABBV upon the initiation of a phase I study by the latter on an ADC for hematologic malignancies using the Seattle Genetics' technology.
In the reported quarter, research and development (R&D) expenses were $85.7 million, up 59.7% year over year primarily due to the $25 million upfront payment to Unum. Selling, general and administrative (SG&A) expenses increased 18.9% year over year to $30.3 million.
Pipeline Update
Seattle Genetics' supplemental biologic license application for Adcetris for post-transplant consolidation treatment of patients suffering from Hodgkin lymphoma, who are at high risk of relapse or progression, is under priority review with the FDA. A response from the agency should be out by Aug 18, 2015.
Meanwhile, the company is enrolling patients in three phase III studies on Adcetris. Patient enrollment in ECHELON-1 (frontline Hodgkin's lymphoma) and ALCANZA (cutaneous T-cell lymphoma) are expected to be completed by 2015-end and in ECHELON-2 (frontline mature T-cell lymphoma) in 2016.
The company also intends to initiate a randomized phase II study on Rituxan (plus Treanda) with or without Adcetris for the treatment of relapsed/refractory CD30-positive diffuse large B-cell lymphoma (DLBCL) and a randomized phase II study on SGN-CD19A for the second-line treatment of DLBCL. Data from ALCANZA should be out in 2016, while that from ECHELON-1 and ECHELON-2 are expected in the 2017-2018 timeframe.
Additionally, Seattle Genetics is looking to expand Adcetris' label in the field of autoimmune diseases. In Jul 2015, the company started a phase II study on the drug for systemic lupus erythematosus (SLE).
Meanwhile, under a partnership with Bristol-Myers Squibb BMY , Seattle Genetics' intends to conduct two studies (expected to begin in 2015) on ADCETRIS in combination with Opdivo for the treatment of relapsed Hodgkin lymphoma and relapsed CD30 positive non-Hodgkin lymphoma.
2015 Outlook
Seattle Genetics increased its Adcetris net sales guidance for 2015 to the range of $210 million - $220 million in the U.S. and Canada (previous guidance: $200 million to $210 million). R&D expenditure is expected in the range of $275 million - $300 million, primarily due to the $25 million upfront payment made to Unum Therapeutics.
Our Take
Although Seattle Genetics' second-quarter 2015 results were disappointing with the company missing both bottom- and top-line estimates, we are pleased with the company's efforts on expanding Adcetris' label. The raise in 2015 Adcetris sales guidance is also encouraging.
Given that Adcetris is the cornerstone of Seattle Genetics' business, approval for the drug in the post-transplant consolidation treatment setting should be a major positive for the company. Seattle Genetics' efforts to develop the in other indications including SLE are also encouraging.
We expect investor focus to remain on regulatory updates on Adcetris.
Seattle Genetics carries a Zacks Rank #4 (Sell). A better-ranked stock in the health care sector is Anacor Pharmaceuticals, Inc. ANAC , carrying a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
SEATTLE GENETIC (SGEN): Free Stock Analysis Report
BRISTOL-MYERS (BMY): Free Stock Analysis Report
ANACOR PHARMACT (ANAC): Free Stock Analysis Report
TAKEDA PHARMACT (TKPYY): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On the other hand, Seattle Genetics received a milestone payment from AbbVie ABBV upon the initiation of a phase I study by the latter on an ADC for hematologic malignancies using the Seattle Genetics' technology. Click to get this free report SEATTLE GENETIC (SGEN): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report ANACOR PHARMACT (ANAC): Free Stock Analysis Report TAKEDA PHARMACT (TKPYY): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. During the quarter, Seattle Genetics entered into a strategic collaboration and license agreement with Unum Therapeutics for the development and commercialization of novel antibody-coupled T-cell receptor therapies for cancer. | Click to get this free report SEATTLE GENETIC (SGEN): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report ANACOR PHARMACT (ANAC): Free Stock Analysis Report TAKEDA PHARMACT (TKPYY): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. On the other hand, Seattle Genetics received a milestone payment from AbbVie ABBV upon the initiation of a phase I study by the latter on an ADC for hematologic malignancies using the Seattle Genetics' technology. Collaboration revenues included revenues earned from the company's Adcetris collaboration with Takeda Pharmaceutical TKPYY as well as other antibody drug conjugate (ADC) collaborations. | Click to get this free report SEATTLE GENETIC (SGEN): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report ANACOR PHARMACT (ANAC): Free Stock Analysis Report TAKEDA PHARMACT (TKPYY): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. On the other hand, Seattle Genetics received a milestone payment from AbbVie ABBV upon the initiation of a phase I study by the latter on an ADC for hematologic malignancies using the Seattle Genetics' technology. Collaboration and license agreement revenues, and royalty revenues were $14.4 million (down 11.2% year over year) and $7.6 million (up 3.8% year over year), respectively. | On the other hand, Seattle Genetics received a milestone payment from AbbVie ABBV upon the initiation of a phase I study by the latter on an ADC for hematologic malignancies using the Seattle Genetics' technology. Click to get this free report SEATTLE GENETIC (SGEN): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report ANACOR PHARMACT (ANAC): Free Stock Analysis Report TAKEDA PHARMACT (TKPYY): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Seattle Genetics Inc. - Earnings Surprise | FindTheBest Revenues increased 12.9% from the year-ago quarter to $77.1 million but missed the Zacks Consensus Estimate of $78 million. |
26882.0 | 2015-07-30 00:00:00 UTC | The Zacks Analyst Blog Highlights: Biogen, AbbVie, Regeneron, Amgen and XOMA - Press Releases | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biogen-abbvie-regeneron-amgen-and-xoma-press-releases | nan | nan | For Immediate Release
Chicago, IL - July 30, 2015 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Biogen ( BIIB ), AbbVie ( ABBV ), Regeneron ( REGN ), Amgen ( AMGN ) and XOMA ( XOMA ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .
Here are highlights from Wednesday's Analyst Blog:
Biotech Stock Roundup
Several major biotech companies like Biogen ( BIIB ), AbbVie ( ABBV ), Celgene and Gilead reported second quarter results over the last five trading days. Biogen has been grabbing headlines for the wrong reasons - although the company's earnings were better-than-expected, revenues missed expectations.
With the company saying that it is cutting its outlook based on revised expectations for its oral multiple sclerosis (MS) treatment, shares were down significantly. Another major bit of news last week was the approval of the first PCSK9 inhibitor in the U.S.
Recap of the Week's Most Important Stories
1. Companies like Biogen, AbbVie, Celgene and Gilead reported second quarter results over the last week. Although Biogen and AbbVie's earnings surpassed expectations, both companies missed revenue estimates. Biogen's shares were down significantly with the company cutting its 2015 outlook based on revised expectations for its oral MS treatment, Tecfidera (Read more: Biogen Tops Q2 Earnings, Cuts View on Tecfidera Issues ).
Meanwhile, sales of AbbVie's Humira fell short of expectations (Read more: AbbVie Tops Earnings, Misses on Revenues, Maintains View ). The company attributed Humira's weak international sales to the timing of shipments and negative currency movement and said that Remicade biosimilars did not impact ex-U.S. Humira sales. Celgene's second quarter results were in-line with expectations (Read more: Celgene Q2 Earnings & Revenues In Line, Keeps View ). Gilead's earnings and revenues were both above expectations.
2. Regeneron ( REGN ) and partner Sanofi are the first to gain approval for a PCSK9 inhibitor in the U.S. The FDA approved their cholesterol treatment, Praluent, late last week. As far as EU approval is concerned, the CHMP has voted in favor of approving the treatment. However, Amgen's ( AMGN ) PCSK9 inhibitor, Repatha, has already been approved in the EU.
Meanwhile, Regeneron and Sanofi are the latest to join the immuno-oncology brigade with the companies entering into a new agreement. The agreement will see Sanofi making a $640 million upfront payment to Regeneron and a major part of the initial expenses will be funded by Sanofi.
3. Amgen gained FDA approval for a label expansion of its cancer treatment, Kyprolis. With this approval, Kyprolis can now be used in combination with Revlimid and dexamethasone (KRd) in multiple myeloma patients who have received one to three prior lines of therapy.
Data from the ASPIRE study had shown that patients treated in the KRd arm lived 50% longer (8.7 months) without their disease worsening compared to patients treated with Revlimid and low-dose dexamethasone (Rd) alone. Median progression-free survival (PFS) was 26.3 months versus 17.6 months
4. XOMA ( XOMA ) suffered a major setback with the company's lead pipeline candidate, gevokizumab, failing in a phase III study in patients with Behçet's disease uveitis. Shares plunged 77.3% on the news (Read more: XOMA Crashes after Gevokizumab Misses Primary Endpoint ).
5. Sunesis' shares plunged more than 70% with the company announcing that the FDA has advised it to not go ahead with a regulatory filing for its experimental leukemia treatment, vosaroxin, without providing additional clinical evidence. Based on feedback from the EU, Sunesis is currently going to focus on submitting a regulatory application in the EU.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today . Find out What is happening in the stock market today on zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BIOGEN INC (BIIB): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
REGENERON PHARM (REGN): Free Stock Analysis Report
AMGEN INC (AMGN): Free Stock Analysis Report
XOMA CORP (XOMA): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include the Biogen ( BIIB ), AbbVie ( ABBV ), Regeneron ( REGN ), Amgen ( AMGN ) and XOMA ( XOMA ). Here are highlights from Wednesday's Analyst Blog: Biotech Stock Roundup Several major biotech companies like Biogen ( BIIB ), AbbVie ( ABBV ), Celgene and Gilead reported second quarter results over the last five trading days. Companies like Biogen, AbbVie, Celgene and Gilead reported second quarter results over the last week. | Here are highlights from Wednesday's Analyst Blog: Biotech Stock Roundup Several major biotech companies like Biogen ( BIIB ), AbbVie ( ABBV ), Celgene and Gilead reported second quarter results over the last five trading days. Click to get this free report BIOGEN INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report XOMA CORP (XOMA): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include the Biogen ( BIIB ), AbbVie ( ABBV ), Regeneron ( REGN ), Amgen ( AMGN ) and XOMA ( XOMA ). | Here are highlights from Wednesday's Analyst Blog: Biotech Stock Roundup Several major biotech companies like Biogen ( BIIB ), AbbVie ( ABBV ), Celgene and Gilead reported second quarter results over the last five trading days. Click to get this free report BIOGEN INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report XOMA CORP (XOMA): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include the Biogen ( BIIB ), AbbVie ( ABBV ), Regeneron ( REGN ), Amgen ( AMGN ) and XOMA ( XOMA ). | Stocks recently featured in the blog include the Biogen ( BIIB ), AbbVie ( ABBV ), Regeneron ( REGN ), Amgen ( AMGN ) and XOMA ( XOMA ). Here are highlights from Wednesday's Analyst Blog: Biotech Stock Roundup Several major biotech companies like Biogen ( BIIB ), AbbVie ( ABBV ), Celgene and Gilead reported second quarter results over the last five trading days. Companies like Biogen, AbbVie, Celgene and Gilead reported second quarter results over the last week. |
26883.0 | 2015-07-30 00:00:00 UTC | Gilead's Hepatitis C Dominance Unchecked By AbbVie | ABBV | https://www.nasdaq.com/articles/gileads-hepatitis-c-dominance-unchecked-abbvie-2015-07-30 | nan | nan | Source: Gilead Sciences via Google Maps.
Worries that Gilead Sciences market dominance in treating hepatitis C would falter following the launch of AbbVie 's Viekira Pak this year have been mostly curbed after Gilead Sciences' stellar second quarter.
Despite Viekira Pak landing an exclusivity deal with pharmacy benefit manager Express Scripts and various Medicaid programs that led to Viekira Pak delivering sales of $385 million in Q2, Gilead Sciences hepatitis C sales soared 40.7% year over year to $4.9 billion last quarter.
A bigger pie
The common refrain heading into this year was that Viekira Pak's approval would lead to a price war that would cause Gilead Sciences' sales and profit to waver. Instead, price cuts have broadly expanded access to hepatitis C drugs, resulting in script volume growth that has more than offset headwinds tied to lower net prices.
Gilead Sciences reports that 60,000 patients initiated treatment with either Sovaldi, which is primarily used to treat non-genotype 1 HCV patients, or Harvoni, which is used mainly to treat genotye 1 HCV patients, in the second quarter alone, up from 45,000 patients in the fourth quarter. That's led to Gilead Sciences treating 130,000 HCV patients in the first six months of this year -- almost the same number of patients as were treated in all of 2014 .
Keeping its lead
Gilead Sciences warns that budgetary hurdles at the Veteran's Administration could lead to fewer patients starting treatment in the third quarter than in the first half, but the company still thinks that as new Medicaid contracts kick in, an annualized run rate of 300,000 patients treated across all genotypes and all competitors is reasonable.
If so, then it's hard to believe that Gilead Sciences' second-half results will fall dramatically from the first half, even if AbbVie's Viekira Pak picks up the pace. Consider this point: AbbVie's Viekira Pak grew 67% sequentially in the second quarter, yet Gilead Sciences hepatitis C market share still stands at 90% of all HCV patients.
That makes for a pretty compelling argument to own Gilead Sciences shares, especially considering that the latter's second-quarter sales annualize out to nearly $20 billion.
Looking forward
In the U.S., there are a lot of moving pieces that could prove to have a larger impact on Gilead Sciences hepatitis C sales than AbbVie's Viekira Pak down the road, including the potential approval of Merck & Co. 's competing combination drug and other competitors ongoing research efforts. Outside the U.S., the landscape is also getting increasingly competitive as Gilead Sciences and AbbVie secure pricing deals with various countries.
Certainly, investors shouldn't ignore the potential for those threats to weigh on Gilead Sciences share price, but it may be more profit friendly to give Gilead Sciences the benefit of the doubt that it can overcome these obstacles.
After all, the company has a long track record of keeping competitors at bay in HIV treatment, and it's possible that Gilead Sciences can apply those lessons learned to maintain its dominance in HCV, too. Aggressive price deals, shorter treatment duration, easier dosing, and enviable cure rates could all help Gilead Sciences relegate AbbVie and others to second-tier status. If so, then Gilead Sciences could continue reaping billions of dollars in hepatitis C sales for the foreseeable future.
This $19 trillion industry could destroy the Internet
One bleeding-edge technology is about to put the World Wide Web to bed. And if you act quickly, you could be among the savvy investors who enjoy the profits from this stunning change. Experts are calling it the single largest business opportunity in the history of capitalism... The Economist is calling it "transformative"... But you'll probably just call it "how I made my millions." Don't be too late to the party -- click here for one stock to own when the Web goes dark.
The article Gilead's Hepatitis C Dominance Unchecked By AbbVie originally appeared on Fool.com.
Todd Campbell owns shares of Gilead Sciences. Todd owns the equity research firm E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool recommends and owns shares of Express Scripts and Gilead Sciences. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking forward In the U.S., there are a lot of moving pieces that could prove to have a larger impact on Gilead Sciences hepatitis C sales than AbbVie's Viekira Pak down the road, including the potential approval of Merck & Co. 's competing combination drug and other competitors ongoing research efforts. Aggressive price deals, shorter treatment duration, easier dosing, and enviable cure rates could all help Gilead Sciences relegate AbbVie and others to second-tier status. Worries that Gilead Sciences market dominance in treating hepatitis C would falter following the launch of AbbVie 's Viekira Pak this year have been mostly curbed after Gilead Sciences' stellar second quarter. | Looking forward In the U.S., there are a lot of moving pieces that could prove to have a larger impact on Gilead Sciences hepatitis C sales than AbbVie's Viekira Pak down the road, including the potential approval of Merck & Co. 's competing combination drug and other competitors ongoing research efforts. Worries that Gilead Sciences market dominance in treating hepatitis C would falter following the launch of AbbVie 's Viekira Pak this year have been mostly curbed after Gilead Sciences' stellar second quarter. If so, then it's hard to believe that Gilead Sciences' second-half results will fall dramatically from the first half, even if AbbVie's Viekira Pak picks up the pace. | Worries that Gilead Sciences market dominance in treating hepatitis C would falter following the launch of AbbVie 's Viekira Pak this year have been mostly curbed after Gilead Sciences' stellar second quarter. If so, then it's hard to believe that Gilead Sciences' second-half results will fall dramatically from the first half, even if AbbVie's Viekira Pak picks up the pace. Consider this point: AbbVie's Viekira Pak grew 67% sequentially in the second quarter, yet Gilead Sciences hepatitis C market share still stands at 90% of all HCV patients. | Worries that Gilead Sciences market dominance in treating hepatitis C would falter following the launch of AbbVie 's Viekira Pak this year have been mostly curbed after Gilead Sciences' stellar second quarter. Consider this point: AbbVie's Viekira Pak grew 67% sequentially in the second quarter, yet Gilead Sciences hepatitis C market share still stands at 90% of all HCV patients. If so, then it's hard to believe that Gilead Sciences' second-half results will fall dramatically from the first half, even if AbbVie's Viekira Pak picks up the pace. |
26884.0 | 2015-07-29 00:00:00 UTC | Gilead (GILD) Beats on Q2 Earnings, Raises 2015 Outlook - Analyst Blog | ABBV | https://www.nasdaq.com/articles/gilead-gild-beats-on-q2-earnings-raises-2015-outlook-analyst-blog-2015-07-29 | nan | nan | Gilead Sciences, Inc. 's GILD second-quarter earnings (including stock-based compensation expenses) of $3.10 per share surpassed the Zacks Consensus Estimate of $2.83. Moreover, reported earnings were way above the year-ago figure of $2.32 per share.
Gilead Sciences Inc. - Earnings Surprise | FindTheBest
Total revenues of $8.2 billion were much above the year-ago figure of $6.5 billion. Quarterly revenues easily surpassed the Zacks Consensus Estimate of $7.4 billion.
Quarter in Detail
Product sales were up approximately 26.7% to $8.1 billion driven by the inclusion of sales of hepatitis C virus (HCV) drug, Harvoni (launched in the U.S. in Oct 2014).
Antiviral product sales for the quarter registered growth of 26.9% to $7.6 billion driven by Harvoni. Harvoni recorded revenues of $3.6 billion in the second quarter of 2015, flat sequentially. Another HCV drug, Sovaldi, registered sales of $1.3 billion, down 62.9% from the year-ago figure, owing to availability of newer HCV therapies.
Other anti-viral products, such as HIV treatments Complera/Eviplera (up 22.7% to $367 million) and Stribild (up 65.6% to $447 million) performed very well. Sales of older HIV drugs like Truvada (up 5.3% to $849 million) and Viread (up 3.8% to $271 million) were also impressive. However, Atripla sales declined 10.1% to $782 million. The company expects Atripla sales to continue to decline.
Other products including Letairis, Ranexa and AmBisome recorded sales of $176 million (up 21.4%), $141 million (up 14.6%) and $103 million (up 9.6%), respectively. Newly launched Zydelig also performed well, recording revenues of $30 million, up 15.4% sequentially.
Research & development (R&D) expenses (including stock-based compensation expenses) climbed 28.5% to $744 million in the second quarter of 2015 due to increased investment in pipeline. Selling, general and administrative (SG&A) expenses (including stock-based compensation expenses) increased 32.2% to $812 million. SG&A expenses shot up primarily due to the increase in expenses associated with HCV products.
2015 Guidance Revised
Gilead upped its product sales guidance. Gilead expects product sales in the range of $29-$30 billion (previous guidance: $28-$29 billion). TheZacks Consensus Estimate of $30 billion is at the higher end of the guidance range.
Adjusted product gross margin for 2015 is projected in the range of 88-90% (previous guidance: 87-90%). R&D expenses (excluding stock-based compensation expenses and other special items) are projected in the range of $2.8-$3 billion (previous guidance: $3-$3.3 billion). SG&A expenses are projected in the range of $3-$3.2 billion (previous guidance: $3-$3.3 billion).
Meanwhile, the company declared its third-quarter dividend. Gilead has declared a quarterly cash dividend of 43 cents per share of common stock, to be paid on Sep 29, 2015, to all stockholders of record as of the close of business on the record date of Sep 16, 2015.
The company also repurchased shares worth $900 million in the second quarter of 2015.
Our Take
Gilead posted strong second-quarter results with both earnings and revenues beating our expectations. We expect investors to react positively to the news.
We are nevertheless concerned about pricing measures in the form of rebates and discounts which could lead to a slowdown in Harvoni sales in 2015. The anticipated continued decline in Atripla sales due to newer HIV therapies is also concerning.
We note that several companies including AbbVie Inc. ABBV have launched their HCV treatments in the market.
Going forward, we expect investor focus to remain on the ramp up of Harvoni. Additionally, we could see some merger & acquisition activity from the company.
Gilead currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Ligand Pharmaceuticals Incorporated LGND and Anacor Pharmaceuticals, Inc. ANAC . While Ligand carries a Zacks Rank #1 (Strong Buy), Anacor holds a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
ANACOR PHARMACT (ANAC): Free Stock Analysis Report
LIGAND PHARMA-B (LGND): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We note that several companies including AbbVie Inc. ABBV have launched their HCV treatments in the market. Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report ANACOR PHARMACT (ANAC): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Gilead Sciences, Inc. 's GILD second-quarter earnings (including stock-based compensation expenses) of $3.10 per share surpassed the Zacks Consensus Estimate of $2.83. | Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report ANACOR PHARMACT (ANAC): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. We note that several companies including AbbVie Inc. ABBV have launched their HCV treatments in the market. Gilead Sciences, Inc. 's GILD second-quarter earnings (including stock-based compensation expenses) of $3.10 per share surpassed the Zacks Consensus Estimate of $2.83. | Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report ANACOR PHARMACT (ANAC): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. We note that several companies including AbbVie Inc. ABBV have launched their HCV treatments in the market. Other products including Letairis, Ranexa and AmBisome recorded sales of $176 million (up 21.4%), $141 million (up 14.6%) and $103 million (up 9.6%), respectively. | We note that several companies including AbbVie Inc. ABBV have launched their HCV treatments in the market. Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report ANACOR PHARMACT (ANAC): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. The company expects Atripla sales to continue to decline. |
26885.0 | 2015-07-28 00:00:00 UTC | Notable ETF Outflow Detected - UPRO, ABT, ABBV, ACN | ABBV | https://www.nasdaq.com/articles/notable-etf-outflow-detected-upro-abt-abbv-acn-2015-07-28 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $66.8 million dollar outflow -- that's a 8.3% decrease week over week (from 12,100,000 to 11,100,000). Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.1%, AbbVie Inc. (Symbol: ABBV) is up about 0.7%, and Accenture plc (Symbol: ACN) is higher by about 0.1%. For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average:
Looking at the chart above, UPRO's low point in its 52 week range is $45.74 per share, with $73.66 as the 52 week high point - that compares with a last trade of $67.00. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.1%, AbbVie Inc. (Symbol: ABBV) is up about 0.7%, and Accenture plc (Symbol: ACN) is higher by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $66.8 million dollar outflow -- that's a 8.3% decrease week over week (from 12,100,000 to 11,100,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.1%, AbbVie Inc. (Symbol: ABBV) is up about 0.7%, and Accenture plc (Symbol: ACN) is higher by about 0.1%. For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $45.74 per share, with $73.66 as the 52 week high point - that compares with a last trade of $67.00. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.1%, AbbVie Inc. (Symbol: ABBV) is up about 0.7%, and Accenture plc (Symbol: ACN) is higher by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $66.8 million dollar outflow -- that's a 8.3% decrease week over week (from 12,100,000 to 11,100,000). For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $45.74 per share, with $73.66 as the 52 week high point - that compares with a last trade of $67.00. | Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.1%, AbbVie Inc. (Symbol: ABBV) is up about 0.7%, and Accenture plc (Symbol: ACN) is higher by about 0.1%. For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $45.74 per share, with $73.66 as the 52 week high point - that compares with a last trade of $67.00. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
26886.0 | 2015-07-28 00:00:00 UTC | The Zacks Analyst Blog Highlights: Gilead Sciences, AbbVie, Merck, Achillion Pharmaceuticals and Express Scripts - Press Releases | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-abbvie-merck-achillion-pharmaceuticals | nan | nan | For Immediate Release
Chicago, IL - July 28, 2015 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Gilead Sciences Inc. ( GILD ), AbbVie Inc. ( ABBV ), Merck & Co., Inc. ( MRK ), Achillion Pharmaceuticals, Inc. ( ACHN ) and Express Scripts ( ESRX ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .
Here are highlights from Monday's Analyst Blog:
4 Stocks to Fight the Virus on World Hepatitis Day
World Hepatitis Day, observed on Jul 28, aims to raise awareness about hepatitis. This Hepatitis Day, the World Health Organization (WHO) will urge policy-makers, health workers and the public to act now to prevent infection and death from hepatitis. Each year the focus is on a specific theme - the theme for 2015 is the "prevention of viral hepatitis."
History of World Hepatitis Day
According to data provided by WHO, 400 million people across the world live with hepatitis B and C. With the virus claiming approximately 1.4 million lives each year, hepatitis has become an epidemic silently spreading and infecting healthy people having no clue that they are being attacked by something they cannot even detect. The reality is that this virus claims more lives than other deadly infectious diseases like HIV/AIDS, tuberculosis and malaria - primarily because more resources and attention are directed toward these diseases.
Finally, in 2010, after long being neglected by physicians, public-health officials and politicians, the WHO marked World Hepatitis Day as one of the only four official disease-specific world health days (HIV/AIDS, tuberculosis and malaria), to be celebrated each year. Setting aside a day for the disease would make the common people across the world more aware about hepatitis and the steps needed to prevent new infections and improve health outcomes for those already infected. Jul 28 was chosen for this purpose as it is Nobel Laureate Professor Baruch Samuel Blumberg's birthday. Professor Blumberg discovered the hepatitis B virus (HBV) and developed the first hepatitis B vaccine.
WHO, in joint partnership with the Scottish government and the World Hepatitis Alliance, is co-organizing the first World Hepatitis Summit to be held in Sep 2015.
What Is Hepatitis?
Hepatitis is an "inflammation of the liver" most commonly caused by one of the five main hepatitis viruses, referred to as types A, B, C, D and E. An estimated half a billion people are chronically infected with hepatitis B or C virus, which together are the most common cause of liver cirrhosis and cancer.
Hepatitis C virus (HCV) is complex and treatments differ depending on its subtypes.
HCV - Medical Miracle Leading to Captivating Market
For a long period of time, the standard-of-care treatment for HCV included peg-interferon (peg-INF - weekly injections) or ribavirin (RBV - oral drug) or pegylated forms of interferon plus RBV for treating genotype 1 HCV infection (most common in the U.S.). However, this treatment regimen was associated with significant side effects like fatigue, flu-like symptoms, rash, depression and anemia.
The treatment paradigm changed in 2011 with the introduction of a couple of directly acting anti-virals - HCV protease inhibitors Victrelis and Incivek - looked to reduce the treatment period. However, both required administration with peg-IFN and RBV leaving the door open for treatments with fewer side effects.
Late 2013 brought to market two cocktail treatments, Gilead Sciences Inc.'s ( GILD ) Sovaldi - a polymerase inhibitor and Johnson and Johnson's Olysio - an NS3/4A inhibitor, both aimed at changing the treatment paradigm for HCV patients yet again by providing them with all-oral treatment regimens without the administration of interferon, thereby doing away with a whole range of side effects and sustained viral responses (SVR) as high as 90%.
Presently, there is immense interest as well as commercial potential in HCV treatments given the size of the market. As per data provided by WHO, 130-150 million people suffer from chronic HCV across the world and about 500,000 people succumb to HCV-related liver diseases each year. Moreover, an estimated 2.7 million people in the U.S. suffer from chronic HCV, 70% of which are caused by genotype 1.
For so many years, HCV patients had to endure severe side effects with no assurance of getting cured. Patients now are postponing their treatment as they await better and safer treatment options.
4 Picks for the HCV Market
Although picking the correct stocks from so many options could be a daunting task, our proprietary methodology makes it fairly simple. One way to narrow down the list of choices is by looking at stocks that carry a favorable Zacks Rank - Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold). Below, we will help you identify three players in the HCV market which are poised for growth.
Foster City, CA-based Gilead Sciences Inc. known for its revolutionary blockbuster HCV drug, Sovaldi, boasting a cure rate of 90%, raked in $10.3 billion in 2014, which helped the company boost its EPS by as much as four times to $7.91 from $1.93 in 2013. Meanwhile, its new HCV drug, Harvoni, which completely did away with interferon, has already registered sales of $5.7 billion since its launch in late 2014.
There is no holding back this Zacks Rank #3 (Hold) stock when it comes to its HCV franchise. Gilead is looking to develop a pan-genotypic, single tablet regimen having the potential to effectively treat chronic HCV patients, regardless of HCV genotype.
North Chicago, IL-based AbbVie Inc. ( ABBV ), a Zacks Rank #3 stock, began to be viewed as a top competitor in the HCV race when its all-oral, interferon-free therapy with/without RBV Viekira gained approval last December in the U.S. Approval was highly expected given the treatment's high rates of response and tolerability along with low discontinuation rates. While Viekira has recorded sales of $279 million since the time it's on the market, AbbVie estimates the drug to achieve global annualized sales of more than $3 billion by the end of 2015.
Currently, AbbVie is working on the development of interferon-free treatments for HCV. It is progressing with the development of its next-generation HCV program which includes ABT-493, a potent protease inhibitor, and ABT-530, a new NS5A inhibitor. The company is aiming to bring a ribavirin-free once-daily pan-genotypic combination to the market.
Our third pick is Whitehouse Station, NJ-based Merck & Co., Inc. ( MRK ) which previously had a presence in the HCV market in the form of Victrelis and is now poised to come back potentially next year with its combination regimen - grazoprevir (NS3/4A protease inhibitor)/elbasvir (NS5A replication complex inhibitor) - for the treatment of adults suffering from chronic HCV genotypes 1, 4 or 6 infections. Merck also intends to seek approval for the combination in other markets by 2015 end. The combination has been granted Breakthrough Therapy designation in the U.S.
This Zacks Rank #3 stock is additionally studying the combination in multiple HCV genotypes and in patients with difficult-to-treat conditions such as HIV/HCV co-infection, advanced chronic kidney disease, inherited blood disorders, cirrhosis and those on opiate substitution therapy. The company had even acquired HCV-focused biotech company, Idenix Pharmaceuticals in 2014 with the intention of boosting its HCV portfolio.
And things look even better with our final pick - Achillion Pharmaceuticals, Inc. ( ACHN ). This New Haven, CT-based company is crafting a short-duration, highly effective, pan-genotypic, oral regimen for the treatment of HCV following a licensing deal worth $1.1 billion struck with Johnson & Johnson this May.
The company has been in the news ever since it reported encouraging interim data from a mid-stage study on ACH-3102 in combination with Sovaldi. Results showed that all patients including those with a high baseline viral load in the six-week treatment duration arm achieved 100% SVR at 12 weeks.
Keep your eyes on this Zacks Rank #3 stock which is looking to cut short the treatment duration further.
Need of the Hour
Though HCV treatments are now available and within the reach of many patients, the real cause of concern is the cost and access to care. As per data provided by pharmacy benefit manager Express Scripts ( ESRX ), patients in the U.S. spent 743% more on HCV treatments in 2014 compared with 2013. Sovaldi, Harvoni and Viekira all come with premium price tags.
However, the companies are working on providing patients access to treatments without barriers. Late last year, AbbVie struck a deal with Express Scripts, to provide Viekira to Express Scripts members (which cover about 25 million Americans) at a reportedly steep discount starting Jan 1, 2015. Consequently, Gilead too announced rebates and discounts and the company is working with public programs and private insurers to broaden the access.
Without a doubt, the entire world needs to come together to put an end to this deadly virus. Invention they say is the mother of necessity and the drugs on the market and in the pipeline are addressing the threat posed by hepatitis.
With regards to investment opportunities, these stocks provide immense upside potential as all are racing to develop better, safer, shorter duration HCV treatment options, irrespective of genotype.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today . Find out What is happening in the stock market today on zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
MERCK & CO INC (MRK): Free Stock Analysis Report
ACHILLION PHARM (ACHN): Free Stock Analysis Report
EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include the Gilead Sciences Inc. ( GILD ), AbbVie Inc. ( ABBV ), Merck & Co., Inc. ( MRK ), Achillion Pharmaceuticals, Inc. ( ACHN ) and Express Scripts ( ESRX ). North Chicago, IL-based AbbVie Inc. ( ABBV ), a Zacks Rank #3 stock, began to be viewed as a top competitor in the HCV race when its all-oral, interferon-free therapy with/without RBV Viekira gained approval last December in the U.S. Approval was highly expected given the treatment's high rates of response and tolerability along with low discontinuation rates. While Viekira has recorded sales of $279 million since the time it's on the market, AbbVie estimates the drug to achieve global annualized sales of more than $3 billion by the end of 2015. | Stocks recently featured in the blog include the Gilead Sciences Inc. ( GILD ), AbbVie Inc. ( ABBV ), Merck & Co., Inc. ( MRK ), Achillion Pharmaceuticals, Inc. ( ACHN ) and Express Scripts ( ESRX ). Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report ACHILLION PHARM (ACHN): Free Stock Analysis Report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report To read this article on Zacks.com click here. North Chicago, IL-based AbbVie Inc. ( ABBV ), a Zacks Rank #3 stock, began to be viewed as a top competitor in the HCV race when its all-oral, interferon-free therapy with/without RBV Viekira gained approval last December in the U.S. Approval was highly expected given the treatment's high rates of response and tolerability along with low discontinuation rates. | Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report ACHILLION PHARM (ACHN): Free Stock Analysis Report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include the Gilead Sciences Inc. ( GILD ), AbbVie Inc. ( ABBV ), Merck & Co., Inc. ( MRK ), Achillion Pharmaceuticals, Inc. ( ACHN ) and Express Scripts ( ESRX ). North Chicago, IL-based AbbVie Inc. ( ABBV ), a Zacks Rank #3 stock, began to be viewed as a top competitor in the HCV race when its all-oral, interferon-free therapy with/without RBV Viekira gained approval last December in the U.S. Approval was highly expected given the treatment's high rates of response and tolerability along with low discontinuation rates. | Stocks recently featured in the blog include the Gilead Sciences Inc. ( GILD ), AbbVie Inc. ( ABBV ), Merck & Co., Inc. ( MRK ), Achillion Pharmaceuticals, Inc. ( ACHN ) and Express Scripts ( ESRX ). North Chicago, IL-based AbbVie Inc. ( ABBV ), a Zacks Rank #3 stock, began to be viewed as a top competitor in the HCV race when its all-oral, interferon-free therapy with/without RBV Viekira gained approval last December in the U.S. Approval was highly expected given the treatment's high rates of response and tolerability along with low discontinuation rates. While Viekira has recorded sales of $279 million since the time it's on the market, AbbVie estimates the drug to achieve global annualized sales of more than $3 billion by the end of 2015. |
26887.0 | 2015-07-27 00:00:00 UTC | Company News for July 27, 2015 - Corporate Summary | ABBV | https://www.nasdaq.com/articles/company-news-for-july-27-2015-corporate-summary-2015-07-27 | nan | nan | • AbbVie Inc.'s ( ABBV ) shares declined 3.5% after posting second quarter revenues of $5.475 billion, missing the Zacks Consensus Estimate of $5.605 billion
• Shares of Cabot Oil & Gas Corporation ( COG ) dropped 4% after reporting second quarter adjusted earnings per share of $0.02, a couple of cents lower than the Zacks Consensus Estimate
• Xerox Corporation's ( XRX ) shares gained 1.2% after announcing fiscal first quarter revenues of $4,590 million, beating the Zacks Consensus Estimate of $4,581 million
• Shares of Johnson Controls Inc. ( JCI ) decreased 4.5% after reporting third quarter revenues of $9.61 billion, down 2.3% year over year
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBVIE INC (ABBV): Free Stock Analysis Report
CABOT OIL & GAS (COG): Free Stock Analysis Report
XEROX CORP (XRX): Free Stock Analysis Report
JOHNSON CONTROL (JCI): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • AbbVie Inc.'s ( ABBV ) shares declined 3.5% after posting second quarter revenues of $5.475 billion, missing the Zacks Consensus Estimate of $5.605 billion • Shares of Cabot Oil & Gas Corporation ( COG ) dropped 4% after reporting second quarter adjusted earnings per share of $0.02, a couple of cents lower than the Zacks Consensus Estimate • Xerox Corporation's ( XRX ) shares gained 1.2% after announcing fiscal first quarter revenues of $4,590 million, beating the Zacks Consensus Estimate of $4,581 million • Shares of Johnson Controls Inc. ( JCI ) decreased 4.5% after reporting third quarter revenues of $9.61 billion, down 2.3% year over year Want the latest recommendations from Zacks Investment Research? Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report CABOT OIL & GAS (COG): Free Stock Analysis Report XEROX CORP (XRX): Free Stock Analysis Report JOHNSON CONTROL (JCI): Free Stock Analysis Report To read this article on Zacks.com click here. Today, you can download 7 Best Stocks for the Next 30 Days. | • AbbVie Inc.'s ( ABBV ) shares declined 3.5% after posting second quarter revenues of $5.475 billion, missing the Zacks Consensus Estimate of $5.605 billion • Shares of Cabot Oil & Gas Corporation ( COG ) dropped 4% after reporting second quarter adjusted earnings per share of $0.02, a couple of cents lower than the Zacks Consensus Estimate • Xerox Corporation's ( XRX ) shares gained 1.2% after announcing fiscal first quarter revenues of $4,590 million, beating the Zacks Consensus Estimate of $4,581 million • Shares of Johnson Controls Inc. ( JCI ) decreased 4.5% after reporting third quarter revenues of $9.61 billion, down 2.3% year over year Want the latest recommendations from Zacks Investment Research? Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report CABOT OIL & GAS (COG): Free Stock Analysis Report XEROX CORP (XRX): Free Stock Analysis Report JOHNSON CONTROL (JCI): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • AbbVie Inc.'s ( ABBV ) shares declined 3.5% after posting second quarter revenues of $5.475 billion, missing the Zacks Consensus Estimate of $5.605 billion • Shares of Cabot Oil & Gas Corporation ( COG ) dropped 4% after reporting second quarter adjusted earnings per share of $0.02, a couple of cents lower than the Zacks Consensus Estimate • Xerox Corporation's ( XRX ) shares gained 1.2% after announcing fiscal first quarter revenues of $4,590 million, beating the Zacks Consensus Estimate of $4,581 million • Shares of Johnson Controls Inc. ( JCI ) decreased 4.5% after reporting third quarter revenues of $9.61 billion, down 2.3% year over year Want the latest recommendations from Zacks Investment Research? Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report CABOT OIL & GAS (COG): Free Stock Analysis Report XEROX CORP (XRX): Free Stock Analysis Report JOHNSON CONTROL (JCI): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • AbbVie Inc.'s ( ABBV ) shares declined 3.5% after posting second quarter revenues of $5.475 billion, missing the Zacks Consensus Estimate of $5.605 billion • Shares of Cabot Oil & Gas Corporation ( COG ) dropped 4% after reporting second quarter adjusted earnings per share of $0.02, a couple of cents lower than the Zacks Consensus Estimate • Xerox Corporation's ( XRX ) shares gained 1.2% after announcing fiscal first quarter revenues of $4,590 million, beating the Zacks Consensus Estimate of $4,581 million • Shares of Johnson Controls Inc. ( JCI ) decreased 4.5% after reporting third quarter revenues of $9.61 billion, down 2.3% year over year Want the latest recommendations from Zacks Investment Research? Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report CABOT OIL & GAS (COG): Free Stock Analysis Report XEROX CORP (XRX): Free Stock Analysis Report JOHNSON CONTROL (JCI): Free Stock Analysis Report To read this article on Zacks.com click here. Today, you can download 7 Best Stocks for the Next 30 Days. |
26888.0 | 2015-07-27 00:00:00 UTC | Noteworthy Monday Option Activity: ABBV, ETFC, CAG | ABBV | https://www.nasdaq.com/articles/noteworthy-monday-option-activity-abbv-etfc-cag-2015-07-27 | nan | nan | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc. (Symbol: ABBV), where a total of 109,107 contracts have traded so far, representing approximately 10.9 million underlying shares. That amounts to about 126.9% of ABBV's average daily trading volume over the past month of 8.6 million shares. Especially high volume was seen for the $72.50 strike call option expiring November 20, 2015 , with 30,793 contracts trading so far today, representing approximately 3.1 million underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $72.50 strike highlighted in orange:
ETFC (Symbol: ETFC) saw options trading volume of 21,118 contracts, representing approximately 2.1 million underlying shares or approximately 65.1% of ETFC's average daily trading volume over the past month, of 3.2 million shares. Particularly high volume was seen for the $33 strike call option expiring October 16, 2015 , with 10,206 contracts trading so far today, representing approximately 1.0 million underlying shares of ETFC. Below is a chart showing ETFC's trailing twelve month trading history, with the $33 strike highlighted in orange:
And ConAgra Foods, Inc. (Symbol: CAG) options are showing a volume of 25,376 contracts thus far today. That number of contracts represents approximately 2.5 million underlying shares, working out to a sizeable 61.7% of CAG's average daily trading volume over the past month, of 4.1 million shares. Particularly high volume was seen for the $35 strike call option expiring September 18, 2015 , with 8,402 contracts trading so far today, representing approximately 840,200 underlying shares of CAG. Below is a chart showing CAG's trailing twelve month trading history, with the $35 strike highlighted in orange:
For the various different available expirations for ABBV options , ETFC options , or CAG options , visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Especially high volume was seen for the $72.50 strike call option expiring November 20, 2015 , with 30,793 contracts trading so far today, representing approximately 3.1 million underlying shares of ABBV. Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc. (Symbol: ABBV), where a total of 109,107 contracts have traded so far, representing approximately 10.9 million underlying shares. That amounts to about 126.9% of ABBV's average daily trading volume over the past month of 8.6 million shares. | Especially high volume was seen for the $72.50 strike call option expiring November 20, 2015 , with 30,793 contracts trading so far today, representing approximately 3.1 million underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $72.50 strike highlighted in orange: ETFC (Symbol: ETFC) saw options trading volume of 21,118 contracts, representing approximately 2.1 million underlying shares or approximately 65.1% of ETFC's average daily trading volume over the past month, of 3.2 million shares. Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc. (Symbol: ABBV), where a total of 109,107 contracts have traded so far, representing approximately 10.9 million underlying shares. | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc. (Symbol: ABBV), where a total of 109,107 contracts have traded so far, representing approximately 10.9 million underlying shares. Below is a chart showing ABBV's trailing twelve month trading history, with the $72.50 strike highlighted in orange: ETFC (Symbol: ETFC) saw options trading volume of 21,118 contracts, representing approximately 2.1 million underlying shares or approximately 65.1% of ETFC's average daily trading volume over the past month, of 3.2 million shares. That amounts to about 126.9% of ABBV's average daily trading volume over the past month of 8.6 million shares. | Especially high volume was seen for the $72.50 strike call option expiring November 20, 2015 , with 30,793 contracts trading so far today, representing approximately 3.1 million underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $72.50 strike highlighted in orange: ETFC (Symbol: ETFC) saw options trading volume of 21,118 contracts, representing approximately 2.1 million underlying shares or approximately 65.1% of ETFC's average daily trading volume over the past month, of 3.2 million shares. Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc. (Symbol: ABBV), where a total of 109,107 contracts have traded so far, representing approximately 10.9 million underlying shares. |
26889.0 | 2015-07-24 00:00:00 UTC | AbbVie Tops Earnings, Misses on Revenues, Maintains View - Analyst Blog | ABBV | https://www.nasdaq.com/articles/abbvie-tops-earnings-misses-revenues-maintains-view-analyst-blog-2015-07-24 | nan | nan | AbbVie Inc.ABBV reported second quarter 2015 earnings of $1.08 per share, up 31.7% from the year-ago quarter and surpassing the Zacks Consensus Estimate of $1.06.
Abbvie Inc. - Earnings Surprise | FindTheBest
Revenues increased 11.1% to $5.475 billion in the second quarter of 2015, missing the Zacks Consensus Estimate of $5.605 billion.
The Quarter in Details
Key drug Humira recorded growth of 7.6% with revenues coming in at $3.5 billion. U.S. sales increased 28.9% ($2.1 billion) driven by double-digit growth across all three major market categories: rheumatology, dermatology and gastroenterology. Ex-U.S. sales declined 14.3% to $1.4 billion, impacted by negative currency movement as well as the timing of shipments. Growing awareness, favorable clinical data, additional indications and expansion into new markets should help the product to continue contributing significantly to the top-line.
Other products that performed well include Lupron (up 6.5% to $198 million), Synthroid (up 11.9% to $187 million) and Creon (up 44.6% to $159 million). HCV product Viekira recorded sales of $385 million, up from $231 million in the first quarter of 2015.
AbbVie recorded Imbruvica U.S. sales of $97 million and $10 million of international profit sharing following the late May closing of the Pharmacyclics acquisition. Imbruvica sales in the second quarter were $234 million in the U.S.
Meanwhile, products like AndroGel and Kaletra (HIV) recorded a decline in revenues. While AndroGel 1% is facing generic competition, Kaletra was most likely impacted by negative market trends.
Maintains Outlook
AbbVie maintained its earnings guidance to $4.10 to $4.30 per share. The Zacks Consensus Estimate of $4.26 is within the guidance range.
Our Take
Although AbbVie's second quarter earnings surpassed expectations, the revenue miss is disappointing. AbbVie is looking to reduce its dependence on Humira and the launch of Viekira is a step in this direction.
Moreover, the Pharmacyclics acquisition added Imbruvica to AbbVie's portfolio and diversified the company's revenue base. Imbruvica, currently approved for four indications, has multi-billion dollar potential and the company is exploring the potential to expand Imbruvica's label into solid tumors and autoimmune diseases.
AbbVie is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include AMAG Pharmaceuticals, Inc. AMAG , Ligand Pharmaceuticals Incorporated LGND and NewLink Genetics Corp. NLNK . All three are Zacks Rank #1 (Strong Buy) stocks.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report > >
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBVIE INC (ABBV): Free Stock Analysis Report
AMAG PHARMA INC (AMAG): Free Stock Analysis Report
LIGAND PHARMA-B (LGND): Free Stock Analysis Report
NEWLINK GENETIC (NLNK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Moreover, the Pharmacyclics acquisition added Imbruvica to AbbVie's portfolio and diversified the company's revenue base. AbbVie Inc.ABBV reported second quarter 2015 earnings of $1.08 per share, up 31.7% from the year-ago quarter and surpassing the Zacks Consensus Estimate of $1.06. Abbvie Inc. - Earnings Surprise | FindTheBest Revenues increased 11.1% to $5.475 billion in the second quarter of 2015, missing the Zacks Consensus Estimate of $5.605 billion. | Abbvie Inc. - Earnings Surprise | FindTheBest Revenues increased 11.1% to $5.475 billion in the second quarter of 2015, missing the Zacks Consensus Estimate of $5.605 billion. Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report NEWLINK GENETIC (NLNK): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV reported second quarter 2015 earnings of $1.08 per share, up 31.7% from the year-ago quarter and surpassing the Zacks Consensus Estimate of $1.06. | AbbVie Inc.ABBV reported second quarter 2015 earnings of $1.08 per share, up 31.7% from the year-ago quarter and surpassing the Zacks Consensus Estimate of $1.06. Abbvie Inc. - Earnings Surprise | FindTheBest Revenues increased 11.1% to $5.475 billion in the second quarter of 2015, missing the Zacks Consensus Estimate of $5.605 billion. Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report NEWLINK GENETIC (NLNK): Free Stock Analysis Report To read this article on Zacks.com click here. | AbbVie Inc.ABBV reported second quarter 2015 earnings of $1.08 per share, up 31.7% from the year-ago quarter and surpassing the Zacks Consensus Estimate of $1.06. AbbVie is a Zacks Rank #3 (Hold) stock. Abbvie Inc. - Earnings Surprise | FindTheBest Revenues increased 11.1% to $5.475 billion in the second quarter of 2015, missing the Zacks Consensus Estimate of $5.605 billion. |
26890.0 | 2015-07-24 00:00:00 UTC | AbbVie (ABBV) Tops 2Q Earnings but Misses Revenues - Tale of the Tape | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-tops-2q-earnings-but-misses-revenues-tale-of-the-tape-2015-07-24 | nan | nan | North Chicago, IL-based AbbVie ( ABBV ), which has been in the news thanks to its hepatitis C virus (HCV) treatment Viekira Pak as well as its acquisition of Pharmacyclics, is best known for its autoimmune disease drug, Humira.
Humira, the company's flagship product which is approved for a wide range of indications, is a major contributor to AbbVie's top line. While Humira will remain the key growth driver at AbbVie, the coming quarters will see investor focus remaining primarily on Viekira's performance. Key players in the HCV market include Gilead's Sovaldi and Harvoni.
Meanwhile, the Pharmacyclics acquisition has diversified AbbVie's product portfolio with the addition of Imbruvica.
ABBV has a pretty good earnings track record with the company delivering positive earnings surprises in the last four quarters with an average surprise of 9.65%. Estimate revisions are mostly positive with analysts raising their estimates for 2015.
Currently, ABBV has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: ABBV beat on second quarter earnings by a couple of cents. The company reported EPS of $1.08 while our consensus called for EPS of $1.06.
Revenues Miss: AbbVie posted revenues of $5.475 billion, missing consensus estimates of $5.605 billion.
Key Stats: Humira sales came in at $3.5 billion. Viekira Pak delivered sales of $385 million, up from $231 million reported in the previous quarter. Second-quarter Imbruvica sales in the U.S. were $234 million with the company recording partial sales following its late May acquisition of Pharmacyclics.
Stock Price: Shares declined 1.45% in pre-market trading following the release.
Check back later for our full write up on this ABBV earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | North Chicago, IL-based AbbVie ( ABBV ), which has been in the news thanks to its hepatitis C virus (HCV) treatment Viekira Pak as well as its acquisition of Pharmacyclics, is best known for its autoimmune disease drug, Humira. Humira, the company's flagship product which is approved for a wide range of indications, is a major contributor to AbbVie's top line. Currently, ABBV has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. | Revenues Miss: AbbVie posted revenues of $5.475 billion, missing consensus estimates of $5.605 billion. Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. North Chicago, IL-based AbbVie ( ABBV ), which has been in the news thanks to its hepatitis C virus (HCV) treatment Viekira Pak as well as its acquisition of Pharmacyclics, is best known for its autoimmune disease drug, Humira. | ABBV has a pretty good earnings track record with the company delivering positive earnings surprises in the last four quarters with an average surprise of 9.65%. Currently, ABBV has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. | Meanwhile, the Pharmacyclics acquisition has diversified AbbVie's product portfolio with the addition of Imbruvica. Currently, ABBV has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. North Chicago, IL-based AbbVie ( ABBV ), which has been in the news thanks to its hepatitis C virus (HCV) treatment Viekira Pak as well as its acquisition of Pharmacyclics, is best known for its autoimmune disease drug, Humira. |
26891.0 | 2015-07-24 00:00:00 UTC | Earnings Reaction History: AbbVie Inc., 44.4% Follow-Through Indicator, 2.0% Sensitive | ABBV | https://www.nasdaq.com/articles/earnings-reaction-history-abbvie-inc-444-follow-through-indicator-20-sensitive-2015-07-24 | nan | nan | Expected Earnings Release: 07/24/2015, Premarket
Avg. Extended-Hours Dollar Volume: $4,355,834
AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement. Historical earnings event related premarket and after-hours trading activity in ABBV indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close.
Last 12 Qtrs Positive Only Price Reactions
Percent of time added to extended-hours gains: 37.5%
Average next regular session additional gain: 2.4%
Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 37.5% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.4%.
Last 12 Qtrs Negative Only Price Reactions
Percent of time added to extended-hours losses: 100%
Average next regular session additional loss: 0.3%
Over that same historical period, when shares of ABBV dropped in the extended-hours in reaction to its earnings announcement, history shows that 100.0% of the time (1 event) the stock dropped further, adding to the extended-hours losses by an average of 0.3% by the following regular session close.
Data provided by the MT Pro service at MTNewswires.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 37.5% Average next regular session additional gain: 2.4% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 37.5% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.4%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 100% Average next regular session additional loss: 0.3% Over that same historical period, when shares of ABBV dropped in the extended-hours in reaction to its earnings announcement, history shows that 100.0% of the time (1 event) the stock dropped further, adding to the extended-hours losses by an average of 0.3% by the following regular session close. Extended-Hours Dollar Volume: $4,355,834 AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 37.5% Average next regular session additional gain: 2.4% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 37.5% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.4%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 100% Average next regular session additional loss: 0.3% Over that same historical period, when shares of ABBV dropped in the extended-hours in reaction to its earnings announcement, history shows that 100.0% of the time (1 event) the stock dropped further, adding to the extended-hours losses by an average of 0.3% by the following regular session close. Extended-Hours Dollar Volume: $4,355,834 AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 37.5% Average next regular session additional gain: 2.4% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 37.5% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.4%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 100% Average next regular session additional loss: 0.3% Over that same historical period, when shares of ABBV dropped in the extended-hours in reaction to its earnings announcement, history shows that 100.0% of the time (1 event) the stock dropped further, adding to the extended-hours losses by an average of 0.3% by the following regular session close. Extended-Hours Dollar Volume: $4,355,834 AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Extended-Hours Dollar Volume: $4,355,834 AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 37.5% Average next regular session additional gain: 2.4% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 37.5% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.4%. Historical earnings event related premarket and after-hours trading activity in ABBV indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close. |
26892.0 | 2015-07-24 00:00:00 UTC | AbbVie's Investments Begin Kicking In | ABBV | https://www.nasdaq.com/articles/abbvies-investments-begin-kicking-2015-07-24 | nan | nan | Source: AbbVie.
AbbVie Inc .'s investments to offset the impact of lost sales tied to expiring patent protection on Humira in 2017 include a big push into hepatitis C and its $21 billion acquisition of the cancer drugmaker Pharmacyclics earlier this year.
Because AbbVie's first hep C drug -- Viekira Pak -- won approval in December, and its Pharmacyclics acquisition closed in May, the company's second-quarter results offer investors an important glimpse into whether the company's spending is starting to pay off.
New kids on the block
Although Viekira Pak's $231 million in first-quarter sales fell far short of the billions of dollars in sales put up by Gilead Sciences ' hepatitis C drugs Sovaldi and Harvoni during their first quarters on the market, AbbVie investors still expect Viekira Pak to become a blockbuster drug -- something that should happen this year given that AbbVie sold $385 million worth of Viekira Pak in the second quarter.
In addition to delivering 67% quarter-over-quarter sales growth for Viekira Pak, AbbVie also recorded solid sales from Imbruvica, the blood cancer drug it acquired when it bought Pharmacyclics. AbbVie and Imbruvica co-developer Johnson & Johnson split global profit on Imbruvica evenly, and in the second quarter, AbbVie's share of Imbruvica's profits totaled $107 million, including $97 million from U.S. sales and $10 million from international sales. That was well above the $56 million in pre-tax profit reported by Pharmacyclics in the first quarter.
That's pretty impressive, but expectations for greater use and label expansion have industry watchers thinking Imbruvica's peak sales opportunity could be as high as $3.6 billion. If so, then AbbVie could be in a position to deliver much larger profit from Imbruvica in the future.
Source: AbbVie.
Filling the gap
In Q2, Humira's $3.5 billion in sales represented 64% of AbbVie's total revenue, and that means Humira sales won't be easily replaced.
Viekira Pak and Imbruvica will likely take some of the sting out of losing patent protection on Humira in 2016, but AbbVie still needs sales growth from its other drugs, too.
That means AbbVie's other fast-growing drugs will need to keep putting up solid results, including Creon, which, aside from Viekira Pak, was AbbVie's fastest-growing drug last quarter.
Sales of Creon, a pancreatic enzyme replacement therapy, increased 44.6% year over year to $159 million last quarter. AbbVie also reported that Lupron's $198 million in sales and Synthroid's $187 million in sales grew by 9.9% and 11.9% versus last year, respectively.
It also means AbbVie's R&D team needs to deliver more top sellers, including venetoclax, a treatment for CLL patients that have a specific gene mutation. AbbVie and its development partners expect to file for approval of venetoclax by the end of this year. AbbVie also plans to file for the approval of its multiple myeloma drug elotuzumab as an adjunct therapy to chemotherapy in both first-line and relapsing patients this year. The company could also get a FDA green light for Zinbryta, a multiple sclerosis drug, and a go-ahead for its next-generation hepatitis C drugs soon.
If all of this pipeline activity pans out, these drugs could begin contributing to sales before Humira's patent expires.
Looking ahead
AbbVie estimates Viekira Pak will close out 2015 at an annualized sales run rate of roughly $3 billion, and that its various oncology programs could yield drugs with peak annual sales of $15 billion. Toss in sales from other drugs in its pipeline, such as Zinbryta, and AbbVie could be in a position to offset the generic threat to Humira.
However, research shows that peak sales projections are often massively incorrect and that promising drugs -- even those in late-stage trials -- often fail and for that reason. AbbVie is still risky relative to other large-cap biopharma stocks, and that means investors should approach it cautiously.
This $19 trillion industry could destroy the Internet
One bleeding-edge technology is about to put the World Wide Web to bed. And if you act quickly, you could be among the savvy investors who enjoy the profits from this stunning change. Experts are calling it the single largest business opportunity in the history of capitalism... The Economist is calling it "transformative"... but you'll probably just call it "how I made my millions." Don't be too late to the party -- click here for one stock to own when the Web goes dark.
The article AbbVie's Investments Begin Kicking In originally appeared on Fool.com.
Todd Campbell owns shares of Gilead Sciences. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days .We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Source: AbbVie. AbbVie also plans to file for the approval of its multiple myeloma drug elotuzumab as an adjunct therapy to chemotherapy in both first-line and relapsing patients this year. AbbVie Inc . | Source: AbbVie. In addition to delivering 67% quarter-over-quarter sales growth for Viekira Pak, AbbVie also recorded solid sales from Imbruvica, the blood cancer drug it acquired when it bought Pharmacyclics. AbbVie and Imbruvica co-developer Johnson & Johnson split global profit on Imbruvica evenly, and in the second quarter, AbbVie's share of Imbruvica's profits totaled $107 million, including $97 million from U.S. sales and $10 million from international sales. | Source: AbbVie. New kids on the block Although Viekira Pak's $231 million in first-quarter sales fell far short of the billions of dollars in sales put up by Gilead Sciences ' hepatitis C drugs Sovaldi and Harvoni during their first quarters on the market, AbbVie investors still expect Viekira Pak to become a blockbuster drug -- something that should happen this year given that AbbVie sold $385 million worth of Viekira Pak in the second quarter. AbbVie and Imbruvica co-developer Johnson & Johnson split global profit on Imbruvica evenly, and in the second quarter, AbbVie's share of Imbruvica's profits totaled $107 million, including $97 million from U.S. sales and $10 million from international sales. | Source: AbbVie. AbbVie Inc . AbbVie and Imbruvica co-developer Johnson & Johnson split global profit on Imbruvica evenly, and in the second quarter, AbbVie's share of Imbruvica's profits totaled $107 million, including $97 million from U.S. sales and $10 million from international sales. |
26893.0 | 2015-07-23 00:00:00 UTC | Celgene Rolling Along (but You Already Knew That) | ABBV | https://www.nasdaq.com/articles/celgene-rolling-along-you-already-knew-2015-07-23 | nan | nan | The big picture numbers when Celgene released second quarter earnings Thursday weren't surprising since the company pre-released its revenue and earnings when it announced the acquisition of Receptos last week.
But the details of where the growth is coming from are still helpful for investors to gauge Celgene's future.
As a reminder, Celgene produced $2,254 million in sales in the second quarter, a 22% year-over-year increase compared to the second quarter of 2014. Almost all of that growth came from an increase in volume. A modest 2.5% price increase was mostly offset by a negative effect from the stronger dollar.
Sales of Celgene's top-selling drug, Revlimid, increased 19% year over year thanks to the addition of sales as a first-line treatment for multiple myeloma, which was approved in February. Treating patients earlier helps with sales because there are more available patients and because treatment durations tend to be longer for newly diagnosed patients. The bump in sales from the new indication will continue into next year since Celgene is still setting up reimbursement for the new indication in Europe.
Pomalyst is on the verge of passing Abraxane for second place in sales thanks to a 46% increase in sales. Much of the sales growth came from international sales, where the launch had just began so sales were small in the year-ago quarter, but U.S. sales are also progressing nicely, jumping 38%. The addition of overall survival data to the drug's label should help grow sales further.
After about a year on the market in the U.S., Otezla's still aren't all that high -- just $85 million in the U.S. in the second quarter -- but that's to be expected given the crowded market. The launch actually looks pretty good compared to recent launches of other drugs to treat autoimmune diseases.
Celgene recently started direct-to-consumer advertisements as it goes after AbbVie 's Humira. Only 14% of new patients are coming off of biologics, such as Humira, so there's plenty of potential to capture more of the market share, which sits at just under 20% of patients.
Adjusted earnings, which adds back upfront collaboration expenses and share-based compensation, came in at $1.23 per share. If you subtract out $0.06 for a one-time investment gain, adjusted earnings per share were still 30% higher than the $0.90 per share seen in the second quarter of 2014.
Most of the discrepancy in the 22% revenue growth and the 30% earnings growth comes from reduced expenses, which helped increase Celgene's operating margin by 100 basis points. A lower share count thanks to the share buyback -- $900 million of repurchases in the second quarter alone -- also helped grow the earnings per share number. The buyback will continue to be a growth driver with $5.1 billion remaining on the board's buyback authorization.
Celgene raised its guidance for adjusted earnings per share for this year to between $4.75-$4.85 from the previous range of $4.60-$4.75. If it hits the midpoint of the new guidance, year-over-year growth will be approximately 29% above 2014 adjusted diluted EPS. The increasing in guidance is especially impressive considering the company will be incorporating Receptos' research and development expenses and interest expenses on the loan Celgene will take out to help pay for the acquisition that will close later this year.
This $19 trillion industry could destroy the Internet
One bleeding-edge technology is about to put the World Wide Web to bed. And if you act quickly, you could be among the savvy investors who enjoy the profits from this stunning change. Experts are calling it the single largest business opportunity in the history of capitalism... The Economist is calling it "transformative"... But you'll probably just call it "how I made my millions." Don't be too late to the party -- click here for one stock to own when the Web goes dark.
The article Celgene Rolling Along (but You Already Knew That) originally appeared on Fool.com.
Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Celgene recently started direct-to-consumer advertisements as it goes after AbbVie 's Humira. Adjusted earnings, which adds back upfront collaboration expenses and share-based compensation, came in at $1.23 per share. Celgene raised its guidance for adjusted earnings per share for this year to between $4.75-$4.85 from the previous range of $4.60-$4.75. | Celgene recently started direct-to-consumer advertisements as it goes after AbbVie 's Humira. Sales of Celgene's top-selling drug, Revlimid, increased 19% year over year thanks to the addition of sales as a first-line treatment for multiple myeloma, which was approved in February. Most of the discrepancy in the 22% revenue growth and the 30% earnings growth comes from reduced expenses, which helped increase Celgene's operating margin by 100 basis points. | Celgene recently started direct-to-consumer advertisements as it goes after AbbVie 's Humira. As a reminder, Celgene produced $2,254 million in sales in the second quarter, a 22% year-over-year increase compared to the second quarter of 2014. Sales of Celgene's top-selling drug, Revlimid, increased 19% year over year thanks to the addition of sales as a first-line treatment for multiple myeloma, which was approved in February. | Celgene recently started direct-to-consumer advertisements as it goes after AbbVie 's Humira. Much of the sales growth came from international sales, where the launch had just began so sales were small in the year-ago quarter, but U.S. sales are also progressing nicely, jumping 38%. A lower share count thanks to the share buyback -- $900 million of repurchases in the second quarter alone -- also helped grow the earnings per share number. |
26894.0 | 2015-07-23 00:00:00 UTC | Will AbbVie (ABBV) Surprise on Earnings Again in Q2? - Analyst Blog | ABBV | https://www.nasdaq.com/articles/will-abbvie-abbv-surprise-earnings-again-q2-analyst-blog-2015-07-23 | nan | nan | AbbVieABBV , which has been in the news thanks to its hepatitis C virus (HCV) treatment Viekira Pak as well as its acquisition of Pharmacyclics, will be reporting second quarter 2015 earnings results on Jul 24, before the market opens.
AbbVie's performance has been pretty impressive with the company beating earnings expectations consistently. The average earnings surprise over the last four quarters is 9.65%.
Humira, Imbruvica and Viekira in Focus
Key drug Humira should remain the main growth driver in the second quarter; growing awareness, strong underlying demand, favorable clinical data, additional indications and market share gains should help the product to continue contributing significantly to the top-line. Humira should witness mid-teens growth on an operational basis in 2015.
However, we expect investor focus to primarily remain on the sales ramp up of Viekira, which is expected to achieve a global annualized sales run rate of more than $3 billion by year end. On the first quarter call, AbbVie reported that the international launch is progressing faster than expected. The company expects a higher level of international sales in 2015 than originally expected.
Meanwhile, many of the company's contracts in the U.S. commenced in the April - May timeframe - these should begin to ramp in the second and third quarters and build up during the rest of the year.
Another focus area will be the performance of Imbruvica which was added to AbbVie's portfolio following its May 2015 acquisition of Pharmacyclics. Imbruvica, currently approved for four indications, has multi-billion dollar potential and the company is exploring the potential to expand Imbruvica's label into solid tumors and autoimmune diseases.
AbbVie is positioning Imbruvica as a "pipeline in a molecule" -- the treatment is in more than 60 studies. AbbVie expects Imbruvica peak sales of more than $7 billion and U.S. sales of $1 billion in 2015. Imbruvica is partnered with Johnson & Johnson JNJ , which recorded second quarter Imbruvica sales of $154 million.
The Duopa launch should get underway in the second and third quarters and sales should ramp up eventually as physicians grow familiar with the product.
Other products include Synagis, AndroGel and the lipid franchise. Synagis, which protects at-risk infants from severe respiratory disease, is a seasonal product with a major part of sales being recorded in the first and fourth quarters of the year. As a result, second quarter sales could be weak. Both AndroGel and lipid franchise sales should decline given the presence of generic competition. Negative market trends will impact HIV sales also. Currency movement will remain a headwind.
What Our Model Indicates
Our proven model does not conclusively show that AbbVie is likely to beat earnings. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank of #1, 2 or 3 for this to happen. That is not the case here as you will see below.
Zacks ESP : Earnings Surprise Prediction or Earnings ESP , which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00%. Both the Most Accurate estimate and the Zacks Consensus Estimate for AbbVie are $1.06, at the higher end of the company's guidance range of $1.04 to $1.06 per share.
Zacks Rank #3 (Hold) : Note that stocks with Zacks Ranks of #1, #2 and #3 have a significantly higher chance of beating earnings. The sell-rated stocks (#4 and #5) should never be considered going into an earnings announcement.
The combination of AbbVie's Zacks Rank #3 and 0.00% ESP does not conclusively point to a positive surprise on Jul 24.
Stocks That Warrant a Look
Here are some health care stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
The Medicines Company MDCO has an Earnings ESP of +125% and carries a Zacks Rank #2 (Buy). It is expected to report results on Jul 29.
The Earnings ESP for Cytokinetics, Inc. CYTK is +10.71% and it carries a Zacks Rank #3. The company is also scheduled to release results on Jul 29.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBVIE INC (ABBV): Free Stock Analysis Report
MEDICINES CO (MDCO): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
CYTOKINETCS INC (CYTK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVieABBV , which has been in the news thanks to its hepatitis C virus (HCV) treatment Viekira Pak as well as its acquisition of Pharmacyclics, will be reporting second quarter 2015 earnings results on Jul 24, before the market opens. AbbVie's performance has been pretty impressive with the company beating earnings expectations consistently. On the first quarter call, AbbVie reported that the international launch is progressing faster than expected. | Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVieABBV , which has been in the news thanks to its hepatitis C virus (HCV) treatment Viekira Pak as well as its acquisition of Pharmacyclics, will be reporting second quarter 2015 earnings results on Jul 24, before the market opens. AbbVie's performance has been pretty impressive with the company beating earnings expectations consistently. | Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVieABBV , which has been in the news thanks to its hepatitis C virus (HCV) treatment Viekira Pak as well as its acquisition of Pharmacyclics, will be reporting second quarter 2015 earnings results on Jul 24, before the market opens. AbbVie's performance has been pretty impressive with the company beating earnings expectations consistently. | The combination of AbbVie's Zacks Rank #3 and 0.00% ESP does not conclusively point to a positive surprise on Jul 24. AbbVieABBV , which has been in the news thanks to its hepatitis C virus (HCV) treatment Viekira Pak as well as its acquisition of Pharmacyclics, will be reporting second quarter 2015 earnings results on Jul 24, before the market opens. AbbVie's performance has been pretty impressive with the company beating earnings expectations consistently. |
26895.0 | 2015-07-23 00:00:00 UTC | Pre-Market Earnings Report for July 24, 2015 : ABBV, BIIB, SPG, STT, VFC, JCI, AAL, MCO, VTR, DTE, XRX, COL | ABBV | https://www.nasdaq.com/articles/pre-market-earnings-report-july-24-2015-abbv-biib-spg-stt-vfc-jci-aal-mco-vtr-dte-xrx-col | nan | nan | The following companies are expected to report earnings prior to market open on 07/24/2015. Visit our Earnings Calendar for a full list of expected earnings releases.
AbbVie Inc. ( ABBV ) is reporting for the quarter ending June 30, 2015. The large cap pharmaceutical company's consensus earnings per share forecast from the 6 analysts that follow the stock is $1.06. This value represents a 29.27% increase compared to the same quarter last year. In the past year ABBV has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 11.9%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABBV is 16.52 vs. an industry ratio of 14.60, implying that they will have a higher earnings growth than their competitors in the same industry.
Biogen Inc. ( BIIB ) is reporting for the quarter ending June 30, 2015. The biomedical (gene) company's consensus earnings per share forecast from the 11 analysts that follow the stock is $4.07. This value represents a 16.62% increase compared to the same quarter last year. BIIB missed the consensus earnings per share in the 1st calendar quarter of 2015 by -2.3%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for BIIB is 23.57 vs. an industry ratio of -30.10, implying that they will have a higher earnings growth than their competitors in the same industry.
Simon Property Group, Inc. ( SPG ) is reporting for the quarter ending June 30, 2015. The reit company's consensus earnings per share forecast from the 10 analysts that follow the stock is $2.35. This value represents a 8.80% increase compared to the same quarter last year. SPG missed the consensus earnings per share in the 3rd calendar quarter of 2014 by -5.94%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for SPG is 18.69 vs. an industry ratio of 15.30, implying that they will have a higher earnings growth than their competitors in the same industry.
State Street Corporation ( STT ) is reporting for the quarter ending June 30, 2015. The bank company's consensus earnings per share forecast from the 19 analysts that follow the stock is $1.37. This value represents a 1.44% decrease compared to the same quarter last year. In the past year STT has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 11.43%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for STT is 15.37 vs. an industry ratio of 15.00, implying that they will have a higher earnings growth than their competitors in the same industry.
V.F. Corporation ( VFC ) is reporting for the quarter ending June 30, 2015. The textile company's consensus earnings per share forecast from the 20 analysts that follow the stock is $0.36. This value represents a no change for the same quarter last year. Zacks Investment Research reports that the 2015 Price to Earnings ratio for VFC is 23.11 vs. an industry ratio of 22.10, implying that they will have a higher earnings growth than their competitors in the same industry.
Johnson Controls, Inc. ( JCI ) is reporting for the quarter ending June 30, 2015. The auto (truck) company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.90. This value represents a 7.14% increase compared to the same quarter last year. JCI missed the consensus earnings per share in the 1st calendar quarter of 2015 by -1.35%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for JCI is 13.74 vs. an industry ratio of 15.20.
American Airlines Group, Inc. ( AAL ) is reporting for the quarter ending June 30, 2015. The airline company's consensus earnings per share forecast from the 10 analysts that follow the stock is $2.59. This value represents a 30.81% increase compared to the same quarter last year. In the past year AAL has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 1.76%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for AAL is 4.59 vs. an industry ratio of 11.10.
Moody's Corporation ( MCO ) is reporting for the quarter ending June 30, 2015. The financial services company's consensus earnings per share forecast from the 7 analysts that follow the stock is $1.19. This value represents a 6.25% increase compared to the same quarter last year. In the past year MCO has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 7.77%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for MCO is 24.38 vs. an industry ratio of 2.20, implying that they will have a higher earnings growth than their competitors in the same industry.
Ventas, Inc. ( VTR ) is reporting for the quarter ending June 30, 2015. The reit company's consensus earnings per share forecast from the 6 analysts that follow the stock is $1.16. This value represents a 3.57% increase compared to the same quarter last year. VTR missed the consensus earnings per share in the 2nd calendar quarter of 2014 by -0.93%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for VTR is 13.56 vs. an industry ratio of 17.50.
DTE Energy Company ( DTE ) is reporting for the quarter ending June 30, 2015. The electric power utilities company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.84. This value represents a 15.07% increase compared to the same quarter last year. Zacks Investment Research reports that the 2015 Price to Earnings ratio for DTE is 16.73 vs. an industry ratio of 27.70.
Xerox Corporation ( XRX ) is reporting for the quarter ending June 30, 2015. The business services company's consensus earnings per share forecast from the 2 analysts that follow the stock is $0.23. This value represents a 14.81% decrease compared to the same quarter last year. In the past year XRX has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2015 Price to Earnings ratio for XRX is 10.92 vs. an industry ratio of 89.00.
Rockwell Collins, Inc. ( COL ) is reporting for the quarter ending June 30, 2015. The aerospace and defense company's consensus earnings per share forecast from the 9 analysts that follow the stock is $1.31. This value represents a 10.08% increase compared to the same quarter last year. COL missed the consensus earnings per share in the 4th calendar quarter of 2014 by -1.79%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for COL is 16.71 vs. an industry ratio of -31.90, implying that they will have a higher earnings growth than their competitors in the same industry.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc. ( ABBV ) is reporting for the quarter ending June 30, 2015. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABBV is 16.52 vs. an industry ratio of 14.60, implying that they will have a higher earnings growth than their competitors in the same industry. | Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABBV is 16.52 vs. an industry ratio of 14.60, implying that they will have a higher earnings growth than their competitors in the same industry. AbbVie Inc. ( ABBV ) is reporting for the quarter ending June 30, 2015. In the past year ABBV has beat the expectations every quarter. | Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABBV is 16.52 vs. an industry ratio of 14.60, implying that they will have a higher earnings growth than their competitors in the same industry. AbbVie Inc. ( ABBV ) is reporting for the quarter ending June 30, 2015. In the past year ABBV has beat the expectations every quarter. | In the past year ABBV has beat the expectations every quarter. AbbVie Inc. ( ABBV ) is reporting for the quarter ending June 30, 2015. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABBV is 16.52 vs. an industry ratio of 14.60, implying that they will have a higher earnings growth than their competitors in the same industry. |
26896.0 | 2015-07-22 00:00:00 UTC | Zacks Industry Outlook Highlights: AbbVie, Allergan, Pfizer, Juno and Johnson & Johnson - Press Releases | ABBV | https://www.nasdaq.com/articles/zacks-industry-outlook-highlights%3A-abbvie-allergan-pfizer-juno-and-johnson-johnson-press | nan | nan | For Immediate Release
Chicago, IL - July 22, 2015 - Today, Zacks Equity Research discusses the Pharmaceuticals, including AbbVie ( ABBV ), Allergan ( AGN ), Pfizer ( PFE ), Juno ( JUNO ) and Johnson & Johnson ( JNJ ).
Industry: Pharmaceuticals
Link: http://www.zacks.com/commentary/51621/pharma-stock-outlook---july-2015
Deals & New Products in Focus
Mergers, acquisitions and deals continue to take center-stage in the pharma sector. While 2014 turned out to be one of the most active years in the pharma sector where mergers and acquisitions (M&As) and licensing agreements are concerned, the trend continues this year as well.
M&As Continue
Although tax inversion deals, which were being actively pursued earlier, have lost their luster considering new rules imposed by the Treasury Department, M&As continue to play a major role in the pharma and biotech sector and are not showing any signs of slowing down.
AbbVie's ( ABBV ) $21 billion acquisition of Pharmacyclics is one of the biggest deals to be announced in recent times. The deal goes to show that lofty valuations will not deter large companies from pursuing acquisitions to boost their pipelines and product portfolios. Other major deals include the ones involving Actavis - Allergan ( AGN ), Shire - NPS Pharmaceuticals, Endo - Auxilium, and Pfizer ( PFE ) - Hospira.
Meanwhile, we expect small bolt-on acquisitions to continue. In-licensing activities and collaborations for the development of pipeline candidates have also increased significantly. Several pharma companies are focusing on in-licensing mid-to-late stage pipeline candidates that look promising, instead of developing a product from scratch, which involves a lot of funds and time.
Small biotech companies are open to such deals -- most of these companies find it challenging to raise cash, thereby making it difficult for them to survive and continue with the development of promising pipeline candidates. Therefore, it makes sense for them to seek deals with pharma companies sitting on huge piles of cash.
We recommend biotech stocks that have attractive pipeline candidates or technology that can be used for the development of novel therapeutics. Therapeutic areas attracting a lot of interest include central nervous system disorders, diabetes and immunology/inflammation. For example, Celgene recently signed a $7.2 billion deal for the acquisition of Receptos that will strengthen its presence in the immune-inflammatory diseases market.
The hepatitis C virus (HCV) market is also attracting a lot of attention. Another lucrative area is immuno-oncology as these therapies have the potential to change the treatment paradigm for cancer -- they basically use the natural capability of the patient's own immune system to fight the cancer. Major players in this field include Bristol-Myers, AstraZeneca, Merck and Roche.
Deals targeting immuno-oncology are being inked by companies like Pfizer, Merck KGaA, Bristol-Myers, AstraZeneca and Incyte. Companies like Juno ( JUNO ) and Kite are also advancing in this area. While Celgene's immunotherapy deal with Juno, which is worth at least a billion dollars raised a few eyebrows given the high price tag, the deal just goes to show the growing interest in the field of immunotherapy.
Another trend being witnessed is the divestment of non-core business segments. Companies like Pfizer, Abbott, UCB, Novartis, GlaxoSmithKline and AstraZeneca have all been a part of this trend. The monetization of non-core assets allows these companies to focus on their areas of expertise.
Restructuring activities are also gaining momentum as large pharma companies look to cut costs and streamline operations. Most of these companies like Merck, Novartis, Eli Lilly, Shire and Sanofi are re-evaluating their pipelines and discontinuing programs with an unfavorable risk-benefit profile.
New Products Should Deliver
Highly-awaited new products that gained approval last year should contribute significantly to revenues. Gilead's HCV combination treatment, Harvoni, is expected to bring in multi-billion dollar sales for the company. The highly lucrative obesity market got a new player with Orexigen's Contrave gaining FDA approval. Meanwhile, it proved to be third time lucky for MannKind with the company finally gaining approval for diabetes product, Afrezza.
The FDA also said yes to Celgene's blockbuster hopeful Otezla and Amgen's leukemia drug, Blincyto. Products like Medivation's Xtandi and AbbVie's Imbruvica gained label expansions.
Other highly anticipated treatments like Opdivo (metastatic melanoma), Viekira (HCV), Esbriet (idiopathic pulmonary fibrosis), Keytruda (melanoma), Orbactiv and Dalvance (skin infections), and Zydelig (blood cancer) were among the 41 new molecular entities (NMEs) and Biologics License Applications (BLAs) approved last year.
Meanwhile, so far in 2015, the FDA has approved 17 NMEs and BLAs. Some of the important new product approvals this year include Vertex's cystic fibrosis treatment, Orkambi, Amgen's heart failure treatment, Corlanor, Pfizer's cancer treatment, Ibrance and Novartis' psoriasis treatment, Cosentyx. Key regulatory events coming up include the FDA's decision regarding the approval of Regeneron/Sanofi's PCSK9 inhibitor Praluent, Amgen's Kyprolis (cancer) and Repatha (PCSK9 inhibitor) and a few product label expansions.
Biosimilars in Focus
With the FDA approving the first biosimilar in the U.S. (Zarxio, a biosimilar version of Amgen's blockbuster drug, Neupogen), the floodgates have opened. While biosimilars have been available in the EU for quite a while, there was no regulatory pathway for biosimilars in the U.S.
Biosimilars should cut healthcare costs and provide a large number of patients with access to much needed biologic treatments. According to information provided by Express Scripts, about $250 billion could be saved in the next decade (2014 - 2024) if biosimilars for 11 products including Neupogen, Avastin, Epogen, Humira, Neulasta, Remicade and Rituxan are approved. According to the company, Neupogen biosimilars alone represent potential savings of about $5.7 billion.
However, at present, there is low visibility on the pricing of biosimilars in the U.S. Unlike generics, which are sometimes priced at even a 90% discount to the branded drug, biosimilars are usually sold at a 20%-30% discount to the price of the reference drug. So, it could be a while before biosimilar sales actually pick up and meet industry expectations.
Apart from Novartis, companies like Merck, Amgen, Hospira, Biogen and Allergan are targeting the highly lucrative biosimilars market.
Earnings Trends
The Q2 earnings season has just started for the Medical sector with Johnson & Johnson ( JNJ ) reporting better-than-expected results. Looking at consensus earnings expectations for 2Q, earnings in the Medical sector are expected to grow 7.2% and revenues 6.9%. While results will be affected by negative currency movement, new products should start contributing significantly to results and increased pipeline visibility and appropriate utilization of cash should increase confidence in the sector.
Overall, 2015 earnings are expected to grow 10.1% and revenues 7.4%. For a detailed look at the earnings outlook for the Medical and other sectors, please check our Zacks Earnings Trends report.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today . Find out What is happening in the stock market today on zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBVIE INC (ABBV): Free Stock Analysis Report
ALLERGAN PLC (AGN): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
JUNO THERAPEUTC (JUNO): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For Immediate Release Chicago, IL - July 22, 2015 - Today, Zacks Equity Research discusses the Pharmaceuticals, including AbbVie ( ABBV ), Allergan ( AGN ), Pfizer ( PFE ), Juno ( JUNO ) and Johnson & Johnson ( JNJ ). AbbVie's ( ABBV ) $21 billion acquisition of Pharmacyclics is one of the biggest deals to be announced in recent times. Products like Medivation's Xtandi and AbbVie's Imbruvica gained label expansions. | For Immediate Release Chicago, IL - July 22, 2015 - Today, Zacks Equity Research discusses the Pharmaceuticals, including AbbVie ( ABBV ), Allergan ( AGN ), Pfizer ( PFE ), Juno ( JUNO ) and Johnson & Johnson ( JNJ ). Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report ALLERGAN PLC (AGN): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report JUNO THERAPEUTC (JUNO): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie's ( ABBV ) $21 billion acquisition of Pharmacyclics is one of the biggest deals to be announced in recent times. | Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report ALLERGAN PLC (AGN): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report JUNO THERAPEUTC (JUNO): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. For Immediate Release Chicago, IL - July 22, 2015 - Today, Zacks Equity Research discusses the Pharmaceuticals, including AbbVie ( ABBV ), Allergan ( AGN ), Pfizer ( PFE ), Juno ( JUNO ) and Johnson & Johnson ( JNJ ). AbbVie's ( ABBV ) $21 billion acquisition of Pharmacyclics is one of the biggest deals to be announced in recent times. | For Immediate Release Chicago, IL - July 22, 2015 - Today, Zacks Equity Research discusses the Pharmaceuticals, including AbbVie ( ABBV ), Allergan ( AGN ), Pfizer ( PFE ), Juno ( JUNO ) and Johnson & Johnson ( JNJ ). AbbVie's ( ABBV ) $21 billion acquisition of Pharmacyclics is one of the biggest deals to be announced in recent times. Products like Medivation's Xtandi and AbbVie's Imbruvica gained label expansions. |
26897.0 | 2015-07-22 00:00:00 UTC | 2015’s Top 6 Big Pharma Headlines Thus Far | ABBV | https://www.nasdaq.com/articles/2015s-top-6-big-pharma-headlines-thus-far-2015-07-22 | nan | nan | The pharmaceutical industry has certainly gotten off to another wild start in 2015. Despite the year being only half over at this point, we've already seen dozens of high profile mergers, several closely-watched experimental drugs report pivotal top-line data, and a number of major developments on the regulatory front.
Source: Pixabay
Given that many of these events are likely to shape the investing landscape going forward, I think it's worth the time to briefly look back at the seven most significant headline-grabbing developments to date. So without further ado, here is a quick recap of what's happened thus far.
Wheeling and dealing
1. Pfizer helped to get the M&A ball rolling this year with its $17 billion buyout of Hospira for its portfolio of injected drugs and robust biosimilar pipeline. The deal came at a hefty 35% premium compared to where Hospira's shares were trading the day before the deal was announced, and it won't immediately add much in the way to Pfizer's top or bottom-lines. Even so, this deal should create value for Pfizer's shareholders in the long run as a hedge against the emerging biosimilar market, and perhaps as a means toward carving out a separate generics/legacy products business down the line.
2. AbbVie joined the M&A frenzy last March with its buyout of cancer drug specialist Pharmacyclics for a mind-boggling premium. Specifically, AbbVie paid a 40% premium for Pharmacyclics and its lead drug Imbruvica. What really caught people's eyes, however, was that AbbVie coughed up $21 billion for about $3 billion in peak revenue for Imbruvica, according to consensus estimates. In a nutshell, Imbruvica is expected to generate somewhere around $6 billion in peak sales by 2020, with roughly half of these sales going to Johnson & Johnson . Although most analysts savaged the deal, the Street has now pushed AbbVie's shares up almost 25% since this buyout was announced.
New classes of drugs are making their way to the market
3. Last June, an advisory committee for the FDA voted to recommend approval of an entirely new class of injected cholesterol lowering drugs known as PCSK9 inhibitors from Amgen and Sanofi/Regeneron , respectively.
The twist, though, was that the agency recommended that both drugs be approved for a far smaller patient population than originally intended -- at least until ongoing cardiovascular outcomes trials lend support to the hypothesis that they do indeed lower the risk of heart attacks and strokes. A decision on the drugs' regulatory fate in the U.S. is expected before the end of summer. That said, the FDA's European counterpart has already approved Amgen's drug, Repatha, although the details regarding the drug's label haven't been disclosed yet.
4. Bristol-Myers Squibb 's Opdivo is proving to be a game-changer in the fight against cancer. Bristol's PD-1 inhibitor Opdivo has been reporting some extremely impressive clinical trial data in various cancers such as advanced melanoma, liver, lung, and most recently, metastatic kidney cancer in the second-line setting. In short, there is a good chance this immuno-therapy could achieve some of the loftier peak sales estimates floating around the Street at present that top the $6 billion mark.
A strong dollar and payer push back are negative headwinds facing the industry
5. A recurring theme throughout Big Pharma this year has been the negative impact of a strong dollar on earnings. Johnson & Johnson, for instance, saw a noteworthy 7.9% decline in revenue in the second-quarter, from a year ago, due to negative currency exchange rates. The hope among J&J's management is that the dollar's heyday has already peaked, easing some of this pressure from FX in subsequent quarters.
6. Top pharmacy benefit managers like Express Scripts have been speaking out about their displeasure regarding the enormous cost of new drugs emanating from Big Pharma of late. Earlier this year, Express Script's Dr. Miller, for instance, took direct aim at the host of costly new cancer medicines coming on the market, proposing a plan that would reimburse companies based on the effectiveness of their drugs.
If his plan is adopted, and there are some rumblings from major players like Novartis that big changes to cancer drug pricing schemes are indeed under consideration, such a drastic change could have a widespread impact on the industry in terms of earnings and revenues. So this is a key issue investors should keep an eye on moving forward.
This $19 trillion industry could destroy the Internet
One bleeding-edge technology is about to put the World Wide Web to bed. And if you act quickly, you could be among the savvy investors who enjoy the profits from this stunning change. Experts are calling it the single largest business opportunity in the history of capitalism... The Economist is calling it "transformative"... But you'll probably just call it "how I made my millions." Don't be too late to the party -- click here for one stock to own when the Web goes dark.
The article 2015's Top 6 Big Pharma Headlines Thus Far originally appeared on Fool.com.
George Budwell owns shares of AbbVie. The Motley Fool recommends Celgene, Exelixis, Johnson & Johnson, and Juno Therapeutics. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie joined the M&A frenzy last March with its buyout of cancer drug specialist Pharmacyclics for a mind-boggling premium. Specifically, AbbVie paid a 40% premium for Pharmacyclics and its lead drug Imbruvica. What really caught people's eyes, however, was that AbbVie coughed up $21 billion for about $3 billion in peak revenue for Imbruvica, according to consensus estimates. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AbbVie joined the M&A frenzy last March with its buyout of cancer drug specialist Pharmacyclics for a mind-boggling premium. Specifically, AbbVie paid a 40% premium for Pharmacyclics and its lead drug Imbruvica. | AbbVie joined the M&A frenzy last March with its buyout of cancer drug specialist Pharmacyclics for a mind-boggling premium. Specifically, AbbVie paid a 40% premium for Pharmacyclics and its lead drug Imbruvica. What really caught people's eyes, however, was that AbbVie coughed up $21 billion for about $3 billion in peak revenue for Imbruvica, according to consensus estimates. | Although most analysts savaged the deal, the Street has now pushed AbbVie's shares up almost 25% since this buyout was announced. AbbVie joined the M&A frenzy last March with its buyout of cancer drug specialist Pharmacyclics for a mind-boggling premium. Specifically, AbbVie paid a 40% premium for Pharmacyclics and its lead drug Imbruvica. |
26898.0 | 2015-07-20 00:00:00 UTC | AbbVie Neurodegenerative Disorder Drug Gets Orphan Status - Analyst Blog | ABBV | https://www.nasdaq.com/articles/abbvie-neurodegenerative-disorder-drug-gets-orphan-status-analyst-blog-2015-07-20 | nan | nan | AbbVie Inc.ABBV and C 2 N Diagnostics announced that the FDA has granted C 2 N-8E12 (ABBV-8E12) orphan drug status for the treatment of patients suffering from progressive supranuclear palsy (PSP; which is also known as Steele-Richardson-Olszewski syndrome).
We note that the FDA usually grants orphan drug status to novel drugs or biologics being developed as a potential treatment for rare diseases/conditions that affect less than 200,000 people in the U.S. Orphan drug status is also granted to drugs addressing diseases afflicting more than 200,000 people but these drugs are not expected to recover the cost of developing and marketing the same. However, this designation does not alter the standards of regulatory requirements and process for obtaining marketing approval for the candidate. Safety and efficacy of the compound for the treatment of a disease must be established through adequate and well-controlled studies.
C 2 N-8E12 (ABBV-8E12), a recombinant humanized anti-tau antibody, is currently in a randomized, double-blind, placebo-controlled, single ascending dose, multi-center phase I study. The study, which is estimated to involve 32 patients with PSP, is being conducted to evaluate the safety, tolerability and pharmacokinetics of the candidate.
We remind investors that AbbVie has an exclusive worldwide license agreement with C 2 N Diagnostics for the development and commercialization of a portfolio of anti-tau antibodies for the treatment of PSP, Alzheimer's disease and other neurological disorders entered into earlier this year.
We are encouraged by the FDA granting orphan drug status to C 2 N-8E12 (ABBV-8E12). As per information provided by AbbVie, PSP, a progressive neurodegenerative disorder, affects about 20,000 individuals in the U.S. with an estimated annual incidence of one per 100,000 people above 60 years of age. With no treatments currently being approved for PSP, there is an unmet need for drugs addressing PSP.
AbbVie currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Agios Pharmaceuticals, Inc. AGIO , AMAG Pharmaceuticals, Inc. AMAG and Eleven Biotherapeutics, Inc. EBIO . All three hold a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AMAG PHARMA INC (AMAG): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
AGIOS PHARMACT (AGIO): Free Stock Analysis Report
ELEVEN BIOTHERP (EBIO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc.ABBV and C 2 N Diagnostics announced that the FDA has granted C 2 N-8E12 (ABBV-8E12) orphan drug status for the treatment of patients suffering from progressive supranuclear palsy (PSP; which is also known as Steele-Richardson-Olszewski syndrome). We remind investors that AbbVie has an exclusive worldwide license agreement with C 2 N Diagnostics for the development and commercialization of a portfolio of anti-tau antibodies for the treatment of PSP, Alzheimer's disease and other neurological disorders entered into earlier this year. As per information provided by AbbVie, PSP, a progressive neurodegenerative disorder, affects about 20,000 individuals in the U.S. with an estimated annual incidence of one per 100,000 people above 60 years of age. | Click to get this free report AMAG PHARMA INC (AMAG): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report AGIOS PHARMACT (AGIO): Free Stock Analysis Report ELEVEN BIOTHERP (EBIO): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV and C 2 N Diagnostics announced that the FDA has granted C 2 N-8E12 (ABBV-8E12) orphan drug status for the treatment of patients suffering from progressive supranuclear palsy (PSP; which is also known as Steele-Richardson-Olszewski syndrome). C 2 N-8E12 (ABBV-8E12), a recombinant humanized anti-tau antibody, is currently in a randomized, double-blind, placebo-controlled, single ascending dose, multi-center phase I study. | AbbVie Inc.ABBV and C 2 N Diagnostics announced that the FDA has granted C 2 N-8E12 (ABBV-8E12) orphan drug status for the treatment of patients suffering from progressive supranuclear palsy (PSP; which is also known as Steele-Richardson-Olszewski syndrome). Click to get this free report AMAG PHARMA INC (AMAG): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report AGIOS PHARMACT (AGIO): Free Stock Analysis Report ELEVEN BIOTHERP (EBIO): Free Stock Analysis Report To read this article on Zacks.com click here. C 2 N-8E12 (ABBV-8E12), a recombinant humanized anti-tau antibody, is currently in a randomized, double-blind, placebo-controlled, single ascending dose, multi-center phase I study. | AbbVie Inc.ABBV and C 2 N Diagnostics announced that the FDA has granted C 2 N-8E12 (ABBV-8E12) orphan drug status for the treatment of patients suffering from progressive supranuclear palsy (PSP; which is also known as Steele-Richardson-Olszewski syndrome). Click to get this free report AMAG PHARMA INC (AMAG): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report AGIOS PHARMACT (AGIO): Free Stock Analysis Report ELEVEN BIOTHERP (EBIO): Free Stock Analysis Report To read this article on Zacks.com click here. C 2 N-8E12 (ABBV-8E12), a recombinant humanized anti-tau antibody, is currently in a randomized, double-blind, placebo-controlled, single ascending dose, multi-center phase I study. |
26899.0 | 2015-07-20 00:00:00 UTC | After Hours Most Active for Jul 20, 2015 : ROSE, BAC, SYNA, ABBV, MSFT, T, TROX, BAX, QQQ, GLW, FB, EXEL | ABBV | https://www.nasdaq.com/articles/after-hours-most-active-jul-20-2015-rose-bac-syna-abbv-msft-t-trox-bax-qqq-glw-fb-exel | nan | nan | The NASDAQ 100 After Hours Indicator is down -.3 to 4,679.38. The total After hours volume is currently 29,651,718 shares traded.
The following are the most active stocks for the after hours session :
Rosetta Resources Inc. ( ROSE ) is -0.004 at $19.98, with 5,517,827 shares traded. ROSE's current last sale is 83.23% of the target price of $24.
Bank of America Corporation ( BAC ) is +0.01 at $18.13, with 4,888,853 shares traded. Over the last four weeks they have had 7 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2015. The consensus EPS forecast is $0.36. As reported by Zacks, the current mean recommendation for BAC is in the "buy range".
Synaptics Incorporated ( SYNA ) is unchanged at $83.28, with 3,665,382 shares traded. As reported by Zacks, the current mean recommendation for SYNA is in the "buy range".
AbbVie Inc. ( ABBV ) is unchanged at $70.80, with 3,505,347 shares traded.ABBV is scheduled to provide an earnings report on 7/24/2015, for the fiscal quarter ending Jun2015. The consensus earnings per share forecast is 1.06 per share, which represents a 82 percent increase over the EPS one Year Ago
Microsoft Corporation ( MSFT ) is unchanged at $46.92, with 2,555,855 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2015. The consensus EPS forecast is $0.6. MSFT is scheduled to provide an earnings report on 7/21/2015, for the fiscal quarter ending Jun2015. The consensus earnings per share forecast is 0.56 per share, which represents a 58 percent increase over the EPS one Year Ago
AT&T Inc. ( T ) is unchanged at $34.90, with 2,051,752 shares traded.T is scheduled to provide an earnings report on 7/23/2015, for the fiscal quarter ending Jun2015. The consensus earnings per share forecast is 0.63 per share, which represents a 62 percent increase over the EPS one Year Ago
Tronox Limited ( TROX ) is unchanged at $12.59, with 1,991,852 shares traded., following a 52-week high recorded in today's regular session.
Baxter International Inc. ( BAX ) is unchanged at $37.66, with 1,831,650 shares traded. BAX's current last sale is 101.78% of the target price of $37.
PowerShares QQQ Trust, Series 1 ( QQQ ) is +0.01 at $113.99, with 1,782,269 shares traded., following a 52-week high recorded in today's regular session.
Corning Incorporated ( GLW ) is unchanged at $18.91, with 1,148,546 shares traded. GLW's current last sale is 90.05% of the target price of $21.
Facebook, Inc. ( FB ) is +0.08 at $97.99, with 591,264 shares traded., following a 52-week high recorded in today's regular session.
Exelixis, Inc. ( EXEL ) is +0.09 at $5.97, with 589,919 shares traded., following a 52-week high recorded in today's regular session.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc. ( ABBV ) is unchanged at $70.80, with 3,505,347 shares traded.ABBV is scheduled to provide an earnings report on 7/24/2015, for the fiscal quarter ending Jun2015. The following are the most active stocks for the after hours session : Rosetta Resources Inc. ( ROSE ) is -0.004 at $19.98, with 5,517,827 shares traded. Facebook, Inc. ( FB ) is +0.08 at $97.99, with 591,264 shares traded., following a 52-week high recorded in today's regular session. | AbbVie Inc. ( ABBV ) is unchanged at $70.80, with 3,505,347 shares traded.ABBV is scheduled to provide an earnings report on 7/24/2015, for the fiscal quarter ending Jun2015. The consensus earnings per share forecast is 1.06 per share, which represents a 82 percent increase over the EPS one Year Ago Microsoft Corporation ( MSFT ) is unchanged at $46.92, with 2,555,855 shares traded. The consensus earnings per share forecast is 0.56 per share, which represents a 58 percent increase over the EPS one Year Ago AT&T Inc. ( T ) is unchanged at $34.90, with 2,051,752 shares traded.T is scheduled to provide an earnings report on 7/23/2015, for the fiscal quarter ending Jun2015. | AbbVie Inc. ( ABBV ) is unchanged at $70.80, with 3,505,347 shares traded.ABBV is scheduled to provide an earnings report on 7/24/2015, for the fiscal quarter ending Jun2015. The consensus earnings per share forecast is 1.06 per share, which represents a 82 percent increase over the EPS one Year Ago Microsoft Corporation ( MSFT ) is unchanged at $46.92, with 2,555,855 shares traded. The consensus earnings per share forecast is 0.56 per share, which represents a 58 percent increase over the EPS one Year Ago AT&T Inc. ( T ) is unchanged at $34.90, with 2,051,752 shares traded.T is scheduled to provide an earnings report on 7/23/2015, for the fiscal quarter ending Jun2015. | AbbVie Inc. ( ABBV ) is unchanged at $70.80, with 3,505,347 shares traded.ABBV is scheduled to provide an earnings report on 7/24/2015, for the fiscal quarter ending Jun2015. The NASDAQ 100 After Hours Indicator is down -.3 to 4,679.38. The consensus earnings per share forecast is 1.06 per share, which represents a 82 percent increase over the EPS one Year Ago Microsoft Corporation ( MSFT ) is unchanged at $46.92, with 2,555,855 shares traded. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.